0000844856-22-000019.txt : 20220331 0000844856-22-000019.hdr.sgml : 20220331 20220331173001 ACCESSION NUMBER: 0000844856-22-000019 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 103 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220331 DATE AS OF CHANGE: 20220331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthier Choices Management Corp. CENTRAL INDEX KEY: 0000844856 STANDARD INDUSTRIAL CLASSIFICATION: TOBACCO PRODUCTS [2100] IRS NUMBER: 841070932 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36469 FILM NUMBER: 22794611 BUSINESS ADDRESS: STREET 1: 3800 NORTH 28TH WAY CITY: HOLLYWOOD STATE: FL ZIP: 33020 BUSINESS PHONE: 305-600-5004 MAIL ADDRESS: STREET 1: 3800 NORTH 28TH WAY CITY: HOLLYWOOD STATE: FL ZIP: 33020 FORMER COMPANY: FORMER CONFORMED NAME: VAPOR CORP. DATE OF NAME CHANGE: 20100108 FORMER COMPANY: FORMER CONFORMED NAME: MILLER DIVERSIFIED CORP DATE OF NAME CHANGE: 19920703 10-K 1 form10k.htm HCMC 2021 - 10-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended: December 31, 2021

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from: _____________ to _____________

HEALTHIER CHOICES MANAGEMENT CORP.
(Exact name of registrant as specified in its charter)

Delaware
 
001-36469
 
84-1070932
(State or Other Jurisdiction of Incorporation or Organization)
 
(Commission File Number)
 
(I.R.S. Employer Identification No.)

Address of Principal Executive Office: 3800 North 28th Way Hollywood, FL 33020

Registrant’s telephone number, including area code: (305) 600-5004

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading Symbol
 
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
 
HCMC
 
OTC Pink Marketplace

Securities registered pursuant to Section 12(g) of the Act:

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes  No 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
 
Accelerated filer
Non-accelerated filer
 
Smaller reporting company
   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management assessment of the effectiveness of its internal controls over financial reporting under Section 4049b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $366.5 million based on the June 30, 2021 closing price of $0.0011 per share.

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date: 339,741,632,384 shares outstanding as of March 31, 2022.




INDEX

Page
   
PART I
 
   
   
   
   
   
   
   
PART II
 
   
   
   
   
   
   
   
   
   
PART III
 
   
   
   
   
   
   
PART IV
 
   
   
   





PART I

Item 1. Business.

Healthier Choices Management Corp. (the “Company”) is a holding company focused on providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives. 

Through its wholly owned subsidiary HCMC Intellectual Property Holdings, LLC, the Company manages and intends to expand on its intellectual property portfolio. 

Through its wholly owned subsidiaries, Healthy Choice Markets, Inc., Healthy Choice Markets 2, LLC, and Healthy Choice Markets 3, LLC, respectively, the Company operates:

Ada’s Natural Market, a natural and organic grocery store offering fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items (www.Adasmarket.com)
Paradise Health & Nutrition’s three stores that likewise offer fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items, (www.ParadiseHealthDirect.com)
The Company acquired Mother Earth’s Storehouse on February 2022, which operates a two store organic and health food and vitamin chain in New York’s Hudson Valley, which has been in existence for over 40 years. (www.MotherEarthStorehouse.com)

Through its wholly owned subsidiary, Healthy Choice Wellness, LLC, the Company operates:
Healthy Choice Wellness Center (Roslyn Heights, NY) a Company owned IV therapy center offering multiple IV drip “cocktails” for clients to choose from. These cocktails are designed to help boost immunity, fight fatigue and stress, reduce inflammation, enhance weight loss, and efficiently deliver anti-oxidants and anti-aging mixes. Additionally, there are cocktails for health, beauty and re-hydration. (www.Eirhydration.com, though rebranded website coming soon)
The Company entered into a licensing agreement in February 2022 for a Healthy Choice Wellness Center at the Casbah Spa & Salon in Fort Lauderdale, FL, offering essentially the same services as the Roslyn Heights, NY location. This center will be opening in the second quarter of 2022.
Through its wholly owned subsidiary, Healthy U Wholesale, the Company sells vitamins and supplements, as well as health, beauty and personal care products on its website www.TheVitaminStore.com.

Additionally, the Company markets its patented Q-Unit™ and Q-Cup® technology. Information on these products and the technology is available on the Company’s website at www.theQcup.com.

NATURAL AND ORGANIC GROCERIES AND DIETARY SUPPLEMENTS BUSINESS

Local. Organic. Fresh.  Three words that define Healthy Choice Markets!  With Ada's Natural Market, a full-service grocery store and Greenleaf Grill, Ada’s flagship fast casual in-store restaurant, serving Fort Myers, FL, along with three (3) Paradise Health & Nutrition locations in the greater Melbourne, FL area, and our two (2) newly acquired as of February 2022, Mother Earth’s Storehouse locations in Hudson Valley, NY, all serving their respective local communities. Our stores provide all-natural and organic products in a friendly and helpful atmosphere, with aisles of traditional grocery complete with frozen, healthy home, vitamins & supplements, health & beauty, fresh produce, hormone and antibiotic free meats and bulk foods. Ada's Natural Market and Mother Earth’s Storehouse also offer chef-prepared ready-to-go foods, a 100% organic juice & smoothie bar (available also at two of our Paradise locations), and a free-trade coffee bar with fresh-baked-daily baked goods.




1

Collectively, we focus on providing high-quality products at affordable prices, exceptional customer service, nutrition education and community outreach. We strive to generate long-term relationships with our customers based on quality and service by:

selling only all-natural and organic groceries;

offering affordable prices and a shopper-friendly retail environment; and

providing dine-in options at our Greenleaf Grill, Organic Juice Bar, and our free-trade coffee bar.

Our History and Founding Principles

We are committed to maintaining the following founding principles, which have helped foster our growth:

Quality. Every product on our shelves must go through a rigorous screening and approval process. Our mission includes providing the highest quality groceries and supplements, Natural Grocers branded products, European and United States Department of Agriculture (USDA) certified organic and fresh produce at the best prices in the industry.

Community. The Ada’s, Paradise, and now Mother Earth’s Storehouse brands have each been serving their respective communities for 40+ years.

Employees. Our employees make our companies great. We work hard to ensure that our employees are able to live a healthy, balanced lifestyle. We support them with free nutrition education programs, competitive pay and excellent benefits.

Our Market

We operate within the natural products retail industry, which is a subset of the United States grocery industry and the dietary supplement business. This industry includes conventional supermarkets, natural, gourmet and specialty food markets, mass and discount retailers, warehouse clubs, independent health food stores, dietary supplement retailers, drug stores, farmers’ markets, food co-ops, mail order and online retailers and multi-level marketers. Industry-wide sales of natural and organic foods and dietary supplements have experienced meaningful growth over the past several years, and we believe that growth will continue for the foreseeable future.

We believe the growth in sales of natural and organic foods and dietary supplements continues to be driven by numerous factors, including:

greater consumer focus on high-quality nutritional products;

an increased awareness of the importance of good nutrition to long-term wellness;

aging communities that are seeking healthy lifestyle alternatives;

heightened consumer awareness about the importance of food quality and a desire to avoid pesticide residues, growth hormones, artificial ingredients and genetically engineered ingredients in foods;

growing consumer concerns over the use of harmful chemical additives in body care and household cleaning supplies;

well-established natural and organic brands, which generate additional industry awareness and credibility with consumers; and

the growth in the number of consumers with special dietary requirements as a result of allergies, chemical sensitivities, auto-immune disorders and other conditions.

Our Competitive Strengths

We are well-positioned to capitalize on favorable natural and organic grocery and dietary supplement industry dynamics as a result of the following competitive strengths:

Strict focus on high-quality natural and organic grocery products. We offer high-quality products and brands, including an extensive selection of widely-recognized natural and organic food, dietary supplements, body care products, pet care products and books. We offer our customers approximately 10,000 Stock Keeping Units (SKUs) of natural and organic products. We believe our broad product offering enables our customers to shop our stores for substantially all of their grocery and dietary supplement purchases. In our grocery departments, we primarily sell USDA certified organic produce and do not approve for sale grocery products that are known to contain artificial colors, flavors, preservatives or sweeteners or partially hydrogenated or hydrogenated oils. In addition, we only sell pasture-raised, humanely-raised dairy products. Consistent with this strategy, our product selection does not include items that do not meet our strict quality guidelines. Our store managers enhance our robust product offering by customizing their stores’ selections to address the preferences of local customers.

Engaging customer service experience based on education and empowerment. We strive to offer consistently exceptional customer service in a shopper-friendly environment, which we believe creates a differentiated shopping experience, enhances customer loyalty and generates repeat visits from our clientele. A key aspect of our customer service model is to provide free nutrition education to our customers. We believe this focus provides an engaging retail experience while also empowering our customers to make informed decisions about their health. We offer our science-based nutrition education through our trained employees, our newsletter and sales flyer, community out-reach programs, one-on-one nutrition health coaching, nutrition classes and cooking demonstrations.

Our Growth Strategies

We expect to pursue several strategies to continue our profitable growth, including:

Expand our store base. We intend to expand our store base through the acquisition of new stores.

Increase sales from existing customers. In order to increase our average ticket and the number of customer transactions, we plan to continue offering an engaging customer experience by providing science-based nutrition education and a differentiated merchandising strategy that delivers affordable, high-quality natural and organic grocery products and dietary supplements. We also plan to continue to utilize targeted marketing efforts to reach our existing customers, which we anticipate will drive customer transactions and convert occasional, single-category customers into core, multi-category customers.

Grow our customer base. We plan to implement several measures aimed at building our brand awareness and growing our customer base, including: (i) redesigning our website (www.adasmarket.com) to enhance functionality, create a more engaging user experience and increase its reach and effectiveness; (ii) introducing customer appreciation programs at all our stores; and (iii) developing new collateral marketing materials. We believe offering nutrition education has historically been one of our most effective marketing strategies for reaching new customers and increasing the demand for natural and organic groceries and dietary supplements in our markets.

Improve operating margins. We expect to continue to improve our operating margins as we benefit from investments we have made or are making in fixed overhead and information technology. As we add additional stores, we expect to achieve greater economies of scale through sourcing and distribution. To achieve additional operating margin expansion, we intend to further optimize performance, maintain appropriate store labor levels and effectively manage product selection and pricing.




2

Our Products

Product Selection Guidelines. We have a set of strict quality guidelines covering all products we sell. For example:

we do not approve for sale food known to contain artificial colors, flavors, preservatives or sweeteners or partially hydrogenated or hydrogenated oils or phthalates or parabens, regardless of the proportion of its natural or organic ingredients;

 we sell USDA certified organic produce; and

we sell meats naturally raised without hormones, antibiotics or treatments and that were not fed animal by-products.

Our product review team analyzes all new products and approves them for sale based on ingredients, price and uniqueness within the current product set. We actively research new products in the marketplace through our product vendors, private label manufacturers, scientific findings, customer requests and general trends in popular media. Our stores are able to fully merchandise all departments by providing an extensive assortment of natural and organic products. We do not believe we need to sell conventional products to fill our selection, increase our margins or attract more customers.

What We Sell. We operate both a full-service natural and organic grocery stores and dietary supplement stores within our retail locations. The following is a breakdown of our product mix:

Grocery. We offer a broad selection of natural and organic grocery products with an emphasis on minimally processed and single ingredient products that are not known to contain artificial colors, flavors, preservatives or sweeteners or partially hydrogenated or hydrogenated oils. Additionally, we carry a wide variety of products associated with special diets such as gluten free, vegetarian and non-dairy.

Produce. We sell USDA-certified organic produce and source from local, organic producers whenever feasible. Our selection varies based on seasonal availability, and we offer a variety of organic produce offerings that are not typically found at conventional food retailers.

Bulk Food and Private Label Products. We sell a wide selection of private label repackaged bulk and other products, including nuts, water, pasta, canned seafood, dried fruits, grains, granolas, honey, eggs, herbs, spices and teas.

Dry, Frozen and Canned Groceries. We offer a wide variety of natural and organic dry, frozen and canned groceries, including cereals, soups, baby foods, frozen entrees and snack items. We offer a broad selection of natural chocolate bars, and energy, protein and food bars.

Meats and Seafood. We offer naturally-raised or organic meat products. The meat products we offer come from animals that have never been treated with antibiotics or hormones or fed animal by-products. Additionally, we only buy from companies we believe employ humane animal-raising practices. Our seafood items are generally frozen at the time of processing and sold from our freezer section, thereby ensuring freshness and reducing food spoilage and safety issues.

Dairy Products and Dairy Substitutes. We offer a broad selection of natural and organic dairy products such as milk, eggs, cheeses, yogurts and beverages, as well as non-dairy substitutes made from almonds, coconuts, rice and soy.

Prepared Foods. Our stores have a convenient selection of refrigerated prepared fresh food items, including salads, sandwiches, salsa, humus and wraps. The size of this offering varies by location.

Bread and Baked Goods. We receive regular deliveries of a wide selection of bakery products for our bakery section, which includes an extensive selection of gluten-free items.

Beverages. We offer a wide variety of non-alcoholic and alcoholic beverages containing natural and organic ingredients.

Dietary Supplements. We offer a wide selection of vitamins, supplements and natural remedies. Our staff is well educated and trained on multiple aspects of natural medicine.

Health, Beauty, and Personal Care. We offer a full range of cosmetics, skin care, hair care, fragrance and personal care products containing natural and organic ingredients. Our body care offerings range from bargain-priced basics to high-end formulations.

Household and General Merchandise. Our offerings include sustainable, hypo-allergenic and fragrance-free household products, including cleaning supplies, paper products, dish and laundry soap and other common household products, including diapers.

Quality Assurance. We endeavor to ensure the quality of the products we sell. We work with reputable suppliers we believe are compliant with established regulatory and industry guidelines. Our purchasing department requires a complete supplier and product profile as part of the approval process. Our dietary supplement suppliers must follow Food and Drug Administration (FDA) current good manufacturing practices supported by quality assurance testing for both the base ingredients and the finished product. We expect our suppliers to comply with industry best practices for food safety.

Many of our suppliers are inspected and certified under the USDA National Organic Program, voluntary industry associations, and other third-party auditing programs with regards to additional ingredients, manufacturing and handling standards. We operate all our stores in compliance with the National Organic Program standards, which restricts the use of certain substances for cleaning and pest control and requires rigorous recordkeeping, among other requirements.

Our Pricing Strategy

We believe our pricing strategy allows our customers to shop our stores on a regular basis for their groceries and dietary supplements.

The key elements of our pricing strategy include:

heavily advertised discounts supported by manufacturer participation;

in-store specials generally lasting for 30 days and not advertised outside the store;

managers’ specials, such as clearance, overstock, short-dated or promotional incentives; and

specials on seasonally harvested produce.

As we expand our store base, we believe there are opportunities for increased leverage in fixed costs, such as administrative expenses, as well as increased economies of scale in sourcing products. We strive to keep our product, operating and general and administrative costs low, which allows us to continue to offer attractive pricing for our customers.

Store Management and Staffing. Our store staffing includes a manager and assistant manager, with department managers in each of the dietary supplement, grocery, dairy and frozen, produce, body care and receiving departments, as well as several non-management employees. Our regional manager is responsible for monthly store profit and loss, including labor, merchandising and inventory costs.




3

To ensure a high level of service, all employees receive training and guidance on customer service skills, product attributes and nutrition education. Employees are carefully trained and evaluated based on a requirement that they present nutrition information in an appropriate and legally compliant educational context while interacting with customers. Additionally, store employees are cross-trained in various functions, including cashier duties, stocking and receiving product.

Inventory. We use a robust merchandise management and perpetual inventory system that values goods at average cost. We manage shelf stock based on weeks-on-hand relative to sales, resupply time and minimum economic order quantity.

Sourcing and Vendors. We source from approximately 460 suppliers, and offer over 4,000 brands. These suppliers range from small independent businesses to multi-national conglomerates. As of December 31, 2021, we purchased approximately 69% of the goods we sell from our top 20 suppliers. For the year ended 2021, approximately 25% of our total purchases were from one vendor. We maintain good relations with all our suppliers and believe we have adequate alternative supply methods, including self-distribution.

We have longstanding relationships with our suppliers, and we require disclosure from them regarding quality, freshness, potency and safety data information. Our bulk food private label products are packaged by us in pre-packed sealed bags to help prevent contamination while in transit and in our stores. Unlike most of our competitors, most of our private label nuts, trail mix and flours are refrigerated in our warehouse and stores to maintain freshness.

Our Employees

Commitment to our employees is one of our founding principles. Employees are eligible for health, long-term disability, vision and dental insurance coverage, as well as Company paid short-term disability and life insurance benefits, after they meet eligibility requirements. Additionally, our employees are offered a 401(k) retirement savings plan with discretionary contribution matching opportunities. This further offers our employees the opportunity to become more familiar with our products, which we believe improves the customer service our employees are able to provide. We believe these and other factors result in higher retention rates and encourage our employees to appreciate our culture, which helps them better promote our brand.

Our Customers

The growth in the natural and organic grocery and dietary supplement industries and growing consumer interest in health and nutrition have led to an increase in our core customer base. We believe the demands for affordable, nutritious food and dietary supplements are shared attributes of our core customers, regardless of their socio-economic status. Additionally, we believe our core customers prefer a retail store environment that offers carefully selected natural and organic products and dietary supplements. Our customers tend to be interested in health and nutrition, and expect our store employees to be highly knowledgeable about these topics and related products.

Competition

The grocery and dietary supplement retail business is a large, fragmented and highly competitive industry, with few barriers to entry. Our competition varies by market and includes conventional supermarkets such as Publix and Winn-Dixie, mass or discount retailers such as Sprout's Farmers Market, Wal-Mart and Target, natural and gourmet markets such as Whole Foods and The Fresh Market, specialty food retailers such as Trader Joe’s, independent health food stores, dietary supplement retailers, drug stores, farmers’ markets, food co-ops, mail order and online retailers and multi-level marketers. These businesses compete with us for customers on the basis of price, selection, quality, customer service, shopping experience or any combination of these or other factors. They also compete with us for products and locations. In addition, some of our competitors are expanding to offer a greater range of natural and organic foods. We believe our commitment to carrying only carefully vetted, affordably priced and high-quality natural and organic products and dietary supplements, as well as our focus on providing nutritional education, differentiate us in the industry and provide a competitive advantage.




4

The Grocery business and COVID-19

The COVID-19 pandemic had little impact on the grocery segment of the business, other than the Green Leaf Grill.  Demand for groceries, vitamins and supplements, and household products remained strong.  However, due to many local businesses temporarily closing and local dinning restrictions, the Green Leaf Grill located at Ada's Natural Market was forced to reduce hours for most of 2020 and 2021.

To address the impact of the virus, we have instituted strict cleaning protocols at all locations, provided PPE equipment for all employees and offered online ordering and curbside pick-up for all customers preferring to not enter the store.

HEALTHY CHOICE WELLNESS CENTERS

Healthier choices extend past just healthy eating. HCMC, through its Healthy Choice Wellness Centers, offers premium and optimized whole person-centered care and services, tailored to promote and maximize one's general health and well-being. Healthy Choice Wellness Centers’ services are designed to address one or more common concerns, including but not limited to immunity, anxiety, mental fortitude, sports recovery, and more. Through these services, which include IV Nutrient Drip Infusions and Intramuscular (IM) Injection Treatments, Healthy Choice Wellness Centers seek to provide healthy alternatives that treat the mind and body to its core, thus offering optimized healthier living.

Defining Healthy Choice Wellness

HEALTHYan adjective
o
indicative of, conducive to, or promoting good health
CHOICE – a noun
o
an act of selecting or making a decision when faced with two or more possibilities
WELLNESS – a noun
o
the state of being in good health, especially as an actively pursued goal

Our Mission

To assist in one's achievement of personal well-being, which is an optimal and dynamic state that allows people to achieve their full potential through both the individual pursuit of wellness and the commitment and support of the communities to which they belong.

To assist in maximizing overall individual wellness, which is an active process that helps individuals reach their optimal well-being by integrating all the dimensions of wellness into their lives; physical, social, emotional, spiritual, environmental, intellectual, occupational, and financial.

To provide the highest standards of professionalism, emphasizing on quality of care, ethical behavior, ensuring client confidentiality, and the treatment of all individuals with respect and dignity.

To provide clients an immaculate wellness facility designed for the optimal benefit of the clients to receive their desired treatments in a clean and sterile environment that fosters a tranquil space to maximize one's overall wellness and well-being.

To continue the powerful pursuit of knowledge and education by all of our professionals and practitioners, to better provide consult to our clients for them to best maximize their overall wellness and well-being.




5

Our Vision

Life comes with a lot of choices - some easier to make than others. Healthier Living should be the easiest of those choices, and so Healthy Choice Wellness Centers offers Health & Wellness services that assist in making those choices a lot easier. Healthy Choice Wellness Centers seek to continue the commitment of its parent company, Healthier Choices Management Corp., in providing consumers with healthier alternatives to everyday lifestyle choices.

Healthy Choice Wellness Centers offer premium and optimized whole person-centered care and services, tailored to promote and maximize one's general health and well-being. All of our services are designed to address one or more common concerns, including but not limited to immunity, anxiety, mental fortitude, sports recovery, and more. Through these services, Healthy Choice Wellness Centers seek to provide healthy alternatives that treat the mind and body to its core, thus offering optimized healthier living. 

Our Values

Healthy Choice Wellness Centers are committed to building a culture of well-being. Our goal is to optimize wellness, both for today and all of our tomorrows.

Healthy Choice Wellness Centers view the communities we serve as being comprised of whole and dynamic individuals. We are sensitive to the communal stresses of life that impact our health, wellness, and overall well-being. We promote and encourage personal responsibility and accountability in one's pursuit of achieving and maintaining their health and wellness. Our Healthy Choice Wellness team not only participates in the facilitation of services in the process of achieving one's wellness, but also are present to provide information, care, and knowledge to maintain course and maximize one's well-being according to their individual health goals, wants, and needs.

Healthy Choice Wellness Center also realizes that the whole is only as strong as its parts when it comes to those communities we serve. Thus, we put forth effort to strengthen the environments in which we live and work as they directly impact our well-being. This effort to support wellness for the individuals (the parts) must include working to create a healthy community at large (the whole) that supports the well-being of its members at large.

Our Growth Strategy

We seek to operate and expand our Healthy Choice Wellness centers by approaching growth via three (3) different pathways:

1)
Corporately owned and operated wellness centers

2)
Wellness Centers implementing the services of Healthy Choice Wellness Centers by way of licensing agreements

3)
Expansion by way of franchised locations

Our Products & Services

Healthy Choice Wellness Centers specialize primarily in IV Nutrient Drip Infusion and Intramuscular (IM) Injection treatments, however we seek to expand these offerings (both in the number of IV and IM options offered, but also by adding additional whole-person centered services for optimizing overall general health).




6

IV Nutrient Drip Infusion Treatments: Healthy Choice Wellness Center’s IV Nutrient Drip Infusions are used to deliver vitamins and minerals directly into the bloodstream, offering superior absorption over oral supplements. We offer server pre-formulated customized solutions to address a variety of issues including:

Immune System Strengthening
Anti-Aging
Optimal Athletic Performance & Recovery
Metabolism
Hangover & Headache Relief
Cold & Flu Symptoms
Chronic Fatigue
Brain Fog

Currently, we offer eleven IV Nutrient Treatment Options: Quench, Get-Up-And-Go, Recovery & Performance, Immunity, Alleviate, Inner Beauty, Myers’ Cocktail, Nad+ (Premium Drip), Reboot, Glutathion, and Brainstorm.

Intramuscular (IM) Injection Treatments: Healthy Choice Wellness Center’s Intramuscular (IM) Injection treatments deliver vitamins and minerals directly into the bloodstream, offering superior absorption over oral supplements. We offer server pre-formulated customized solutions to address a variety of issues including:

Immune Functioning
General Health
Fight Illness
Boost Metabolism
Improve Mood
Increase Energy
Appetite Suppression
Burning Fat

Currently we offer four Injection Treatment Options: Vitamin B-12, Vitamin D-3, Glutathione, and our Skinny Shot.

Our Employees

Each Healthy Choice Wellness Center is led by licensed and accredited medical professionals and practitioners who share a like-minded philosophy with that of the Wellness Centers, as does all our support staff – we do not just practice healthy choices, we live it! We encourage and support all of our professionals and practitioners to continue the powerful pursuit of knowledge and education, to better provide consult to our clients for them to best maximize their overall wellness and well-being.

Our Customers

The client base for our wellness centers is not bound by age groups or genders. Our clients consist of a broad range of individuals all seeking a common universal goal of seeking to improve their overall wellness.  These individuals tend to be those who consciously live a healthy lifestyle, and are seeking treatments to maximize and optimize their overall well-being. This includes athletes seeking treatments to help recover quicker from injury and/or rehydrate, middle aged men and women seeking treatments to maximize their cognitive fortitude, those wanting to help alleviate indigestion or stomach pains, and a slew of other individual reasons all ending with the drive for healthier living.


7

ONLINE SALES

HCMC is your online source for the leading products in the all-natural vitamin and supplement, and health, beauty, and personal care categories of Healthier Living.

Backed by 30+ years of combined experience in the health and nutrition industry, we provide our customers with only the best products on the market — Try our exclusive offering of Ada’s Naturals brand products or any of the top products from the most recognized national natural health brands in the industry.

VITAMINS & SUPPLEMENTS:
o
Product categories include, but are not limited to: Vitamins, Minerals & Herbals, Immunity, Multivitamins, Sports Nutrition, Protein Powders, Collagen, Stress & Anxiety, Sleep & Relax, Brain Health, Pain & Inflammation, Probiotics, Energy & Stamina, Joint & Bone Support, Digestion, Fish Oils, Just for Men, Kids/Children/Teens, and more.

o
Product varieties include, but are not limited to: Apple Cider Vinegar, BCAA, Biotin, Calcium, Chlorophyll, CLA, Collagen Peptides, Creatine, Elderberry, Omega-3’s, Garlin, Glucosamine, Iron, Magnesium, Melatonin, Potassium, Prenatals, Probiotics, Protein Powders (Plant and Whey), Ashwaghanda Turmeric, Ginseng, Vitamin B,C,D,E,K+, Zinc, and more.

o
Product brands include, but are not limited to: Ada’s Naturals, Enzymedica, Garden of Life, Natural Vitality, New Chapter, Renew Life, Solgar, and more.
HEALTH, BEAUTY, AND PERSONAL CARE:
o
Product categories include, but are not limited to: Oral Care, Hair Care, Body Wash, Skin & Face, Deodorant, Suncare, Soaps, Shaving, Feminine Hygiene, Lip Balms, Ear Candles, Lotions, Hand Sanitizers, Essential Oils, and more.

o
Product varieties include, but are not limited to: Body Wash, Deodorant, Ear Candles, Shampoos, Conditioners, Toothpaste, Mouthwashes, Shaving, Bar Soaps, Liquid Soaps, Suncare, and more.

o
Product brands include, but are not limited to: Ada’s Naturals, Alba Botanica, Aura Cacia, Derma-E, Desert Essence, Dr. Bronners, Every Man Jack, Heritage Store, Himalaya Botanique, Life-Flo, Lily of the Desert, Natracare, Naturally Fresh, Oral Essentials, South of France, Tea Tree Therapy, Thai Deodorant Stone, Thayers, and more.
VAPORIZER BUSINESS

Retail Stores

While evaluating retail store operations in 2021, management decided to decrease the inventory levels on hand for all of its vape stores, due to a major decrease in foot traffic or temporary closure of some stores a result of the COVID-19 pandemic.





8

Vaporizers

“Vaporizers” are battery-powered products that enable users to inhale nicotine vapor. Regardless of their construction, they are comprised of three functional components:

a mouthpiece, which is a small plastic cartridge that contains a liquid nicotine solution;

the heating element that vaporizes the liquid nicotine so that it can be inhaled; and

the electronic devices which include: a lithium-ion battery, an airflow sensor, a microchip controller and an LED, which illuminates to indicate use.

When a user draws air through the vaporizer, the air flow is detected by a sensor, which activates a heating element that vaporizes the solution stored in the mouthpiece/cartridge, the solution is then vaporized and it is this vapor that is inhaled by the user. The cartridge contains either a nicotine solution or a nicotine free solution, either of which may be flavored.

Vaporizers feature a tank or chamber, a heating element and a battery. The vaporizer user fills the tank with e-liquid or the chamber with dry herb or leaf. The vaporizer battery can be recharged and the tank and chamber can be refilled.

Our Brands

We sell a wide variety of our e-liquid under the Vape Store brand. Our in-house engineering and graphic design teams work to provide aesthetically pleasing, technologically advanced and affordable vaporizer and e-liquid flavor options. We are in the process of preparing to commercialize additional brands which we intend to market to new customers and demographics.

Our Improvements and Product Development on Intellectual Property

We have developed, trademarked and are preparing to commercialize additional products. We include product development expenses as part of our operating expenses. In October 2018, we announced the granting of three US patents related to our Q-Cup™ technology. This Q-Cup™ technology provides microdosing potentially more efficiency depending on the vaping method and an “on the go” solution for consumers who prefer to vape concentrates either medicinally or recreationally. In addition, we have a suite of patent applications pending in the United States. There is no assurance that we will be awarded patents for of any of these pending patent applications.

The Market for Vaporizers

We market our vaporizers as an alternative to traditional tobacco cigarettes and cigars. We offer our products in multiple nicotine strengths and flavors.

Distribution and Sales

The Company sells directly to consumers through the Company owned retail vape stores. Our management believes that consumers are shifting towards vape stores for an enhanced experience. This enhanced experienced is derived from the greater variety of products at the stores, the knowledgeable staff and the social atmosphere. The Company anticipates an even smaller portion of future revenue will continue to come from its retail stores as underperforming stores are being closed.

Business Strategy

We believe and are seeing in our current stores that there is a large consumer demand centered on vaporizer products and the “atmosphere” created by the vape stores. We believe that our reputation and our experience in the vaporizer industry, from a development, customer service and production perspective, give us an advantage in attracting customers.


9

Moreover, we believe that our history with our suppliers, including the volume of products we source, gives us an advantage over other market participants as it relates to favorable pricing, priority as to inventory supply and delivery and first access to new products, including first access to next generation products and technology.

Competition

Competition in the vaporizer and e-liquid industry is intense. We compete with other sellers of vaporizes, most notably Altria Group, Inc., JT International, Imperial Tobacco, and Reynolds American, Inc., which are big tobacco companies that have vaporizer and electronic cigarette business segments. The nature of our competitors is varied as the market is highly fragmented and the barriers to entry into the business are low. Our direct competitors sell products that are substantially similar to ours excluding any products which we hold patents. As a general matter, we have access to market and sell the similar vaporizers as our competitors and we sell our products at substantially similar prices as our competitors; accordingly, the key competitive factors for our success is the quality of service we offer our customers, the scope and effectiveness of our marketing efforts, including media advertising campaigns and, increasingly, the ability to identify and develop new sources of customers.

As discussed above, we compete against “big tobacco”, U.S. cigarette manufacturers of both conventional tobacco cigarettes and electronic cigarettes like Altria Group, Inc., JT International, Imperial Tobacco, and Reynolds American, Inc. We compete against “big tobacco” who offers not only conventional tobacco cigarettes and electronic cigarettes and vaporizers, but also smokeless tobacco products such as “snus” (a form of moist ground smokeless tobacco that is usually sold in sachet form that resembles small tea bags), chewing tobacco and snuff. “Big tobacco” has nearly limitless resources, global distribution networks in place and a customer base that is fiercely loyal to their brands. Furthermore, we believe that “big tobacco” is devoting more attention and resources to developing, acquiring technology patents, and offering electronic cigarettes, vaporizers and e-liquids as these markets grow. Because of their well-established sales and distribution channels, marketing expertise and significant resources, “big tobacco” is better positioned than small competitors like us to capture a larger share of the electronic cigarette market. We also compete against numerous other smaller manufacturers or importers of cigarettes. There can be no assurance that we will be able to compete successfully against any of our competitors, some of whom have far greater resources, capital, experience, market penetration, sales and distribution channels than us. If our major competitors were, for example, to significantly increase the level of price discounts offered to consumers, we could respond by offering price discounts, which could have a materially adverse effect on our business, results of operations and financial condition.

Manufacturing

We have no manufacturing capabilities and do not intend to develop any manufacturing capabilities. Third party manufacturers make our products to meet our design specifications. We depend on third party manufacturers for our vaporizer e-liquid and accessories. Our customers associate certain characteristics of our products including the weight, feel, draw, unique flavor, packaging and other attributes of our products to the brands we market, distribute and sell. Any interruption in supply and or consistency of our products may harm our relationships and reputation with customers, and have a material adverse effect on our business, results of operations and financial condition. In order to minimize the risk of supply interruption, we currently utilize several third-party manufacturers to manufacture our products to our specifications.

We currently utilize several manufacturers both domestically and internationally. We contract with our manufacturers on a purchase order basis. We do not have any output or requirements contracts with any of our manufacturers. Our manufacturers provide us with finished products, which we hold in inventory for distribution, sale and use.




10

Patent Litigation

Third party patent lawsuits alleging our infringement of patents, trade secrets or other intellectual property rights have and could force us to do one or more of the following:

stop selling products or using technology that contains the allegedly infringing intellectual property;

incur significant legal expenses;

pay substantial damages to the party whose intellectual property rights we may be found to be infringing;

redesign those products that contain the allegedly infringing intellectual property; or

attempt to obtain a license to the relevant intellectual property from third parties, which may not be available to us on reasonable terms or at all.

Future third party lawsuits alleging our infringement of patents, trade secrets or other intellectual property rights could have a material adverse effect on our business, results of operations and financial condition.

We are required to obtain licenses to patents or proprietary rights of others and may be required to obtain more in the future and as the product continues to evolve. We cannot assure you that any future licenses required under any such patents or proprietary rights would be made available on terms acceptable to us or at all. If we do not obtain such licenses, we could encounter delays in product market introductions while we attempt to design around such patents, or could find that the development, manufacture, or sale of products requiring such licenses could be foreclosed. Litigation may be necessary to defend against claims of infringement asserted against us by others, or assert claims of infringement to enforce patents issued to us or exclusively licensed to us, to protect trade secrets or know-how possessed by us, or to determine the scope and validity of the proprietary rights of others. In addition, we may become involved in oppositions in foreign jurisdictions, reexamination declared by the United States Patent and Trademark Office, or interference proceedings declared by the United States Patent and Trademark Office to determine the priority of inventions with respect to our patent applications or those of our licensors. Litigation, opposition, reexamination or interference proceedings could result in substantial costs to and diversion of effort by us, and may have a material adverse impact on us. In addition, we cannot assure you that our efforts to maintain or defend our patents will be successful.

Patent Enforcement

On November 30, 2020, the Company filed a patent infringement lawsuit against Philip Morris USA, Inc. and Philip Morris Products S.A. in the U.S. District Court (“District Court”) for the Northern District of Georgia (the “Complaint”).  The lawsuit alleged infringement on HCMC-owned patent(s) by the Philip Morris product known and marketed as “IQOS™.”  Philip Morris claims that it is currently approaching 14 million users of its IQOS® product and has reportedly invested over $3 billion in their smokeless tobacco products. On December 3, 2021, the District Court effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A.  On December 14, 2021, the Company filed an appeal of the District Court’s dismissal of the Company’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. HCMC believes the District Court committed legal error by dismissing its complaint for patent infringement and also by denying the Company’s motion to amend its pleading.

Regulations

Since a 2010 U.S. Court of Appeals decision, the Food and Drug Administration (“FDA”) is permitted to regulate electronic cigarettes as “tobacco products” under the Family Smoking Prevention and the Tobacco Control Act. Under this decision, the FDA is not permitted to regulate electronic cigarettes as “drugs” or “devices” or a “combination product” under the Federal Food, Drug and Cosmetic Act unless they are marketed for therapeutic purposes. This is contrary to anti-smoking devices like nicotine patches, which undergo more extensive FDA regulation. Because the Company does not market its electronic cigarettes for therapeutic purposes, the Company’s electronic cigarettes are subject to being classified as “tobacco products” under the Tobacco Control Act. The Tobacco Control Act grants the FDA broad authority over the manufacture, sale, marketing and packaging of tobacco products, although the FDA is prohibited from issuing regulations banning all cigarettes or all smokeless tobacco products, or requiring the reduction of nicotine yields of a tobacco product to zero.

On September 9, 2020 the FDA began enforcing rules that extended its regulatory authority to electronic cigarettes and certain other tobacco products under the Tobacco Control Act. The rules required that electronic cigarette and e-liquid manufacturers (i) register with the FDA and report electronic cigarette products and ingredient listings; (ii) market new electronic cigarette products only after FDA review; (iii) only make direct and implied claims of reduced risk if the FDA confirms that scientific evidence supports the claim and that marketing the electronic cigarette product will benefit public health as a whole; (iv) not distribute free samples; (v) implement minimum age and identification restrictions to prevent sales to individuals under age 21; (vi) include a health warning; and (vii) not sell electronic cigarettes in vending machines, unless in a facility that never admits youth. It is not known how long finalizing and implementing this regulatory process may take. Accordingly, the Company has responded by beginning to take the necessary steps to ensure compliance.




11

In this regard, total compliance and related costs are not possible to predict and depend substantially on the future requirements imposed by the FDA under the Tobacco Control Act. Costs, however, could be substantial and could have a material adverse effect on the Company’s business, results of operations and financial condition. In addition, failure to comply with the Tobacco Control Act and with FDA regulatory requirements could result in significant financial penalties and could have a material adverse effect on the Company’s business, financial condition and results of operations and ability to market and sell the Company’s products. At present, it is difficult to predict whether the Tobacco Control Act will impact the Company to a greater degree than competitors in the industry, thus affecting the Company’s competitive position.

State and local governments currently legislate and regulate tobacco products, including what is considered a tobacco product, how tobacco taxes are calculated and collected, to whom and by whom tobacco products can be sold and where tobacco products may or may not be smoked. State and local regulation of the e-cigarette market and the usage of e-cigarettes is beginning to accelerate.

As local regulations expand, vaporizers and electronic cigarettes may lose their appeal as an alternative to cigarettes, which may have the effect of reducing the demand for the Company’s products and as a result have a material adverse effect on the Company’s business, results of operations and financial condition.

At present, neither the Prevent All Cigarette Trafficking Act (which prohibits the use of the U.S. Postal Service to mail most tobacco products, which would require individuals and businesses that make interstate sales of cigarettes or smokeless tobacco to comply with state tax laws) nor the Federal Cigarette Labeling and Advertising Act (which governs how cigarettes can be advertised and marketed) apply to electronic cigarettes. The application of either or both of these federal laws to vaporizers and electronic cigarettes would have a material adverse effect on the Company’s business, results of operations and financial condition.

On July 1, 2015, the FDA published a document entitled “Advanced notice of proposed rulemaking” or the Advance. Through the Advance, the FDA solicited public comments on whether it should issue rules with respect to nicotine exposure warning and child-resistant packaging for e-liquids containing nicotine. Following public comment, the FDA may issue proposed rules in furtherance of the purposes outlined in the Advance and ultimately pass the rules as proposed or in modified form. We cannot predict whether rules will be passed or if they will have a material adverse effect on our future results of operations and financial conditions.

The Company expects that the tobacco industry will experience significant regulatory developments over the next few years, driven principally by the World Health Organization’s FCTC. The FCTC is the first international public health treaty on tobacco, and its objective is to establish a global agenda for tobacco regulation with the purpose of reducing initiation of tobacco use and encouraging cessation. Regulatory initiatives that have been proposed, introduced or enacted include:

the levying of substantial and increasing tax and duty charges;

restrictions or bans on advertising, marketing and sponsorship;

the display of larger health warnings, graphic health warnings and other labelling requirements;

restrictions on packaging design, including the use of colors and generic packaging;

restrictions or bans on the display of tobacco product packaging at the point of sale, and restrictions or bans on cigarette vending machines;

requirements regarding testing, disclosure and performance standards for tar, nicotine, carbon monoxide and other smoke constituents’ levels;

requirements regarding testing, disclosure and use of tobacco product ingredients;

increased restrictions on smoking in public and work places and, in some instances, in private places and outdoors;

elimination of duty free allowances for travelers; and

encouraging litigation against tobacco companies.

If Vaporizers, electronic cigarettes, or e-liquids, are subject to one or more significant regulatory initiates enacted under the FCTC, the Company’s business, results of operations and financial condition could be materially and adversely affected.

Seasonality

Our business is active throughout the calendar year and does not experience significant fluctuation caused by seasonal changes in consumer purchasing.




12

The Vape Business and COVID-19

The COVID-19 pandemic had moderate to significant impact on the vape business depending on the location of the retail store.  Several stores, located in smaller towns, saw a greater negative impact than stores located in larger retail environments.  As stores reopened and retail consumers re-emerged, operations at all locations have stabilized.

To address the impact of the virus, we have instituted strict cleaning protocols at all locations, provided PPP equipment for all employees and offered curbside pick-up for all customers preferring to not enter the store.

Insurance and Risk Management

We use a combination of insurance and self-insurance to cover workers’ compensation, general liability, product liability, director and officers’ liability, employment practices liability, associate healthcare benefits and other casualty and property risks. Changes in legal trends and interpretations, variability in inflation rates, changes in the nature and method of claims settlement, benefit level changes due to changes in applicable laws, insolvency of insurance carriers and changes in discount rates could all affect ultimate settlements of claims. We evaluate our insurance requirements and providers on an ongoing basis.

Information Technology Systems

We have made significant investments in overhead and information technology infrastructure, including purchasing, receiving, inventory, point of sale, warehousing, distribution, accounting, reporting and financial systems.

Segment Information

We have two reporting segments, natural and organic retail stores (“Grocery”) and vapor products (“Vapor”), through which we conduct all of our business.

The Company has included the results of the Healthy Choice Wellness Centers under the grocery segment due to its sales being de minimis.

Going Concern and Liquidity

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate the continuation of the Company as a going concern for the next twelve months from the issuance of this Form 10-K and realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of any uncertainties related to our going concern assessment. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values.

The Company currently and historically has reported net losses and cash outflows from operations. As of December 31, 2021, cash and cash equivalents totaled approximately $26.5 million. The Company anticipates that its current cash, cash equivalent and cash generated from operations will be sufficient to meet the projected operating expenses for the foreseeable future through at least twelve months from the issuance of these consolidated financial statements.

Item 1A. Risk Factors.

Not applicable to smaller reporting companies.

Item 1B. Unresolved Staff Comments.

None

Item 2. Properties.

The Company operates its business from numerous facilities in Florida and New York. These leased facilities include our headquarters location, warehouse and retail stores.

Grocery Segment. As of December 31, 2021, our Grocery segment had 4 retail stores in Florida which aggregate approximately 28,000 square feet, all of which are leased by our grocery segment. Healthy Choice Wellness Centers leases a facility in New York.

Vapor Segment. As of December 31, 2021, our Vapor segment operated 6 retail stores in Florida, aggregating approximately 8,000 square feet.

Our headquarters and warehouse are located in Hollywood, Florida which aggregates approximately 10,000 square feet.

Item 3. Legal Proceedings.

No response is required under Item 103 of Regulation S-K.

Item 4. Mine Safety Disclosures.

None.


13



PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Our common stock is currently listed on the OTC Pink marketplace under the symbol “HCMC”.

As of March 31, 2022, there were approximately 1,400 stockholders of record for our common stock. A substantially greater number of stockholders may be “street name” or beneficial holders, whose shares are held of record by banks, brokers and other financial institutions.

As of March 31, 2022, the last reported sale price of our common stock on the OTC Pink Marketplace was $0.0003 per share.

We have never declared or paid, and do not anticipate declaring or paying, any cash dividends on any of our capital stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends in the foreseeable future. Future determination as to the declaration and payment of dividends, if any, will be at the discretion of our Board and will depend on then existing conditions, including our operating results, financial conditions, contractual restrictions, capital requirements, business prospects and other factors our Board may deem relevant.

On February 7, 2021, the Company entered into a Securities Purchase Agreement, pursuant to which the Company sold and issued 5,000 shares of its Series D Convertible Preferred Stock (the “Preferred Stock”) to a single institutional, accredited investor for $1,000 per share or an aggregate subscription of $5,000,000. Subject to a customary “9.99% Beneficial Ownership Limitation blocker,” the Preferred Stock is currently convertible into 2,083,333,333.33 shares of the Company’s Common Stock at a conversion price of $0.0024 per share, with such conversion price subject to adjustment as set forth below and described in the Certificate of Designation.

As of December 31, 2021, the Company has issued 6,562,500,000 shares of Company common stock in connection with the exercise of 4,200 shares of the Series D Convertible Preferred Stock at a conversion price of $0.00064 per share. The conversion price for the exercise of the preferred stock was reset to the 80% of the lowest daily volume-weighted average price ("VWAP") during the 5 Trading Days immediately preceding the Effective Date of August 11, 2021.

On June 18, 2021, the Company issued 27,046,800,310 shares of common stock in connection with the Rights Offering at a subscription price of $0.0010 per share, generating gross proceeds of approximately $27.0 million.

Item 6. Selected Financial Data.

Not required for smaller reporting companies.




14

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion in conjunction with our audited historical consolidated financial statements, which are included elsewhere in this report. “Management’s Discussion and Analysis of Financial Condition” and “Results of Operations” contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements.

Cautionary Note Regarding Forward Looking Statements

This report includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this report, including statements regarding our future financial position, liquidity, business strategy, plans and objectives of management for future operations, are forward-looking statements.

Forward-looking statements contained in this report include:

 Our liquidity;

 Opportunities for our business; and

 Growth of our business.

The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “expect,” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

The results anticipated by any or all of these forward-looking statements might not occur. Important factors, uncertainties and risks that may cause actual results to differ materially from these forward-looking statements are contained in the Risk Factors contained herein. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. For more information regarding some of the ongoing risks and uncertainties of our business, see the Risk Factors below.

Factors Affecting Our Performance

We believe the following factors affect our performance:

Retail: We believe the operating performance of our retail stores will affect our revenue and financial performance. The Company has (1) a total of [six] retail vape stores and (2) [four] natural and organic groceries and dietary supplement stores located in Florida, as well as two located in New York. The Company has reduced the number of retail vape stores due to adverse industry trends and increasing federal and state regulations that, if implemented, may negatively impact future retail revenues.

Increased Competition: Food retail is a large and competitive industry. Our competition varies and includes national, regional, and local conventional supermarkets, national superstores, alternative food retailers, natural foods stores, smaller specialty stores, and farmers’ markets. In addition, we compete with restaurants and other dining options in the food-at-home and food-away-from-home markets. The opening and closing of competitive stores, as well as restaurants and other dining options, in regions where we operate will affect our results. In addition, changing consumer preferences with respect to food choices and to dining out or at home can impact us. We also expect increased product supply and downward pressure on prices to continue and impact our operating results in the future.

Our Response to the COVID-19 Pandemic: We are proud to provide our guests with high quality, fresh foods and restaurant quality meals, delivered with impeccable service in an exceptionally clean and well-stocked store. With the ongoing COVID-19 pandemic, we continue to carefully monitor and adjust our safety protocols while following public health guideline and local ordinances. We have maintained many of the protocols established at the beginning of the pandemic to keep our team members and guests safe. The COVID-19 pandemic has presented many risks and challenges that we must manage. While we have experienced many challenges, including but not limited to, product shortages, staffing difficulties, and evolving customer shopping behaviors, our focus remains on both offering our customers a high quality service experience and supporting our essential front-line team members. Though we have successfully managed these challenges to date, our operations and financial condition could still be negatively affected by the COVID-19 pandemic and future developments, which are highly uncertain and cannot be predicted.




15

Results of Operations

The following table sets forth our Consolidated Statements of Operations for the years ended December 31, 2021 and 2020 which is used in the following discussions of our results of operations:

 
For the Year Ended December 31,
   
2021 to 2020
 
   
2021
   
2020
   
Change $
 
SALES:
                 
Vapor sales, net
 
$
2,084,813
   
$
2,458,945
   
$
(374,132
)
Grocery sales, net
   
11,235,041
     
11,461,800
     
(226,759
)
Total Sales
   
13,319,854
     
13,920,745
     
(600,891
)
Cost of sales vapor
   
839,599
     
1,033,805
     
(194,206
)
Cost of sales grocery
   
7,187,701
     
7,109,719
     
77,982
 
GROSS PROFIT
   
5,292,554
     
5,777,221
     
(484,667
)
                         
EXPENSES:
                       
Impairment of goodwill and intangible assets
   
-
     
380,646
     
(380,646
)
Selling, general and administrative
   
10,033,048
     
8,844,947
     
1,188,101
 
Total operating expenses
   
10,033,048
     
9,225,593
     
807,455
 
Operating loss
   
(4,740,494
)
   
(3,448,372
)
   
(1,292,122
)
                         
OTHER INCOME (EXPENSES):
                       
Gain on debt settlements
   
767,930
     
-
     
767,930
 
Other expenses, net
   
(26
)
   
(100
)
   
74
 
Interest expense, net
   
(65,281
)
   
(272,651
)
   
207,370
 
Gain (loss) on investment
   
412
     
(1,269
)
   
1,681
 
Total other income (expense), net
   
703,035
     
(274,020
)
   
977,055
 
                         
NET LOSS
 
$
(4,037,459
)
 
$
(3,722,392
)
 
$
(315,067
)

Net vapor sales decreased $0.4 million to $2.1 million for the year ended December 31, 2021 as compared to $2.5 million for the same period in 2020. The decrease in sales was primarily due to a major decrease in foot traffic and a decrease in the number of stores open compared to prior year.  Net grocery sales decreased $0.2 million to $11.2 million for the year ended December 31, 2021 as compared to $11.5 million for the same period in 2020. The decrease in sales was primarily due to a decrease in the customer count compared to prior year.

Vapor cost of goods sold for the year ended December 31, 2021 and 2020 were $0.8 million and $1.0 million, respectively, a decrease of $0.2 million. The decrease in cost of goods sold was primarily due to a decreased in sales and product cost. Grocery store cost of goods sold for the year ended December 31, 2021 and 2020 were $7.2 million and $7.1 million, respectively, an increase of $0.1 million primarily due to a write-off of inventory.

Total operating expenses increased $0.8 million to $10.0 million for the year ended December 31, 2021. The increase was primarily due to an increase in professional fees of $1.1 million and payroll benefits of $0.4 million, partially offset by the impairment of goodwill and intangible assets of $0.4 million in prior year.

Net other income of $0.7 million for the year ended December 31, 2021 includes a gain on debt settlements of $0.8 million, partially offset by an interest expense of $0.1 million. Net other expense of $0.3 million for the year ended December 31, 2020 includes primarily interest expense.




16

Liquidity and Capital Resources

 
For the year ended December 31,
 
   
2021
   
2020
 
Net cash provided by (used in):
           
Operating activities
 
$
(3,528,205
)
 
$
(2,281,797
)
Investing activities
   
(87,322
)
   
(75,202
)
Financing activities
   
27,186,456
     
1,771,293
 
   
$
23,570,929
   
$
(585,706
)

Our net cash used in operating activities of $3.5 million for the year ended December 31, 2021 resulted from our net loss of $4.0 million and a net cash usage of $0.6 million from changes in operating assets and liabilities, offset by a non-cash adjustments of $1.0 million. Our net cash used in continuing operating activities of $2.3 million for the year ended December 31, 2020 resulted from our net loss from continuing operations of $3.7 million, offset by a net cash usage of $0.5 million from changes in operating assets and liabilities and a non-cash adjustments of $1.9 million.

The net cash used in investing activities of $0.1 million for the year ended December 31, 2021 resulted from the collection of a note receivable, the acquisition of new business and purchases of a patent and property and equipment. The net cash provided by investing activities of $0.1 million for the year ended December 31, 2020 resulted from the issuance and collection of a note receivable, and purchases of a patent and property and equipment.

The net cash provided by financing activities of $27.2 million for the year ended December 31, 2021 is due to proceeds received from the Rights Offering of $24.3 million and a Securities Purchase Agreement of $5.0 million, partially offset by a principal payment of $2.0 million on the line of credit. The net cash used in financing activities of $1.8 million for the year ended December 31, 2020 is due to proceeds received from the Paycheck Protection Program of $0.9 million and Term Loan of $2.5 million, partially offset by payments of $1.7 million on the loan payable.

At December 31, 2021 and December 31, 2020, we did not have any material financial guarantees or other contractual commitments with trade vendors that are reasonably likely to have an adverse effect on liquidity.

Our cash balances are kept liquid to support our growing acquisition and infrastructure needs for operational expansion. The majority of our cash and cash equivalents are concentrated in three large financial institutions and are generally in excess of the Federal Deposit Insurance Corporation (FDIC) insurance limit. The Company has not experienced any losses on its cash and cash equivalents. The following table presents the Company’s cash position as of December 31, 2021 and December 31, 2020.

 
December 31, 2021
   
December 31, 2020
 
             
Cash
 
$
26,496,404
   
$
925,475
 
Total assets
 
$
34,443,487
   
$
11,874,993
 
Percentage of total assets
   
76.9
%
   
7.8
%

The Company reported net loss of approximately $4.0 million for the year ended December 31, 2021. The Company also had positive working capital of $26.2 million. The Company expects to continue incurring losses for the foreseeable future and may need to raise additional capital to satisfy business obligations, and to continue as a going concern.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements other than operating leases for retail locations, equipment, and vehicles.

Seasonality

We do not consider our business to be seasonal.




17

Non-GAAP Financial Measures

The following discussion and analysis contains a non-GAAP financial measure. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flows that either excludes or includes amounts that are not normally included or excluded in the most directly comparable measure calculated and presented in accordance with generally accepted accounting principles (GAAP). Non-GAAP financial measures should be viewed as supplemental to, and should not be considered as alternative to, net income, operating income, and cash flow from operating activities, liquidity or any other financial measures. Non-GAAP financial measures may not be indicative of the historical operating results of the Company nor are they intended to be predictive of potential future financial results. Investors should not consider non-GAAP financial measures in isolation or as substitutes for performance measures calculated in accordance with GAAP.

Management believes stockholders benefit from referring to the Adjusted EBITDA in planning, forecasting, and analyzing future periods. Management uses this non-GAAP financial measure in evaluating its financial and operational decision making and as a means of evaluating period to period comparison.

We define Adjusted EBITDA as net loss from operations adjusted for non-cash charges for depreciation and amortization and stock compensation. Management believes Adjusted EBITDA is an important measure of our operating performance because it allows management, investors and analysts to evaluate and assess our core operating results from period to period after removing the impact of significant non-cash charges that effect comparability between reporting periods. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items.

We have included a reconciliation of our non-GAAP financial measure to loss from operations as calculated in accordance with GAAP. We believe that providing the non-GAAP financial measure, together with the reconciliation to GAAP, helps investors make comparisons between the Company and other companies. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to specific definitions being used and to the reconciliation between such measures and the corresponding GAAP measures provided by each company under applicable rules of the Securities and Exchange Commission.

 
2021
   
2020
 
Reconciliation of Adjusted EBITDA to net loss allocable to common stockholders:
           
Operating loss
 
$
(4,740,494
)
 
$
(3,448,372
)
Impairment of goodwill and intangible assets
   
-
     
380,646
 
Depreciation and amortization
   
497,408
     
550,098
 
Stock-based compensation expense
   
34,375
     
78,029
 
Adjusted EBITDA
 
$
(4,208,711
)
 
$
(2,439,599
)




18

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable to smaller reporting companies.

Item 8. Financial Statements and Supplementary Data.

See pages F-1 through F-23.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

We are required to report under Section 404(a) of Sarbanes-Oxley regarding the effectiveness of our internal control over financial reporting.

Evaluation of Disclosure Controls and Procedures. Our management, including our Principal Executive Officer and Principal Financial Officer, did not carry out an evaluation on internal controls during the year ended December 31, 2021 in regard to the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act. As an evaluation was not carried out, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report.

Management’s Annual Report on Internal Control over Financial Reporting. Our management is responsible for establishing and maintaining adequate internal controls over financial reporting, as such term is defined in Rule 13a-15(f) of the Securities Exchange Act of 1934. Our management, including our Principal Executive Officer and Principal Financial Officer, conducted an evaluation of the effectiveness of our internal controls over financial reporting as of December 31, 2021.

In planning and performing its audit of our financial statements for the year ended December 31, 2021 in accordance with standards of the Public Company Accounting Oversight Board, our independent registered public accounting firm noted material weaknesses in internal control over financial reporting. A list of our material weaknesses are as follows:

Failure to have properly documented and designed disclosure controls and procedures and testing of the operating effectiveness of our internal control over financial reporting.

Failure to perform periodic and year-end inventory observations in a timely manner and adequate controls to sufficiently perform required rollback procedures of inventory counts to the year-end.

Weakness around our purchase orders and inventory procedures, inclusive of year-end physical inventory observation procedures as well as physical count procedures.

Segregation of duties due to lack of personnel.

Our management concluded that considering internal control deficiencies that, in the aggregate, rise to the level of material weaknesses, we did not maintain effective internal control over financial reporting as of December 31, 2021 based on the criteria set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

Remediation Efforts

Following this assessment and during the twelve months ended December 31, 2021, we have undertaken an action plan to strengthen internal controls and procedures:

Management continues to devote significant efforts toward improvement of effectiveness of control over financial reporting. This includes analyzing non-routine transactions before booking journal entries; implemented a monthly variance fluctuation analysis across all segments. Variance analyses are communicated to operations and executives to make sure the results are accurate.

Our management continues to remain focused on the Company’s purchase order process in order to better manage inventory thereby improving cash management and ultimately leading to more reliable and precise financial reporting.

The Company is evaluating the addition of a new position, Inventory Analyst, to handle all matters related to the implementation of a cycle-count procedure as well as coordinating all physical inventory counts with third parties.

Vendor payments and cash disbursement are reviewed on weekly basis by management and accounting team to ensure timely payment. Cash balance are communicated to management on weekly basis to improve cash management.

Our management continues to review ways in which we can make improvements in internal control over financial reporting.

Item 9B. Other Information.

None.


19


PART III

Item 10. Directors, Executive Officers and Corporate Governance

Directors and Executive Officers

The following table sets forth information regarding our executive officers and directors as of December 31, 2021:

Name
 
Age
 
Position
Executive Officers:
       
Jeffrey Holman
 
55
 
Chief Executive Officer, Chairman and Director
John A. Ollet
 
59
 
Chief Financial Officer
Christopher Santi
 
51
 
President and Chief Operating Officer
         
Non-Employee Directors:
       
Clifford J. Friedman
 
60
 
Director
Dr. Anthony Panariello
 
62
 
Director

Executive Officers

Jeffrey Holman has been our Chairman of the Board and Chief Executive Officer since April 2014. From February 2013 until March 4, 2015, Mr. Holman serviced as our President. Mr. Holman has been a member of our Board since May 2013 and has served as a member of the Board of Directors of our subsidiary Smoke Anywhere, USA since its inception on March 24, 2008. Since 1998, Mr. Holman has been the President of Jeffrey E. Holman & Associates, P.A., a South Florida based law firm. He has also been a Partner in the law firm of Holman, Cohen & Valencia since 2000. Mr. Holman was selected as a director for his business and legal experience. In addition, as one of the founders of Smoke Anywhere, Mr. Holman possesses an in-depth understanding of the challenges, risks and characteristics unique to our industry.

Christopher Santi has been our Chief Operating Officer since December 12, 2012 and has also served as the President since April 11, 2016. Previously, Mr. Santi served as Director of Operations of the Company beginning in October 2011. Mr. Santi served as the National Sales Manager of Collages.net from November 2007 to October 2011.

John A. Ollet has been our Chief Financial Officer since December 12, 2016. Mr. Ollet previously served as Executive Vice President-Finance for Systemax, Inc. (NYSE:SYX) from 2006 to 2016. His prior chief financial officer experience also includes serving as Vice President and Chief Financial Officer of Arrow Cargo Holdings, Inc., an airline logistics company, and VP Finance /CFO - The Americas - Cargo Division, KLM Royal Dutch Airlines, an airline company. He also previously served as Vice President Finance/Administration at Sterling-Starr Maritime Group, Inc. and served on the audit staff of Arthur Andersen & Co. Mr. Ollet received a bachelor’s degree in Finance/Economics and a master’s degree in business administration from Florida International University. Mr. Ollet is a Certified Public Accountant.

Non-Employee Directors

Anthony Panariello, M.D. has been a director since April 15, 2016. Dr. Panariello is a Board Certified in Pulmonology and Internal Medicine in Florida and has been in private practice since 1996, serving as an attending physician at a number of hospitals. Dr. Panariello is a member of the College of Physicians and the American College of Chest Physicians. Additionally, Dr. Panariello currently serves as a Lieutenant Commander in the Medical Corps of the United States Navy Reserve. Dr. Panariello received his Bachelor of Science from the State University of New York at Stony Brook and his medical degree from the Autonomous University of Guadalajara.

Clifford J. Friedman has been a director since April 15, 2016. Mr. Friedman is a certified public accountant in Coral Springs, Florida and manages his own public accounting, tax and consulting practice since 2001. From 1992 to 2000, Mr. Friedman was Vice President - Finance and Administration of the Box Worldwide, Inc., a Viacom company. He received an M.B.A. from Nova Southeastern University and his B.B.A. from Pace University.


20

Corporate Governance

Board Responsibilities

The Board oversees, counsels, and directs management in the long-term interest of the Company and its stockholders. The Board’s responsibilities include establishing broad corporate policies and reviewing the overall performance of the Company. The Board is not, however, involved in the operating details on a day-to-day basis.

Board Committees and Charters

The Board and its Committees meet throughout the year and act by written consent from time-to-time as appropriate. The Board delegates various responsibilities and authority to different Board Committees. Committees regularly report on their activities and actions to the Board.

The Board currently has and appoints the members of: The Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. Each of these committees have a written charter which can be found on our corporate website at www.healthiercmc.com/committee-charters/.

The following table identifies the independent and non-independent current Board and committee members:

Name
 
Independent
 
Audit
 
Compensation
 
Nominating And Corporate Governance
Jeffrey Holman
               
Dr. Anthony Panariello
 
X
 
X
 
X
 
X
Clifford J. Friedman
 
X
 
X
 
X
 
X

Director Independence

Our Board has determined that Clifford J. Friedman and Dr. Anthony Panariello are independent in accordance with standards under the OTC Pink Marketplace. Our Board determined that as a result of being executive officer, Messrs. Jeffrey Holman is not independent under the OTC Pink Marketplace Bulletin Boards. Our Board has also determined that Clifford J. Friedman and Dr. Anthony Panariello are independent under the OTC Pink Marketplace independence standards for Audit and Compensation Committee members.

Committees of the Board

Audit Committee

The Audit Committee, which currently consists of Clifford J. Friedman (chair) and Dr. Anthony Panariello, reviews the Company’s financial reporting process on behalf of the Board and administers our engagement of the independent registered public accounting firm. The Audit Committee approves all audit and non-audit services, and reviews the independence of our independent registered public accounting firm.

Audit Committee Financial Expert

Our Board has determined that Clifford J. Friedman is qualified as an Audit Committee Financial Expert, as that term is defined by the rules of the SEC and in compliance with the Sarbanes-Oxley Act of 2002.

Compensation Committee

The function of the Compensation Committee is to determine the compensation of our executive officers. The Compensation Committee has the power to set performance targets for determining periodic bonuses payable to executive officers and may review and make recommendations with respect to stockholder proposals related to compensation matters. Additionally, the Compensation Committee is responsible for administering the Company’s equity compensation plans including the Company’s 2015 Equity Incentive Plan, as amended


21

The members of the Compensation Committee are all independent directors within the meaning of applicable Nasdaq Listing Rules and all of the members are “non-employee directors” within the meaning of Rule 16b-3 under the Exchange Act.

Nominating and Corporate Governance Committee

The responsibilities of the Nominating and Corporate Governance Committee include the identification of individuals qualified to become Board members, the selection of nominees to stand for election as directors, the oversight of the selection and composition of committees of the Board, establish procedures for the nomination process including procedures and the oversight of the evaluations of the Board and management. The Nominating and Corporate Governance Committee has not established a policy with regard to the consideration of any candidates recommended by stockholders since no stockholders have made any recommendations. If we receive any stockholder recommended nominations, the Nominating Committee will carefully review the recommendation(s) and consider such recommendation(s) in good faith.

Compensation Committee Interlocks and Insider Participation

None of the members of our compensation committee has ever been an officer or employee of the Company. None of our executive officers serve, or have served during the last fiscal year, as a member of our compensation committee or other Board committee performing equivalent functions of any entity that has one or more executive officers serving on our Board or on our compensation committee.

Board Assessment of Risk

The Board is actively involved in the oversight of risks that could affect the Company. This oversight is conducted primarily through the Audit Committee, but the full Board has retained responsibility for general oversight of risks. The Audit Committee considers and reviews with our independent public accounting firm and management the adequacy of our internal controls, including the processes for identifying significant risks and exposures, and elicits recommendations for the improvements of such procedures where desirable. In addition to the Audit Committee’s role, the full Board is involved in oversight and administration of risk and risk management practices. Members of our senior management have day-to-day responsibility for risk management and establishing risk management practices, and members of management are expected to report matters relating specifically to the Audit Committee directly thereto, and to report all other matters directly to the Board as a whole. Members of our senior management have an open line of communication to the Board and have the discretion to raise issues from time-to-time in any manner they deem appropriate, and management’s reporting on issues relating to risk management typically occurs through direct communication with directors or committee members as matters requiring attention arise. Members of our senior management regularly attend portions of the Board’s meetings, and often discuss the risks related to our business.

Presently, the largest risks affecting the Company are the Company’s ability to manage and satisfy the Series A Warrant obligations and evaluation of potential adverse impact of the FDA’s final regulations on vaporizers and e-liquids on the retail business operations. The Board actively interfaces with management on seeking solutions.

Code of Ethics

The Company has a code of ethics, “Business Conduct: “Code of Conduct and Policy,” that applies to all of the Company’s employees, including its principal executive officer, principal financial officer and principal accounting officer, and the Board. A copy of this code is available on the Company’s website at http://www.healthiercmc.com/code-of-conduct. The Company intends to disclose any changes in or waivers from its code of ethics by posting such information on its website or by filing a Current Report on Form 8-K.




22

Stockholder Communications

Although we do not have a formal policy regarding communications with our Board, stockholders may communicate with the Board by writing to us at Healthier Choices Management Corp., 3800 N 28th Way, Hollywood, FL 33020, Attention: Corporate Secretary, or by facsimile (954) 272-7773. Stockholders who would like their submission directed to a member of the Board may so specify, and the communication will be forwarded, as appropriate.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Exchange Act requires our officers and directors, and persons who own more than 10% of a registered class of our equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and the other equity securities. Officers, directors and greater than ten percent stockholders are required by SEC rules to furnish us with copies of all Section 16(a) reports they file.

Based solely on a review of the reports furnished to us, or written representations from reporting persons that all reportable transactions were reported and that no Form 5s were required, we believe that during 2021 our officers, directors and greater than 10% owners timely filed all reports they were required to file under Section 16(a).

ITEM 11. Executive Compensation

The following information is related to the compensation paid, distributed or accrued by us for fiscal 2021 to all Chief Executive Officers (principal executive officers) serving during the last fiscal year and the other most highly compensated executive officers serving at the end of the last fiscal year whose compensation exceeded $100,000. We refer to these individuals as our “named executive officers.”

Summary Compensation Table

Name and Principal Position
Year
 
Salary ($)
   
Bonus ($)
   
Restricted Stock/ (Forfeited) (1)$
   
Restricted Stock Awards(1) $
   
All Other Compensation ($)
   
Total
 
                                       
Jeffrey Holman
2021
   
578,579
     
250,000
     
(302,500
)
   
110,000
     
-
     
636,079
 
Chief Executive Officer
2020
   
494,430
     
-
     
-
     
-
     
-
     
494,430
 
                                                   
Christopher Santi
2021
   
359,192
     
160,000
     
(220,000
)
   
80,000
     
-
     
379,192
 
President and Chief Operating Officer
2020
   
331,058
     
-
     
-
     
-
     
-
     
331,058
 

(1)  Amounts reflect the aggregate grant date fair value, without regard to forfeitures, computed in accordance with ASC 718. These amounts represent options and restricted stock of the Company’s common stock and do not reflect the actual amounts that may be realized by the Named Executive Officers. Our assumptions with respect to the calculation of the stock options and restricted stock value are set forth in Note 2 to the consolidated financial statements contained herein.

Named Executive Officer Employment Agreements

On August 13, 2018, the Company amended and restated its existing employment agreement with Jeffrey Holman, the Company’s Chief Executive Officer (the “Holman Employment Agreement”). The Holman Employment Agreement is for an additional three year term and provides for an annual base salary of $450,000 and a target bonus for 2020 only in an amount ranging from 20% to 200% of his base salaries subject to the Company meeting certain earnings before interest, taxes depreciation and amortization performance milestones. Mr. Holman is entitled to receive severance payments, including two years of his then base salary and other benefits in the event of a change of control, termination by the Company without cause, termination for good reason by the executive or non-renewal by the Company. Mr. Holman was also granted 11 billion shares of restricted common stock pursuant to the Holman Employment Agreement Amendment on the condition that 11 billion of his options to purchase Company common stock are forfeited. This restricted stock will vest one year following the date of issuance provided that the grantee remains an employee of the Company through each applicable vesting date. On August 12, 2019, the Company agreed to extend the expiration date of the vesting period for the restricted stock by six months to February 13, 2020. On August 12, 2020, the Company agreed to extend for a second time the expiration date of the vesting period for the restricted stock by six months to February 13, 2021. The Term shall be automatically renewed for successive one-year terms unless notice of non-renewal is given by either party at least 30 days before the end of the Term. The above description of the terms of the Holman Employment Agreement is not complete and is qualified by reference to the complete document.

On February 26, 2021, the Company entered into an amended and restated employment agreement (the “Employment Agreement Amendment”) with the Company’s President and Chief Operating Officer, Christopher Santi. Pursuant to the Employment Agreement Amendment, Mr. Santi will continue to be employed as the Company’s President and Chief Operating Officer through January 30, 2024.  Mr. Santi will receive a base salary of $0.4 million for 2021 and his salary will increase 10% in each subsequent year. The Term shall be automatically renewed for successive one-year terms unless notice of non-renewal is given by either party at least 30 days before the end of the Term. The above description of the terms of the Santi Employment Agreement is not complete and is qualified by reference to the complete document.

On February 02, 2022, the Company entered into a second amended and restated employment agreement (the “Employment Agreement Amendment”) with the Company’s Chief Financial Officer, John Ollet.  Pursuant to the Employment Agreement Amendment, Mr. Ollet will continue to be employed as the Company’s Chief Financial Officer through February 14, 2025.  Mr. Ollet will receive a base salary of $300,000 for 2022 and his salary will increase 10% in each subsequent calendar year. The Term shall be automatically renewed for successive one-year terms unless notice of non-renewal is given by either party at least 30 days before the end of the Term. The above description of the terms of the Ollet Employment Agreement is not complete and is qualified by reference to the complete document.




23

Termination Provisions

The table below describes the severance payments that our Named Executive Officers are entitled to in connection with a termination of their employment upon death, disability, dismissal without cause, Change of Control or for Good Reason. All of the termination provisions are intended to comply with Section 409A of the Internal Revenue Code of 1986 and the Regulations thereunder.

   
Holman
 
Santi/Ollet
Death or Total Disability
 
Any amounts due at time of termination plus full vesting of equity awards
 
Any amounts due at time of termination
         
Dismissal Without Cause or Termination by Executive for Good Reason or upon a Change of Control (1)
 
Two years of Base Salary, full vesting of equity awards, benefit continuation for eighteen months plus pro-rated bonus if, any, that would have been earned for the fiscal year in which the termination occurs
 
Fifteen months of Base Salary plus one additional month for every additional four months of service, up to eighteen months’ maximum
         
Termination upon a Change of Control (2)
 
Two years of Base Salary, full vesting of equity awards, benefit continuation for eighteen months plus pro-rated bonus if, any, that would have been earned for the fiscal year in which the termination occurs
 
Eighteen months of Base Salary

(1) Good reason is generally (with certain exceptions) defined, in the case of Holman, as (i) a material diminution in their authority, duties or responsibilities, (y) the Company failing to maintain an office in the stated area or (ii) any other action or inaction that constitutes a material breach by the Company of the Employment Agreement. Messrs. Ollet and Santi’s employment agreement do not include the concept of good reason.

(2) Change of Control is generally defined (i) in the case of Holman, as any Change of Control Event as defined in Treasury Regulation Section 1.409A-3(i)(5); and (ii) in the case of Santi, as (w) a sale of substantially all of the Company, (x) any “person” (as such term is defined under the Exchange Act) becomes the beneficial owners of over 50% of the Company’s voting power, (y) a change in the majority of the composition of the Board or (z) a transaction that results in over 50% of the Company’s voting power ceasing to hold a majority of the voting power post-transaction.

Risk Assessment Regarding Compensation Policies and Practices as they Relate to Risk Management

Our compensation program for employees does not create incentives for excessive risk taking by our employees or involve risks that are reasonably likely to have a material adverse effect on us. Our compensation has the following risk-limiting characteristics:

Our base pay programs consist of competitive salary rates that represent a reasonable portion of total compensation and provide a reliable level of income on a regular basis, which decreases incentive on the part of our executives to take unnecessary or imprudent risks; and

Cash bonus awards are not tied to formulas that could focus executives on specific short-term outcomes.

Outstanding Awards at Fiscal Year End

Listed below is information with respect to unexercised options that have not vested, and equity incentive plan awards for each named executive officer outstanding as of December 31, 2021:

Outstanding Equity Awards at 2021 Fiscal Year-End

 
Number of Shares Issued Under Stock Options
   
Number of Shares Issued Under Restricted Stock
   
Stock Options and Restricted Stock Exercise Price ($) Per Share of Stock
 
Expiration Date
 
Number of Shares That Have Not Vested (#)
   
Market Value of Shares That Name Have Not Vested ($)
 
Jeffrey Holman
   
-
     
9,075,000,000
     
0.0001
 
8/13/2028
   
9,075,000,000
     
907,500
 
Jeffrey Holman
   
39,000,000,000
     
-
     
0.0001
 
2/1/2027
   
-
     
-
 
Christopher Santi
   
-
     
6,600,000,000
     
0.0001
 
8/13/2028
   
6,600,000,000
     
660,000
 
Christopher Santi
   
17,000,000,000
     
-
     
0.0001
 
2/1/2027
   
-
     
-
 
John Ollet
   
-
     
2,475,000,000
     
0.0001
 
8/13/2028
   
2,475,000,000
     
247,500
 
John Ollet
   
1,000,000,000
     
-
     
0.0001
 
12/9/2026
   
-
     
-
 
John Ollet
   
4,000,000,000
     
-
     
0.0001
 
8/30/2027
   
-
     
-
 


Director Compensation

Non-employee directors are paid a monthly fee of $1,000 per month and $1,000 for each meeting attended. Because we do not pay any compensation to employee directors, Mr. Holman is omitted from the following table. Non-employee members of our Board of Directors were compensated for as follows:




24

Fiscal 2021 Director Compensation

Name
Fees Earned or Paid in Cash ($)
 
     
Dr. Anthony Panariello
 
$
26,000
 
Clifford J. Friedman
 
$
26,000
 

Equity Compensation Plan Information

The 2015 Equity Incentive Plan (the “Plan”) was approved by the Company’s stockholders at the June 26, 2015 stockholders meeting. On November 21, 2016, the Company’s Board of Directors increased the number of shares of common stock available for issuance pursuant to the Plan to 100,000,000,000. The Plan is a broad-based plan in which all employees, consultants, officers, and directors of the Company are eligible to participate. The purpose of the Plan is to further the growth and development of the Company by providing, through ownership of stock of the Company and other equity-based awards, an incentive to its officers and other key employees and consultants who are in a position to contribute materially to the prosperity of the Company, to increase such persons’ interests in the Company’s welfare, by encouraging them to continue their services to the Company, and by enabling the Company to attract individuals of outstanding ability to become employees, consultants, officers and directors of the Company.

The following chart reflects the number of awards granted under equity compensation plans approved and not approved by stockholders and the weighted average exercise price for such plans as of December 31, 2021.

Name of Plan
 
Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)
   
Weighted average exercise price of outstanding options, warrants and rights (b)
   
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c)
 
Equity compensation plans approved by security holders
                 
2015 Equity Incentive Plan
   
89,712,508,480
     
0.0001
     
10,287,491,520
 
Total
   
89,712,508,480
     
-
     
10,287,491,520
 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters.

The following table sets forth the number of shares of our common stock beneficially owned as of December 31, 2021, by (i) those persons known by us to be owners of more than 5% of our common stock, (ii) each director, (iii) our Named Executive Officers and (iv) all of our executive officers and directors of as a group. Unless otherwise specified in the notes to this table, the address for each person is: c/o Healthier Choices Management Corp., 3800 North 28th Way, Hollywood, Florida 33020.

Title of Class
Beneficial Owner
 
Amount and Nature of Beneficial Owner (1)
   
Percent of Class (1)
 
Directors and Executive Officers:
             
Common Stock
Jeffrey E. Holman (2)
   
43,537,500,000
     
11.50
%
Common Stock
Christopher Santi (3)
   
20,300,000,000
     
5.69
%
Common Stock
John Ollet (4)
   
6,237,500,000
     
1.81
%
Common Stock
Dr. Anthony Panariello (5)
   
1,206,250,000
     
0.35
%
Common Stock
Clifford J. Friedman (6)
   
1,500,000,000
     
0.44
%
All directors and officers as a group (5 persons) (7)
   
72,781,250,000
     
18.07
%
                   
5% Stockholders:
                 
None
     
-
     
0
%
Total:
     
72,781,250,000
     
18.07
%

(1) Beneficial Ownership. Applicable percentages are based on 339,741,632,384 shares of common stock outstanding as of March 31, 2022. Beneficial ownership is determined under the rules of the SEC and generally includes voting or investment power with respect to securities. Shares of common stock subject to options, warrants, convertible notes and preferred stock currently exercisable or convertible or exercisable or convertible within 60 days are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding for computing the percentage of any other person. The table includes shares of common stock, options, warrants, and preferred stock exercisable or convertible into common stock and vested or vesting within 60 days. Unless otherwise indicated in the footnotes to this table, we believe that each of the stockholders named in the table has sole voting and investment power with respect to the shares of common stock indicated as beneficially owned by them. The table does not include: (i) restricted stock units that do not have the right to vote until they vest and the shares are delivered or (ii) unvested options that do not vest within 60 days of the date listed above in this footnote.

(2) Holman. Chairman and Chief Executive Officer. Includes 39,000,000,000 vested options and 4,537,500,000 shares of unvested restricted Common Stock. This restricted stock vests 12.5% on the last day of each calendar quarter commencing March 31, 2021.

(3) Santi. President and Chief Operation Officer. Includes 17,000,000,000 vested options and 3,300,000,000 shares of unvested restricted Common Stock. This restricted stock vests 12.5% on the last day of each calendar quarter commencing March 31, 2021.

(4) Ollet. Chief Financial Officer. Includes 5,000,000,000 vested options. He also holds 1,237,500,000 shares of unvested restricted Common Stock. This restricted stock vests 12.5% on the last day of each calendar quarter commencing March 31, 2021.

(5) Panariello. A director. Includes 1,000,000,000 vested options. He also holds 206,250,000 shares of unvested restricted Common Stock. This restricted stock vests 12.5% on the last day of each calendar quarter commencing March 31, 2021.

(6) Friedman. A director. Includes 990,000,000 vested options and 510,000,000 shares of Common Stock.

(7) Directors and Executive Officers. Includes executive officers who are not Named Executive Officers under the SEC’s rules and regulations.




25

Item 13. Certain Relationships and Related Transactions, and Director Independence.

For the year ended December 31, 2021, the Company did not have any related party transactions.

Policies and Procedures for Related Party Transactions

We have adopted a policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the prior consent of our audit committee. Our audit committee will review and oversee all transactions with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock or any member of the immediate family of any of the foregoing persons and such person would have a direct or indirect interest. In approving or rejecting any such transactions, our audit committee is to consider the material facts of the transaction, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person’s interest in the transaction.

Item 14. Principal Accounting Fees and Services.

Our Audit Committee pre-approves audit and permissible non-audit services performed by its independent registered public accounting firm, as well as the fees charged for such services. All of the services related to audit fees and audit-related fees charged were pre-approved by the Audit Committee. The following table shows the fees for the years ended December 31, 2021 and 2020.

 
2021 ($)
   
2020 ($)
 
Audit Fees (1)
 
$
226,000
   
$
188,000
 
Total
 
$
226,000
   
$
188,000
 

(1) Audit fees — these fees relate to the audit of our annual financial statements and the review of our interim quarterly financial statements and our registration statements.




26

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a)
Documents filed as part of the report.

(1)
Financial Statements. See Index to Consolidated Financial Statements, which appears on page F-1 hereof.  The financial statements listed in the accompanying Index to Consolidated Financial Statements are filed herewith in response to this Item.

(2)
Financial Statements Schedules.  All schedules are omitted because they are not applicable or because the required information is contained in the consolidated financial statements or notes included in this report.

(3)
Exhibits. The exhibits listed in the accompanying Exhibit Index are filed or incorporated by reference as part of this report.




27

FINANCIAL STATEMENT INDEX

Report of Independent Registered Public Accounting Firm (PCAOB ID # 688)
   
Consolidated Financial Statements
 
   
Consolidated Balance Sheets as of December 31, 2021 and 2020
   
Consolidated Statements of Operations for the Years Ended December 31, 2021 and 2020
   
Consolidated Statements of Changes in Stockholders’ Equity for the Years Ended December 31, 2021 and 2020
   
Consolidated Statements of Cash Flows for the Years Ended December 31, 2021 and 2020
   
Notes to Consolidated Financial Statements




F - 1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


To the Shareholders and Board of Directors of
Healthier Choices Management Corp.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Healthier Choices Management Corp. (the “Company”) as of December 31, 2021 and 2021, the related consolidated statements of operations, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the “financial statements”).  In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit[s] also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.


/s/ Marcum LLP

Marcum LLP

We have served as the Company’s auditor since 2017.


New York, NY
March 31, 2022


F - 2


HEALTHIER CHOICES MANAGEMENT CORP.
CONSOLIDATED BALANCE SHEETS

 
December 31, 2021
   
December 31, 2020
 
             
ASSETS
           
CURRENT ASSETS
           
Cash and cash equivalents
 
$
26,496,404
   
$
925,475
 
Accounts receivable
   
28,481
     
23,675
 
Notes receivable
   
247,915
     
-
 
Inventories
   
1,521,199
     
1,749,246
 
Prepaid expenses and vendor deposits
   
456,397
     
286,065
 
Investment
   
23,143
     
22,731
 
TOTAL CURRENT ASSETS
   
28,773,539
     
3,007,192
 
                 
Restricted Cash
   
-
     
2,000,000
 
Property and equipment, net of accumulated depreciation
   
176,988
     
230,719
 
Intangible assets, net of accumulated amortization
   
947,593
     
1,248,352
 
Goodwill
   
916,000
     
916,000
 
Notes receivable
   
-
     
304,511
 
Right of use asset – operating lease, net
   
3,543,930
     
4,078,621
 
Other assets
   
85,437
     
89,598
 
TOTAL ASSETS
 
$
34,443,487
   
$
11,874,993
 
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
CURRENT LIABILITIES
               
Accounts payable and accrued expenses
 
$
1,642,848
   
$
1,085,663
 
Contract liabilities
   
23,178
     
21,262
 
Operating lease liability, current
   
437,328
     
474,686
 
Current portion of line of credit
   
418,036
     
2,000,000
 
Current portion of loan payment
   
2,604
     
2,072,484
 
TOTAL CURRENT LIABILITIES
   
2,523,994
     
5,654,095
 
                 
Loan payable, net of current portion
   
815
     
849,009
 
Operating lease liability, net of current
   
2,685,021
     
3,114,521
 
TOTAL LIABILITIES
   
5,209,830
     
9,617,625
 
                 
COMMITMENTS AND CONTINGENCIES (SEE NOTE 12)
   
     
 
                 
STOCKHOLDERS’ EQUITY
               
Series C convertible preferred stock, $1,000 par value per share, 30,000 shares authorized; 0 and 16,277 shares issued and outstanding as of December 31, 2021 and 2020, respectively; aggregate liquidation preference of $16.3 million for 2020.
   
-
     
16,277,116
 
Series D convertible preferred stock, $1,000 par value per share, 5,000 shares authorized; 800 and 0 shares issued and outstanding as of  December 31, 2021 and 2020, respectively; aggregate liquidation preference of $0.8 million
   
800,000
     
-
 
Common Stock, $0.0001 par value per share, 750,000,000,000 shares authorized; 339,741,632,384 and 143,840,848,017 shares issued and outstanding as of December 31, 2021 and 2020, respectively
   
33,974,163
     
14,384,084
 
Additional paid-in capital
   
30,855,824
     
3,955,039
 
Accumulated deficit
   
(36,396,330
)
   
(32,358,871
)
TOTAL STOCKHOLDERS’ EQUITY
   
29,233,657
     
2,257,368
 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
 
$
34,443,487
   
$
11,874,993
 

See notes to consolidated financial statements


F - 3


HEALTHIER CHOICES MANAGEMENT CORP.
CONSOLIDATED STATEMENTS OF OPERATIONS

 
For the Year Ended December 31,
 
   
2021
   
2020
 
SALES:
           
Vapor sales, net
 
$
2,084,813
   
$
2,458,945
 
Grocery sales, net
   
11,235,041
     
11,461,800
 
TOTAL SALES, NET
   
13,319,854
     
13,920,745
 
                 
Cost of sales vapor
   
839,599
     
1,033,805
 
Cost of sales grocery
   
7,187,701
     
7,109,719
 
GROSS PROFIT
   
5,292,554
     
5,777,221
 
                 
OPERATING EXPENSES:
               
Impairment of goodwill and intangible assets
   
-
     
380,646
 
Selling, general and administrative
   
10,033,048
     
8,844,947
 
Total operating expenses
   
10,033,048
     
9,225,593
 
                 
LOSS FROM OPERATIONS
   
(4,740,494
)
   
(3,448,372
)
                 
OTHER INCOME (EXPENSE):
               
Gain on debt settlements
   
767,930
     
-
 
Other expense, net
   
(26
)
   
(100
)
Interest expense, net
   
(65,281
)
   
(272,651
)
Gain (loss) on investment
   
412
     
(1,269
)
Total other income (expense), net
   
703,035
     
(274,020
)
                 
NET LOSS
 
$
(4,037,459
)
 
$
(3,722,392
)
                 
NET LOSS PER SHARE BASIC AND DILUTED
 
$
0.00
   
$
0.00
 
                 
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
               
BASIC AND DILUTED
   
307,912,959,368
     
90,351,540,618
 

See notes to consolidated financial statements



F - 4


HEALTHIER CHOICES MANAGEMENT CORP.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020

 
Convertible Preferred Stock
   
Common Stock
   
Additional Paid-In
   
Accumulated
       
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Deficit
   
Total
 
Balance – January 1, 2020
   
20,150
   
$
20,150,116
     
67,698,494,244
   
$
6,769,849
   
$
7,618,245
   
$
(28,636,479
)
 
$
5,901,731
 
                                                         
Issuance of common stock in connection with cashless exercise of Series A warrants
   
-
     
-
     
37,412,353,772
     
3,741,235
     
(3,741,235
)
   
-
     
-
 
Cancellation of Series B Convertible Preferred Stock
   
(20,150
)
   
(20,150,116
)
   
-
     
-
     
-
     
-
     
(20,150,116
)
Issuance of Series C Convertible Preferred Stock
   
20,150
     
20,150,116
     
-
     
-
     
-
     
-
     
20,150,116
 
Series C Preferred stock exercised
   
(3,873
)
   
(3,873,000
)
   
38,730,000,001
     
3,873,000
     
-
     
-
     
-
 
Stock-based compensation expense
   
-
     
-
     
-
     
-
     
78,029
     
-
     
78,029
 
Net loss
   
-
     
-
     
-
     
-
     
-
     
(3,722,392
)
   
(3,722,392
)
Balance – December 31, 2020
   
16,277
     
16,277,116
     
143,840,848,017
   
$
14,384,084
   
$
3,955,039
   
$
(32,358,871
)
 
$
2,257,368
 
Series C Preferred stock exercised
   
(16,277
)
   
(16,277,116
)
   
162,771,153,001
     
16,277,116
     
-
     
-
     
-
 
Stock options exercised
   
-
     
-
     
2,275,000,000
     
227,500
     
-
     
-
     
227,500
 
Issuance of Series D Convertible Preferred stock in connection with the Securities Purchase Agreement
   
5,000
     
5,000,000
     
-
     
-
     
-
     
-
     
5,000,000
 
Series D Convertible Preferred Stock exercised
   
(4,200
)
   
(4,200,000
)
   
6,562,500,000
     
656,250
     
3,543,750
     
-
     
-
 
Issuance of common stock
   
-
     
-
     
1,182,831,056
     
118,283
     
1,289,273
     
-
     
1,407,556
 
Issuance of common stock in connection with the Rights Offering, net of offering expenses
   
-
     
-
     
27,046,800,310
     
2,704,680
     
21,639,637
     
-
     
24,344,317
 
Issuance of awarded stock for officers
   
-
     
-
     
2,200,000,000
     
220,000
     
(220,000
)
   
-
     
-
 
Issuance of awarded stock for board member
   
-
     
-
     
50,000,000
     
5,000
     
(5,000
)
   
-
     
-
 
Cancellation of awarded stock for officers
   
-
     
-
     
(6,050,000,000
)
   
(605,000
)
   
605,000
     
-
     
-
 
Cancellation of awarded stock for board member
   
-
     
-
     
(137,500,000
)
   
(13,750
)
   
13,750
     
-
     
-
 
Stock-based compensation expense
   
-
     
-
     
-
     
-
     
34,375
     
-
     
34,375
 
Net loss
   
-
     
-
     
-
     
-
     
-
     
(4,037,459
)
   
(4,037,459
)
Balance – December 31, 2021
   
800
   
$
800,000
     
339,741,632,384
   
$
33,974,163
   
$
30,855,824
   
$
(36,396,330
)
 
$
29,233,657
 

See notes to consolidated financial statements



F - 5


HEALTHIER CHOICES MANAGEMENT CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS

 
For the year ended December 31,
 
   
2021
   
2020
 
OPERATING ACTIVITIES:
           
             
Net loss
 
$
(4,037,459
)
 
$
(3,722,392
)
Adjustments to reconcile net loss to net cash used in operating activities:
               
Depreciation and amortization
   
497,408
     
550,098
 
Net gain on debt settlements
   
(767,930
)
   
-
 
Amortization of right-of-use asset
   
534,691
     
584,398
 
Gain (loss) on investment
   
(412
)
   
1,269
 
Write-down of obsolete and slow-moving inventory
   
707,710
     
340,905
 
Stock-based compensation expense
   
34,375
     
78,029
 
Impairment of goodwill and intangible assets
   
-
     
380,646
 
Accrued interest on loan payable
   
60,809
     
7,117
 
Changes in operating assets and liabilities:
               
Accounts receivable
   
(4,806
)
   
41,726
 
Inventories
   
(478,663
)
   
(333,139
)
Prepaid expenses and vendor deposits
   
(170,332
)
   
(16,233
)
Contract assets
   
-
     
-
 
Other assets
   
4,161
     
57,269
 
Accounts payable and accrued liabilities
   
557,185
     
265,552
 
Contract liabilities
   
1,916
     
(5,561
)
Lease liability
   
(466,858
)
   
(511,481
)
NET CASH USED IN OPERATING ACTIVITIES
   
(3,528,205
)
   
(2,281,797
)
                 
INVESTING ACTIVITIES:
               
Payment for acquisition
   
(75,000
)
   
-
 
Collection of note receivable
   
56,596
     
38,876
 
Purchases of patent
   
(12,500
)
   
(89,415
)
Purchases of property and equipment
   
(56,418
)
   
(24,663
)
NET CASH USED IN INVESTING ACTIVITIES
   
(87,322
)
   
(75,202
)
                 
FINANCING ACTIVITIES:
               
Proceeds from line of credit
   
418,036
     
-
 
Principal payment on the line of credit
   
(2,000,000
)
   
-
 
Principal payments on loan payable
   
(803,397
)
   
(1,659,456
)
Proceeds from paycheck protection program
   
-
     
876,515
 
Proceeds from loan and security agreement
   
-
     
2,540,000
 
Proceeds from issuance of preferred stock
   
5,000,000
     
-
 
Proceeds from rights offering, net of offering costs
   
24,344,317
     
-
 
Proceeds from exercise of stock options
   
227,500
     
-
 
NET CASH PROVIDED BY FINANCING ACTIVITIES
   
27,186,456
     
1,757,059
 
                 
INCREASE (DECREASE) IN CASH
   
23,570,929
     
(599,940
)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — BEGINNING OF YEAR
   
2,925,475
     
3,525,415
 
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — END OF YEAR
 
$
26,496,404
   
$
2,925,475
 
                 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
               
Cash paid for interest
 
$
115,584
   
$
314,925
 
NON-CASH INVESTING AND FINANCING ACTIVITIES:
               
Issuance of common stock in connection with the exchange agreement
 
$
1,407,556
   
$
-
 

See notes to consolidated financial statements


F - 6



HEALTHIER CHOICES MANAGEMENT CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1. ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS

Organization

Healthier Choices Management Corp. (the “Company”) is a holding company focused on providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives. The Company currently operates six retail vape stores in the Southeast region of the United States, through which it offers e-liquids, vaporizers and related products. The Company also operates Ada’s Natural Market, a natural and organic grocery store, through its wholly owned subsidiary Healthy Choice Markets, Inc. Ada’s Natural Market and Paradise Health and Nutrition offers fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items. The Company also sells vitamins and supplements on the Amazon.com marketplace through its wholly owned subsidiary Healthy U Wholesale, Inc. The Company also operates HCMC Intellectual Property Holdings, LLC, a wholly owned subsidiary formed to hold, market and expand on its current intellectual property assets. The Company markets the Q-Cup™ technology under the vape segment; this patented technology is based on a small, quartz cup called the Q-Cup™, which a customer partially fills with either cannabis or CBD concentrate (approximately 50mg) purchased from a third party. The Q-Cup™ is then inserted into the Q-Cup™ Tank or Globe, that heats the cup from the outside without coming in direct contact with the solid concentrate. This Q-Cup™ technology provides significantly more efficiency and an “on the go” solution for consumers who prefer to vape concentrates either medicinally or recreationally. The Company acquired Mother Earth’s Storehouse on February 2022, which operates a two store organic and health food and vitamin chain in New York’s Hudson Valley, a business that has been operating for over 40 years.

COVID-19 Management Update

The global outbreak of COVID-19 was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020 and has negatively impacted the U.S. and global economies, disrupted global supply chains and, mandated closures and stay-at-home orders and created significant disruptions of the global financial markets. The Company adjusted certain aspects of the operations to protect their employees and customers while still meeting customers’ needs. While to date the Company has not been required to close any of its stores, the Company is currently operating under regular hours and we are expecting COVID-19 to have a long-term beneficial impact to the future financial results of the grocery segment. The Company continues to monitor the impact of the COVID-19 outbreak closely.  The extent to which the COVID-19 outbreak will impact our operations is manageable, and there is no imminent risk on business continuity and future operations.

Sourcing and Vendors

We source from multiple suppliers. These suppliers range from small independent businesses to multinational conglomerates. For the fiscal years ended December 31, 2021 and 2020, approximately 25% and 27% of our total purchases were from one vendor.

Basis of Presentation and Principles of Consolidation

The Company’s consolidated financial statements are prepared in accordance with GAAP. The consolidated financial statements include the accounts of all subsidiaries in which the Company holds a controlling financial interest as of the financial statement date.

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Healthy Choice Markets, Inc., Healthy Choice Markets 2, LLC (“Paradise Health and Nutrition”), Healthy Choice Markets 3, LLC (“Mother Earth’s Storehouse”), Healthy Choices Markets 3 Real Estate LLC, HCMC Intellectual Property Holdings, LLC, Healthy Choice Wellness, LLC, The Vitamin Store, LLC, Healthy U Wholesale, Inc., The Vape Store, Inc. (“Vape Store”), Vaporin, Inc. (“Vaporin”), Smoke Anywhere U.S.A., Inc. (“Smoke”), Emagine the Vape Store, LLC (“Emagine”), IVGI Acquisition, Inc., Vapormax Franchising LLC, Vaporin LLC, and Vaporin Florida, Inc. All intercompany accounts and transactions have been eliminated in consolidation.


F - 7


Note 2. LIQUIDITY

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of any uncertainties related to our going concern assessment. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values.

The Company incurred a loss from operations of approximately $4.7 million for the year ended December 31, 2021. As of December 31, 2021, cash and cash equivalents totaled approximately $26.5 million. Management anticipates that its current cash, cash equivalent and cash generated from operations will be sufficient to meet the projected operating expenses for the foreseeable future through at least the next twelve months from the issuance of these consolidated financial statements.

Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the operating decision makers, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company’s decision-making group are the senior executive management team. The Company and the decision-making group view the Company’s operations and manage its business as two operating segments. All long-lived assets of the Company reside in the U.S.

Use of Estimates in the Preparation of the Financial Statements

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting periods. Actual results could differ from those estimates. These estimates and assumptions include allowances, reserves and write-downs of inventory, valuing equity securities and hybrid instruments, share-based payment arrangements, deferred taxes and related valuation allowances, and the valuation of the assets and liabilities acquired in business combinations. Certain of management’s estimates could be affected by external conditions, including those unique to our industry, and general economic conditions. It is possible that these external factors could have an effect on our estimates that could cause actual results to differ from our estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary.

Revenue Recognition

Revenues from product sales and services rendered, net of promotional discounts, manufacturer coupons and rebates, return allowances, and sales and consumption taxes, are recorded when products are delivered, title passes to customers and collection is likely to occur. Title passes to customers at the point of sale for retail and upon delivery of products for wholesale. Return allowances, which reduce revenue, are estimated using historical experience.

The Company recognizes revenue in accordance with the following five-step model:

identify arrangements with customers;

identify performance obligations;

determine transaction price;

allocate transaction price to the separate performance obligations in the arrangement, if more than one exists; and

recognize revenue as performance obligations are satisfied.

Shipping and Handling

Shipping charges billed to customers are included in net sales and the related shipping and handling costs are included in cost of sales. For the years ended December 31, 2021 and 2020, shipping and handling costs of approximately $68,000 and $48,000, were included in cost of sales, respectively.



F - 8

Cash and Cash Equivalents

The Company considers all highly liquid instruments with an original maturity of three months or less, when purchased, to be cash and cash equivalents. The majority of the Company’s cash and cash equivalents are concentrated in one large financial institution, which is in excess of Federal Deposit Insurance Corporation (FDIC) coverage. At December 31, 2021, cash in excess of FDIC limits of $250,000 per financial institution were approximately $26.0 million. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests, as deposits are held in excess of federally insured limits. The Company’s cash equivalent at December 31, 2021 was a money market account. The Company has not experienced any losses in such accounts.

Accounts Receivable, Contract Assets and Contract Liabilities

Accounts receivables are claims to consideration which are unconditional; meaning no performance obligations remain for the Company and only the passage of time is necessary before collection. Contract assets are distinguished from accounts receivable as performance obligations remain before claims to consideration become unconditional. By nature of the Company’s operations, contract assets are typically not recognized. Contract liabilities are recorded when customers transfer consideration in advance of delivery of products or services, which the Company records for gift cards and loyalty reward programs. When one party to an arrangement performs before the other(s), the Company records an account receivable, contract asset or contract liability.

The majority of arrangements with customers contain one performance obligation: to provide a distinct set of products or services. Most performance obligations are satisfied simultaneously as the Company exchanges products or services for customer payment. Exceptions include gift cards and loyalty rewards, for which the Company has a performance obligation to deliver products or services at a future date. As gift cards are purchased and loyalty points earned, contract liabilities are recorded until the performance obligations are satisfied through delivery of products or services or breakage based on gift card and loyalty reward program term limits.

The Company’s breakage policy is twenty-four months for gift cards, twelve months for Grocery loyalty rewards, and six months for Vapor loyalty rewards. Loyalty rewards are earned at five percent on qualifying purchases and the reward functions as an allocation of transaction price from the period earned by the customer to the period the performance obligation is satisfied by the Company. As such, all contract liabilities are expected to be recognized within a twenty-four month period.

Concentration of accounts receivable consist of the following:

 
December 31, 2021
   
December 31, 2020
 
             
Customer A
   
30
%
   
0
%
Customer B
   
12
%
   
0
%
Customer C
   
0
%
   
34
%

Due from Merchant Credit Card Processor

Due from merchant credit card processor represents monies held by the Company’s credit card processors. The funds are being held by the merchant credit card processors pending satisfaction of their hold requirements and expiration of charge backs/refunds from customers.

Inventories

Inventories are stated at average cost. If the cost of the inventories exceeds their net realizable value, adjustments are recorded to write down excess inventory to their net realizable value. The Company’s inventories consist primarily of merchandise available for resale, such as vaporizers, electronic cigarettes, e-liquids, fresh produce, perishable grocery items and non-perishable consumable goods.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the expected useful life of the respective asset, after the asset is placed in service. Revenue earning property and equipment includes signage, furniture and fixtures, computer hardware, appliance, cooler, displays with useful lives range from two to seven years. Leasehold improvements are amortized over life of lease.



F - 9

Identifiable Intangible Assets and Goodwill

Identifiable intangible assets are recorded at cost, or when acquired as part of a business acquisition, at estimated fair value. Certain identifiable intangible assets are amortized over 4 and 10 years. Similar to tangible personal property and equipment, the Company periodically evaluates identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Indefinite-lived intangible assets, such as goodwill are not amortized.

Impairment of Long-Lived Assets

The Company reviews all long-lived assets such as property and equipment and amortized intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future cash flows expected to be generated by the asset or asset group. Impairment is measured by the amount by which the carrying value of the asset(s) exceeds their fair value. There were no triggering events that would indicate impairment of long-lived assets at December 31, 2021. For the year ended December 31, 2020, the Company determined the estimated undiscounted cash flows related to the sales of the VitaminStore.com were less than the carrying value of the intangible assets and recorded an impairment charge of $0.3 million.

Goodwill

The Company assesses the carrying amounts of goodwill for recoverability on at least an annual basis or when events or changes in circumstances indicate evidence of potential impairment exists, using a fair value based test. Application of the goodwill impairment test requires significant judgments including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the businesses, and the useful life over which cash flows will occur. Changes in these estimates and assumptions could materially affect the determination of fair value and/or conclusions on goodwill impairment for the Company. Our annual impairment test is conducted on September 30 of each year or more often if deemed necessary. As part of management's qualitative analysis at December 31, 2021 management determines whether any triggering events have occurred since the annual test date of September 30, 2021, which would indicate an impairment. Management determined no triggering events had occurred through December 31, 2021. The Company recorded an impairment charge of $40,000 for the year ended December 31, 2020.

Advertising

The Company expenses advertising costs as incurred. For the years ended December 31, 2021 and 2020, the company incurred advertising expenses of $43,000 and $92,000, respectively.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021 or December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

Stock-Based Compensation

The Company accounts for stock-based compensation for employees and directors under ASC Topic No. 718, “Compensation-Stock Compensation” (“ASC 718”). These standards define a fair value based method of accounting for stock-based compensation. In accordance with ASC 718, the cost of stock-based compensation is measured at the grant date based on the value of the award and is recognized over the vesting period. The value of the stock-based award is determined using an appropriate valuation model, whereby compensation cost is the fair value of the award as determined by the valuation model at the grant date. The resulting amount is charged to expense on the straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period. The Company recognize forfeitures as they are incur. Stock-based compensation for non-employees is measured at the grant date, is re-measured at subsequent vesting dates and reporting dates, and is amortized over the service period.



F - 10

Fair Value Measurements

The fair value framework under FASB’s guidance requires the categorization of assets and liabilities into three levels based upon the assumptions used to measure the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3, if applicable, would generally require significant management judgment. The three levels for categorizing assets and liabilities under the fair value measurement requirements are as follows:

Level 1: Fair value measurement of the asset or liability using observable inputs such as quoted prices in active markets for identical assets or liabilities;

Level 2: Fair value measurement of the asset or liability using inputs other than quoted prices that are observable for the applicable asset or liability, either directly or indirectly, such as quoted prices for similar (as opposed to identical) assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and

Level 3: Fair value measurement of the asset or liability using unobservable inputs that reflect the Company’s own assumptions regarding the applicable asset or liability.

Nonfinancial assets such as goodwill, other intangible assets, and long-lived assets held and used are measured at fair value when there is an indicator of impairment and recorded at fair value when impairment is recognized or for a business combination.

Sequencing Policy

Under ASC 815-40-35, the Company has adopted a sequencing policy, whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares.

Note 4. DISAGGREGATION OF REVENUES

The Company reports the following segments in accordance with management guidance: Vapor and Grocery. When the Company prepares its internal management reporting to evaluate business performance, we disaggregate revenue into the following categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 
December 31, 2021
   
December 31, 2020
 
             
Vapor sales, net
 
$
2,084,813
   
$
2,458,945
 
Grocery sales, net
   
11,235,041
     
11,461,800
 
Total revenue
 
$
13,319,854
   
$
13,920,745
 
                 
Retail Vapor
 
$
2,084,744
   
$
2,458,945
 
Retail Grocery
   
9,923,137
     
10,047,437
 
Food service/restaurant
   
1,202,122
     
1,088,162
 
Online/e-Commerce
   
93,600
     
307,487
 
Wholesale Grocery
   
16,182
     
18,714
 
Wholesale Vapor
   
69
     
-
 
Total revenue
 
$
13,319,854
   
$
13,920,745
 



F - 11


Note 5. INVESTMENT

In 2018, the Company invested $150,000 in 85,714 common stock shares at MJ Holdings, Inc. (“MJNE”), a publicly traded company. The investment was made based on the assumption of an increase in MJNE stock due to the sales agreement with the Company. The Company recorded the investment in MJNE at fair value with changes in the fair value reported through the income statement as the stock is traded on the OTC market. Investment is classed with Level 1 of the valuation hierarchy. Fair value for the investment is based on quoted prices in active markets.

The following table summarizes the investment measured at fair value on a recurring basis as of December 31, 2021:

Description
Fair Value Measurements Using Quoted Prices in Active Market (Level 1)
 
Mark to Market
 
December 31, 2021
 
Investment
 
$
22,731
   
$
412
   
$
23,143
 

The following table summarizes the investment measured at fair value on a recurring basis as of December 31, 2020:

Description
Fair Value Measurements Using Quoted Prices in Active Market (Level 1)
 
Mark to Market
 
December 31, 2021
 
Investment
 
$
24,000
   
$
(1,269
)
 
$
22,731
 

Note 6. INVENTORIES

Inventories are stated at average cost. If the cost of the inventories exceeds their market value, adjustments are recorded to write down excess inventory to its net realizable value. Throughout the year, the Company did not have independent third party counts of its inventory due to the Coronavirus (COVID-19) pandemic and recorded the write down of inventories amounting to $0.7 million and $0.3 million, approximately, in 2021 and 2020, respectively. The Company’s inventories consist primarily of merchandise available for resale.

 
December 31, 2021
   
December 31, 2020
 
             
Vapor Business
 
$
188,793
   
$
304,614
 
Grocery Business
   
1,332,406
     
1,444,632
 
Total
 
$
1,521,199
   
$
1,749,246
 

Note 7. NOTES RECEIVABLE AND OTHER INCOME

On September 6, 2018, the Company entered into a secured, 36-month promissory note with VPR Brands L.P. for $582,260. The Note bears an interest rate of 7%, which payments thereunder are $4,141 weekly. The Company records all proceeds related to the interest of the Note as interest income as proceeds are received.

On August 31, 2021, the Company amended and restated the Secured Promissory Note (the "Note") with VPRB Brands L.P. for the outstanding balance in the note of $268,126. The Note bears an interest rate of 7%, which payments thereunder are $1,500 weekly, with such payments commencing as of September 03, 2021. The Note has a balloon payment of $213,028 for all remaining accrued interest and principal balance due in the final week of the 1-year extension of the Note.

A summary of the Note as of December 31, 2021 and 2020 is presented below:

 
December 31,
 
Description
2021
 
2020
 
Promissory Note
 
$
247,915
   
$
304,511
 

For the years ended December 31, 2021 and 2020, the Company had notes receivable collections of approximately $57,000 and $39,000, respectively. These collections are recorded to other income in the Consolidated Statement of Operations.


F - 12


Note 8. PROPERTY & EQUIPMENT

Property and equipment consists of the following

 
Year Ended December 31,
 
   
2021
   
2020
 
             
Displays
 
$
305,558
   
$
305,558
 
Furniture and fixtures
   
246,496
     
246,496
 
Leasehold improvements
   
136,504
     
128,004
 
Computer hardware & equipment
   
151,924
     
143,082
 
Other
   
315,788
     
276,711
 
     
1,156,270
     
1,099,851
 
Less: accumulated depreciation and amortization
   
(979,282
)
   
(869,132
)
Total property and equipment
 
$
176,988
   
$
230,719
 

The Company incurred approximately $0.1 million and $0.1 million of depreciation expense for the years ended December 31, 2021 and 2020, respectively.

Note 9. GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows:

 
December 31, 2021
   
December 31, 2020
 
             
Beginning balance
 
$
916,000
   
$
956,000
 
Impairment of goodwill-retail business
   
-
     
(40,000
)
Ending balance
 
$
916,000
   
$
916,000
 

Intangible assets, net are as follows:

December 31, 2021
Useful Lives (Years)
 
Gross Carrying Amount
   
Accumulated Amortization
   
Net Carrying Amount
 
Customer relationships
4-5 years
 
$
883,000
   
$
(685,823
)
 
$
197,177
 
Trade names
8-10 years
   
923,000
     
(536,661
)
   
386,339
 
Patents
10 years
   
372,165
     
(122,233
)
   
249,932
 
Non-compete
4 years
   
238,000
     
(133,646
)
   
104,354
 
Website
4 years
   
10,000
     
(209
)
   
9,791
 
Intangible assets, net
   
$
2,426,165
   
$
(1,478,572
)
 
$
947,593
 

December 31, 2020
Useful Lives (Years)
 
Gross Carrying Amount
   
Accumulated Amortization
   
Net Carrying Amount
 
Customer relationships
4-10 years
 
$
883,000
   
$
(475,073
)
 
$
407,927
 
Trade names
8-10 years
   
923,000
     
(441,786
)
   
481,214
 
Patents
10 years
   
359,665
     
(85,641
)
   
274,024
 
Non-compete
4 years
   
174,000
     
(88,813
)
   
85,187
 
Intangible assets, net
   
$
2,339,665
   
$
(1,091,313
)
 
$
1,248,352
 

Amortization expense was approximately $0.4 million for the years ended December 31, 2021 and 2020.

Acquisition of EIR Hydration

On November 30, 2021, the Company, through its wholly owned subsidiary, Healthy Choice Wellness Center, LLP, acquired EIR Hydration, an IV therapy center located in Roslyn Heights, NY. The cost of the transaction was $75,000 and it was treated as an asset purchase.


F - 13

The weighted-average remaining amortization period of the Company’s amortizable intangible assets is approximately 6 years as of December 31, 2021. The estimated future amortization of the intangible assets is as follows:

For the years ending December 31,
     
2022
 
$
389,456
 
2023
   
150,591
 
2024
   
150,591
 
2025
   
143,549
 
2026
   
48,655
 
Thereafter
   
64,751
 
Total
 
$
947,593
 

Note 10. CONTRACT LIABILITIES

The Company’s contract liabilities consist of customer deposits, gift cards and loyalty rewards, for which the Company has a performance obligation to deliver products when customers redeem balances or terms expire through breakage. The Company’s breakage policy is twenty-four months for gift cards, twelve months for Grocery loyalty rewards, and six months for Vapor loyalty rewards. As such, all contract liabilities are expected to be recognized within a twenty-four month period.

A summary of the contract liabilities activity for the years ended December 31, 2021 and 2020 is presented below:

 
Year ended December 31,
 
   
2021
   
2020
 
Beginning balance as of January1,
 
$
21,262
   
$
26,823
 
Issued
   
39,469
     
53,929
 
Redeemed
   
(37,463
)
   
(58,263
)
Breakage recognized
   
(90
)
   
(1,227
)
Ending balance as of December 31,
 
$
23,178
   
$
21,262
 

Note 11. LINE OF CREDIT AND DEBT

The following table provides a breakdown of the Company's debt as of December 31, 2021 and 2020 is presented below:

 
December 31,
 
2021
 
2020
Line of Credit
$
418,036
 
$
2,000,000
Term Loan Credit Agreement
 
-
   
800,924
Paycheck Protection Program
 
-
   
882,264
Loan and Security Agreement ("PPE Loan")
 
-
   
1,232,414
Other debt
 
3,419
   
5,891
Total Line of Credit and Debt
$
421,455
 
$
4,921,493

Revolving Line of Credit

On November 3, 2021, the Company entered into an agreement for a new revolving line of credit of $2.0 million and a blocked/restricted deposit account (“blocked account”) with Professional Bank in Coral Gables, Florida. The agreement included a variable interest rate that it is based on a rate of 1.0% over what is earned on the collateral account. Based on the agreement with the bank, each draw request from the credit line will be 100% cash secured with moneys held from the blocked account.

Term Loan Credit Agreement

On December 31, 2018, the Company entered into a Term Loan Credit Agreement (the “Credit Agreement”) with Professional Bank, a Florida banking corporation (the “Bank”), pursuant to which the Company issued a Term Note (the “Term Note”) in the principal amount of $1,400,000 in favor of the Bank. The Term Note bears interest at a rate equal to 1.5 percentage points in excess of that rate shown in the Wall Street Journal as the prime rate, adjusted annually (which was 5.50% as of December 31, 2020 and 2021). The proceeds of the Term Note were used for acquisitions and for general working capital requirements.

On December 21, 2021, the Company paid in full the outstanding balance of $410,000 from the Term Loan.

Paycheck Protection Program

On May 15, 2020, the Company was granted a loan (the “Loan”) from Customers Bank, in the aggregate amount of $876,515, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020.

The Loan, which was in the form of a Note dated May 6, 2020 issued by the Company, matures on May 6, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 6, 2020. Note may be prepaid by the Borrower at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, costs used to continue group health care benefits, mortgage payments, rent, utilities, and interest on other debt obligations incurred after May 6, 2020. The Company intends to use the entire Loan amount for these qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. On December 9, 2020, the Company submitted the forgiveness application for the PPP Loan to the Small Business Bureau.

On May 3, 2021, the Company received a letter from Customers Bank to inform the Company that the PPP Loan was paid and fully forgiven by the Small Business Administration (SBA). The forgiveness of $885,227 was reported in gain on debt settlements on the consolidated statements of operations.


F - 14


Note 12. COMMITMENTS AND CONTINGENCIES

Employment Agreements 
 
On August 13, 2018, the Company amended and restated its existing employment agreement with Jeffrey Holman, the Company’s Chief Executive Officer (the “Holman Employment Agreement”). The Holman Employment Agreement is for an additional three year term and provides for an annual base salary of $450 and a target bonus for 2020 only in an amount ranging from 20% to 200% of his base salaries subject to the Company meeting certain earnings before interest, taxes depreciation and amortization performance milestones. Mr. Holman is entitled to receive severance payments, including two years of his then base salary and other benefits in the event of a change of control, termination by the Company without cause, termination for good reason by the executive or non-renewal by the Company. Mr. Holman was also granted 11 billion shares of restricted common stock pursuant to the Holman Employment Agreement Amendment on the condition that 11 billion of his options to purchase Company common stock are forfeited. This restricted stock will vest one year following the date of issuance provided that the grantee remains an employee of the Company through each applicable vesting date. On August 12, 2019, the Company agreed to extend the expiration date of the vesting period for the restricted stock by six months to February 13, 2020. On August 12, 2020, the Company agreed to extend for a second time the expiration date of the vesting period for the restricted stock by six months to February 13, 2021. The Term shall be automatically renewed for successive one-year terms unless notice of non-renewal is given by either party at least 30 days before the end of the Term. The above description of the terms of the Holman Employment Agreement is not complete and is qualified by reference to the complete document.

On February 26, 2021, the Company entered into an amended and restated employment agreement (the “Employment Agreement Amendment”) with the Company’s President and Chief Operating Officer, Christopher Santi. Pursuant to the Employment Agreement Amendment, Mr. Santi will continue to be employed as the Company’s President and Chief Operating Officer through January 30, 2024.  Mr. Santi will receive a base salary of $0.4 million for 2021 and his salary will increase 10% in each subsequent year. The Term shall be automatically renewed for successive one-year terms unless notice of non-renewal is given by either party at least 30 days before the end of the Term. The above description of the terms of the Santi Employment Agreement is not complete and is qualified by reference to the complete document.

Legal Proceedings

Two lawsuits were filed against the Company and its subsidiaries in connection with alleged claimed battery defects for an electronic cigarette device. Plaintiffs claim these batteries were sold by a store of the Company’s subsidiary and have sued for an undetermined amount of damages (other than a total of $0.4 million of medical costs). The initial complaints were filed between January 2019 and April 2019. We responded to the complaints on April 2019 and May 2019, respectively. Given the lack of information presented by the plaintiffs to date, the Company is unable to predict the outcome of these matters and, at this time, cannot reasonably estimate the possible loss or range of loss with respect to these legal proceedings.

On November 30, 2020, the Company filed a patent infringement lawsuit against Philip Morris USA, Inc. and Philip Morris Products S.A. in the U.S. District Court for the Northern District of Georgia.  The lawsuit alleges infringement on HCMC-owned patent(s) by the Philip Morris product known and marketed as “IQOS®”.  Philip Morris claims that it is currently approaching 14 million users of its IQOS® product and has reportedly invested over $3 billion in their smokeless tobacco products. On December 3, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A.  On December 14, 2021, the Company filed an appeal of the District Court for the Northern District of Georgia’s dismissal of the Company’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. HCMC believes the Georgia Court committed legal error by dismissing its complaint for patent infringement and also by denying the Company’s motion to amend its pleading.

From time to time the Company is involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations December 31, 2021. With respect to legal costs, we record such costs as incurred.

Fontem License Agreement

The Company has a non-exclusive license to certain products with Fontem Ventures B.V. (“Fontem”). The Company will make quarterly license and royalty payments in perpetuity to Fontem, based on the sale of qualifying products as defined in the license agreement at a royalty rate of 5.25%. For the years ended December 31, 2021 and 2020, the Company recorded expenses of $12,000 and $15,000 as part of its cost of goods.


F - 15


Note 13. STOCKHOLDERS’ EQUITY

Equity Compensation Plans

The Company’s 2015 Equity Incentive Plan, as amended (the “2015 Plan”), awards grants to employees. The plan can award up to 100 billion shares of common stock and currently 10.3 billion shares are available for grant as of December 31, 2021.

The Company’s 2009 Equity Incentive Plan (the “2009 Plan”) awards grants to employees, non-employee directors and consultants in connection with their retention and/or continued employment by the Company. The 2009 Plan had no shares of common stock available for grant as of December 31, 2021.

Rights Offering

On June 18, 2021, the Company issued 27,046,800,310 shares of common stock in connection with the Rights Offering at a subscription price of $0.0010 per share, generating gross proceeds of $27.0 million. The Company incurred direct financing costs of $2.7 million in connection with the offering resulting in net proceeds to the Company of $24.3 million.

Exchange Agreement

On March 29, 2021, the Company entered into exchange agreements with the holders of the $2.7 million Loan and Security Agreement (the "Credit Agreement"). The agreement with the holders of the Company’s indebtedness (the “Notes”) in an aggregate amount of $1.3 million to exchange the Notes for 1,172,964,218 shares at a conversion price of $0.0011. The Notes were issued pursuant to the Credit Agreement dated as of August 18, 2020, among The Vape Store, Inc., the Company, Healthy Choice Markets, Inc., Sabby Healthcare Master Fund, Ltd., and Sabby Volatility Warrant Master Fund, Ltd.  In connection with the Exchange, the Credit Agreement and all related loan documents was terminated and the Holder’s on the assets of the Company and its subsidiaries was cancelled.  The Company recognized a loss on debt extinguishment of $0.1 million for the year ended December 31, 2021.

Preferred Stock

The Company’s amended and restated articles of incorporation authorizes the Company’s Board of Directors to issue up to 1,000,000 shares of “blank check” preferred stock, having a $0.001 par value, in one or more series without stockholder approval. Each such series of preferred stock may have such number of shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges as determined by the Company’s Board of Directors. See below for details associated with the designation of the 1,000,000 shares of the Series A preferred stock.

Series C Convertible Preferred Stock

On November 17, 2020, the Company finalized the closing of the stock exchange with certain holders of its Series B Stock to exchange all the Series B Stock for 20,150 shares of Series C Convertible Preferred Stock (the “Series C Stock”). Each share of Series C Stock has a stated value equal to $1,000 and is convertible into Common Stock on a fixed basis at a conversion price of $0.0001 per share.

During the years ended December 31, 2021 and 2020, the Company issued 162.8 billion shares and 38.7 billion shares of Company common stock in connection with the exercise of Series C stock.




F - 16

Series D Convertible Preferred Stock

On February 7, 2021, the Company entered into a Securities Purchase Agreement, pursuant to which the Company sold and issued 5,000 shares of its Series D Convertible Preferred Stock (the “Preferred Stock”) to accredited investors for $1,000 per share or an aggregate subscription of $5.0 million. As of December 31, 2021, the Company has issued 6.6 billion shares of Company common stock in connection with the exercise of 4,200 shares of the Series D Convertible Preferred Stock at a conversion price of $0.00064 per share. The conversion price for the exercise of the preferred stock was reset to the 80% of the lowest daily volume-weighted average price ("VWAP") during the 5 Trading Days immediately preceding the effective date of August 11, 2021.

Warrants

October 5, 2016, the Company’s amended and restated its Series A Warrant Standstill Agreements (the "Amended Standstill Agreements") to permit each holder (each, a "Holder") to effect a "cashless" exercise of the Series A Warrants only on dates when the closing bid price used to determine the "net number" of shares to be issued upon exercise is at or above $0.00. The shares issuable upon the exercise of the Series A Warrants are calculated (1) using a Black Scholes Value of 1,517,936 per share and a closing stock bid price at or above 0.00 and (2) the Company will deliver only common stock upon exercise of the Series A Warrants.

On July 27, 2020, the Company's Series A Warrants expired and the balance of outstanding warrants not exercised was 355,661 warrants.

During the year ended December 31, 2020, the Company issued 3,466,153 shares of the Company Common Stock in connection with the exercise of the Series A Warrant.

Modification of share-based payment awards to officers

On August 13, 2018, the Compensation Committee of the Company approved a modification of share-based payment awards to the Chief Executive Officer and Chief Operating Officer of the Company. As part of the share modification, the Chief Executive Officer and Chief Operating Officer were granted 11 billion and 8 billion shares of restricted common stock on the condition that the same number of shares from their options to purchase the Company’s common stock are forfeited. However, the shares were issued to the officers and have been reflected in the statement of stockholders’ equity. Initially, this restricted stock was schedule to vest one year following the date of issuance provided that the grantee remains an employee of the Company through the vesting date.

On August 12, 2019, the Company agreed to extend the expiration date of the vesting period for the restricted stock by six months to February 13, 2020.

On August 12, 2020, the Company agreed to extend for a second time the expiration date of the vesting period for the restricted stock by six months to February 13, 2021.

On January 14, 2021, the Compensation Committee of the Company approved an issuance of restricted stock to the Officers and a Director of the Company, in consideration for agreeing to a new vesting schedule for the existing awarded restricted stock. Each individual was granted a 10% increase from the original award agreement for a total of 2.3 billion shares of restricted common stock, which will vest quarterly in equal amounts until December 31, 2022, provided that the grantee remains an employee of the Company through the vesting date.

Restricted Stock

On August 13, 2018, the Compensation Committee of the Company approved an issuance of restricted stock to the Chief Financial Officer (the "Officer") of the Company. The Officer was granted 3 billion shares of restricted common stock, which will vest one year following the date of issuance, provided that the grantee remains an employee of the Company through the vesting date.

On August 12, 2019, the Company agreed to extend the expiration date of the vesting period for the restricted stock by six months to February 13, 2020.

On August 12, 2020, the Company agreed to extend for a second time the expiration date of the vesting period for the restricted stock by six months to February 13, 2021.

On January 14, 2021, the Compensation Committee of the Company approved an issuance of restricted stock to the Officers and a Director of the Company, in consideration for agreeing to a new vesting schedule for the existing awarded restricted stock. Each individual was granted a 10% increase from the original award agreement for a total of 2.3 billion shares of restricted common stock, which will vest quarterly in equal amounts until December 31, 2022, provided that the grantee remains an employee of the Company through the vesting date.

On March 30, 2021, the Company and the Officers and a Director of the Company agreed to forfeit a total of 3.09 billion of restricted shares of common stock that were due to vest on March 31, 2021.

On June 29, 2021, the Company and the Officers and a Director of the Company agreed to forfeit a total of 3.09 billion of restricted shares of common stock that were due to vest on June 30, 2021.


F - 17


Stock Options

During the years ended December 31, 2021 and 2020, the Company did not grant any options for the purchase of shares of its common stocks.

A summary of option activity during the years ended December 31, 2021 and 2020 is as follows:

 
Number of Options
   
Weighted Average
Exercise
Price
   
Weighted Average Remaining Term (Yrs.)
   
Aggregate Intrinsic Value
 
                         
Outstanding, January 1, 2020
   
69,862,230,680
   
$
0.00
     
7
   
$
-
 
Options granted
   
-
     
0.00
             
-
 
Options forfeited or expired
   
-
     
0.00
             
-
 
Outstanding, December 31, 2020
   
69,862,230,680
   
$
0.00
     
6
   
$
-
 
Options granted
   
-
     
0.00
             
-
 
Options exercised
   
(2,275,000,000
)
   
0.00
             
-
 
Options forfeited or expired
   
-
     
0.00
             
-
 
Outstanding, December 31, 2021
   
67,587,230,680
   
$
0.00
     
5
     
-
 
Exercisable at December 31, 2021
   
67,587,230,680
   
$
0.00
     
5
   
$
-
 

During the years ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense of approximately $34,375 and $78,029, respectively, in connection with the amortization of stock options, net of recovery of stock-based charges for forfeited stock options. Stock-based compensation expense is included as part of selling, general and administrative expense in the accompanying consolidated statements of operations.

Income (Loss) per Share

Basic income (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon (a) the exercise of stock options (using the treasury stock method); (b) the conversion of Series A convertible preferred stock; (c) the exercise of warrants (using the if-converted method); (d) the vesting of restricted stock units; and (e) the conversion of convertible notes payable. Diluted income (loss) per share excludes the potential common shares, as their effect is antidilutive. The following table summarizes the Company’s securities that have been excluded from the calculation of basic and dilutive income (loss) per share as their effect would be anti-dilutive:

 
December 31,
 
   
2021
   
2020
 
             
Preferred stock
   
1,250,000,000
     
162,771,153,000
 
Stock options
   
67,587,230,680
     
69,862,230,680
 
Total
   
68,837,230,680
     
232,633,383,680
 



F - 18


Note 14. LEASE

The Company has various lease agreements with terms up to 20 years, including leases of retail stores, headquarter and equipment. All the leases are classified as operating leases.

The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of December 31, 2021.

Maturity of Lease Liabilities by Fiscal Year
     
2022
 
$
572,335
 
2023
   
450,877
 
2024
   
342,005
 
2025
   
337,685
 
2026
   
267,759
 
Thereafter
   
1,941,250
 
Total undiscounted operating lease payments
 
$
3,911,911
 
Less: Imputed interest
   
(789,562
)
Present value of operating lease liabilities
 
$
3,122,349
 

The following summarizes the Company's operating leases:

Balance Sheet Classification
 
December 31, 2021
   
December 31, 2020
 
Right of use asset
 
$
3,543,930
   
$
4,078,621
 
                 
Operating lease liability, current
 
$
437,328
   
$
474,686
 
Operating lease liability, net of current
   
2,685,021
     
3,114,521
 
Total operating lease liabilities
 
$
3,122,349
   
$
3,589,207
 

The amortization of the right-of-use asset of $534,691 was included in operating cash flows.

Other Information
     
Weighted-average remaining lease term for operating leases
 
10 years
 
Weighted-average discount rate for operating leases
   
4.74
%

Rent expense for the years ended December 31, 2021 and 2020 was approximately $0.9 million and $1.0 million, respectively, is included in selling, general and administrative expenses in the accompanying consolidated statement of operations.

The following table represents the components of lease cost are as follows for twelve months ended December 31, 2021:

 
December 31, 2021
 
Operating lease cost
 
$
389,538
 
Variable lease cost
   
372,608
 
Short-term lease cost
   
139,291
 
Total rent expense
 
$
901,437
 

The aggregate cash payments under the leasing arrangement was approximately $467,000 for the year ended December 31, 2021 and was included in operating cash flows.



F - 19


Note 15. INCOME TAXES

The Company did not have a provision for income taxes (current or deferred tax expense) for tax years ended December 31, 2021 and 2020. The following is a reconciliation of the expected tax expense (benefit) at the U.S. statutory rate to the actual tax expense (benefit) reflected in the accompanying statement of operations:

 
Year Ended December 31,
 
   
2021
   
2020
 
             
U.S. federal statutory rate
 
$
(847,867
)
 
$
(781,704
)
State and local taxes, net of federal benefit
   
(111,900
)
   
(132,291
)
Change in valuation allowance
   
734,615
     
1,201,450
 
True-up & deferred adjustment
   
11,441
     
23,614
 
Stock based compensation
   
8,171
     
19,159
 
Forgiveness of PPP loan
   
(210,432
)
   
-
 
Other permanent items
   
-
     
935
 
Change in tax rate
   
89,360
     
2,429
 
Expired warrants
   
-
     
(422,655
)
Other
   
326,612
     
89,063
 
   
$
-
   
$
-
 

As of December 31, 2021 and 2020, the Company’s deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following:

 
Year Ended December 31,
 
   
2021
   
2020
 
Deferred tax assets:
           
Net operating losses
 
$
14,136,491
   
$
13,366,483
 
Inventory reserves and allowances
   
30,156
     
31,249
 
Accrued Expenses and Deferred Income
   
136,686
     
45,358
 
Charitable contribution
   
5,134
     
5,303
 
Stock based compensation
   
1,903,413
     
1,966,058
 
Net book value of fixed assets
   
1,961
     
6,574
 
Net book value of intangible assets
   
671,954
     
731,365
 
ASC 842 - Lease Accounting
   
33,891
     
32,681
 
Total deferred tax assets
   
16,919,686
     
16,185,071
 
                 
Net deferred tax assets
   
16,919,686
     
16,185,071
 
Valuation allowance
   
(16,919,686
)
   
(16,185,071
)
Net deferred tax assets
 
$
-
   
$
-
 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the positive and negative evidence available, management has determined that a valuation allowance is required at December 31, 2021 and 2020 to reduce the deferred tax assets to amounts that are more likely than not to be realized. The Company’s valuation increased by $734,615 and $1,201,450 for the tax years ended 2021 and 2020, respectively. Should the factors underlying management’s analysis change, future valuation adjustments to the Company’s net deferred tax assets may be necessary.

At December 31, 2021 the Company had U.S. federal and state net operating loss carryforwards (“NOLS”) of 61.0 million and 46.6 million, respectively. Federal NOLs of $46.3 million expire beginning in 2032 through 2037 and $14.7 million do not expire and are subject to 80% of taxable income under Internal Revenue Code Section 172. State NOLs of $35.4 million expire beginning in 2032 through 2037 and $11.2 million do not expire and maybe subject to income limitations under each State statute. Utilization of our NOLS may be subject to an annual limitation under section 382 and similar state provisions of the Internal Revenue Code due to changes of ownership that may have occurred or that could occur in the future, as defined under the regulations.



F - 20

On March 27, 2020, the CARES Act was enacted in response to COVID-19 pandemic, which, among other things, outlines the provisions of the Paycheck Protection Program (the “PPP”). The Company determined that it met the criteria to be eligible to obtain a loan under the PPP because, among other reasons, in light of the COVID-19 outbreak and the uncertainty of economic conditions related thereto, the loan was considered necessary to support the Company’s ongoing operations and retain all its employees. Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of loan granted under the program. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The Company submitted its application for 100% loan forgiveness and in May 2021 the loan was 100% forgiven by the SBA. As a result, the Company recorded a gain on the forgiveness of the loan in the amount of $885,226.

The Company files a federal income tax return and income tax returns in various state tax jurisdictions and the Company is generally no longer subject examinations by federal and state tax authorities for years before 2018.

Note 16. SEGMENT INFORMATION

Management determines the reportable segments based on the internal reporting used by our executives to evaluate performance and to assess where to allocate resources. The Company evaluates segment performance based on the segment gross profit before corporate expenses.

Summarized below are the total net sales and segment operating profit for each reporting segment:

 
Year Ended
 
   
Net Sales
   
Segment Gross Profit
 
   
December 31, 2021
   
December 31, 2020
   
December 31, 2021
   
December 31, 2020
 
Vapor
 
$
2,084,813
   
$
2,458,945
   
$
1,245,214
   
$
1,425,140
 
Grocery
   
11,235,041
     
11,461,800
     
4,047,340
     
4,352,081
 
Total
 
$
13,319,854
   
$
13,920,745
     
5,292,554
     
5,777,221
 
Corporate expenses
                   
10,033,048
     
9,225,593
 
Operating loss
                   
(4,740,494
)
   
(3,448,372
)
Corporate other income (expense), net
                   
703,035
     
(274,020
)
Net loss
                   
(4,037,459
)
   
(3,722,392
)

For the year ended December 31, 2021 depreciation and amortization was approximately $1,000 and $0.5 million for Vapor and Grocery, respectively.

For the year ended December 31, 2020 depreciation and amortization was approximately $10,000 and $0.5 million for Vapor and Grocery, respectively.

Note 17. SUBSEQUENT EVENTS

Acquisition of Mother Earth's Storehouse

On February 8, 2022, the Company through its wholly owned subsidiary, Healthy Choice Markets 3, LLC, entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Mother Earth’s Storehouse Inc. (“HCM3”) and its shareholders.  Pursuant to the Purchase Agreement, HCM3 acquired certain assets and assume certain liabilities related to Mother Earth’s grocery stores in Kingston and Saugerties, New York.  The Company intends to continue to operate the grocery stores under their existing name.  The cash purchase price under the Purchase Agreement is approximately $3.9 million, with an additional $677,500 paid for inventory at closing.  In addition, the Company assumed a lease obligation for the Kingston, NY store and entered into an employment agreement with the store manager.

In connection with the HCM3 acquisition of the assets of Mother Earth's, a wholly owned subsidiary of HCMC acquired for approximately $575,000 the historic building that houses the Saugerties, NY store.

John Ollet Employment Agreement

On February 02, 2022, the Company entered into a Second Amended and Restated Employment Agreement (the “Employment Agreement Amendment”) with the Company’s Chief Financial Officer, John Ollet.  Pursuant to the Employment Agreement Amendment, Mr. Ollet will continue to be employed as the Company’s Chief Financial Officer through February 14, 2025.  Mr. Ollet will receive a base salary of $300,000 for 2022 and his salary will increase 10% in each subsequent calendar year.

Patent infringement litigation

On December 31, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. In connection with such dismissal, the defendants sought to recover attorney’s fees from the Plaintiff. On February 22, 2022, the District Court for the Northern District of Georgia granted the defendant’s an award of approximately $575,000 in attorneys’ fees to be paid by the Company. The Company has fully provisioned this amount as of December 31, 2021.


F - 21


EXHIBIT INDEX

Exhibit
     
Incorporated by Reference
 
Filed or Furnished
No.
 
Exhibit Description
 
Form
 
Date
 
Number
 
Herewith
                     
1.1
   
S-1
 
7/10/15
 
1.1
   
2.1(a)
   
8-K
 
5/23/16
 
2.1
   
2.1(b)
   
8-K
 
8/3/16
 
1.1
   
2.1(c)
   
8-K
 
11/21/18
 
2.1
   
2.1(d)
   
8-K
 
12/26/18
 
2.2
   
2.1(e)
   
8-K
 
2/8/22
 
2.1
   
2.1(f)
               
X
3.1
   
10-Q
 
11/16/15
 
3.1
   
3.1(a)
   
8-K
 
3/03/17
 
3.1
   
3.1(b)
   
S-1
 
7/10/15
 
3.2
   
3.1(c)
   
S-4
 
12/11/15
 
3.2
   
3.1(d)
   
8-K
 
2/2/16
 
3.1
   
3.1(e)
   
8-K
 
3/9/16
 
3.1
   
3.1(f)
   
8-K
 
6/1/16
 
3.1
   
3.1(g)
   
8-K
 
8/5/16
 
3.1
   
3.1(h)
   
8-K
 
2/4/21
 
3.1
   
3.1(i)
               
X
3.2
   
8-K
 
12/31/13
 
3.4
   
10.1
   
8-K
 
3/05/15
 
10.1
   
10.2*
   
S-1
 
6/01/15
 
10.28
   
10.3
   
8-K
 
6/25/15
 
10.4
   
10.4
   
8-K
 
6/25/15
 
10.5
   
10.9
               
X
10.10
               
X


28


Exhibit
     
Incorporated by Reference
 
Filed or Furnished
No.
 
Exhibit Description
 
Form
 
Date
 
Number
 
Herewith
10.11*
   
S-8
 
2/8/17
 
4.2
   
10.12*
   
8-K
 
8/20/18
 
10.4
   
10.13*
   
8-K
 
3/5/21
 
10.1
 
 X
10.14*
   
 10-K
 
 3/8/21
 
 10.12
 
   
10.15*
   
 10-K
 
 3/8/21
 
 10.13
   
10.16*
   
 10-K
 
 3/8/21
 
 10.14
   
10.17*
   
 10-K
 
 3/8/21
 
 10.15
   
10.18*
   
8-K
 
2/2/22
 
10.1
   
10.19*
   
8-K
 
8/20/18
 
10.3
   
16.1
   
8-K
 
4/28/17
 
16.1
   
21.1
               
X
23.1
               
Filed
31.1
               
Filed
31.2
               
Filed
32.1
               
Furnished**
101.INS
 
XBRL Instance Document
             
Filed
101.SCH
 
XBRL Taxonomy Extension Schema Document
             
Filed
101.CAL
 
XBRL Taxonomy Extension Calculation Link base Document
             
Filed
101.DEF
 
XBRL Taxonomy Extension Definition Link base Document
             
Filed
101.LAB
 
XBRL Taxonomy Extension Label Link base Document
             
Filed
101.PRE
 
XBRL Taxonomy Extension Presentation Link base Document
             
Filed

* Management contract or compensatory plan or arrangement.

** This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.

Copies of this report (including the financial statements) and any of the exhibits referred to above will be furnished at no cost to our stockholders who make a written request to our Corporate Secretary at 3800 North 28th Way, Hollywood, Florida 33020.


29


SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 31, 2022.

 
Healthier Choices Management Corp.
     
 
By:
/s/ Jeffrey Holman
   
Jeffrey Holman
   
Chief Executive Officer
   
(Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature
 
Title
 
Date
         
/s/ Jeffrey Holman
 
Principal Executive Officer
 
March 31, 2022
Jeffrey Holman
 
and Director
   
         
/s/ John A. Ollet
 
Chief Financial Officer
 
March 31, 2022
John A. Ollet
 
(Principal Financial and Accounting Officer)
   
         
/s/ Clifford J. Friedman
 
Director
 
March 31, 2022
Clifford J. Friedman
       
         
/s/ Anthony Panariello
 
Director
 
March 31, 2022
Anthony Panariello
       




30
EX-2.1 (F) 2 ex2_1-f.htm COMMERCIAL CONTRACT OF SALE - HCMC WITH MOTHER EARTH'S - 249 MAIN STREET SAUGERTIES NY  
Exhibit 2.1(f)
COMMERCIAL CONTRACT OF SALE

Contract of Sale (“Contract”) made as of  9th day of February, 2022

BETWEEN

Name: MOTHER EARTH’S STOREHOUSE, INC., a New York Corporation with offices located at 249 Main Street, Saugerties, NY 12477

EIN #: 14-1714086
hereinafter called “Sellers” and

Name: HEALTHY CHOICE MARKETS 3 REAL ESTATE LLC, a Florida limited liability company with offices located at 3800 N 28th Way, Hollywood, FL 33020

EIN# 87-4585533
hereinafter called “Purchasers”.

The parties hereby agree as follows:

1. Premises.
 Sellers shall sell and convey and Purchasers shall purchase the property, together with all buildings and improvements thereon (collectively the “Premises”) more fully described as:

Street Address: 249 Main Street, Saugerties, New York 12477

Deed Reference:  Ulster County Clerk Liber 2434 of Deeds at page 211
Tax Map Designation: SBL# 18.247-1-18.1 as more fully described in Schedule A attached hereto.
Together with Sellers’ ownership and rights, if any, to land lying in the bed of any street or highway, opened or proposed, adjoining the Premises to the center line thereof, including any right of Sellers to any unpaid award by reason of any taking by condemnation and/or for any damage to the Premises by reason of change of grade of any street or highway.  Sellers shall deliver at no additional cost to Purchasers, at Closing (as hereinafter defined), or thereafter, on demand, any documents that Purchasers may reasonably require for the conveyance of such title and the assignment and collection of such award or damages.
2. Personal Property.
 This sale also includes all fixtures and articles of personal property now attached or appurtenant to the Premises, unless specifically excluded below.  Sellers represents and warrants that at Closing they will be paid for and owned by Sellers, free and clear of all liens and encumbrances, except any existing mortgage to which this sale may be subject.  They include the “Assets and shall include all of
all in strictly “as is” condition.
Excluded from this sale are furniture and household furnishings not separately handled between the parties hereto.
3. Purchase Price.
The Purchase Price is Five Hundred Seventy-Five Thousand Dollars ($575,000.00).  There shall be no down payment upon the execution of this Contract and the parties agree  that entire Purchase Price shall be payable in full at Closing.  Notwithstanding the foregoing, Seller acknowledges receipt of payment from Purchaser of $100.00, as independent consideration for Seller entering into this Contract, and such independent consideration is non-refundable and is hereby earned by Seller but shall not be credited against the Purchase Price at Closing.
4. Water, pest, septic, and dye.
 This contract, and the Purchasers’ obligation to purchase pursuant thereto, shall be conditioned upon the subject premises having a water supply of good and potable quality, the premises being free from infestation by termites, carpenter ants, or any other insect or pest capable of inflicting material damage or destruction to the premises, the septic system being in good operating condition, and the premises being in sound structural condition.  Purchasers may within the Due Diligence Period as set forth in Paragraph 4 of Purchaser’s Rider, have the premises inspected at the Purchasers’ sole expense.  In the event that the inspections indicate the water to be unpotable, a condition of infestation, or structural defects in the premises, the Purchasers shall have the option of terminating this contract or of notifying the Sellers of the defect and requesting correction of the same.  Such notification shall be in writing to Sellers’ attorney.  Once Sellers is notified of such defect, Sellers shall correct the defect prior to closing at Sellers’ expense or the parties shall agree on an adjustment to the Purchase Price and Seller shall have no obligation to correct the defect prior to closing.
4(a)  Radon testing:  Purchasers may within the Due Diligence Period as set forth in Paragraph 4 of Purchaser’s Rider, at Purchaser’s cost and expense to have the premises inspected for the existence of radon.  In the event that radon is found to exist in excess of 4.0 pico-curies per liter, the Sellers may elect to remediate the radon condition at Sellers’ cost and expense, so as to reduce said condition to 4.0 pico-curies or less, in which event, Purchasers agree to consummate this transaction.  As an alternative to remediating the radon condition, the parties shall agree on an adjustment to the Purchase Price and thereafter Seller shall have no obligation to remediate the radon condition.
4(b).  Lead.  This contract is contingent upon a risk assessment or inspection of the property for the presence of lead-based paint and/or lead-based paint hazards. Purchasers may within the Due Diligence Period as set forth in Paragraph 4 of Purchaser’s Rider, at Purchaser’s cost and expense to have performed the risk assessment or inspection.(Intact lead-based paint that is in good condition is not necessarily a hazard.  See the EPA pamphlet Protect Your Family From Lead in Your Home for more information.) This contingency will terminate at the above predetermined deadline unless the Purchaser delivers to the Sellers a written contract addendum listing the specific existing deficiencies and corrections needed, together with a copy of the inspection and/or risk assessment report.  The Sellers may at the Sellers’ option, within ten days after the delivery of the addendum, elect in writing whether to correct the condition(s) prior to settlement.  If the Sellers will correct the condition, the Sellers shall furnish the Purchasers with certification from a risk assessor or inspector demonstrating that the condition has been remedied before the date of closing.  As an alternative to correcting the condition, the parties shall agree on an adjustment to the Purchase Price and thereafter Seller shall have no obligation to correct the lead based paint condition.
All testing listed in Paragraphs 4, 4(a), and 4(b) must be completed within the Due Diligence Period.  Purchasers must inform Sellers of any concern within the Due Diligence Period, otherwise Purchasers will accept property “as is”.
5. Acceptable Funds.
 All money payable under this contract, unless otherwise specified, shall be paid by:
(a)
Cash, but not over $1,000.00;
(b)
Good certified check of Purchasers drawn on or official check issued by any bank, savings bank, trust company or savings and loan association having a banking office in the State of New York, unendorsed and payable to the order of Sellers, or as Sellers may otherwise direct upon not less than 3 business days’ notice to Purchaser;
(c)
Wire transfer to Seller’s account or the account of the title company insuring title pursuant to wire instructions provided at least two (2) days prior to Closing;
(d)
As to money other than the purchase price payable to Sellers at Closing, uncertified check of Purchasers up to the amount of $1,000.00; and
(e)
As otherwise agreed to in writing by Sellers or Sellers’ attorney.
6. Permitted Exceptions.
  The Premises are sold and shall be conveyed subject to:
(a)
Zoning and subdivision laws and regulations, and landmark, historic or wetlands designation, provided that they are not violated by the existing buildings and improvements erected on the property or their use or prohibit the continued use of the Premises as now being used;
(b)
Consents for the erection of any structures on, under or above any streets on which the Premises abut provided same do not render title unmarketable;
(c)
De minimis encroachments of stoops, areas, cellar steps, trim and cornices, if any, upon any street or highway;
(d)
Real estate taxes that are a lien, but are not yet due and payable; and
(e)
The premises are conveyed subject to easements of record provided the same do not render title unmarketable or substantially reduce the usable area of the premises or threaten the continued existence of the structures thereon or prohibit the continued use of the Premises as now being used.
7. Governmental Violations and Orders.
  (a) Sellers shall comply with all notes or notices of violations of law or municipal ordinances, orders or requirements noted or issued as of the date of Closing by any governmental department having authority as to lands, housing, buildings, fire, health, environmental and labor conditions affecting the Premises.  The Premises shall be conveyed free of them at Closing.  Sellers shall furnish Purchasers with any authorizations necessary to make the searches that could disclose these matters.
8. Sellers’ Representations.
(a)
Sellers represents and warrants to Purchasers that:
(i) The Premises abut or have a right to access to a public road;
(ii) Sellers is the sole owner of the Premises and has the full right, power and authority to sell, convey and transfer the same in accordance with the terms of this contract.
(iii) Sellers is not a “foreign person”, as that term is defined for purposes of the Foreign Investment in Real Property Tax Act, Internal Revenue Code (“IRC”) Section 1445, as amended, and the regulations promulgated thereunder (collectively “FIRPTA”);
(iv) The Premises are not affected by any exemptions or abatements of taxes except as may be disclosed by tax search; and
(v) Sellers has been known by no other name for the past ten years.
(b)
Sellers covenants and warrants that all of the representations and warranties set forth in this contract shall be true and correct at Closing.
(c)
Except as otherwise expressly set forth in this contract, none of Sellers’ covenants, representations, warranties or other obligations contained in this contract shall survive Closing.
(d)
Additional Seller representations and warranties are set forth in Purchaser’s Rider Paragraph 3.
9. Conditions of Property.
  Following completion of Purchaser’s inspection during the Due Diligence Period, Purchaser acknowledges and represents that Purchaser will be fully aware of the physical condition and state of repair of the Premises and of all other property included in this sale, based on Purchaser’s own inspection and investigation thereof, and that Purchaser is entering into this Contract based solely upon such inspection and investigations and not upon any information, data, statements or representations, written or oral, as to the physical condition, state of repair, use, cost of operation or any other matter related to the Premises or the other property included in the sale, given or made by Sellers or its representatives, and shall accept the same “as is” in their present condition and state of repair, subject to reasonable use, wear, tear and natural deterioration between the date hereof and the date of Closing (except as otherwise set forth in Paragraph 14(d) and Paragraph 8 of Purchaser’s Rider), without any reduction in the purchase price, except as otherwise specifically provided in this Contract, or claim of any kind for any change in such condition by reason thereof subsequent to the date of this Contract.  Purchasers and their authorized representatives shall have the right, at reasonable times and upon reasonable notice (by telephone or otherwise) to Sellers, to inspect the Premises before Closing.
10. Insurable Title.
  Sellers shall give and Purchaser shall accept such title as any reputable title company shall be willing to approve and insure in accordance with its standard form of title policy approved by the New York State Insurance Department, at regular rates without additional premium, subject only to the matters provided for in this Contract.
11. Closing, Deed and Title.
  (a)  “Closing” means the settlement of the obligations of Sellers and Purchaser to each other under this contract, including the payment of the Purchase Price to Sellers, and the delivery to Purchaser of a Bargain & Sale Deed with Covenants against Grantor’s Acts (“Deed”) Nin proper statutory short form for recording, duly executed and acknowledged, so as to convey to Purchaser fee simple title to the Premises, free of all encumbrances, except as otherwise herein stated.  The Deed shall contain a covenant by Sellers as required by subd. 5 of Section 13 of the Lien Law.
(b)
If Seller is a corporation, it shall deliver to Purchasers at the time of Closing (i) a resolution of its Board of Directors authorizing the sale and delivery of the Deed, and (ii) a certificate by the Secretary of the corporation certifying such resolution and setting forth facts showing that the transfer is in conformity with the requirements of Section 909 of the Business Corporation Law.  The Deed in such case shall contain a recital sufficient to establish compliance with that Section.
12. Contingent Sale/Purchase.
  The purchase and sale of the Premises by the parties under this Contract is expressly conditioned on the simultaneous closing by the parties and/or their affiliates of the transaction set forth in that certain Asset Purchase Agreement of even date herewith.  In the event the closing under the Asset Purchase Agreement does not occur, then the sale and purchase of the Premises shall not occur.
13. Closing Date and Place.
  The Closing will take place through escrow with the title company, or as the parties shall otherwise agree, on or about February 9, 2022.
14. Conditions to Closing.
  This contract and Purchasers’ obligation to purchase the Premises are also subject to and conditioned upon the fulfillment of the following conditions precedent:
(a)
The delivery by Sellers to Purchaser of a valid and subsisting Certificate of Occupancy or other required certificate of compliance, or evidence that none was required, covering the building(s) and all of the other improvements located on the Premises authorizing their use as commercial space/retail store on the first floor and two (2) residential apartment dwelling units as of the date of Closing.
(b)
The delivery by Sellers to Purchaser of a certification stating that Seller is not a foreign person, which certification shall be in the form then required by FIRPTA.  If Sellers fails to deliver the aforesaid certification or if Purchasers are not entitled under FIRPTA to rely on such certification.  Purchasers shall deduct and withhold from the purchase price a sum equal to 10% thereof (or any lesser amount permitted by law) and shall at Closing remit the withheld amount with the required forms to the Internal Revenue Service.
(c)
The delivery of the Premises and all building(s) and improvements comprising a part thereof in broom clean condition, subject to the two month to month residential tenancies listed in the Rent Schedule attached hereto as Schedule B, together with keys to the Premises.
(d)
All plumbing (including water supply and septic systems, if any), heating and electrical systems located on the Premises being in working order as of the date of Closing, all appliances located on the Premises being in working order as of the date of Closing, and all store fixtures and equipment located in the commercial space/retail store on the first floor of the Premises being in working order as of the date of Closing.
(e)
If the Premises are a one or two family house, delivery by the parties at Closing of affidavits in compliance with state and local law requirements to the effect that there is installed in the Premises a smoke detecting alarm and carbon monoxide detecting device or devices.
(f)
The delivery by the parties of any other affidavits required as a condition of recording the deed and as may be reasonably required by the title company.
15. Deed Transfer and Recording Taxes.
  At Closing, checks payable to the order of the appropriate State, City or County officer in the amount of any applicable transfer taxes payable by reason of the delivery of the deed shall be delivered by Seller in payment of the applicable transfer taxes, together with any required tax returns duly executed and sworn to, and Seller shall cause any such checks and returns to be delivered to the appropriate officer promptly after Closing.  The obligation to pay any additional tax or deficiency and any interest or penalties thereon shall survive Closing.  Purchaser shall be responsible for the cost of title insurance and such other title related costs and fees, including the cost of recording the Deed and any mortgage taxes for any mortgage obtained by Purchaser, if any.
16. Apportionments and Other Adjustment; Water Meter and Installment Assessment.
(a)
To the extent applicable the following shall be apportioned as of midnight of the day before the day of Closing:
(i) taxes, water charges and sewer rents, on the basis of the fiscal period for which assessed.
(b)
If Closing shall occur before a new tax rate is fixed, the apportionment of taxes shall be upon the basis of the tax rate for the immediately preceding fiscal period applied to the latest assessed valuation.
(c)
If there is a water meter on the Premises, Sellers shall furnish a reading to a date not more than 30 days before Closing and the unfixed meter charge and sewer rent, if any, shall be apportioned on the basis of such last reading.
(d)
If at the date of Closing the Premises are affected by an assessment which is or may become payable in annual installments, and the first installment is then a lien, or has been paid, then for the purposes of this contract all the unpaid installments shall be considered due and shall be paid by Sellers at or prior to Closing.
(e)
Any errors or omissions in computing apportionments or other adjustments at Closing shall be corrected within a reasonable time following Closing.  This subparagraph shall survive Closing.
(f)
Rents under the Leases set forth in Schedule B.  In addition, Seller shall credit Purchaser with the security deposits then held by Seller pursuant to the Leases identified in Schedule B.
17. Allowance for Unpaid Taxes, etc.
Sellers has the option to credit Purchaser as an adjustment to the Purchase Price with the amount of any unpaid taxes, assessments, water charges and sewer rents, together with any interest and penalties thereon, provided that official bills therefor computed to said date are produced at Closing.
18. Use of Purchase Price to Remove Encumbrances.
  If at Closing there are other liens or encumbrances that Sellers are obligated to pay or discharge, Sellers may use any portion of the cash balance of the purchase price to pay or discharge them, provided Sellers shall simultaneously deliver to Purchaser at Closing instruments in recordable form and sufficient to satisfy such liens or encumbrances of record, together with the cost of recording or filing said instruments.  As an alternative, Sellers may deposit sufficient monies with the title company employed by Purchaser acceptable to and required by the title company to assure their discharge, but only if the title company will insure Purchasers’ title clear of the matters or insure against their enforcement out of the Premises and will insure Purchasers’ lender, if any, clear of such matters.  Upon notice (by telephone or otherwise), given not less than 3 business days before Closing, Purchaser shall provide separate certified or official bank checks as requested to assist in clearing up these matters.
19. Title Examination; Sellers’ Inability to Convey; Limitations of Liability.
  (a)  Purchasers shall order an examination of title in respect of the Premises from a title company licensed or authorized to issue title insurance by the New York State Insurance Department or any agent for such title company promptly after the execution of this Contract.  Purchasers shall cause a copy of the title report and of any additions thereto to be delivered to the attorney(s) for Sellers promptly after receipt thereof.
(i)  If at the date of Closing Sellers are unable to transfer title to Purchasers in accordance with this contract, or Purchasers has other valid grounds for refusing to close, whether by reason of liens, encumbrances or other objections to title or otherwise (herein collectively called “Defects”), other than those subject to which Purchasers is obligated to accept title hereunder or which Purchasers may have waived and other than those which Sellers has herein expressly agreed to remove, remedy or discharge and if Purchasers shall be unwilling to waive the same and to close title without abatement of the Purchase Price, then, except as hereinafter set forth, Sellers shall have the right, at Sellers’ sole election, either to take such action as Sellers may deem advisable to remove, remedy, discharge or comply with such Defects or to the parties may agree upon an adjustment to the Purchase Price; (ii) if Sellers elects to take action to remove, remedy or comply with such Defects, Sellers shall be entitled from time to time, upon Notice to Purchasers, to adjourn the date for Closing hereunder for a period or periods not exceeding 60 days in the aggregate and the date for Closing shall be adjourned to a date specified by Sellers not beyond such period.  If for any reason whatsoever, Sellers shall not have succeeded in removing, remedying or complying with such Defects at the expiration of such adjournment(s), then either party may cancel this contract by Notice to the other given within 10 days after such adjourned date; (iii) notwithstanding the foregoing, the existing mortgage and any matter created by Sellers after the date hereof shall be released, discharged or otherwise cured by Sellers at or prior to Closing.
If this Contract is so cancelled, this Contract shall terminate and come to an end, and neither party shall have any further rights, obligations or liabilities against or to the other hereunder or otherwise, except that Sellers shall promptly reimburse Purchaser for the net cost of examination of title, and the net cost, if actually paid or incurred by Purchaser, for updating the existing survey of the Premises or of a new survey.
20. Affidavit as to Judgments, Bankruptcies, etc.
  If a title examination discloses judgments, bankruptcies or other returns against persons having names the same as or similar to that of Sellers, Sellers shall deliver an affidavit at Closing showing that they are not against Sellers.
21. Defaults and Remedies.
  (a) If Purchaser defaults, hereunder, Sellers’ sole remedy shall be to cancel and terminate this Contract and to retain the $100.00 independent consideration [aid by Purchaser to Seller upon Contract execution.
(b)
If Sellers default hereunder, Purchaser shall have such remedies as Purchaser shall be entitled to at law or in equity, including, but not limited to, specific performance.
22. Purchasers’ Lien.
  The reasonable expenses of examination of title to the Premises and of any survey and survey inspection charges, are hereby made liens on the Premises, but such liens shall not continue after default by Purchasers under this contract.
23. Notices.
  Any notice or other communication (“Notice”) shall be in writing and either:
 (a)
sent by either of the parties hereto or by their respective attorneys who are hereby authorized to do so on their behalf, by certified mail, postage prepaid, or
(b)
delivered in person or by overnight courier, with receipt acknowledged, to the respective addresses given in this contract for the party, to whom the Notice is to be given, or to such other address as such party shall hereafter designate by Notice given to the other party or parties pursuant to this paragraph.  Each Notice mailed shall be deemed given on the third business day following the date of mailing the same and each Notice delivered in person or by overnight courier shall be deemed given when delivered.
24. Intentionally Deleted.
25. Broker.
  Seller and Purchaser each represent and warrant to the other that they have not dealt with any broker in connection with this sale other than Vondell & Associates Realty, LLC (“Broker”).  It is the responsibility of the Seller to pay the broker’s fee of 5% of the Purchase Price and such amount shall be paid to the Broker at closing and adjusted from the Seller’s proceeds.
26. Miscellaneous.
  (a) All prior understandings, agreements, representations and warranties, oral or written, between Sellers and Purchaser are merged in this Contract; it completely expresses their full agreement and has been entered into after full investigation, neither party relying upon any statement made by anyone else that is not set forth in this Contract.
(b)
Neither this Contract nor any provision thereof may be waived, changed or cancelled except in writing.  This Contract shall also apply to and bind the heirs, distributees, legal representatives, successors and permitted assigns of the respective parties.  The parties hereby authorize their respective attorneys to agree in writing to any changes in dates and time periods provided for in this Contract.
(c)
Any singular word or term herein shall also be read as in the plural and the neuter shall include the masculine and feminine gender, whenever the sense of this contract may require it.
(d)
The captions in this contract are for convenience of reference only and in no way define, limit or describe the scope of this contract and shall not be considered in the interpretation of this contract or any provision hereof.
(e)
This Contract shall not be binding or effective until duly executed and delivered by Sellers and Purchasers.
(f)
Sellers and Purchasers shall comply with IRC reporting requirements, if applicable.  This subparagraph shall survive Closing.  This Contract may be executed by the parties by electronic signatures or by exchanging signatures by email or PDF which signatures once exchanged shall be deemed original signatures binding upon the parties.
(g)
Each party shall, at any time and from time to time, execute, acknowledge where appropriate and deliver such further instruments and documents and take such other action as may be reasonably requested by the other in order to carry out the intent and purpose of this Contract.  This subparagraph shall survive Closing.
(h)
This Contract is intended for the exclusive benefit of the parties hereto and except as otherwise expressly provided herein, shall not be for the benefit of, and shall not create any rights in, or be enforceable by, any other person or entity.
(i)
Notwithstanding the liability for risk of loss or damage of the Premises due to fire, the Sellers agree that should the Premises be substantially damaged by fire or elements, the Purchaser shall have the option of proceeding with this Contract or declaring the same null and void.
27. 
Both parties represent that this conveyance is not subject to a 1031 transfer under the Internal Revenue Code.
28. Compliance with Property Condition Disclosure Act:
Receipt of Property Condition Disclosure Statement.
If this property is a dwelling used or intended to be used as the home or residence of one or more persons and is not exempt from the application of the Property Condition Disclosure Act (the “Act”), a complete Disclosure Statement is intended to be delivered to the Purchaser herein.  The return of the Contracts signed by the Purchaser to the Seller’s attorney shall be an acknowledgment that the Purchaser has received the Disclosure Statement either as a Rider to this Contract or from the Seller or one of the Seller’s agents.  The Purchaser shall not be considered to have received the complete Contract for the sale of property subject to the Act which will be binding upon the parties when accepted until they have received the Disclosure Statement or the Seller has consented in writing to waive compliance with the Act and to give Purchaser a $500.00 credit at closing of title.  The Purchaser is expressly advised to obtain her own independent professional inspections and environmental tests and to check public records pertaining to the premises.  Nothing in the Disclosure Statement shall modify, change or affect the terms of the Contract, including any Rider(s).  In the event of a conflict with the other Contract provisions, including any and all Riders, those provisions shall supersede the Disclosure Statement and any information and/or representation contained in the Disclosure Statement which shall not survive the closing of title.

29. HOME EQUITY THEFT PREVENTION ACT
Seller(s) represent that they are not now, nor will they be deemed at the time of closing, “equity seller(s)”.  “Equity seller(s) are defined by The Home Equity Theft Prevention Act as codified in Section 265-a of the Real Property Law, who are in foreclosure; or in default under a mortgage as defined therein.  This is a material representation, relied upon by the Purchaser(s).  At closing, Purchaser(s) or Purchaser’s title insurance agent will provide the Seller(s) with an affidavit averring that the representation of this paragraph is true and accurate.  Seller(s) shall execute said affidavit at closing.
30. PURCHASER’S RIDER
The parties acknowledge that additional agreed upon terms and provisions are set forth in the Purchaser’s Rider attached to and made a part of this Contract.
-
Signatures Appear on Following Page      -



IN WITNESS WHEREOF, this contract has been duly executed by the parties hereto.
SELLERS: PURCHASERS:
MOTHER EARTH’S STOREHOUSE, INC.
HEALTHY CHOICE MARKETS 3 REAL ESTATE LLC

By:  /s/ Christopher Schneider By:  /s/ Christopher Santi
       Christopher Schneider                   Christopher Santi
       President       President and Chief Operating Officer
Attorney for Sellers: Attorney for Purchaser:
REDDER, BOCK & ASSOCIATES, PLLC COZEN O’CONNOR
George W. Redder, Esq. Joseph A. Mascia, Esq.
P.O. Box 3100 3 WTC, 175 Greenwich Street, 55th Floor
Kingston, New York 12401 New York, New York 10007
845-331-1000 212-883-4939



SCHEDULE A

Metes and Bounds Description of Premises

ALL that tract or parcel of land situate in the Village of Saugerties, County of Ulster and State of
New York, bounded and described as follows:

BEGINNING at a point on the northerly side of Main Street, said point being the southwesterly corner of the herein described premises and the southeasterly corner of lands of Natalie Maclary and other, Liber 1314 page 870; and running

1)
Thence from said point of beginning along the easterly line of lands of Maclary on a line between the building on lands of Maclary and a two-story brick building on the lands herein described premises, North 9 degrees 54 minutes 47 seconds West, 84.00 feet to the northwesterly corner of the aforementioned two-story brick building;

2)
Thence still along lands of Maclary and others the following courses and distances:

North 8 degrees 02 minutes 28 seconds West, 23.73 feet to the northwesterly corner of a one- story brick building on the herein described premises;

3)
Thence North 2 degrees 28 minutes 00 seconds East, 12.55 feet to a point;

4)
Thence North 4 degrees 05 minutes 40 seconds West, 81.36 feet to a point;

5)
Thence along the southerly line of lands of P.C. Smith and Son, Inc., Liber 2203 page 145, North 82 degrees 36 minutes 00 seconds East, 16.64 feet to a point;

6)
Thence along the westerly line of lands of Jerome and Faye Schackne, Liber 1528 page 85, on a line between the two-story brick building on the herein described premises and a
three-story brick building on lands of Schackne, South 8 degrees 56 minutes 00 seconds East, 200.62 feet to a point on the northerly side of Main Street;

7)
Thence along the northerly side of Main Street, South 81 degrees 04 minutes 00 seconds West, 24.90 feet to the place of BEGINNING.

CONTAINING 0.108 acres.

ALL BEARINGS are referred to magnetic North as of July 1973.

The above described premises are subject to any rights of the Central Hudson Gas and Electric Corporation and/or New York Telephone Co. for overhead service line crossing the rear of said premises.

ALSO included herewith is the right to the use of a right of way extending from Main Street, northerly and westerly along lands of now or formerly David W. and Beatrice S. Bright and lands of Jerome and Faye Schackne, to the herein described premises.

Said premises to be known as 249 Main Street, Saugerties, NY 12477.
Section 18.247 Block 1 Lot 18.1.

The policy to be issued under the report will insure the title to such building and improvements erected on the premises which by law constitute real property.

For conveyancing only: Together with all right, title and interest of the party of the first part, of, in and to the land lying in the street in front of and adjoining said premises.



SCHEDULE B

Omitted
EX-3.1(I) 3 ex_3-1i.htm HCMC CANCELLATION OF CERTIFICATE OF DESIGNATIONS  
Exhibit 3.1(i)


CANCELLATION OF
CERTIFICATE OF POWERS, DESIGNATIONS, PREFERENCES AND RIGHTS
OF THE
SERIES A CONVERTIBLE PREFERRED STOCK, SERIES B CONVERTIBLE PREFERRED STOCK AND THE SERIES C CONVERTIBLE PREFERRED STOCK
OF
HEALTHIER CHOICES MANAGEMENT CORP.
PURSUANT TO SECTION 151(g)
OF THE
GENERAL CORPORATION LAW OF THE STATE OF DELAWARE

The undersigned Jeffrey Holman, being the Chief Executive Officer and Chairman of the Board of Healthier Choices Management Corp., a Delaware corporation (the “Corporation”), does hereby certify that, pursuant to the provisions of Section 151(g) of the General Corporation Law of the State of Delaware (the “General Corporation Law”), the following resolution was duly adopted by unanimous written consent by the Board of Directors of the Corporation (the “Board of Directors”) on March 22, 2022, and, pursuant to authority conferred upon the Board of Directors by the provisions of the Corporation’s certificate of incorporation, as amended and in effect (the “Certificate of Incorporation”), in accordance with Section 141 of the General Corporation Law by unanimous written consent of the Board of Directors, the Board of Directors adopted resolutions eliminating the designation and the relative powers, preferences, rights, qualifications, limitations and restrictions of the Corporation’s Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock.  These composite resolutions eliminating the designation and relative powers, preferences, rights, qualifications, limitations and restrictions of such Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock are as follows:
WHEREAS, the Certificate of Incorporation of the Corporation, as amended from time to time, authorizes preferred stock consisting of 1,000,000,000 shares, par value $0.001 per share, issuable from time to time in one or more series;
WHEREAS, the Board of Directors of the Corporation is authorized, subject to limitations prescribed by law and by the provisions of the Corporation’s Certificate of Incorporation, to establish and fix the number of shares to be included in any series of preferred stock and the designation, rights, preferences, powers, restrictions and limitations of the shares of such series;
WHEREAS, all authorized Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock have been redeemed or converted, and pursuant to the Certificate of Powers, Designations, Preferences and Rights of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock (collectively, the “Certificates of Designation”) all such stock shall not be reissued, sold or transferred;
WHEREAS, the Board of Directors has determined it is advisable and in the best interest of the Corporation and its shareholders to eliminate and cancel all designation, rights, preferences and limitations of the shares of such series, and strike all references to Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock from the books and records of the Corporation;
NOW, THEREFORE, BE IT RESOLVED, that pursuant to authority granted to and vested in the Board of Directors by the provisions of the Certificate of Incorporation, the Board of Directors hereby cancels the Certificates of Designation and eliminates all Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock; and
RESOLVED FURTHER, that the appropriate officers of the Corporation be, and each of them individually is, in accordance with the foregoing resolutions, authorized, in the name and on behalf of the Corporation, to prepare, execute and delivery any and all agreements, amendments, certificates, reports, applications, notices, instruments, schedules, statements, consents, letters or other documents with respect to the matters contemplated by the foregoing resolutions, to make any filings pursuant to federal, state or local laws, to incur any fees and expenses and to do or cause to be done any and all such other acts and things as, in the opinion of any such Authorized Officer, may be necessary, appropriate or desirable in order to comply with the applicable laws and regulations of any jurisdiction, or otherwise in order to enable the Corporation fully and promptly to carry out the purposes and intent of the foregoing resolutions and to permit the matters contemplated thereby to be lawfully consummated.


[Signature Page Follows]

IN WITNESS WHEREOF, this Cancellation of Certificate of Powers, Designations, Preferences and Rights of the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock of Healthier Choices Management Corp. has been executed by a duly authorized officer of the Corporation on this 22nd day of March, 2022.

 
By: /s/ Jeffrey Holman
Jeffrey Holman, Chief Executive Officer


EX-10.9 4 ex10_9.htm HCMC CREDIT AGREEMENT (PB - HEALTHY CHOICE) 2021  
Exhibit 10.9
 


RLOC CREDIT AGREEMENT


by and among

HEALTHIER CHOICES MANAGEMENT CORP.

and

PROFESSIONAL BANK


Dated December 23, 2021

 
 
 
 


 
 
 

RLOC CREDIT AGREEMENT

This RLOC CREDIT AGREEMENT is dated December 23, 2021, by and among Healthier Choices Management Corp., a Delaware corporation (“HCMC” and “Borrower”) and Professional Bank, a Florida banking corporation (the “Bank”).

RECITALS

The Borrower has requested the Bank to extend credit to the Borrower.  The Bank is willing to extend credit to the Borrower, subject to the terms and conditions hereinafter set forth.

Accordingly, the Borrower and the Bank agree as follows:

ARTICLE I
DEFINITIONS AND ACCOUNTING TERMS
 
Section 1.1 Definitions.  As used herein, the following words and terms shall have the following meanings:

Affiliate” shall mean with respect to any Person, any corporation, partnership, limited liability company, limited liability partnership, joint venture, trust or unincorporated organization which, directly or indirectly, controls or is controlled by or is under common control with such Person.  For the purpose of this definition, “control” of a Person shall mean the power, direct or indirect, to direct or cause the direction of the management or policies of such Person whether through the ownership of voting securities by contract or otherwise; provided that, in any event, any person who owns directly or indirectly twenty (20%) percent or more of the securities having ordinary voting power for the election of directors or other governing body of a corporation or twenty (20%) percent or more of the partnership, membership or other ownership interest of any Person (other than as a limited partner of such other Person) will be deemed to control such corporation or other Person.

Agreement” shall mean this RLOC Credit Agreement dated as of December 23, 2021, as the same may be amended, supplemented, modified, or restated from time to time.

AML Legislation” shall have the meaning provided in Section 9.15.

Anti-Terrorism Laws” shall mean any laws relating to terrorism or money laundering, including Executive Order No. 13224, the USA Patriot Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by the United States Treasury Department's Office of Foreign Asset Control (as any of the foregoing laws may from time to time be amended, renewed, extended, or replaced).

Banking Services” means each and any of the following bank services provided to the Borrower by the Bank:  (i) commercial credit, credit cards, purchase or debit cards and (ii) cash management, treasury or related services (including, without limitation, controlled deposit accounts, overnight draft, funds transfer, automated clearinghouse, zero accounts, lockbox, account reconciliation, disbursement, ACH transactions, return items and interstate depository network services).

Banking Services Obligations” of the Borrower means any and all obligations of the Borrower, whether absolute or contingent and however and whenever created, arising, evidenced or acquired (including all renewals, extensions and modifications thereof and substitutions therefor) in connection with Banking Services.

Blocked Account” shall mean that certain money market account maintained by the Borrower at the Bank, Account #53620125262, which account shall be a blocked account in which the Bank will maintain a priority perfected security interest.

Blocked Person” shall have the meaning provided in Section 4.19(b).

Borrowing Base” shall mean, at any time, the amount on deposit in the Blocked Account.

Borrowing Date” shall mean, with respect to any Revolving Credit Loan, the date on which such Revolving Credit Loan is disbursed to the Borrower.

Business Day” shall mean any day that is not a Saturday, Sunday or legal holiday, on which banks in Miami, Florida are not required or authorized by law or other governmental action to close.

Capital Lease” shall mean (i) any lease of property, real or personal, if the then present value of the minimum rental commitment thereunder should, in accordance with Generally Accepted Accounting Principles, be capitalized on the balance sheet of the lessee, and (ii) any other such lease the obligations of which are required to be capitalized on the balance sheet of the lessee.

Closing Date” shall mean December 23, 2021.

Code” shall mean the Internal Revenue Code of 1986, as amended from time to time.

Collateral” shall mean the Blocked Account and all proceeds (as defined in Section 9-102 of the UCC) and products of the foregoing, all supporting obligations related thereto, and all accessions to, substitutions and replacements for, and rents, profits and products of the foregoing, and any and all proceeds of any insurance, indemnity, warranty or guaranty payable to the Borrower from time to time with respect to the foregoing.

Commitment Period” shall mean the period from and including the Closing Date to, but not including, the Commitment Termination Date.

Commitment Termination Date” shall mean December 23, 2024, or such earlier date as the Revolving Credit Commitment shall terminate as provided herein.

Default” shall mean any event or condition which upon notice, lapse of time, or both, would constitute an Event of Default.

Dollar” and the symbol “$” shall mean lawful money of the United States of America.

ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended from time to time.  Section references to ERISA are to ERISA, as in effect at the date of this Agreement and any subsequent provisions of ERISA, amendatory thereof, supplemental thereto or substituted therefor.

ERISA Affiliate” shall mean each person (as defined in Section 3(9) of ERISA) which together with the Borrowers would be deemed to be a member of the same “controlled group” within the meaning of Section 414(b), (c), (m) and (o) of the Code.

Event of Default” shall mean any Event of Default set forth in Article VIII.
 
Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

Executive Officer” shall mean Jeffrey Holman, as Chief Executive Officer, John Ollet, as Chief Financial Officer, and Christopher Santi, as Chief Operating Officer.

Executive Order” shall mean the Executive Order No. 13224 on Terrorist Financing, effective September 24, 2001, as the same has been, or shall hereafter be, renewed, extended, amended or replaced.

Governmental Authority” shall mean any nation or government, any state, province, city or municipal entity or other political subdivision thereof, and any governmental, executive, legislative, judicial, administrative or regulatory agency, department, authority, instrumentality, commission, board or similar body, whether federal, state, provincial, territorial, local or foreign which possesses jurisdiction over the Borrower or the operations of the Borrower.

Hazardous Materials” includes, without limit, any flammable explosives, radioactive materials, hazardous materials, hazardous wastes, hazardous or toxic substances, or related materials defined in the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (42 U.S.C. Sections 9601, et seq.), the Hazardous Materials Transportation Act, as amended (49) U.S.C. Sections 1801, et seq.), the Resource Conservation and Recovery Act, as amended (42 U.S.C. Sections 9601, et seq.), and in the regulations adopted and publications promulgated pursuant thereto, or any other federal, state or local environmental law, ordinance, rule or regulation.

Indebtedness”  shall mean, without duplication, as to any Person or Persons (i) indebtedness for borrowed money; (ii) indebtedness for the deferred purchase price of property or services; (iii) indebtedness evidenced by bonds, debentures, Revolving Credit Note or other similar instruments; (iv) obligations and liabilities secured by a Lien upon property owned by such Person, whether or not owing by such Person and even though such Person has not assumed or become liable for the payment thereof; (v) obligations and liabilities directly or indirectly guaranteed by such Person; (vi) obligations or liabilities created or arising under any conditional sales contract or other title retention agreement with respect to property used and/or acquired by such Person; (vii) obligations of such Person as lessee under Capital Leases; (viii) net liabilities of such Person under hedging agreements and foreign currency exchange agreements, as calculated on a basis satisfactory to the Bank and in accordance with accepted practice; (ix) all obligations of such Person in respect of bankers’ acceptances; (x) all obligations, contingent or otherwise of such Person as an account party in respect of letters of credit; and (xi) all liabilities which would be reflected on a balance sheet of such Person, prepared in accordance with Generally Accepted Accounting Principles applied on a consistent basis.

Lien” shall mean any lien (statutory or otherwise), security interest, mortgage, deed of trust, pledge, charge, conditional sale, title retention agreement, Capital Lease or other encumbrance or similar right of others, or any agreement to give any of the foregoing.

Loan Documents” shall mean, collectively, this Agreement, the Revolving Credit Note, and each other document or agreement executed in connection with the transactions contemplated hereby or thereby.

Material Adverse Effect” shall mean a material adverse effect on (i) the business, operations, properties, prospects or condition (financial or otherwise) of Borrower (other than general market conditions out of Borrower’s control), or (ii) the ability of Borrower to perform any of its material obligations under any Loan Document to which it is a party.

Material Contract” shall mean, with respect to any Person, each contract, instrument or agreement to which such Person is a party which is not entered into in the ordinary course of such Person’s business and which is material to the business, operations, properties, prospects or condition (financial or otherwise) of such Person.

Notice of Revolving Credit Loan Borrowing” shall mean the Notice of Revolving Credit Loan Borrowing substantially in the form attached hereto as Exhibit A.

Obligations” shall mean all obligations, liabilities and indebtedness of the Borrower to the Bank under the Loan Documents, whether now existing or hereafter created, absolute or contingent, direct or indirect, due or not, whether created directly or acquired by assignment or otherwise, including, without limitation, all obligations, liabilities and indebtedness of the Borrower arising under this Agreement, the Revolving Credit Note, or any other Loan Document including, without limitation, all obligations, liabilities and indebtedness of the Borrower with respect to the principal of and interest on the Revolving Credit Loans, any Banking Services Obligations arising under this Agreement and foreign currency exchange agreements relating to the Indebtedness of the Borrower arising under this Agreement and all fees, costs, expenses and indemnity obligations of the Borrower hereunder or under any other Loan Document.

Operating Account” shall mean Borrower’s bank account #2013555 at the Bank, into which Bank shall credit the proceeds from each Revolving Credit Loan, and from which Bank may, in its sole discretion, debit payments to the Bank on the Revolving Credit Loans as permitted under this Agreement and the Loan Documents.
 
Payment Office” shall mean the Bank’s office located at 396 Alhambra Circle, Ste. 255, Coral Gables, Florida 33134, or such other office hereinafter designated in writing at least seven (7) days in advance by the Bank as its Payment Office.

PBGC” shall mean the Pension Benefit Guaranty Corporation established pursuant to Section 4002 of ERISA, or any successor thereto.

Person” shall mean any natural person, corporation, limited liability company, limited liability partnership, business trust, joint venture, association, company, partnership or Governmental Authority.

Plan” shall mean any multi-employer or single-employer plan defined in Section 4001 of ERISA, which is maintained, or at any time during the five calendar years preceding the date of this Agreement was maintained for employees of Borrower or an ERISA Affiliate.

Regulation D” shall mean Regulation D of the Board of Governors of the Federal Reserve System as the same may be amended or supplemented from time to time.

Reportable Event” shall mean an event described in Section 4043(b) of ERISA with respect to a Plan as to which the 30-day notice requirement has not been waived by the PBGC.

Revolving Credit Commitment” shall mean the obligation of the Bank to make Revolving Credit Loans to the Borrowers in aggregate amount not to exceed Two Million ($2,000,000) Dollars, subject to, and as reduced from time to time in accordance with, the terms of this Agreement.

Revolving Credit Loan” and “Revolving Credit Loans” shall mean any loans and advances made by the Bank pursuant to this Agreement, including, but not limited to, those loans made under Section 2.1 of this Agreement.

Revolving Credit Note” shall mean that certain Revolving Credit Note dated concurrently herewith, issued by the Borrower to the Bank in the original principal amount of Two Million Dollars ($2,000,000), as the same may be amended, supplemented, modified, or restated from time to time.

SEC Reports” shall have the meaning specified in Section 4.10.

Securities Act” shall mean the Securities Act of 1933, as amended.

Security Documents” shall mean, collectively, each collateral security document delivered to the Bank hereunder.

Unfunded Current Liability” of any Plan shall mean the amount, if any, by which the present value of the accrued benefits under the Plan as of the close of its most recent plan year exceeds the fair market value of the assets allocable thereto, determined in accordance with Section 412 of the Code.

Uniform Commercial Code” or “UCC” shall mean the Uniform Commercial Code as enacted in the State of Florida.

USA Patriot Act” shall mean the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, Public Law 107-56, as the same has been, or shall hereafter be, renewed, extended, amended or replaced.

Section 1.2 Accounting Terms.  Except as otherwise herein specifically provided, each accounting term used herein shall have the meaning given to it under GAAP.  “GAAP” shall mean those generally accepted accounting principles and practices which are recognized as such by the American Institute of Certified Public Accountants acting through the Financial Accounting Standards Board (“FASB”) or through other appropriate boards or committees thereof, except that any accounting principle or practice required, in the good faith opinion of the CPA, to be changed by the FASB (or other appropriate board or committee of the FASB) in order to continue as a generally accepted accounting principle or practice may be so changed.  Any dispute or disagreement between the Borrower and the Bank relating to the determination of GAAP shall, in the absence of manifest error, be conclusively resolved for all purposes hereof by a written opinion with respect thereto delivered to the Bank by the CPA.
 
ARTICLE II
LOANS
 
Section 2.1 Revolving Credit Loans.

(a) Subject to the terms and conditions and relying upon the representations and warranties set forth herein, the Bank agrees to make Revolving Credit Loans to the Borrower at any time or from time to time on or after the date hereof and until the Commitment Termination Date, provided, however, that no Revolving Credit Loan shall be made if, after giving effect to such Revolving Credit Loan, the aggregate outstanding principal amount of all Revolving Credit Loans would exceed the lesser of the Revolving Credit Commitment and the Borrowing Base.  During the Commitment Period, the Borrower may from time to time borrow, repay and reborrow Revolving Credit Loans hereunder on or after the date hereof and prior to the Commitment Termination Date, subject to the terms, provisions and limitations set forth herein.

(b) The Borrower shall, not later than 10:00 a.m., Miami, Florida time, on the date of each proposed Revolving Credit Loan under this Section 2.1, deliver to the Bank either (i) a duly completed Notice of Revolving Credit Loan Borrowing, executed by an Executive Officer; or (ii) an electronic mail containing the information that would otherwise be set forth in a Notice of Revolving Credit Loan Borrowing, originated by an Executive Officer and sent to Melissa Norman, Vice President, which electronic mail shall be confirmed by the foregoing parties orally prior to being processed by the Bank.  Such notice shall be irrevocable.  
 
(c) The Revolving Credit Commitment shall automatically terminate on the Commitment Termination Date.  

(d) Revolving Credit Loans made by the Bank shall be evidenced by the Revolving Credit Note, appropriately completed, duly executed and delivered on behalf of the Borrower on the Closing Date and payable to the order of the Bank in a principal amount equal to the Revolving Credit Commitment.  Accrued and unpaid interest on the outstanding principal amount of Revolving Credit Loans shall be payable monthly commencing on January 24, 2022, and continuing on the twenty-fourth (24th) day of each month thereafter until the Commitment Termination Date, at which point the Borrower shall immediately repay in full the principal amount of the Revolving Credit Loans then outstanding together with all accrued interest thereon and all other amounts due and payable hereunder.  Borrower shall be liable for all amounts outstanding under the Revolving Credit Note.  The aggregate unpaid amount of the Revolving Credit Loans of the Bank at any time shall be the principal amount owing on the Revolving Credit Note of the Borrower at such time.

ARTICLE III
INTEREST RATE; FEES AND PAYMENTS; USE OF PROCEEDS; SECURITY INTEREST
 
Section 3.1 Revolving Credit Loan Interest Rates.

(a) Base Interest Rates.  Revolving Credit Loans shall bear interest on the unpaid principal amount thereof at a variable rate per annum equal to the interest rate paid on the Blocked Account plus one (1.00%) percent.  The initial interest rate will be One and 25/100 (1.25%) percent (Blocked Account rate of twenty-five (0.25%) basis points plus one (1.00%) percent).

(b) Default Interest Rates.  Upon the occurrence and during the continuance of an Event of Default the outstanding principal amount of each Revolving Credit Loan, shall, at the option of the Bank, bear interest payable on demand, at a rate per annum equal to the applicable rate set forth under Section 3.1(a) for each Revolving Credit Loan plus five (5.00%) percent.

(c) Late Charges.  A late charge equal to the greater of (i) five (5.00%) percent or (ii) $250 shall be imposed on each and every payment required hereunder that is not received by Bank within ten (10) days after it is due.  The late charge is not a penalty, but liquidated damages to defray administrative and related expenses due to such late payment.  The late charge shall be immediately due and payable and shall be paid by the Borrower to the Bank without notice or demand.  This provision for late charge is not and shall not be deemed a grace period, and Bank has no obligation to accept a late payment.  Further, the acceptance of a late payment shall not constitute a waiver of any Event of Default then existing or thereafter arising.

(d) Maximum Allowable Interest Rates.  Anything in this Agreement or the Revolving Credit Note to the contrary notwithstanding, the obligation of the Borrower to make payments of interest shall be subject to the limitation that payments of interest shall not be required to be paid to the Bank to the extent that the charging or receipt thereof would not be permissible under the law or laws applicable to the Bank limiting the rates of interest that may be charged or collected by the Bank.  In each such event payments of interest required to be paid to the Bank shall be calculated at the highest rate permitted by applicable law until such time as the rates of interest required hereunder may lawfully be charged and collected by the Bank.  If the provisions of this Agreement or the Revolving Credit Note would at any time otherwise require payment by the Borrower to the Bank of any amount of interest in excess of the maximum amount then permitted by applicable law, the interest payments to the Bank shall be reduced to the extent necessary so that the Bank shall not receive interest in excess of such maximum amount.  
 
(e) Interest Rate Calculations.  Interest shall be calculated on the basis year of 360 days and shall be payable for the actual days elapsed.  Each determination by the Bank of an interest rate or fee hereunder shall, absent manifest error, be conclusive and binding for all purposes.

Section 3.2 Use of Proceeds.  The proceeds of the Revolving Credit Loans shall be used by the Borrower to payoff that certain Term Note dated December 31, 2018, issued by the Borrower to the Bank in the original principal amount of One Million Four Hundred Thousand Dollars ($1,400,000) and for general working capital requirements in the ordinary course of business.

Section 3.3 Prepayments.

(a) The Borrower may prepay from time to time any then outstanding Revolving Credit Loan, in whole or in part, without penalty, upon irrevocable written notice to the Bank, specifying the date and amount of repayment.  If such notice is given, the Borrower shall make such repayment and the repayment amount specified in such notice shall be due and payable, on the date specified therein, together with accrued interest to such date on the amount repaid to the Bank.
 
(b) To the extent that the aggregate outstanding principal amount of Revolving Credit Loans exceeds the lesser of the Revolving Credit Commitment or the Borrowing Base as then in effect, the Borrower shall immediately prepay the Revolving Credit Loans to the extent necessary to cause compliance therewith.

(c) Each prepayment of principal of a Revolving Credit Loan pursuant to this Section 3.3 shall be accompanied by accrued interest on the amount prepaid through the date of prepayment.

Section 3.4 Other Events.

(a) In the event that any introduction of or change in, on or after the date hereof, any applicable law, regulation, treaty, order, directive or in the interpretation or application thereof (including, without limitation, any request, guideline or policy, whether or not having the force of law, of or from any central bank or other Governmental Authority, agency or instrumentality and including, without limitation, Regulation D), by any authority charged with the administration or interpretation thereof shall occur, which:
 
(i) shall subject the Bank to any tax of any kind whatsoever with respect to this Agreement, the Revolving Credit Note, any Revolving Credit Loan, or change the basis of taxation of payments to the Bank of principal, interest, fees or any other amount payable hereunder (other than any tax that is measured with respect to the overall net income of the Bank or lending office of the Bank and that is imposed by the United States of America, or any political subdivision or taxing authority thereof or therein, or by any jurisdiction in which the Bank’s lending office is located, or by any jurisdiction in which the Bank is organized, has its principal office or is managed and controlled); or
 
(ii) shall impose, modify or hold applicable any reserve, special deposit, compulsory loan or similar requirement (whether or not having the force of law) against assets held by, or deposits or other liabilities in or for the account of, advances or loans by, or other credit extended by, or any other acquisition of funds by, any office of the Bank; or
 
(iii) shall impose on the Bank any other condition, or change therein directly relating to this Agreement, the Revolving Credit Note, or any Revolving Credit Loan; and the result of any of the foregoing is to increase the cost to the Bank of making, renewing or maintaining or participating in advances or extensions of credit hereunder or to reduce any amount receivable hereunder, in each case by an amount which the Bank reasonably deems material, then, in any such case, the Borrower shall pay the Bank, upon demand, such additional amount or amounts as will reimburse the Bank for such actual increased costs or reduction, upon Bank furnishing sufficient evidence to verify the actual increased costs or reduction.
 
(b) A certificate of the Bank setting forth the basis and calculation of any such determination, and the amount or amounts payable pursuant to Sections 3.4(a) above, shall be conclusive absent manifest error.  The Borrower shall pay the Bank the amount shown as due on any such certificate within ten (10) days after receipt thereof.

Section 3.5 Taxes.  Except as required by law, all payments made by the Borrower under this Agreement shall be made free and clear of, and without reduction for or on account of, any present or future taxes, levies, imposts, duties, charges, fees, deductions or withholdings, now or hereafter imposed, levied, collected, withheld or assessed by any Governmental Authority, excluding income and franchise taxes imposed on the Bank by (i) the United States of America or any political subdivision or taxing authority thereof or therein, (ii) the jurisdiction under the laws of which the Bank is organized or in which it has its principal office or is managed and controlled or any political subdivision or taxing authority thereof or therein, or (iii) any jurisdiction in which the Bank’s lending office is located or any political subdivision or taxing authority thereof or therein (such non-excluded taxes being called “Taxes”).  If any Taxes are required to be withheld from any amounts payable to the Bank hereunder, or under the Revolving Credit Note, the amount so payable to the Bank shall be increased to the extent necessary to yield to the Bank (after payment of all Taxes and free and clear of all liability in respect of such Taxes) interest or any such other amounts payable hereunder at the rates or in the amounts specified in this Agreement and the Revolving Credit Note.  Whenever any Taxes are payable by the Borrower, as promptly as possible thereafter, the Borrower shall send to the Bank a certified copy of an original official receipt showing payment thereof.  If the Borrower fails to pay Taxes when due to the appropriate taxing authority or fail to remit to the Bank the required receipts or other required documentary evidence, the Borrower shall indemnify the Bank for any incremental taxes, interest or penalties that may become payable by the Bank as a result of any such failure together with any actual expenses payable by the Bank in connection therewith.

Section 3.6 Payments.  All payments (including prepayments) to be made by the Borrower on account of principal, interest, fees and reimbursement obligations shall be made without set-off or counterclaim and shall be made to the Bank, at the Payment Office of the Bank in Dollars in immediately available funds not later than 4:00 p.m., Miami, Florida time, on the date on which they are payable.  
 
Section 3.7 Disbursement of Revolving Credit Loans.  The Bank shall make Revolving Credit Loans available to the Borrower by crediting an amount equal to the Revolving Credit Loan amount to the Operating Account, unless otherwise agreed upon by the parties hereto.

Section 3.8 Manner of Payment.   The Bank may in its sole discretion, but shall not be obligated to, directly charge by auto debit the Operating Account or one or more of the Borrower’s other accounts at the Payment Office or other office of the Bank for all interest and principal payments due in respect of the Revolving Credit Loans and all fees payable hereunder.  If any payment hereunder becomes due and payable on a day other than a Business Day, such payment shall be extended to the next succeeding Business Day, and, with respect to payments of principal, interest thereon shall be payable at the then applicable rate during such extension.

Section 3.9 Security Interest in CollateralThe Borrower hereby grants the Bank, as security for the payment in full of the Obligations and all other obligations of the Borrower under the Loan Documents, a security interest in the Collateral.

Section 3.10 Facility FeesThe Borrower shall pay the Bank, on or before Closing, a nonrefundable Revolving Credit Commitment fee in the amount of Four Thousand Dollars ($4,000).  In the event the Commitment Period is extended the Bank may elect to charge an extension fee, in its sole discretion, which shall not exceed ten (10) basis points of the amount of the Revolving Credit Commitment for each year the Commitment Period is extended.

ARTICLE IV
REPRESENTATIONS AND WARRANTIES
 
In order to induce the Bank to enter into this Agreement and to make the Revolving Credit Loans as provided herein, the Borrower represents and warrants to the Bank as follows:

Section 4.1 Organization, Corporate Powers, etc.   (a) Borrower is a publicly traded corporation duly formed, validly existing and in good standing under the laws of the State of Delaware, (b) Borrower has the power and authority to own properties and to carry on its business as now being conducted, (c) Borrower is duly qualified to do business in every jurisdiction wherein the conduct of its business or the ownership of its properties are such as to require such qualification, (d) Borrower has the power to execute and perform each of the Loan Documents to which it is a party, (e) Borrower has the power to borrow hereunder and to execute and deliver the Revolving Credit Note, and (f) Borrower is in compliance with all applicable federal, state and local laws, rules and regulations except where the failure to be in compliance could not reasonably be expected to have a Material Adverse Effect.

Section 4.2 Authorization of Borrowing, Enforceable Obligations.  The execution, delivery and performance by the Borrower of this Agreement and the other Loan Documents to which Borrower is a party, and the borrowings by the Borrower hereunder, (a) have been duly authorized by all requisite corporate action, (b) will not violate or require any consent under (i) any provision of law applicable to the Borrower, any governmental rule or regulation, or the articles of incorporation, bylaws or other organizational documents of the Borrower, as amended, as the case may be, or (ii) any order of any court or other agency of government binding on the Borrower or any indenture, agreement or other instrument to which Borrower is a party, or by which Borrower or any of its property is bound, and (c) will not be in conflict with, result in a breach of or constitute (with due notice and/or lapse of time) a default under, any such indenture, agreement or other instrument, or result in the creation or imposition of any lien, charge or encumbrance of any nature whatsoever upon any of the property or assets of Borrower other than as contemplated by this Agreement or the other Loan Documents.  This Agreement and each other Loan Document to which the Borrower is a party constitutes a legal, valid and binding obligation of the Borrower enforceable against the Borrower in accordance with its terms.
 
Section 4.3 Taxes.  All assessed deficiencies resulting from examinations by any Governmental Authority of the income tax returns of the Borrower has been discharged or reserved against in accordance with Generally Accepted Accounting Principles.  The Borrower has filed or caused to be filed all federal, state, local and other tax returns which are required to be filed, and have paid or has caused to be paid all taxes as shown on said returns or on any assessment received by them, to the extent that such taxes have become due, except taxes which are being contested in good faith and which are reserved against in accordance with Generally Accepted Accounting Principles.

Section 4.4 Title to Properties.  The Borrower has good and valid title to its properties and assets, except for such properties and assets as have been disposed of since the date of such financial statements as no longer used or useful in the conduct of its business or as have been disposed of in the ordinary course of business.

Section 4.5 Litigation.  There are no actions, suits or proceedings (whether or not purportedly on behalf of the Borrower) pending or, to the knowledge of the Borrower, threatened against or affecting Borrower at law or in equity or before or by any Governmental Authority, which involve any of the transactions contemplated herein or which, if adversely determined against Borrower, could reasonably be expected to result in a Material Adverse Effect; and Borrower is not in default with respect to any judgment, writ, injunction, decree, rule or regulation of any Governmental Authority.

Section 4.6 Agreements.    Borrower is not a party to any agreement or instrument or subject to any charter or other corporate restriction or any judgment, order, writ, injunction, decree or regulation which could reasonably be expected to have a Material Adverse Effect.  Borrower is not in default in any manner which could have a Material Adverse Effect in the performance, observance or fulfillment of any of the obligations, covenants or conditions contained in any agreement or instrument to which it is a party.

Section 4.7 Compliance with ERISA.  Each Plan (if any) is in compliance with ERISA; no Plan is insolvent or in reorganization, no Plan has an Unfunded Current Liability, and no Plan has an accumulated or waived funding deficiency or permitted decreases in its funding standard account within the meaning of Section 412 of the Code; neither the Borrower nor any ERISA Affiliate have incurred any material liability to or on account of a Plan pursuant to Section 515, 4062, 4063, 4064, 4201 or 4204 of ERISA or expects to incur any liability under any of the foregoing sections on account of the termination of participation in or contributions to any such Plan, no proceedings have been instituted to terminate any Plan, no condition exists which presents a risk to the Borrower of incurring a liability to or on account of a Plan pursuant to the foregoing provisions of ERISA and the Code; no lien imposed under the Code or ERISA on the assets of the Borrower exists or is likely to arise on account of any Plan; and the Borrower may terminate contributions to any other employee benefit plans maintained by it without incurring any material liability to any person interested therein.

Section 4.8 Federal Reserve Regulations; Use of Proceeds.

(a) Borrower is not engaged principally in, nor as one of their important activities, the business of extending credit for the purpose of purchasing or carrying any “margin stock” (within the meaning of Regulation U of the Board of Governors of the Federal Reserve System of the United States, as amended to the date hereof).  If requested by the Bank, the Borrower will furnish to the Bank such a statement on Federal Reserve Form U-1.

(b) No part of the proceeds of any Revolving Credit Loan will be used, whether directly or indirectly, and whether immediately, incidentally or ultimately, (i) to purchase or to carry margin stock or to extend credit to others for the purpose of purchasing or carrying margin stock, or to refund indebtedness originally incurred for such purposes, or (ii) for any purpose which violates or is inconsistent with the provisions of the Regulations T, U, or X of the Board of Governors of The Federal Reserve System.

(c) The proceeds of each Revolving Credit Loan shall be used solely for the purposes permitted under Section 3.2.

Section 4.9 Approvals.  No registration with or consent or approval of, or other action by, any Governmental Authority or any other Person is required in connection with the execution, delivery and performance of this Agreement or the other Loan Documents by the Borrower.

Section 4.10 SEC Reports; Financial Statements.  Borrower has filed all reports and registration statements required to be filed by it under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) of the Exchange Act, for the two years preceding the date hereof (the foregoing materials, including the exhibits thereto, being collectively referred to herein as the “SEC Reports”).  As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the Securities and Exchange Commission promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.  The financial statements of Borrower included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Securities and Exchange Commission with respect thereto as in effect at the time of filing.  Such financial statements have been prepared in accordance with GAAP applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of Borrower and its consolidated subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

Section 4.11 Hazardous Materials.  The Borrower is in compliance with all federal, state or local laws, ordinances, rules, regulations or policies governing Hazardous Materials and Borrower has not used Hazardous Materials on, from, or affecting any property now owned or occupied or hereafter owned or occupied by the Borrower in any manner which violates federal, state or local laws, ordinances, rules, regulations, or policies governing the use, storage, treatment, transportation, manufacture, refinement, handling, production or disposal of Hazardous Materials.

Section 4.12 Investment Company Act.   Borrower is not an “investment company”, or a company “controlled” by an “investment company”, within the meaning of the Investment Company Act of 1940, as amended.

Section 4.13 Security InterestThe security interest in the Collateral (i) will constitute and will continue to constitute perfected security interests under the UCC or other applicable law, entitled to all of the rights, benefits and priorities provided by the UCC or other applicable law, and (ii) will be and will continue to be superior and prior to the rights of all third parties existing on the date of this Agreement or arising after the date of this Agreement whether by Lien or otherwise, to the full extent provided by law.  All such action as is necessary or advisable to establish such rights of the Bank has been taken or will be taken at or prior to the time required for such purpose and there will be upon execution and delivery of the Loan Documents no necessity of any further action in order to preserve, protect and continue such rights except continued possession or control by the Bank of the Collateral delivered to it as required by the UCC or other applicable law.  All filing fees and other expenses in connection with each such action shall be paid by the Borrower and the Bank shall be reimbursed by the Borrower for any such fees and expenses incurred by the Bank.  

Section 4.14 No Default or Event of Default.  No event has occurred and is continuing and no condition exists which constitutes a Default or an Event of Default.

Section 4.15 Material Contracts.  Each Material Contract of the Borrower (a) is in full force and effect and is binding upon and enforceable against Borrower, and, to the knowledge of the Borrower, all other parties thereto in accordance with its terms, and (b) there exists no default under any Material Contract by Borrower or, to the knowledge of the Borrower, by any other party thereto which has not been fully cured or waived.

Section 4.16 Permits and Licenses.  Borrower has all material licenses, permits, franchises, or other governmental authorizations necessary to the ownership of its property or to the conduct of its activities, and shall obtain all such licenses, permits, franchises, or other governmental authorizations as may be required in the future to the extent that the failure to obtain them would materially and adversely affect the ability of the Borrower to conduct its activities as currently conducted, or in the future may be conducted, or the condition (financial or otherwise) of Borrower.

Section 4.17 Compliance with Law.   Borrower is in compliance in all material respects with all laws, rules, regulations, orders and decrees which are applicable to the Borrower or to any of its properties.

Section 4.18 Anti-Terrorism Laws.

(a) Neither Borrower nor an Affiliate of Borrower is in violation of any Anti-Terrorism Law or engages in or conspires to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law.

(b) Neither Borrower nor any Affiliate of Borrower, or to its knowledge, its respective agents acting or benefiting in any capacity in connection with the Revolving Credit Loans or other transactions hereunder, is any of the following (each a “Blocked Person”): (i) a Person that is listed in the annex to, or is otherwise subject to the provisions of, the Executive Order; (ii) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, the Executive Order; (iii) a Person with which the Bank is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law; (iv) a Person that commits, threatens or conspires to commit or supports “terrorism” as defined in the Executive Order; (v) a Person that is named as a “specially designated national” on the most current list published by the U.S. Treasury Department Office of Foreign Asset Control at its official website or any replacement website or other replacement official publication of such list; or (vi) a Person who is affiliated or associated with a person or entity listed above.

(c) Neither Borrower, or to the knowledge of Borrower, any of its agents acting in any capacity in connection with the Revolving Credit Loans or other transactions hereunder (i) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (ii) deals in, or otherwise engages in any transaction relating to, any property or interests in property blocked pursuant to the Executive Order.

Section 4.19 Disclosure.  No representation or warranty of the Borrower contained in this Agreement, any other Loan Document, or any other document, certificate or written statement furnished to the Bank by or on behalf of the Borrower for use in connection with the transactions contemplated by this Agreement contains any untrue statement of material fact or omits to state a material fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances in which they were made.

ARTICLE V
CONDITIONS OF LENDING
 
The obligation of the Bank to make each Revolving Credit Loan hereunder is subject to the following conditions precedent:

Section 5.1 Revolving Credit Note.  On or prior to the Closing Date the Bank shall have received the Revolving Credit Note duly executed by the Borrower.
 
Section 5.2 Other Loan Documents.  On or prior to the Closing Date, the Bank shall have received (i) this Agreement duly executed by the Borrower; and (ii) each other Loan Document duly executed by the signatories thereto.

Section 5.3 Supporting Documents.  The Bank shall have received on or prior to the Closing Date (i) a certificate of an Executive Officer of Borrower, dated the Closing Date and certifying (a) that attached thereto is a true and complete copy (including any amendments thereto) of the Articles of Incorporation and Bylaws of Borrower; (b) that attached thereto is a true and complete copy of resolutions adopted by the Board of Directors of Borrower authorizing the execution, delivery and performance of this Agreement and of each Loan Document to be delivered on the Closing Date to which it is a party; and (c) the incumbency and specimen signature of each Executive Officer of Borrower executing each Loan Document and any certificates or instruments furnished pursuant hereto or thereto; and (ii) such other documents as the Bank may reasonably request.

Section 5.4 No Material Adverse Effect.  Except as otherwise set forth on Schedule 5.4, there shall not have occurred, in the sole opinion of the Bank, any Material Adverse Effect since September 30, 2021.

Section 5.5 Fees.  The Borrower shall have paid Bank (i) all costs and expenses incurred by the Bank in connection with the negotiation, preparation and execution of the Loan Documents (including, without limitation, the fees and expenses of counsel), and (ii) all costs, expenses and fees incurred by Bank in connection with the transactions contemplated by the Loan Documents.

Section 5.6 Banking Relationship The Borrower shall have established its primary depository relationship with the Bank, including, but not limited to, the Operating Account and payment and cash management relationship.

Section 5.7 Blocked AccountThe Borrower shall have established the Blocked Account and shall maintain funding therein in the amount of the Revolving Credit Loans outstanding.

Section 5.8 Representations and Warranties.  The representations and warranties by the Borrower pursuant to this Agreement and the other Loan Documents to which it is a party shall be true and correct in all material respects on and as of the Borrowing Date, with the same effect as though such representations and warranties had been made on and as of such date unless such representation is as of a specific date, in which case, as of such date.

Section 5.9 No Default The Borrower shall be in compliance with all the terms and provisions set forth in this Agreement and in the other Loan Document, and no Default or Event of Default shall have occurred and be continuing on the Borrowing Date or will result after giving effect to the Revolving Credit Loan requested.

Section 5.10 Other Information, Documentation.  The Bank shall receive such other and further information and documentation as it may reasonably require provided reasonable advance notice is provided to Borrower.

ARTICLE VI
AFFIRMATIVE COVENANTS
 
Until the Revolving Credit Commitment has expired or been terminated and the principal of and interest on each Revolving Credit Loan and all fees payable hereunder shall have been paid in full, Borrower covenants and agrees with the Bank as follows:
 
Section 6.1 Notice of Adverse Change.  The Borrower will promptly notify the Bank in writing of (a) any change in the business or the operations which, in the good faith judgment of Borrower, could reasonably be expected to have a Material Adverse Effect disclosing the nature thereof, and (b) any information which indicates that any financial statements which are the subject of any representation contained in this Agreement, or which are furnished to the Bank pursuant to this Agreement, fail, in any material respect, to present fairly the financial condition and results of operations purported to be presented therein, disclosing the nature thereof.
 
Section 6.2 Notice of Default.  The Borrower will promptly notify the Bank of any Default or Event of Default which shall have occurred, which notice shall include a written statement as to such occurrence, specifying the nature thereof and the action which is proposed to be taken with respect thereto.

Section 6.3 Notice of Litigation.  The Borrower will give the Bank prompt written notice of any action, suit or proceeding at law or in equity or by or before any Governmental Authority (not previously disclosed to the Bank on or before the Closing Date) which, if adversely determined against the Borrower on the basis of the allegations and information set forth in the complaint or other notice of such action, suit or proceeding, or in the amendments thereof, if any, could reasonably be expected to either (a) have a Material Adverse Effect; or (b) result in a judgment in excess of One Hundred Fifty Thousand ($150,000) Dollars.

Section 6.4 Compliance with Applicable Laws and Rules.  The Borrower will comply in all material respects with the requirements of all applicable laws, rules, regulations and orders of any Governmental Authority.

Section 6.5 Default in Other Agreements.  The Borrower will promptly notify the Bank of any default in the performance, observance or fulfillment of any of the obligations, covenants or conditions contained in any agreement or instrument to which Borrower is a party which could reasonably be expected to have a Material Adverse Effect.

Section 6.6 Banking Relationship The Borrower will maintain the Blocked Account, fully funded as set forth herein, and its primary depository relationship and payment and cash management relationship with the Bank.

Section 6.7 Preservation of Business. The Borrower will keep its business and properties intact in all material respects, including its present operations, physical facilities, working conditions, and relationships with suppliers and clients.

Section 6.8 Further Assurances Upon the request of the Bank from time to time, the Borrower shall, at its expense, duly execute and deliver, or cause to be duly executed and delivered, such further agreements, documents and instruments, and do or cause to be done such further acts as may be reasonably necessary or proper to evidence, perfect, maintain and enforce the security interests and the priority thereof in the Collateral and to otherwise effectuate the provisions or purposes of this Agreement or any of the other Loan Documents.

ARTICLE VII
NEGATIVE COVENANTS
 
Until the Revolving Credit Commitment has expired or been terminated and the principal of and interest on each Revolving Credit Loan and all fees payable hereunder shall have been paid in full, Borrower covenants and agrees with the Bank that Borrower will not:

Section 7.1. Sale of Revolving Credit Note.  Sell, transfer, discount or otherwise dispose of Revolving Credit Note without the prior written consent of Bank.

Section 7.2 Nature of Business.  Except as set forth on Schedule 7.2, change or alter the nature of its business, in any material respect, from the nature of the business engaged in by it on the date hereof.

Section 7.3 Federal Reserve Regulations.  Permit any Revolving Credit Loan or the proceeds of any Revolving Credit Loan to be used for any purpose which violates or is inconsistent with the provisions of Regulations T, U or X of the Board of Governors of the Federal Reserve System.
 
Section 7.4 Impairment of Security Interest.  Take or omit to take any action which might or would have the result of effecting or impairing the security interest in any property subject to a security interest in favor of the Bank and Borrower shall not grant to any person any interest whatsoever in any property subject to a security interest in favor of the Bank.

Section 7.5 Anti-Terrorism LawsThe Borrower and its Affiliates and agents shall not (a) conduct any business or engage in any transaction or dealing with any Blocked Person, including making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, (b) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to the Executive Order; or (c) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in the Executive Order, the USA Patriot Act or any other Anti-Terrorism Law.  The Borrower shall deliver to the Bank any certification or other evidence requested from time to time by the Bank in its sole discretion, confirming the Borrower's compliance with this Section.

ARTICLE VIII
EVENTS OF DEFAULT
 
Section 8.1  Events of Default.  In the case of the happening of any of the following events (each an “Event of Default”):

(a) failure by the Borrower to pay the principal of or any interest on any Revolving Credit Loan within three (3) Business Days of when said payment is due and payable or any fees or other amounts payable under this Agreement or any other Loan Document;

(b) failure by the Borrower to observe or perform any covenant, condition or agreement of Borrower to be observed or performed pursuant to this Agreement or any other Loan Document (other than those specified in clause (a) of this Section 8.1) and the expiration of fifteen (15) days after notice from Bank to Borrower without cure;

(c) any representation or warranty made or deemed made in this Agreement or any other Loan Document shall prove to be false or misleading in any material respect when made or given or when deemed made or given;

(d) any material report, certificate, financial statement or other instrument furnished in connection with this Agreement or any other Loan Document or the borrowings hereunder, shall prove to be false or misleading in any material respect when made or given or when deemed made or given;
 
(e) default in the performance or compliance in respect of any agreement or condition relating to (i) any Indebtedness of the Borrower in excess of Fifty ($50,000) Dollars (other than as described in clause (ii) below), individually or in the aggregate, if the effect of such default is to accelerate the maturity of such Indebtedness or to permit the holder or obligee thereof (or a trustee on behalf of such holder or obligee) to cause such Indebtedness to become due prior to the stated maturity thereof, (ii) any Indebtedness of the Borrower or its Affiliates owing to the Bank or any Bank Affiliate (other than the Revolving Credit Loans);

(f) Borrower shall (i) voluntarily commence any proceeding or file any petition seeking relief under Title 11 of the United States Code or any other federal or state bankruptcy, insolvency or similar law, (ii) consent to the institution of, or fail to controvert in a timely and appropriate manner, any such proceeding or the filing of any such petition, (iii) apply for or consent to the employment of a receiver, trustee, custodian, or similar official for itself or for a substantial part of its property; (iv) file an answer admitting the material allegations of a petition filed against it in such proceeding, (v) make a general assignment for the benefit of creditors, (vi) take corporate action for the purpose of effecting any of the foregoing, (vii) become unable or admit in writing its inability or fail generally to pay its debts as they become due, or (viii) take corporate action for the purpose of effecting any of the foregoing;

(g)           an involuntary proceeding shall be commenced or an involuntary petition shall be filed in a court of competent jurisdiction seeking (i) relief in respect of Borrower or of a substantial part of its property, under Title 11 of the United States Code or any other federal or state bankruptcy insolvency or similar law, (ii) the appointment of a receiver, trustee, custodian, or similar official for Borrower or for a substantial part of its property, or (iii) the winding-up or liquidation of Borrower and such proceeding or petition shall continue undismissed for 60 days or an order or decree approving or ordering any of the foregoing shall continue unstayed and in effect for 60 days;

(h) One or more orders, judgments or decrees for the payment of money in excess of One Hundred Fifty Thousand ($150,000) Dollars in the aggregate shall be rendered against Borrower and the same shall not have been paid in accordance with such judgment, order or decree and either (i) an enforcement proceeding shall have been commenced by any creditor upon such judgment, order or decree, or (ii) there shall have been a period of thirty (30) days during which a stay of enforcement of such judgment order or decree, by reason of pending appeal or otherwise, was not in effect;

(i) any Loan Document or any material provision thereof shall for any reason cease to be in full force and effect in accordance with its terms or Borrower shall so assert in writing; or

(j) any of the Liens purported to be granted pursuant to the Bank shall cease for any reason to be legal, valid and enforceable liens on the collateral purported to be covered thereby or shall cease to have the priority purported to be created thereby, unless such Lien has been released by the Bank in accordance with the terms and conditions hereof;

then, during the continuance of any such event, the Bank may, in its sole discretion, without further notice to the Borrower, take any or all of the following actions, at the same or different times, (1) (a) terminate the Revolving Credit Commitment and the Revolving Credit Loans and (b) declare (i) the Revolving Credit Note, both as to principal and interest, and (ii) all other Obligations, to be forthwith due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained herein, in the Revolving Credit Note, or in the other Loan Documents to the contrary notwithstanding; (2) exercise any or all of the rights and remedies afforded to the Bank by the Uniform Commercial Code or the Loan Documents or otherwise possessed by the Bank; provided, however, that if an event specified in Section 8.1(f) or (g) shall have occurred, the Revolving Credit Commitment and the Revolving Credit Loans shall automatically terminate and interest, principal and amounts referred to in the preceding clauses (i) and (ii) shall be immediately due and payable without presentment, demand, protest, or other notice of any kind, all of which are expressly waived, anything contained herein or in the Revolving Credit Note to the contrary notwithstanding.
 
ARTICLE IX
MISCELLANEOUS
 
Section 9.1  Notices.  Any notice shall be in writing and shall be conclusively deemed to have been received by a party hereto and to be effective on the day on which delivered to such party at the address set forth below, or, in the case of telecopy notice, when acknowledged as received, or if sent by registered or certified mail, on the third Business Day after the day on which mailed in the United States, addressed to such party at said address, or if sent by email, when actually received:

(a)           if to the Bank, at

Professional Bank
5100 PGA Boulevard, Suite 101
Palm Beach Gardens, FL 33418
Attention:  Melissa Norman, Vice President
Email:  mnorman@myprobank.com

With copies to:

Dickinson Wright PLLC
350 East Las Olas Boulevard, Suite 1750
Fort Lauderdale, Florida 33301
Attention:  Clint J. Gage
Email:  cgage@dickinsonwright.com
Facsimile:  844-670-6009

(b)           if to the Borrower, at

Healthier Choices Management Corp.
3800 N. 28th Way, #1
Hollywood, Florida 33020
Attention:  Jeffrey E. Holman, CEO
Email: jholman@hcmc1.com
Facsimile: 

With copies to:

Cozen O’Connor
Southeast Financial Center
200 South Biscayne Blvd., 30th Floor
Miami, Florida 33131
Attention:  Martin Schrier, Esq.
Email:  mschrier@cozen.com

as to each such party at such other address as such party shall have designated to the other in a written notice complying as to delivery with the provisions of this Section 9.1.
 
Section 9.2 Effectiveness; Survival of Agreement.  This Agreement shall become effective on the date on which all parties hereto shall have signed a counterpart copy hereof and shall have delivered the same to the Bank.  All covenants, agreements, representations and warranties made herein and in the other Loan Documents and in the certificates delivered pursuant hereto or thereto shall survive the making by the Bank of the Revolving Credit Loans herein contemplated and the execution and delivery to the Bank of the Revolving Credit Note evidencing the Revolving Credit Loans and shall continue in full force and effect so long as any Revolving Credit Note is outstanding and unpaid.  Whenever in this Agreement any of the parties hereto is referred to, such reference shall be deemed to include the successors and assigns of such party; and all covenants, promises and agreements by or on behalf of the Borrower which are contained in this Agreement shall bind and inure to the benefit of the respective successors and assigns of the Bank.  The Borrower may not assign or transfer any of its interest under this Agreement, the Revolving Credit Note, or any other Loan Document without the prior written consent of the Bank.  The obligations of the Borrower pursuant to Section 3.5, Section 3.6, Section 3.8, Section 9.3 and Section 9.10 shall survive termination of this Agreement and payment of the Obligations.

Section 9.3 Expenses of the Bank.  The Borrower agrees (a) to indemnify, defend and hold harmless the Bank and its officers, directors, employees, agents, advisors and affiliates (each, an “indemnified person”) from and against any and all losses, claims, damages, liabilities or judgments to which any such indemnified person may be subject and arising out of or in connection with the Loan Documents, the financings contemplated hereby, the use of any proceeds of such financings or any related transaction or any claim, litigation, investigation or proceeding relating to any of the foregoing, whether or not any of such indemnified persons is a party thereto, and to reimburse each of such indemnified persons upon demand for any expenses, including reasonable legal fees, incurred in connection with the investigation or defending any of the foregoing; provided that the foregoing indemnity will not, as to any indemnified person, apply to losses, claims, damages, liabilities, judgments or related expenses to the extent arising from the willful misconduct or gross negligence of such indemnified person; and (b) to reimburse the Bank from time to time, upon demand, all out-of-pocket expenses (including reasonable expenses of its due diligence investigation, along with disbursements and reasonable fees of counsel and the allocated costs of internal counsel) incurred in connection with the financings contemplated under this Agreement, the preparation, execution and delivery of this  Agreement and the other Loan Documents, any amendments and waivers hereof or thereof, the security arrangements contemplated thereby and the enforcement thereof.  

Section 9.4 No Waiver of Rights by the Bank.  Neither any failure nor any delay on the part of the Bank in exercising any right, power or privilege hereunder or under the Revolving Credit Note or any other Loan Document shall operate as a waiver thereof, nor shall a single or partial exercise thereof preclude any other or further exercise of any other right, power or privilege.

Section 9.5 Submission to Jurisdiction; Jury Waiver.  THE BORROWER HEREBY IRREVOCABLY SUBMITS TO THE JURISDICTION OF ANY STATE OR FEDERAL COURT IN THE STATE OF FLORIDA, COUNTY OF BROWARD, IN ANY ACTION, SUIT OR PROCEEDING BROUGHT AGAINST IT AND RELATED TO OR IN CONNECTION WITH THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, AND TO THE EXTENT PERMITTED BY APPLICABLE LAW, THE BORROWER HEREBY WAIVES AND AGREES NOT TO ASSERT BY WAY OF MOTION, AS A DEFENSE OR OTHERWISE, IN ANY SUCH SUIT, ACTION OR PROCEEDING ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF SUCH COURTS, THAT THE SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM, THAT THE VENUE OF THE SUIT, ACTION OR PROCEEDING IS IMPROPER, OR THAT THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR ANY OTHER DOCUMENT OR INSTRUMENT REFERRED TO HEREIN OR THEREIN WHERE THE SUBJECT MATTER THEREOF MAY NOT BE LITIGATED IN OR BY SUCH COURTS.  TO THE EXTENT PERMITTED BY APPLICABLE LAW, THE BORROWER AGREES NOT TO (i) SEEK AND HEREBY WAIVE THE RIGHT TO ANY REVIEW OF THE JUDGMENT OF ANY SUCH COURT BY ANY COURT OF ANY OTHER NATION OR JURISDICTION WHICH MAY BE CALLED UPON TO GRANT AN ENFORCEMENT OF SUCH JUDGMENT AND (ii) ASSERT ANY COUNTERCLAIM IN ANY SUCH SUIT, ACTION OR PROCEEDING UNLESS SUCH COUNTERCLAIM CONSTITUTES A COMPULSORY OR MANDATORY COUNTERCLAIM UNDER APPLICABLE RULES OF CIVIL PROCEDURE.  THE BORROWERS AGREE THAT SERVICE OF PROCESS MAY BE MADE UPON THEM BY CERTIFIED OR REGISTERED MAIL TO THE ADDRESS FOR NOTICES SET FORTH IN THIS AGREEMENT OR ANY METHOD AUTHORIZED BY THE LAWS OF FLORIDA.  EACH PARTY HERETO WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT, THE REVOLVING CREDIT NOTE OR ANY OTHER LOAN DOCUMENT.

Section 9.6  Extension of Maturity.  Except as otherwise expressly provided herein, whenever a payment to be made hereunder shall fall due and payable on any day other than a Business Day, such payment may be made on the next succeeding Business Day, and such extension of time shall be included in computing interest.

Section 9.7 Modification of Agreement.  No modification, amendment or waiver of any provision of this Agreement, the Revolving Credit Note or any other Loan Document, nor consent to any departure by the Borrower therefrom shall in any event be effective unless the same shall be in writing and signed by the Bank and the Borrower, as the case may be, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given.  No notice to or demand on the Borrower in any case shall entitle the Borrower to any other or further notice or demand in the same, similar or other circumstance unless required by the terms of this Agreement.
 
Section 9.8 Severability.  In case any one or more of the provisions contained in this Agreement, the Revolving Credit Note or in any other Loan Document should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and therein shall not in any way be affected or impaired thereby.

Section 9.9 Sale of Participations; Assignments.  The Bank reserves the right to sell participations in or to sell and assign its rights, duties or obligations with respect to the Revolving Credit Loans to such banks, lending institutions or other parties as it may choose and without the consent of the Borrower, provided that the Bank shall notify the Borrower promptly following such participation or assignment.  The Bank may furnish any information concerning the Borrower in its possession from time to time to any assignee or participant (or proposed assignee or participant), provided that the Bank shall notify any such assignee or participant (or proposed assignee or participant) in connection with any contemplated participation in, or assignment of, the Revolving Credit Loans, that such information is confidential and shall obtain an agreement from such transferee or participant requiring that such transferee or participant treat such information as confidential and use commercially reasonable efforts to maintain the confidentiality of same.

Section 9.10 Reinstatement; Certain Payments.  If claim is ever made upon the Bank for repayment or recovery of any amount or amounts received by the Bank in payment or on account of any of the Obligations under this Agreement, the Bank shall give prompt notice of such claim to the Borrower, and if the Bank repays all or part of said amount by reason of (a) any judgment, decree or order of any court or administrative body having jurisdiction over the Bank or any of its property, or (b) any settlement or compromise of any such claim effected by the Bank with any such claimant, then and in such event the Borrower agrees that any such judgment, decree, order, settlement or compromise shall be binding upon such Borrower notwithstanding the cancellation of the Revolving Credit Note or other instrument evidencing the Obligations under this Agreement or the termination of this Agreement, and the Borrower shall be and remain liable to the Bank hereunder for the amount so repaid or recovered to the same extent as if such amount had never originally been received by the Bank.

Section 9.11 Right of Setoff.  If an Event of Default shall have occurred and be continuing, the Bank and each other Affiliate of the Bank are each hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by the Bank to or for the credit or the account of the Borrowers against any and all the Obligations.  The rights of the Bank under this Section 9.11 are in addition to other rights and remedies (including, without limitation, other rights of setoff) which the Bank may have.

Section 9.12  Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which, taken together, shall constitute one and the same instrument.

Section 9.13 Headings.  Section headings used herein are for convenience of reference only and are not to affect the construction of or be taken into consideration in interpreting this Agreement.
 
Section 9.14 Construction.  This Agreement is the result of negotiations between, and has been reviewed by, the Borrowers and the Bank and their respective counsel.  Accordingly, this Agreement shall be deemed to be the product of each party hereto, and no ambiguity shall be construed in favor of or against either the Borrowers or the Bank.

Section 9.15 USA PATRIOT Act; Anti-Money Laundering Legislation. Borrower acknowledges that, pursuant to the USA Patriot Act, and other applicable anti-money laundering, anti-terrorist financing, government sanction and “know your client” laws, whether within the United States or elsewhere (collectively, including any guidelines or orders thereunder, “AML Legislation”), the Bank may be required to obtain, verify and record information regarding Borrower, its respective directors, authorized signing officers, direct or indirect shareholders or other Persons in control of Borrower, and the transactions contemplated hereby.  Borrower shall promptly provide all such information, including supporting documentation and other evidence, as may be reasonably requested by the Bank, or any prospective assign or participant of the Bank, in order to comply with any applicable AML Legislation, whether now or hereafter in existence.

Section 9.16 Choice of LawThis Agreement shall be construed in accordance with and governed by the laws of the State of Florida without giving effect to principles of conflict or choice of laws.


[SIGNATURES ON FOLLOWING PAGES]
  

IN WITNESS WHEREOF, the Borrower and the Bank have caused this Agreement to be duly executed by their duly authorized officers, as of the day and year first above written.

PROFESSIONAL BANK

By: /s/ Melissa Norman
Name: Melissa Norman
Title: Vice President


HEALTHIER CHOICES MANAGEMENT CORP.

By: /s/ Jeffrey E. Holman
Name: Jeffrey E. Holman
Title: Chief Executive Officer



EXHIBIT A

NOTICE OF REVOLVING CREDIT LOAN BORROWING



                                               [Date]


Professional Bank
5100 PGA Boulevard, Suite 101
Palm Beach Gardens, FL 33418
Attention: Melissa Norman, Vice President

Re: HEALTHIER CHOICES MANAGEMENT CORP.

Gentlemen:

Pursuant to the RLOC Credit Agreement dated as of December 23, 2021 (as the same may have been and may hereafter be amended, modified or supplemented the “Credit Agreement”) by and between Healthier Choices Management Corp., a Delaware corporation, as “Borrower”, and Professional Bank, a Florida banking corporation, as “Bank”, the undersigned hereby gives the Bank notice that Borrower requests a Revolving Credit Loan as follows:
 
1. The requested Borrowing Date is ____________________.

2. The amount of the requested borrowing is $____________________, which shall be deposited into the Operating Account on  (date).

The Borrower hereby certifies that (i) the representations and warranties contained in the Credit Agreement and the other Loan Documents are true, correct and complete in all material respects on and as of the date hereof to the same extent as though made on and as of the date hereof, except for such representations and warranties that are made as of a specific date; (ii) no Default or Event of Default has occurred and is continuing under the Credit Agreement or will result after giving effect to the Revolving Credit Loan requested hereunder; and (iii) the amount of the proposed borrowing hereunder will not cause the aggregate outstanding principal amount of Revolving Credit Loans (after giving effect to the proposed borrowing requested hereunder) to exceed the Revolving Credit Commitment or the Borrowing Base.

Capitalized terms used herein but not defined shall have the respective meanings given to them in the Credit Agreement.

IN WITNESS WHEREOF, the undersigned has caused this document to be executed and delivered by its Executive Officer as of the date written above.

HEALTHIER CHOICES MANAGEMENT CORP.

By:  
Name: Jeffrey E. Holman
Title: Chief Executive Officer


EX-10.10 5 ex10_10.htm HCMC REVOLVING NOTE (IWT)  
Exhibit 10.10



FLORIDA DOCUMENTARY STAMP TAX IN THE AMOUNT OF $2,450.00 HAS BEEN PAID OR WILL BE PAID DIRECTLY TO THE FLORIDA DEPARTMENT OF REVENUE

REVOLVING CREDIT NOTE

$2,000,000
December 23, 2021

FOR VALUE RECEIVED, HEALTHIER CHOICES MANAGEMENT CORP., a Delaware corporation (the “Borrower”), promises to pay PROFESSIONAL BANK, a Florida banking corporation (the “Bank”), on or before the Commitment Termination Date, TWO MILLION DOLLARS ($2,000,000) or, if less, the unpaid principal amount of all Revolving Credit Loans made by the Bank to the Borrower under the Credit Agreement referred to below.

Accrued interest on the principal balance from time to time outstanding under this Note shall be payable monthly, commencing on January 24, 2022, and continuing on the twenty-fourth (24th) day of each month thereafter.

This Note, as amended, restated, amended and restated, supplemented or otherwise from time to time, is the “Note” referred to in that certain Credit Agreement dated as of the date hereof, between the Borrower and the Bank (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”) and is issued pursuant to and entitled to the benefits of the Credit Agreement to which reference is hereby made for a more complete statement of the terms and conditions under which the Revolving Credit Loans evidenced hereby were made and are to be repaid.  Capitalized terms used herein without definition shall have the meanings set forth in the Credit Agreement.

The Bank shall record the date and amount of each Revolving Credit Loan and the date and amount of each payment or prepayment of principal of each Revolving Credit Loan on the grid schedule annexed to this Note; provided, however, that the failure of the Bank to set forth such Revolving Credit Loans, payments and other information on the attached grid schedule shall not in any manner affect the obligation of the Borrower to repay the Revolving Credit Loans made by the Bank in accordance with the terms of this Note.

This Note is subject to prepayment as provided in Section 3.3 of the Credit Agreement.  Subject to the immediately preceding sentence, no reference herein to the Credit Agreement and no provision of this Note or the Credit Agreement shall alter or impair the obligation of the Borrower, which is absolute and unconditional, to pay the principal of and interest on this Note at the place, at the respective times, and in the currency herein prescribed.

Upon the occurrence and during the continuance of an Event of Default, the unpaid balance of the principal amount of this Note together with all accrued but unpaid interest thereon, may become, or may be declared to be, due and payable in the manner, upon the conditions and with the effect provided in the Credit Agreement.

All payments of principal and interest in respect of this Note shall be made in lawful money of the United States of America in immediately available funds at the Payment Office of the Bank, or in such other manner in accordance with the terms of the Credit Agreement and the other Loan Documents.

The Borrower waives presentment, demand, protest, and notice of any kind in connection with this Note.

THIS NOTE SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF FLORIDA WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW.


[SIGNATURE ON THE FOLLOWING PAGE]

IN WITNESS WHEREOF, the Borrower has caused this Note to be executed and delivered by its duly authorized officer as of the day and year first above written.

HEALTHIER CHOICES MANAGEMENT CORP.

By: /s/ Jeffrey E. Holman
Name: Jeffrey E. Holman
Title: Chief Executive Officer




SCHEDULE OF LOANS


Date of Loan
Principal Amount of
Loan
Interest Rate
Amount of
Principal Paid
Notation Made by

EX-10.12 6 ex10_12.htm EXHIBIT 10.12  
HEALTHIER CHOICES MANAGEMENT CORP.
THIRD AMENDED AND RESTATED RESTRICTED STOCK AWARD AGREEMENT

THIRD AMENDED AND RESTATED RESTRICTED STOCK AWARD AGREEMENT (this “Agreement”), effective as of February 12, 2021 (the “Date of Grant”), between Healthier Choices Management Corp., a Delaware corporation (the “Company”), and Jeffrey E. Holman (the “Grantee”).
WHEREAS, the Company has adopted the Vapor Corp 2015 Equity Incentive Plan, as amended (the “Plan”), in order to provide incentive compensation to certain employees and directors of the Company and its Subsidiaries;
WHEREAS, the Committee has previously granted to the Grantee an Award of Restricted Stock (as defined in the Plan) (the “Original Grant”) as provided under the Plan to encourage the Grantee’s efforts toward the continuing success of the Company;
WHEREAS, the Original Grant was evidenced by the Restricted Stock Award Agreement dated August 12, 2019 and such agreement was amended and restated as of August 12, 2019 and August 12, 2020 (the “Award Agreement”); and
WHEREAS, the Committee and Grantee have agreed to amend and restate the Award Agreement pursuant to the terms and conditions set forth herein.
NOW, THEREFORE, the parties hereto agree as follows:

1.
Grant of Restricted Stock.

1.1. The Company has granted to the Grantee an award of 11,000,000,000 shares of Restricted Stock (the “Initial Award”) pursuant to the Original Agreement.  In addition, the Company has granted to the Grantee an award of 1,100,000,000 shares of Restricted Stock (the “New Award” and together with the Initial Award, the “Award”) in consideration for agreeing to a new vesting schedule for the Awards in accordance with Section 3 hereto.  The shares of Restricted Stock granted pursuant to the Award shall be issued in the form of book entry shares in the name of the Grantee as soon as reasonably practicable after the Date of Grant and shall be subject to the execution and return of this Agreement by the Grantee (or the Grantee’s estate, if applicable) to the Company as provided in Section 9 hereof.
1.2. Except as otherwise expressly set forth herein, the capitalized terms used in this Agreement shall have the same definitions as set forth in the Plan.  This grant and the Award are subject to the terms of the Plan, except as expressly provided herein.

2. Restrictions on Transfer.  The shares of Restricted Stock issued under this Agreement may not be sold, transferred or otherwise disposed of and may not be pledged or otherwise hypothecated until all restrictions on such Restricted Stock shall have lapsed in the manner provided in Section 3, 4 or 5 hereof.
3. Lapse of Restrictions Generally.  Except as provided in Sections 4, 5 and 6 hereof, all of the shares of Restricted Stock issued hereunder (rounded down to the nearest whole share, if necessary) shall vest, and the restrictions with respect to such Restricted Stock shall lapse, as set forth in the vesting schedule attached as Exhibit A hereto.
4. Effect of Certain Terminations of Employment.  If the Grantee’s employment terminates as a result of the Grantee’s death, retirement or becoming disabled after the Date of Grant, all shares of Restricted Stock which have not become vested in accordance with Section 3 or 5 hereof shall vest, and the restrictions on such Restricted Stock shall lapse, as of the date of such termination.
5. Effect of Change in Control.  In the event of a Change in Control at any time on or after the Date of Grant, all shares of Restricted Stock which have not become vested in accordance with Section 3 or 4 hereof shall vest, and the restrictions on such Restricted Stock shall lapse, immediately.
6. Forfeiture of Restricted Stock.  In addition to the circumstance described in Section 9(a) hereof, any and all shares of Restricted Stock which have not become vested in accordance with Section 3, 4 or 5 hereof shall be forfeited and shall revert to the Company upon the termination by the Grantee, the Company or its subsidiaries of the Grantee’s employment for any reason other than those set forth in Section 4 or other than without “Cause” prior to the date on which such shares of Restricted Stock would otherwise vest.  All or any portion of the Restricted Stock may be forfeited by the Grantee prior to vesting at his or her sole discretion.
7. Delivery of Restricted Stock.  A stock certificate with respect to shares attributable to Restricted Stock for which the restrictions have lapsed shall be delivered to the Grantee or the Grantee’s estate, if applicable, as soon as practicable following the date on which the restrictions on such Restricted Stock have lapsed, free of all restrictions hereunder.
8. Dividends and Voting Rights.  Subject to the terms of the Plan, upon issuance of the Restricted Stock, the Grantee shall have all of the rights of a stockholder with respect to such Stock, including the right to vote the Stock; provided, however, that the Grantee shall have no right to receive all dividends or other distributions paid or made with respect thereto until such Restricted Stock has vested.
9. No Right to Continued Employment.  Nothing in this Agreement or the Plan shall interfere with or limit in any way the right of the Company or its Subsidiaries to terminate the Grantee’s employment, nor confer upon the Grantee any right to continuance of employment by the Company or any of its Subsidiaries or continuance of service as a Board member.
10. Withholding of Taxes.  Except as otherwise agreed by the Company and Grantee, prior to the delivery to the Grantee (or the Grantee’s estate, if applicable) of a stock certificate with respect to shares of Restricted Stock for which all restrictions have lapsed, the Grantee (or the Grantee’s estate) shall pay to the Company the federal, state and local income taxes and other amounts as may be required by law to be withheld by the Company (the “Withholding Taxes”) with respect to such Restricted Stock.  By executing and returning this Agreement, the Grantee (or the Grantee’s estate) shall be deemed to elect to have the Company withhold a portion of such Restricted Stock having an aggregate Fair Market Value equal to the Withholding Taxes in satisfaction of the Withholding Taxes, such election to continue in effect until the Grantee (or the Grantee’s estate) notifies the Company before such delivery that the Grantee (or the Grantee’s estate) shall satisfy such obligation in cash, in which event the Company shall not withhold a portion of such Restricted Stock as otherwise provided in this Section 10.
11. Grantee Bound by the Plan.  The Grantee hereby acknowledges receipt of a copy of the Plan and this Agreement, and that he or she has been granted the opportunity to review and consult with advisors on such agreements, and agrees to be bound by all the terms and provisions thereof.
12. Modification of Agreement.  This Agreement may be modified, amended, suspended or terminated, and any terms or conditions may be waived by the Company prior to the lapse of restriction.  Notwithstanding the foregoing, no such modification may negatively impact the rights of the Grantee without the Grantee’s written consent.
13. Severability.  Should any provision of this Agreement be held by a court of competent jurisdiction to be unenforceable or invalid for any reason, the remaining provisions of this Agreement shall not be affected by such holding and shall continue in full force in accordance with their terms.
14. Governing Law.  The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Delaware without giving effect to the conflicts of laws principles thereof.
15. Successors in Interest.  This Agreement shall inure to the benefit of and be binding upon any successor to the Company.  This Agreement shall inure to the benefit of the Grantee’s legal representatives.  All obligations imposed upon the Grantee and all rights granted to the Company under this Agreement shall be binding upon the Grantee’s heirs, executors, administrators and successors.
16. Entire Agreement.  This Agreement and the Plan constitute the entire understanding between the Grantee and the Company and its Subsidiaries, and supersede all other agreements, whether written or oral, with respect to the Award.
17. Headings.  The headings of this Agreement are inserted for convenience only and do not constitute a part of this Agreement.
18. Counterparts.  This Agreement may be executed simultaneously in two or more counterparts, each of which shall constitute an original, but all of which taken together shall constitute one and the same agreement.

[REMINDER OF PAGE INTENTIONALLY LEFT BLANK.]

IN WITNESS WHEREOF, the Company has caused this Third Amended and Restated Restricted Stock Award Agreement to be executed by its duly authorized representative and Grantee has executed this Agreement.

 
HEALTHIER CHOICES MANAGEMENT CORP.
  
 
By:          /s/ Christopher Santi
 
Name: Christopher Santi
 
Title:   President
  
 
By:          /s/ Jeffrey Holman
 
Name:   Jeffrey Holman

EXHIBIT A
VESTING SCHEDULE

March 31, 2021 – 12.5%
June 30, 2021 – 12.5%
September 30, 2021 – 12.5%
December 31, 2021 –- 12.5%
March 31, 2022 – 12.5%
June 30, 2022 – 12.5%
September 30, 2022 – 12.5%
December 31, 2022 –- 12.5%
EX-10.13 7 ex10_13.htm EXHIBIT 10.13  
HEALTHIER CHOICES MANAGEMENT CORP.
THIRD AMENDED AND RESTATED RESTRICTED STOCK AWARD AGREEMENT

THIRD AMENDED AND RESTATED RESTRICTED STOCK AWARD AGREEMENT (this “Agreement”), effective as of February 12, 2021 (the “Date of Grant”), between Healthier Choices Management Corp., a Delaware corporation (the “Company”), and Christopher Santi (the “Grantee”).
WHEREAS, the Company has adopted the Vapor Corp 2015 Equity Incentive Plan, as amended (the “Plan”), in order to provide incentive compensation to certain employees and directors of the Company and its Subsidiaries;
WHEREAS, the Committee has previously granted to the Grantee an Award of Restricted Stock (as defined in the Plan) (the “Original Grant”) as provided under the Plan to encourage the Grantee’s efforts toward the continuing success of the Company;
WHEREAS, the Original Grant was evidenced by the Restricted Stock Award Agreement dated August 12, 2019 and such agreement was amended and restated as of August 12, 2019 and August 12, 2020 (the “Award Agreement”); and
WHEREAS, the Committee and Grantee have agreed to amend and restate the Award Agreement pursuant to the terms and conditions set forth herein.
NOW, THEREFORE, the parties hereto agree as follows:

1. Grant of Restricted Stock.

1.1. The Company has granted to the Grantee an award of 8,000,000,000 shares of Restricted Stock (the “Initial Award”) pursuant to the Original Agreement.  In addition, the Company has granted to the Grantee an award of 800,000,000 shares of Restricted Stock (the “New Award” and together with the Initial Award, the “Award”) in consideration for agreeing to a new vesting schedule for the Awards in accordance with Section 3 hereto.  The shares of Restricted Stock granted pursuant to the Award shall be issued in the form of book entry shares in the name of the Grantee as soon as reasonably practicable after the Date of Grant and shall be subject to the execution and return of this Agreement by the Grantee (or the Grantee’s estate, if applicable) to the Company as provided in Section 9 hereof.
1.2. Except as otherwise expressly set forth herein, the capitalized terms used in this Agreement shall have the same definitions as set forth in the Plan.  This grant and the Award are subject to the terms of the Plan, except as expressly provided herein.

2. Restrictions on Transfer.  The shares of Restricted Stock issued under this Agreement may not be sold, transferred or otherwise disposed of and may not be pledged or otherwise hypothecated until all restrictions on such Restricted Stock shall have lapsed in the manner provided in Section 3, 4 or 5 hereof.
3. Lapse of Restrictions Generally.  Except as provided in Sections 4, 5 and 6 hereof, all of the shares of Restricted Stock issued hereunder (rounded down to the nearest whole share, if necessary) shall vest, and the restrictions with respect to such Restricted Stock shall lapse, as set forth in the vesting schedule attached as Exhibit A hereto.
4. Effect of Certain Terminations of Employment.  If the Grantee’s employment terminates as a result of the Grantee’s death, retirement or becoming disabled after the Date of Grant, all shares of Restricted Stock which have not become vested in accordance with Section 3 or 5 hereof shall vest, and the restrictions on such Restricted Stock shall lapse, as of the date of such termination.
5. Effect of Change in Control.  In the event of a Change in Control at any time on or after the Date of Grant, all shares of Restricted Stock which have not become vested in accordance with Section 3 or 4 hereof shall vest, and the restrictions on such Restricted Stock shall lapse, immediately.
6. Forfeiture of Restricted Stock.  In addition to the circumstance described in Section 9(a) hereof, any and all shares of Restricted Stock which have not become vested in accordance with Section 3, 4 or 5 hereof shall be forfeited and shall revert to the Company upon the termination by the Grantee, the Company or its subsidiaries of the Grantee’s employment for any reason other than those set forth in Section 4 or other than without “Cause” prior to the date on which such shares of Restricted Stock would otherwise vest.  All or any portion of the Restricted Stock may be forfeited by the Grantee prior to vesting at his or her sole discretion.
7. Delivery of Restricted Stock.  A stock certificate with respect to shares attributable to Restricted Stock for which the restrictions have lapsed shall be delivered to the Grantee or the Grantee’s estate, if applicable, as soon as practicable following the date on which the restrictions on such Restricted Stock have lapsed, free of all restrictions hereunder.
8. Dividends and Voting Rights.  Subject to the terms of the Plan, upon issuance of the Restricted Stock, the Grantee shall have all of the rights of a stockholder with respect to such Stock, including the right to vote the Stock; provided, however, that the Grantee shall have no right to receive all dividends or other distributions paid or made with respect thereto until such Restricted Stock has vested.
9. No Right to Continued Employment.  Nothing in this Agreement or the Plan shall interfere with or limit in any way the right of the Company or its Subsidiaries to terminate the Grantee’s employment, nor confer upon the Grantee any right to continuance of employment by the Company or any of its Subsidiaries or continuance of service as a Board member.
10. Withholding of Taxes.  Except as otherwise agreed by the Company and Grantee, prior to the delivery to the Grantee (or the Grantee’s estate, if applicable) of a stock certificate with respect to shares of Restricted Stock for which all restrictions have lapsed, the Grantee (or the Grantee’s estate) shall pay to the Company the federal, state and local income taxes and other amounts as may be required by law to be withheld by the Company (the “Withholding Taxes”) with respect to such Restricted Stock.  By executing and returning this Agreement, the Grantee (or the Grantee’s estate) shall be deemed to elect to have the Company withhold a portion of such Restricted Stock having an aggregate Fair Market Value equal to the Withholding Taxes in satisfaction of the Withholding Taxes, such election to continue in effect until the Grantee (or the Grantee’s estate) notifies the Company before such delivery that the Grantee (or the Grantee’s estate) shall satisfy such obligation in cash, in which event the Company shall not withhold a portion of such Restricted Stock as otherwise provided in this Section 10.
11. Grantee Bound by the Plan.  The Grantee hereby acknowledges receipt of a copy of the Plan and this Agreement, and that he or she has been granted the opportunity to review and consult with advisors on such agreements, and agrees to be bound by all the terms and provisions thereof.
12. Modification of Agreement.  This Agreement may be modified, amended, suspended or terminated, and any terms or conditions may be waived by the Company prior to the lapse of restriction.  Notwithstanding the foregoing, no such modification may negatively impact the rights of the Grantee without the Grantee’s written consent.
13. Severability.  Should any provision of this Agreement be held by a court of competent jurisdiction to be unenforceable or invalid for any reason, the remaining provisions of this Agreement shall not be affected by such holding and shall continue in full force in accordance with their terms.
14. Governing Law.  The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Delaware without giving effect to the conflicts of laws principles thereof.
15. Successors in Interest.  This Agreement shall inure to the benefit of and be binding upon any successor to the Company.  This Agreement shall inure to the benefit of the Grantee’s legal representatives.  All obligations imposed upon the Grantee and all rights granted to the Company under this Agreement shall be binding upon the Grantee’s heirs, executors, administrators and successors.
16. Entire Agreement.  This Agreement and the Plan constitute the entire understanding between the Grantee and the Company and its Subsidiaries, and supersede all other agreements, whether written or oral, with respect to the Award.
17. Headings.  The headings of this Agreement are inserted for convenience only and do not constitute a part of this Agreement.
18. Counterparts.  This Agreement may be executed simultaneously in two or more counterparts, each of which shall constitute an original, but all of which taken together shall constitute one and the same agreement.

[REMINDER OF PAGE INTENTIONALLY LEFT BLANK.]

IN WITNESS WHEREOF, the Company has caused this Third Amended and Restated Restricted Stock Award Agreement to be executed by its duly authorized representative and Grantee has executed this Agreement.

 
HEALTHIER CHOICES MANAGEMENT CORP.
  
  
 
By:           /s/ Jeffrey Holman
 
Name:  Jeffrey Holman
 
Title:    CEO
  
  
 
By:           /s/ Christopher Santi
 
Name:   Christopher Santi

EXHIBIT A
VESTING SCHEDULE

March 31, 2021 – 12.5%
June 30, 2021 – 12.5%
September 30, 2021 – 12.5%
December 31, 2021 –- 12.5%
March 31, 2022 – 12.5%
June 30, 2022 – 12.5%
September 30, 2022 – 12.5%
December 31, 2022 –- 12.5%
EX-10.14 8 ex10_14.htm EXHIBIT 10.14  
HEALTHIER CHOICES MANAGEMENT CORP.
THIRD AMENDED AND RESTATED RESTRICTED STOCK AWARD AGREEMENT

THIRD AMENDED AND RESTATED RESTRICTED STOCK AWARD AGREEMENT (this “Agreement”), effective as of February 12, 2021 (the “Date of Grant”), between Healthier Choices Management Corp., a Delaware corporation (the “Company”), and John Ollet (the “Grantee”).
WHEREAS, the Company has adopted the Vapor Corp 2015 Equity Incentive Plan, as amended (the “Plan”), in order to provide incentive compensation to certain employees and directors of the Company and its Subsidiaries;
WHEREAS, the Committee has previously granted to the Grantee an Award of Restricted Stock (as defined in the Plan) (the “Original Grant”) as provided under the Plan to encourage the Grantee’s efforts toward the continuing success of the Company;
WHEREAS, the Original Grant was evidenced by the Restricted Stock Award Agreement dated August 12, 2019 and such agreement was amended and restated as of August 12, 2019 and August 12, 2020 (the “Award Agreement”); and
WHEREAS, the Committee and Grantee have agreed to amend and restate the Award Agreement pursuant to the terms and conditions set forth herein.
NOW, THEREFORE, the parties hereto agree as follows:

1. Grant of Restricted Stock.

1.1. The Company has granted to the Grantee an award of 3,000,000,000 shares of Restricted Stock (the “Initial Award”) pursuant to the Original Agreement.  In addition, the Company has granted to the Grantee an award of 300,000,000 shares of Restricted Stock (the “New Award” and together with the Initial Award, the “Award”) in consideration for agreeing to a new vesting schedule for the Awards in accordance with Section 3 hereto.  The shares of Restricted Stock granted pursuant to the Award shall be issued in the form of book entry shares in the name of the Grantee as soon as reasonably practicable after the Date of Grant and shall be subject to the execution and return of this Agreement by the Grantee (or the Grantee’s estate, if applicable) to the Company as provided in Section 9 hereof.
1.2. Except as otherwise expressly set forth herein, the capitalized terms used in this Agreement shall have the same definitions as set forth in the Plan.  This grant and the Award are subject to the terms of the Plan, except as expressly provided herein.

2. Restrictions on Transfer.  The shares of Restricted Stock issued under this Agreement may not be sold, transferred or otherwise disposed of and may not be pledged or otherwise hypothecated until all restrictions on such Restricted Stock shall have lapsed in the manner provided in Section 3, 4 or 5 hereof.
3. Lapse of Restrictions Generally.  Except as provided in Sections 4, 5 and 6 hereof, all of the shares of Restricted Stock issued hereunder (rounded down to the nearest whole share, if necessary) shall vest, and the restrictions with respect to such Restricted Stock shall lapse, as set forth in the vesting schedule attached as Exhibit A hereto.
4. Effect of Certain Terminations of Employment.  If the Grantee’s employment terminates as a result of the Grantee’s death, retirement or becoming disabled after the Date of Grant, all shares of Restricted Stock which have not become vested in accordance with Section 3 or 5 hereof shall vest, and the restrictions on such Restricted Stock shall lapse, as of the date of such termination.
5. Effect of Change in Control.  In the event of a Change in Control at any time on or after the Date of Grant, all shares of Restricted Stock which have not become vested in accordance with Section 3 or 4 hereof shall vest, and the restrictions on such Restricted Stock shall lapse, immediately.
6. Forfeiture of Restricted Stock.  In addition to the circumstance described in Section 9(a) hereof, any and all shares of Restricted Stock which have not become vested in accordance with Section 3, 4 or 5 hereof shall be forfeited and shall revert to the Company upon the termination by the Grantee, the Company or its subsidiaries of the Grantee’s employment for any reason other than those set forth in Section 4 or other than without “Cause” prior to the date on which such shares of Restricted Stock would otherwise vest.  All or any portion of the Restricted Stock may be forfeited by the Grantee prior to vesting at his or her sole discretion.
7. Delivery of Restricted Stock.  A stock certificate with respect to shares attributable to Restricted Stock for which the restrictions have lapsed shall be delivered to the Grantee or the Grantee’s estate, if applicable, as soon as practicable following the date on which the restrictions on such Restricted Stock have lapsed, free of all restrictions hereunder.
8. Dividends and Voting Rights.  Subject to the terms of the Plan, upon issuance of the Restricted Stock, the Grantee shall have all of the rights of a stockholder with respect to such Stock, including the right to vote the Stock; provided, however, that the Grantee shall have no right to receive all dividends or other distributions paid or made with respect thereto until such Restricted Stock has vested.
9. No Right to Continued Employment.  Nothing in this Agreement or the Plan shall interfere with or limit in any way the right of the Company or its Subsidiaries to terminate the Grantee’s employment, nor confer upon the Grantee any right to continuance of employment by the Company or any of its Subsidiaries or continuance of service as a Board member.
10. Withholding of Taxes.  Except as otherwise agreed by the Company and Grantee, prior to the delivery to the Grantee (or the Grantee’s estate, if applicable) of a stock certificate with respect to shares of Restricted Stock for which all restrictions have lapsed, the Grantee (or the Grantee’s estate) shall pay to the Company the federal, state and local income taxes and other amounts as may be required by law to be withheld by the Company (the “Withholding Taxes”) with respect to such Restricted Stock.  By executing and returning this Agreement, the Grantee (or the Grantee’s estate) shall be deemed to elect to have the Company withhold a portion of such Restricted Stock having an aggregate Fair Market Value equal to the Withholding Taxes in satisfaction of the Withholding Taxes, such election to continue in effect until the Grantee (or the Grantee’s estate) notifies the Company before such delivery that the Grantee (or the Grantee’s estate) shall satisfy such obligation in cash, in which event the Company shall not withhold a portion of such Restricted Stock as otherwise provided in this Section 10.
11. Grantee Bound by the Plan.  The Grantee hereby acknowledges receipt of a copy of the Plan and this Agreement, and that he or she has been granted the opportunity to review and consult with advisors on such agreements, and agrees to be bound by all the terms and provisions thereof.
12. Modification of Agreement.  This Agreement may be modified, amended, suspended or terminated, and any terms or conditions may be waived by the Company prior to the lapse of restriction.  Notwithstanding the foregoing, no such modification may negatively impact the rights of the Grantee without the Grantee’s written consent.
13. Severability.  Should any provision of this Agreement be held by a court of competent jurisdiction to be unenforceable or invalid for any reason, the remaining provisions of this Agreement shall not be affected by such holding and shall continue in full force in accordance with their terms.
14. Governing Law.  The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Delaware without giving effect to the conflicts of laws principles thereof.
15. Successors in Interest.  This Agreement shall inure to the benefit of and be binding upon any successor to the Company.  This Agreement shall inure to the benefit of the Grantee’s legal representatives.  All obligations imposed upon the Grantee and all rights granted to the Company under this Agreement shall be binding upon the Grantee’s heirs, executors, administrators and successors.
16. Entire Agreement.  This Agreement and the Plan constitute the entire understanding between the Grantee and the Company and its Subsidiaries, and supersede all other agreements, whether written or oral, with respect to the Award.
17. Headings.  The headings of this Agreement are inserted for convenience only and do not constitute a part of this Agreement.
18. Counterparts.  This Agreement may be executed simultaneously in two or more counterparts, each of which shall constitute an original, but all of which taken together shall constitute one and the same agreement.

[REMINDER OF PAGE INTENTIONALLY LEFT BLANK.]

IN WITNESS WHEREOF, the Company has caused this Third Amended and Restated Restricted Stock Award Agreement to be executed by its duly authorized representative and Grantee has executed this Agreement.

 
HEALTHIER CHOICES MANAGEMENT CORP.
  
  
 
By: /s/ Jeffrey Holman
 
Name:  Jeffrey Holman
 
Title:    CEO
  
  
 
By: /s/ John Ollet
 
Name:  John Ollet

EXHIBIT A
VESTING SCHEDULE

March 31, 2021 – 12.5%
June 30, 2021 – 12.5%
September 30, 2021 – 12.5%
December 31, 2021 –- 12.5%
March 31, 2022 – 12.5%
June 30, 2022 – 12.5%
September 30, 2022 – 12.5%
December 31, 2022 –- 12.5%

EX-10.15 9 ex10_15.htm EXHIBIT 10.15  
HEALTHIER CHOICES MANAGEMENT CORP.
THIRD AMENDED AND RESTATED RESTRICTED STOCK AWARD AGREEMENT

THIRD AMENDED AND RESTATED RESTRICTED STOCK AWARD AGREEMENT (this “Agreement”), effective as of February 12, 2021 (the “Date of Grant”), between Healthier Choices Management Corp., a Delaware corporation (the “Company”), and Dr. Anthony Panariello (the “Grantee”).
WHEREAS, the Company has adopted the Vapor Corp 2015 Equity Incentive Plan, as amended (the “Plan”), in order to provide incentive compensation to certain employees and directors of the Company and its Subsidiaries;
WHEREAS, the Committee has previously granted to the Grantee an Award of Restricted Stock (as defined in the Plan) (the “Original Grant”) as provided under the Plan to encourage the Grantee’s efforts toward the continuing success of the Company;
WHEREAS, the Original Grant was evidenced by the Restricted Stock Award Agreement dated August 12, 2019 and such agreement was amended and restated as of August 12, 2019 and August 12, 2020 (the “Award Agreement”); and
WHEREAS, the Committee and Grantee have agreed to amend and restate the Award Agreement pursuant to the terms and conditions set forth herein.
NOW, THEREFORE, the parties hereto agree as follows:

1. Grant of Restricted Stock.

1.1. The Company has granted to the Grantee an award of 1,000,000,000 shares of Restricted Stock (the “Initial Award”) pursuant to the Original Agreement.  In addition, the Company has granted to the Grantee an award of 50,000,000 shares of Restricted Stock (the “New Award” and together with the Initial Award, the “Award”) in consideration for agreeing to a new vesting schedule for the Awards in accordance with Section 3 hereto.  The shares of Restricted Stock granted pursuant to the Award shall be issued in the form of book entry shares in the name of the Grantee as soon as reasonably practicable after the Date of Grant and shall be subject to the execution and return of this Agreement by the Grantee (or the Grantee’s estate, if applicable) to the Company as provided in Section 9 hereof.
1.2. Except as otherwise expressly set forth herein, the capitalized terms used in this Agreement shall have the same definitions as set forth in the Plan.  This grant and the Award are subject to the terms of the Plan, except as expressly provided herein.

2. Restrictions on Transfer.  The shares of Restricted Stock issued under this Agreement may not be sold, transferred or otherwise disposed of and may not be pledged or otherwise hypothecated until all restrictions on such Restricted Stock shall have lapsed in the manner provided in Section 3, 4 or 5 hereof.
3. Lapse of Restrictions Generally.  Except as provided in Sections 4, 5 and 6 hereof, all of the shares of Restricted Stock issued hereunder (rounded down to the nearest whole share, if necessary) shall vest, and the restrictions with respect to such Restricted Stock shall lapse, as set forth in the vesting schedule attached as Exhibit A hereto.
4. Effect of Certain Terminations of Employment.  If the Grantee’s employment terminates as a result of the Grantee’s death, retirement or becoming disabled after the Date of Grant, all shares of Restricted Stock which have not become vested in accordance with Section 3 or 5 hereof shall vest, and the restrictions on such Restricted Stock shall lapse, as of the date of such termination.
5. Effect of Change in Control.  In the event of a Change in Control at any time on or after the Date of Grant, all shares of Restricted Stock which have not become vested in accordance with Section 3 or 4 hereof shall vest, and the restrictions on such Restricted Stock shall lapse, immediately.
6. Forfeiture of Restricted Stock.  In addition to the circumstance described in Section 9(a) hereof, any and all shares of Restricted Stock which have not become vested in accordance with Section 3, 4 or 5 hereof shall be forfeited and shall revert to the Company upon the termination by the Grantee, the Company or its subsidiaries of the Grantee’s employment for any reason other than those set forth in Section 4 or other than without “Cause” prior to the date on which such shares of Restricted Stock would otherwise vest.  All or any portion of the Restricted Stock may be forfeited by the Grantee prior to vesting at his or her sole discretion.
7. Delivery of Restricted Stock.  A stock certificate with respect to shares attributable to Restricted Stock for which the restrictions have lapsed shall be delivered to the Grantee or the Grantee’s estate, if applicable, as soon as practicable following the date on which the restrictions on such Restricted Stock have lapsed, free of all restrictions hereunder.
8. Dividends and Voting Rights.  Subject to the terms of the Plan, upon issuance of the Restricted Stock, the Grantee shall have all of the rights of a stockholder with respect to such Stock, including the right to vote the Stock; provided, however, that the Grantee shall have no right to receive all dividends or other distributions paid or made with respect thereto until such Restricted Stock has vested.
9. No Right to Continued Employment.  Nothing in this Agreement or the Plan shall interfere with or limit in any way the right of the Company or its Subsidiaries to terminate the Grantee’s employment, nor confer upon the Grantee any right to continuance of employment by the Company or any of its Subsidiaries or continuance of service as a Board member.
10. Withholding of Taxes.  Except as otherwise agreed by the Company and Grantee, prior to the delivery to the Grantee (or the Grantee’s estate, if applicable) of a stock certificate with respect to shares of Restricted Stock for which all restrictions have lapsed, the Grantee (or the Grantee’s estate) shall pay to the Company the federal, state and local income taxes and other amounts as may be required by law to be withheld by the Company (the “Withholding Taxes”) with respect to such Restricted Stock.  By executing and returning this Agreement, the Grantee (or the Grantee’s estate) shall be deemed to elect to have the Company withhold a portion of such Restricted Stock having an aggregate Fair Market Value equal to the Withholding Taxes in satisfaction of the Withholding Taxes, such election to continue in effect until the Grantee (or the Grantee’s estate) notifies the Company before such delivery that the Grantee (or the Grantee’s estate) shall satisfy such obligation in cash, in which event the Company shall not withhold a portion of such Restricted Stock as otherwise provided in this Section 10.
11. Grantee Bound by the Plan.  The Grantee hereby acknowledges receipt of a copy of the Plan and this Agreement, and that he or she has been granted the opportunity to review and consult with advisors on such agreements, and agrees to be bound by all the terms and provisions thereof.
12. Modification of Agreement.  This Agreement may be modified, amended, suspended or terminated, and any terms or conditions may be waived by the Company prior to the lapse of restriction.  Notwithstanding the foregoing, no such modification may negatively impact the rights of the Grantee without the Grantee’s written consent.
13. Severability.  Should any provision of this Agreement be held by a court of competent jurisdiction to be unenforceable or invalid for any reason, the remaining provisions of this Agreement shall not be affected by such holding and shall continue in full force in accordance with their terms.
14. Governing Law.  The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Delaware without giving effect to the conflicts of laws principles thereof.
15. Successors in Interest.  This Agreement shall inure to the benefit of and be binding upon any successor to the Company.  This Agreement shall inure to the benefit of the Grantee’s legal representatives.  All obligations imposed upon the Grantee and all rights granted to the Company under this Agreement shall be binding upon the Grantee’s heirs, executors, administrators and successors.
16. Entire Agreement.  This Agreement and the Plan constitute the entire understanding between the Grantee and the Company and its Subsidiaries, and supersede all other agreements, whether written or oral, with respect to the Award.
17. Headings.  The headings of this Agreement are inserted for convenience only and do not constitute a part of this Agreement.
18. Counterparts.  This Agreement may be executed simultaneously in two or more counterparts, each of which shall constitute an original, but all of which taken together shall constitute one and the same agreement.

[REMINDER OF PAGE INTENTIONALLY LEFT BLANK.]

IN WITNESS WHEREOF, the Company has caused this Third Amended and Restated Restricted Stock Award Agreement to be executed by its duly authorized representative and Grantee has executed this Agreement.

 
HEALTHIER CHOICES MANAGEMENT CORP.
  
  
 
By: /s/ Jeffrey Holman
 
Name:  Jeffrey Holman
 
Title:    CEO
  
  
 
By: /s/ Anthony Panariello
 
Name:  Dr. Anthony Panariello

EXHIBIT A
VESTING SCHEDULE

March 31, 2021 – 12.5%
June 30, 2021 – 12.5%
September 30, 2021 – 12.5%
December 31, 2021 –- 12.5%
March 31, 2022 – 12.5%
June 30, 2022 – 12.5%
September 30, 2022 – 12.5%
December 31, 2022 –- 12.5%
EX-21.1 10 ex21_1.htm EXHIBIT 21.1  
Exhibit 21.1

List of Subsidiaries

Subsidiaries
 
Jurisdiction
   
The Vape Store Inc.
 
Florida
   
Vaporin, Inc. (inactive)
 
Delaware
   
Healthy Choice Markets, Inc.
 
Florida
   
Smoke Anywhere USA Inc. (inactive)
 
Florida
   
Emagine the Vape Store, LLC (inactive)
 
Delaware
   
IVGI Acquisitions, Inc. (inactive)
 
Delaware
   
Vapormax Franchising LLC. (inactive)
 
Delaware
   
Vaporin, LLC (inactive)
 
Florida
   
Healthy Choice Markets 2, LLC
 
Florida
   
The Vitamin Store, LLC
 
Florida
   
HCMC Intellectual Property Holdings, LLC
 
Florida
   
Healthy Choice Wellness, LLC
 
Florida
   
Healthy Choice Markets 3, LLC
 
Florida
   
Healthy Choices Markets 3 Real Estate LLC
 
New York

EX-23.1 11 ex23_1.htm EXHIBIT 23.1  
Exhibit 23.1

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
 
We consent to the incorporation by reference in the Registration Statement of Healthier Choices Management Corp. on Form S-8 (File No. 333-215971) of our report dated March 31, 2022, with respect to our audits of the consolidated financial statements of Healthier Choices Management Corp. as of December 31, 2021 and 2020 and for each of the two years in the period ended December 31, 2021, which report is included in this Annual Report on Form 10-K of Healthier Choices Management Corp. for the year ended December 31, 2021.
 
/s/ Marcum LLP
 
New York, NY
March 31, 2022

EX-31.1 12 exhibit31_1.htm EXHIBIT 31.1  
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Jeffrey Holman, certify that:

1.
 I have reviewed this annual report on Form 10-K of Healthier Choices Management Corp.;

2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 31, 2022

 
/s/ Jeffrey Holman
 
Jeffrey Holman
 
Chief Executive Officer
 
(Principal Executive Officer)

EX-31.2 13 exhibit31_2.htm EXHIBIT 31.2  
Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, John Ollet, certify that:

1.
I have reviewed this annual report on Form 10-K of Healthier Choices Management Corp.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting

Date: March 31, 2022

 
/s/ John Ollet
 
John Ollet
 
Chief Financial Officer
 
(Principal Financial Officer)


EX-32.1 14 exhibit32_1.htm EXHIBIT 32.1  
Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Healthier Choices Management Corp. (the “Company”) on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof, I, Jeffrey Holman, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1.
The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2.
The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 31, 2022

 
/s/ Jeffrey Holman
 
Jeffrey Holman
 
Chief Executive Officer
 
(Principal Executive Officer)

In connection with the quarterly report of Healthier Choices Management Corp. (the “Company”) on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof, I, John Ollet, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1.
The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2.
The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 31, 2022

 
/s/ John Ollet
 
John Ollet
 
Chief Financial Officer
 
(Principal Financial Officer)

EX-101.SCH 15 hcmc-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - DISAGGREGATION OF REVENUES link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - INVESTMENT link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - PROPERTY & EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - CONTRACT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - LINE OF CREDIT AND DEBT link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 061400 - Disclosure - LEASE link:presentationLink link:calculationLink link:definitionLink 061500 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 061600 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 061700 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 070100 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 070300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - DISAGGREGATION OF REVENUES (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - INVESTMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - PROPERTY & EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 080900 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - CONTRACT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 081100 - Disclosure - LINE OF CREDIT AND DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 081300 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 081400 - Disclosure - LEASE (Tables) link:presentationLink link:calculationLink link:definitionLink 081500 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 081600 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - LIQUIDITY (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 090302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Shipping and Handling (Details) link:presentationLink link:calculationLink link:definitionLink 090304 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 090306 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable, Contract Assets and Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 090308 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 090310 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Identifiable Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 090312 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-Lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 090314 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 090316 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Advertising (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - DISAGGREGATION OF REVENUES (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - INVESTMENT (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - PROPERTY & EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, Changes in Carrying Amount (Details) link:presentationLink link:calculationLink link:definitionLink 090902 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 090904 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, Future Annual Estimated Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - CONTRACT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - LINE OF CREDIT AND DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 091102 - Disclosure - TERM LOAN CREDIT AGREEMENT (Details) Calc 2 link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - STOCKHOLDERS' EQUITY, Equity Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 091302 - Disclosure - STOCKHOLDERS' EQUITY, Rights Offering (Details) link:presentationLink link:calculationLink link:definitionLink 091304 - Disclosure - STOCKHOLDERS' EQUITY, Exchange Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 091306 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock and Convertible Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 091308 - Disclosure - STOCKHOLDERS' EQUITY, Summary of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 091310 - Disclosure - STOCKHOLDERS' EQUITY, Share-based Awards to Officers and Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 091312 - Disclosure - STOCKHOLDERS' EQUITY, Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 091314 - Disclosure - STOCKHOLDERS' EQUITY, Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 091400 - Disclosure - LEASE, Summary (Details) link:presentationLink link:calculationLink link:definitionLink 091402 - Disclosure - LEASE, Maturity of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 091404 - Disclosure - LEASE, Balance Sheet Classification and Other Information (Details) link:presentationLink link:calculationLink link:definitionLink 091404 - Disclosure - LEASE, Maturity of Lease Liabilities (Details) CALC 01 link:presentationLink link:calculationLink link:definitionLink 091406 - Disclosure - LEASE, Components of Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 091500 - Disclosure - INCOME TAXES, Reconciliation of Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 091502 - Disclosure - INCOME TAXES, Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 091504 - Disclosure - INCOME TAXES, Other Information (Details) link:presentationLink link:calculationLink link:definitionLink 091600 - Disclosure - SEGMENT INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 091700 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 16 hcmc-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 17 hcmc-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 18 hcmc-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Award Type [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] ASC842 [Member] ASU 2016-02 [Member] Accounting Standards Update 2016-02 [Member] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] Accounts payable and accrued expenses Accounts receivable Receivable Type [Axis] Accounts Receivable [Member] Accounts Receivable [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Investment at Fair Value [Abstract] Additional paid-in capital Additional Paid-In Capital [Member] Additional Paid-in Capital [Member] Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation expense Adjustments for New Accounting Pronouncements [Axis] Advertising Advertising Cost [Policy Text Block] Advertising expenses Advertising Expense Amortization expense Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of basic and dilutive income (loss) per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities, Name [Domain] Consideration paid for acquisition Asset purchase transaction cost Asset Acquisition, Consideration Transferred, Transaction Cost Asset Acquisition [Axis] Asset Acquisition [Domain] TOTAL ASSETS Assets ASSETS Assets [Abstract] TOTAL CURRENT ASSETS Assets, Current CURRENT ASSETS Basis of Presentation Business Acquisition [Axis] Business Acquisition [Line Items] Business Acquisition, Acquiree [Domain] Cash and Cash Equivalents [Abstract] DECREASE IN CASH Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect CASH, CASH EQUIVALENTS AND RESTRICTED CASH - END OF YEAR CASH, CASH EQUIVALENTS AND RESTRICTED CASH - BEGINNING OF YEAR Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value NON-CASH INVESTING AND FINANCING ACTIVITIES: FDIC insured amount Cash, FDIC Insured Amount Changes in Contract Liabilities Activity [Roll Forward] Class of Warrant or Right [Axis] Class of Stock [Line Items] Class of Stock [Domain] Class of Warrant or Right [Domain] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Class of Warrant or Right, Outstanding Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] COMMITMENTS AND CONTINGENCIES [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES (SEE NOTE 12) Commitments and Contingencies Series C Stock [Member] Common Class C [Member] Common Stock [Member] Common Stock [Member] Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Common Stock, $0.0001 par value per share, 750,000,000,000 shares authorized; 339,741,632,384 and 143,840,848,017 shares issued and outstanding as of December 31, 2021 and 2020, respectively Common stock, shares authorized (in shares) Common stock, shares outstanding (in shares) Computer Hardware & Equipment [Member] Concentration Risk [Table] Concentration Risk Type [Domain] Concentration risk percentage Concentration Risk Benchmark [Domain] Concentration Risk Type [Axis] Concentration Risk [Line Items] Concentration Risk Benchmark [Axis] Principles of Consolidation Contract with Customer, Sales Channel [Domain] Contract with Customer, Sales Channel [Axis] Deferred Revenue [Abstract] Accounts Receivable, Contract Assets and Contract Liabilities [Abstract] CONTRACT LIABILITIES [Abstract] Contract liabilities Contract with Customer, Liability, Current Contract Liabilities Activity Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Contract assets Ending balance Beginning balance Contract with Customer, Liability Converted and cancelled of shares (in shares) Number of warrants exchanged for preferred stock (in shares) Conversion of Stock, Shares Converted Series C Preferred stock exercised Convertible Preferred Stock Converted to Other Securities Number of convertible preferred stock issued on conversion of warrants (in shares) Convertible Preferred Stock [Member] Cost of sales Credit Facility [Axis] Credit Facility [Domain] Customer Concentration Risk [Member] Customer Relationships [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Table] Disaggregate Revenue Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Basis adjustment to variable rate LINE OF CREDIT AND DEBT [Abstract] Debt Instrument [Axis] Frequency of payment Plus: Payments made during 2020 Face amount Total Payments Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Debt instrument interest rate Debt Instruments [Abstract] Interest rate Debt Instrument, Interest Rate, Stated Percentage Maturity date Maturity date Interest rate Debt Instrument, Name [Domain] Monthly principle payments Additional employment agreement term Increment percentage on salary each subsequent year Net book value of intangible assets Net book value of fixed assets Deferred Tax Assets, Property, Plant and Equipment Net operating losses Inventory reserves and allowances Net deferred tax assets Deferred Tax Assets, Net Total deferred tax assets Deferred Tax Assets, Gross Deferred tax assets [Abstract] Deferred Tax Assets, Gross [Abstract] Charitable contribution Accrued Expenses and Deferred Income Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Stock based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Deferred tax liabilities [Abstract] Deferred Tax Liabilities, Gross [Abstract] Change in valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Depreciation expense Depreciation and amortization Depreciation and amortization Derivative liabilities - warrants Derivative Liability, Current U.S. Federal [Member] Domestic Tax Authority [Member] NET LOSS PER SHARE, BASIC (in dollars per share) Basic and Diluted Net Income (Loss) Per Share [Abstract] NET LOSS PER SHARE, DILUTED (in dollars per share) Weighted average amortization period Stock Options [Member] Share-based Payment Arrangement, Option [Member] Stock Options [Abstract] Unamortized stock based compensation expense Equity Component [Domain] Equity Securities, Restricted [Abstract] STOCKHOLDERS' EQUITY [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Hierarchy [Axis] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Fair Value Hierarchy and NAV [Domain] Fair Value Measurements Using Quoted Prices in Active Market (Level 1) [Member] Fair Value, Inputs, Level 1 [Member] Intangible Assets, Net [Abstract] Weighted-average remaining amortization period 2025 2023 Useful lives Amortization period Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets [Line Items] 2024 Future Annual Estimated Amortization Expense [Abstract] 2026 Thereafter Gross carrying amount 2022 Finite-Lived Intangible Assets by Major Class [Axis] Net carrying amount Intangible assets, net of accumulated amortization Furniture and Fixtures [Member] Grantee Status [Domain] Grantee Status [Axis] Gain (loss) on investment Gain (loss) on investment Gain (Loss) on Investments Gain on Debt Settlements Loss on extinguishment of debt Net gain on debt settlements Gain on debt settlements GOODWILL AND INTANGIBLE ASSETS Ending balance Beginning balance Goodwill Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Impairment of goodwill and intangible assets Impairment of goodwill and intangible assets Goodwill [Abstract] Impairment of goodwill-retail business Impairment charge of goodwill Identifiable Intangible Assets and Goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] GOODWILL AND INTANGIBLE ASSETS [Abstract] GROSS PROFIT Segment gross profit Gross Profit Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets [Abstract] Impairment of intangible assets Impairment charge of intangible assets INCOME TAXES [Abstract] Income Tax Authority [Axis] CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Income Tax Authority [Domain] INCOME TAXES U.S. federal statutory rate Change in tax rate Income tax provision (benefit) Income Tax Expense (Benefit) Change in valuation allowance State and local taxes, net of federal benefit Other Stock based compensation Other permanent items Income Taxes Income Tax, Policy [Policy Text Block] Contract assets Increase (Decrease) in Contract with Customer, Asset Contract liabilities Increase (Decrease) in Contract with Customer, Liability Change in fair value of derivative liabilities Increase (Decrease) in Derivative Liabilities Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Inventories Increase (Decrease) in Inventories Changes in operating assets and liabilities: Other assets Increase (Decrease) in Other Operating Assets Accounts receivable Increase (Decrease) in Receivables Increase (Decrease) in Stockholders' Equity [Roll Forward] Effect of exercise warrants (in shares) Effect of exercise stock options (in shares) Interest expense, net Interest Expense Accrued interest on loan payable Interest Expense, Debt Cash paid for interest Website [Member] INVENTORIES [Abstract] Inventory [Line Items] Inventory write down Write-down of obsolete and slow-moving inventory Inventory Write-down INVENTORIES Inventory, Current [Table] Inventories Inventory, Policy [Policy Text Block] Inventories Inventory, Net Inventories [Abstract] Inventory, Net [Abstract] INVESTMENT INVESTMENT [Abstract] Fair Value of Investment Interest income Investment Investment Owned, at Fair Value Investment cost LEASE Lessee, Operating Leases [Text Block] 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Total undiscounted operating lease payments Lessee, Operating Lease, Liability, to be Paid Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Lease agreements term 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Maturity of Lease Liabilities 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Operating Leases [Abstract] Components of Lease Cost [Abstract] Total Rent Expense Lease, Cost Components of Lease Cost Leasehold Improvements [Member] LEASE [Abstract] TOTAL LIABILITIES Liabilities LIABILITIES AND STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity TOTAL CURRENT LIABILITIES Liabilities, Current CURRENT LIABILITIES Line of Credit [Member] Renewal period Line of Credit Facility, Expiration Period Collateral arrangement amount Maximum borrowing capacity Current portion of line of credit Attorney fees paid Litigation Settlement, Amount Awarded to Other Party Current portion of loan payment NOTES RECEIVABLE AND OTHER INCOME Total Line of Credit and Debt Expected payments for the upcoming years Long-term Debt LINE OF CREDIT AND DEBT Long-term Debt [Text Block] Principal Repayments of Long-Term Debt [Abstract] Long-term Debt, Fiscal Year Maturity [Abstract] 2022 Long-Term Debt, Maturity, Year One Debt [Abstract] Long-term Debt, by Current and Noncurrent [Abstract] Loan payable, net of current portion 2023 Long-Term Debt, Maturity, Year Two 2024 Long-Term Debt, Maturity, Year Three Loss Contingency Nature [Axis] Damages sought Loss Contingency, Damages Sought, Value Loss Contingencies [Line Items] Loss Contingencies [Table] Loss Contingency, Nature [Domain] Number of lawsuits Loss Contingency, New Claims Filed, Number Legal Proceedings [Abstract] Loss Contingency, Information about Litigation Matters [Abstract] Advertising [Abstract] Measurement Input Type [Axis] Measurement Input Type [Domain] Mark to Market [Member] NET CASH USED IN FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities FINANCING ACTIVITIES: NET CASH USED IN OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities INVESTING ACTIVITIES: OPERATING ACTIVITIES: NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities NET LOSS Net loss Non-compete [Member] Noncompete Agreements [Member] Total other income (expense), net Corporate other income (expense), net OTHER INCOME (EXPENSE): Notes Receivable Financing Receivable, after Allowance for Credit Loss, Current Note receivable Number of stores Number of Stores Number of operating segments Number of Operating Segments Favorable Lease [Member] Operating lease liability, current Operating Lease, Liability, Current Weighted-average discount rate for operating leases Operating lease liability, net of current Operating Lease, Liability, Noncurrent Maturity of Lease Liabilities by Fiscal Year [Abstract] Cash paid for leasing arrangement Right of use asset - operating lease, net Right of use asset Operating lease cost Weighted-average remaining lease term for operating leases Present value of operating lease liabilities Total operating lease liabilities Operating Lease, Liability Amortization of right-of-use asset Amortization of right-of-use asset Operating Segments [Member] OPERATING EXPENSES: Total operating expenses Corporate expenses Operating Expenses LOSS FROM OPERATIONS Loss from operations Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Table] Operating Loss Carryforwards ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS [Abstract] Commitments [Abstract] Other Commitments [Abstract] Other assets Other Assets, Noncurrent Other [Member] Other Machinery and Equipment [Member] Other expense, net Prime Rate [Member] Patents [Member] Direct financing costs Purchases of patent Payments to Acquire Intangible Assets Payment for acquisition Payments to Acquire Businesses, Gross Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Plan Name [Domain] Plan Name [Axis] Preferred Stock [Member] Preferred stock, aggregate liquidation preference Preferred stock conversion price (in dollars per share) Conversion price (in dollars per share) Preferred Stock, Convertible, Conversion Price Convertible preferred stock Preferred stock, shares authorized (in shares) Preferred stock, shares authorized ( (in shares) Preferred stock, par value (in dollars per share) Preferred stock stated value (in dollars per share) Preferred shares, par value (in dollars per share) Preferred stock, shares outstanding (in shares) Preferred stock, shares issued (in shares) Number of preferred stock, shares sold and issued (in shares) Preferred Stock [Abstract] Aggregate subscription price Principal payments on loan payable Proceeds from preferred stock Proceeds from line of credit Net proceeds Proceeds from rights offering, net of offering costs Proceeds from loan and security agreement Proceeds Collection of note receivable Proceeds from exercise of stock options Product Information [Line Items] Property, Plant and Equipment [Line Items] PROPERTY & EQUIPMENT Expected useful life Property, Plant and Equipment, Useful Life PROPERTY & EQUIPMENT [Abstract] Property and Equipment Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Total property and equipment Property and equipment, net of accumulated depreciation Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Property plant and equipment, gross Property and equipment [Abstract] Change in provision for doubtful accounts Remaining balance Receivable [Domain] Due date Interest rate Receivable with Imputed Interest, Effective Yield (Interest Rate) Loan amount Receivable with Imputed Interest, Face Amount Receivables with Imputed Interest [Abstract] NOTES RECEIVABLE AND OTHER INCOME [Abstract] Principal payment on the line of credit Revolving credit line Repayment of debt Restricted Cash Restricted Stock [Member] Accumulated Deficit [Member] Retained Earnings [Member] Accumulated deficit DISAGGREGATION OF REVENUES [Abstract] SALES, NET Revenue Net sales DISAGGREGATION OF REVENUES Revenue Recognition Revenue [Policy Text Block] SALES: Royalty expense Weighted average remaining term, outstanding Aggregate intrinsic value, exercisable Weighted average remaining term, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Future Annual Estimated Amortization Expense Base salary Annual base salary Closing bid stock price (in dollars per share) Total Purchases [Member] Summary of Option Activity Inventories Schedule of Inventory, Current [Table Text Block] Schedule of Product Information [Table] Deferred Tax Assets and Liabilities Reconciliation of Expected Tax Expense (Benefit) Intangible Assets, Net Schedule of Finite-Lived Intangible Assets [Table] Breakdown of Debt Collaborative Arrangement and Arrangement Other than Collaborative [Table] Securities Excluded from Calculation of Basic and Dilutive Income (loss) per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Business Acquisitions, by Acquisition [Table] Changes in Carrying Amount of Goodwill Property, Plant and Equipment [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Segment Reporting Information, by Segment [Table] Summary of Reporting Segment Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Stock by Class [Table] Concentration of Accounts Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Segment Reporting Information [Line Items] Segment Reporting Information, Profit (Loss) [Abstract] SEGMENT INFORMATION [Abstract] SEGMENT INFORMATION Segment Reporting Segment Reporting, Policy [Policy Text Block] Selling, general and administrative Vesting period Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Equity Compensation Plans [Abstract] Options forfeited or expired (in dollars per share) Equity instruments exercised (in shares) Stock-based compensation expense Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Options exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Options granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Granted (in shares) Restricted common stock grants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Common stock available for grant (in shares) Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options forfeited or expired (in shares) Options forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Weighted Average Remaining Term and Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Outstanding, Beginning (in shares) Outstanding, Ending (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding, Beginning (in dollars per share) Outstanding, Ending (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Aggregate intrinsic value, outstanding Summary of Options Activity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Award Type [Domain] Stock-Based Compensation Share-based Payment Arrangement [Policy Text Block] Common stock at a price per share (in dollars per share) Subscription price (in dollars per share) Balance (in shares) Balance (in shares) Shares, Outstanding Investment Short-term Investments Short-term lease cost SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] State [Member] CONSOLIDATED BALANCE SHEETS [Abstract] Class of Stock [Axis] Statement [Table] Statement [Line Items] CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] Equity Components [Axis] CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY [Abstract] Stock options exercised (in shares) Options exercised (in shares) Number of common stock shares issued upon conversion preferred stock (in shares) Preferred Stock exercised (in shares) Issuance of Convertible Preferred stock in connection with the Securities Purchase Agreement (in shares) Issuance of common stock (in shares) Exchange of notes for shares of common stock (in shares) Common stock shares issued from offering (in shares) Issuance of awarded stock (in shares) Cancellation of awarded stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Issuance of awarded common stock for professional services (in shares) Stock Issued During Period, Shares, Issued for Services Issuance of awarded common stock for professional services Stock Issued During Period, Value, Issued for Services Options aggregate grant date value Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture Stock Options [Member] Equity Option [Member] Stock options exercised Issuance of common stock Issuance of common stock pursuant to exchange agreement Stock Issued During Period, Value, New Issues Issuance of Convertible Preferred stock in connection with the Securities Purchase Agreement Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of awarded stock Cancellation of awarded stock Balance TOTAL STOCKHOLDERS' EQUITY Balance Stockholders' Equity Attributable to Parent STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY Subsequent Event [Member] Subsequent Event Type [Domain] Subsequent Event [Line Items] Subsequent Event Type [Axis] SUBSEQUENT EVENTS [Abstract] Subsequent Event [Table] SUBSEQUENT EVENTS Subsequent Events [Text Block] Subsidiary, Sale of Stock [Line Items] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Supplier Concentration Risk [Member] Tax Period [Axis] Tax Period [Domain] Total Cash in excess of FDIC limits of $250,000 Time Deposits, at or Above FDIC Insurance Limit Trade Names [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Type of Adoption [Domain] Use of Estimates in the Preparation of the Financial Statements Use of Estimates, Policy [Policy Text Block] Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Variable lease cost Variable Rate [Axis] Variable Rate [Domain] Warrant [Member] Warrants [Member] Diluted (in shares) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, DILUTED (in shares) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC (in shares) Basic (in shares) Board [Member] Board of Directors [Member] Board of Directors Chairman [Member] Counterparty Name [Axis] Chief Operating Officer [Member] Chief Executive Officer [Member] Chief Financial Officer [Member] Consolidation Items [Domain] Consolidation Items [Axis] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption, Adjustment [Member] Cumulative Effect, Period of Adoption [Axis] Director [Member] Litigation Case [Axis] Litigation Case [Domain] Customer [Axis] Maximum [Member] Minimum [Member] Customer [Domain] Officer [Member] Product and Service [Domain] Product and Service [Axis] Statistical Measurement [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Counterparty Name [Domain] Title of Individual [Domain] Title of Individual [Axis] Cover [Abstract] Document Type Document Annual Report Document Transition Report Entity Interactive Data Current Amendment Flag ICFR Auditor Attestation Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Legal Entity [Axis] Entity [Domain] Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Public Float Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Auditor Name Auditor Location Auditor Firm ID Series A Warrants [Member] Series A Warrants [Member] Number of trading days for the exercise of the convertible preferred stock as the conversion price for the shares was reset to the lowest daily volume-weighted average price ("VWAP"), in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of Trading Days for Conversion of Shares Number of trading days for conversion of shares Convertible Preferred Stock [Abstract] Convertible Preferred Stock [Abstract] Tabular disclosure of balance sheet information and other information related to operating leases. Balance Sheet Classification and Other Information Related to Operating Leases [Table Text Block] Balance Sheet Classification and Other Information Persons with designation of chief executive officer, chief operating officer and chief financial officer. Officers and a Director [Member] Officers and a Director [Member] The amount of customer deposits in contract with customer. Contract with Customer, Liability, Customer Deposits Fulfillment of Obligations Amount of gift cards and loyalty rewards issued as obligation to transfer good or service to customer for which consideration has been received or is receivable. Contract with Customer, Liability, Issued Issued Amount of increase (decrease) in revenue recognized for adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Contract with Customer, Liability, Breakage Recognized Breakage recognized Amount of expense from redemption of gift cards and loyalty rewards in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Contract with Customer, Liability, Redeemed Redeemed The number of common stock shares for investment. Investment in Common Stock Shares Investment of common stock at MJ Holdings, Inc. (in shares) Common Share Equivalents Excluded from Calculation of Basic and Dilutive Income (Loss) Per Share [Abstract] Common Share Equivalents Excluded from Calculation of Basic and Dilutive Income (Loss) Per Share [Abstract] The gross proceeds from the additional capital contribution to the entity. Gross Proceeds from Issuance of Common Stock Gross proceeds Rights Offering [Abstract] Rights Offering [Abstract] Refers to product of the vapor loyalty rewards. Vapor Loyalty Rewards [Member] Vapor Loyalty Rewards [Member] Customer One [Member] Customer A [Member] Period of time between issuance and redemption of gift cards, rewards and points, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Breakage Policy Period Breakage policy period Customer Three [Member] Customer C [Member] Customer Four [Member] Customer D [Member] Customer Two [Member] Customer B [Member] Customers Balances in Excess of 10% of Total Accounts Receivable [Abstract] Customers Balances in Excess of 10% of Total Accounts Receivable [Abstract] Period in which contract liabilities is expected to be recognized, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Contract Liabilities Expected Recognition Period Contract liabilities expected recognition period Percentage of loyalty reward earnings on purchases. Percentage, Loyalty Rewards Earned Loyalty rewards earned percentage Refers to product of the grocery loyalty rewards. Grocery Loyalty Rewards [Member] Grocery Loyalty Rewards [Member] Refers to product of gift cards. Gift Cards [Member] Gift Cards [Member] Disclosure of accounting policy for sequencing policies. Sequencing [Policy Text Block] Sequencing Policy Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs. Shipping And Handling Costs [Text Block] Shipping and Handling Disclosure of accounting policy for due from merchant credit card processor. Due from Merchant Credit Card Processor [Text Block] Due from Merchant Credit Card Processor Disclosure of accounting policy for accounts receivable related to contract assets and contract liabilities. Accounts Receivable Contract Assets And Contract Liabilities [Policy Text Block] Accounts Receivable, Contract Assets and Contract Liabilities Property, Plant and Equipment, Useful Life [Abstract] Property, Plant and Equipment [Abstract] Shipping and handling costs Shipping and handling costs Shipping and Handling Costs [Abstract] Shipping and Handling Costs [Abstract] Going Concern [Abstract] Going Concern And Liquidity [Line Items] Schedule that describes going concern and liquidity. Going Concern And Liquidity [Table] Two thousand fifteen equity incentive plan is an arrangement where employees own a percentage of their company's shares so that they make money when the company makes a profit. Two Thousand and Fifteen Equity Incentive Plan [Member] 2015 Equity Incentive Plan [Member] Two thousand nine equity incentive plan is an arrangement where employees own a percentage of their company's shares so that they make money when the company makes a profit. Two Thousand and Nine Equity Incentive Plan [Member] 2009 Equity Incentive Plan [Member] Detail of Segment Reporting [Abstract] Segment Reporting [Abstract] Other Information Other Information [Abstract] Balance Sheet Classification Balance Sheet Classification [Abstract] Identifiable Intangible Assets and Goodwill [Abstract] Identifiable Intangible Assets and Goodwill [Abstract] Percentage of stock associated with the financial instrument issued in exchange for the original being converted in a noncash or part noncash transaction. Conversion of Stock Percentage Shares Converted Shares conversion percentage The patent infringement litigation. Patent Infringement Litigation [Member] Patent Infringement Litigation [Member] The percentage of increase in grants from its original award agreement, made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Grants, Increase in Vesting Percentage from its Original Awards In Period Percentage of increase in restricted stock grants from its original award agreement to officers Percentage of increase in restricted stock grants from its original award agreement to officers Name of purchase agreement. Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] Name of purchase agreement. Asset Purchase Agreement [Member] Asset Purchase Agreement [Member] Series D Preferred Stock [Abstract] The cash outflow associated with the acquisition of assets during the period. The cash portion only of the asset acquisition price. Payments to Acquire Assets Gross Cash purchase price The cash outflow for purchases of inventory. Payments to Acquire Inventory Cash paid for inventory Subsequent Event [Abstract] Subsequent Event [Abstract] Professional Bank Coral Gables Florida [Member] Professional Bank Coral Gables, Florida [Member] Independent Third Party [Member] Third Party [Member] Exchange Agreement [Abstract] Exchange Agreement [Abstract] Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of vendor deposits that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Prepaid Expense and Vendor Deposits, Current Prepaid expenses and vendor deposits Amount of deferred tax asset before allocation of valuation allowances attributable to deductible differences and carryforwards, without jurisdictional netting, net of deferred tax liability. Deferred Tax Assets, Gross, Net of Deferred Tax Liabilities Net deferred tax assets Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from leasing arrangements. Deferred Tax Assets, Leasing Arrangements ASC 842 - Lease Accounting Amount of deferred tax liability attributable to taxable temporary differences from extinguishment of warrants. Deferred Tax Liabilities, Extinguishment of Warrants Extinguishment of Warrants Amount, before deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting. Deferred Income Tax Liability Total deferred tax liabilities Weighted average exercise price of warrants expired during the period. Warrants, Weighted Average Exercise Price, Expired Warrants expired Weighted average exercise price of warrants as of the balance sheet date. Warrants, Weighted Average Exercise Price Outstanding at ending of period Outstanding at beginning of period Weighted average exercise price of warrants exercised during the period. Warrants, Weighted Average Exercise Price exercised Warrants exercised Weighted Average Exercise Price, Warrants [Abstract] Weighted Average Exercise Price [Abstract] Number of warrants exercised during the period. Warrants, Exercised Warrants exercised (in shares) A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Warrants Activity, Outstanding [Roll Forward] Number of Warrants [Abstract] Warrants remaining contractual term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class of Warrant or Right, Remaining Contractual Term Weighted average remaining term outstanding Weighted Average Remaining Term, Warrants [Abstract] Weighted Average Remaining Term [Abstract] Number of warrants or rights expired. Class of Warrant or Right, Expired Warrants expired (in shares) Fair value of warrants outstanding determined using the black-Scholes model. Warrants Outstanding, Black Scholes Value Black Scholes value Warrants [Abstract] Warrants [Abstract] Identified as tax year 2032 through 2037. Tax Year 2032 through 2037 [Member] 2032 through 2037 [Member] Operating Loss Carryforwards [Abstract] Identified with no expiration date. Tax Year No Expiration Date [Member] No Expiration Date [Member] Identified as tax year 2030 through 2037. Tax Year 2030 through 2037 [Member] 2030 through 2037 [Member] The amount of gain recorded on forgiveness of loan. Gain on Loan Forgiveness Gain on loan forgiveness The duration of company existence in market, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Duration of Company Existence in Market Duration of company existence in market Name of the acquiree. Mother Earth's Storehouse [Member] Mother Earth's Storehouse [Member] Organization [Abstract] A party from whom the goods or services were or are to be received. Vendor [Member] The number of vendors considered a major supplier. Number of vendors Number of vendor Sources and Vendors [Abstract] Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to forgiveness of paycheck protection program loan. Effective Income Tax Rate Reconciliation Forgiveness of Paycheck Protection Program Loan Forgiveness of PPP loan Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to true-up & deferred adjustment. True-up & deferred adjustment True-up & deferred adjustment Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expired warrants. Effective Income Tax Rate Reconciliation Expired Warrants Amount Expired warrants Related to other debt. Other Debt [Member] Other Debt [Member] Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format. Debt Instrument, Extended Maturity Date Extended maturity date The percentage of cash secured with moneys held from the blocked account under the revolving line of credit. Percentage of Cash Secured with Funds Held from Blocked Account Percentage of cash secured with funds held from blocked account A revolving credit line (together with a money market account) with Professional Bank in Coral Gables, Florida agreed to on April 13, 2018. Revolving Credit Line [Member] Revolving Credit Line [Member] The Paycheck Protection Program (the "PPP") under Division A, Title I of the CARES Act, which was enacted March 27, 2020. Paycheck Protection Program [Member] Paycheck Protection Program [Member] On August 18, 2020, the Company agreed to a term loan and security agreement (the "Loan") with Sabby Healthcare Master Fund, LTD and Sabby Volatility Warrant Master Fund, LTD ("collectively, the Lender"). Term Loan and Security Agreement [Member] Loan and Security Agreement [Member] Term Loan and Security Agreement [Member] The term loan credit agreement with Professional Bank. Term Loan Credit Agreement [Member] Term Loan Credit Agreement [Member] The remaining balance of loan amount used for operational purposes. Debt Instrument, Remaining Balance Amount Loan amount used for operational purposes It represent money market amount. Repayments Of Money Market Money market amount Percentage of net profits received from the sales of personal protective equipment ("PPE"). Percentage of net profits received from sales of personal protective equipment Percentage of net profits received from sales of PPE The customary financial covenant for a minimum debt service coverage ratio. Debt Instrument Covenant Minimum Debt Service Coverage Ratio Debt service coverage ratio Non-refundable discount to the face amount of the loan under the debt agreement. Debt Instrument, Discount Percentage Non-refundable discount percentage Notice Period need to be given by either party for non-renewal of agreement term. Notice Period for Non-Renewal of Agreement Term Notice period for non-renewal of agreement term Successive automatically renewal of agreement term unless notice of non-renewal is given. Automatic Renewal of Agreement Term Automatic renewal of agreement term Second extension period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. Share-based Compensation Arrangement by Share-based Payment Award, Second Extension Award Vesting Period Second extension to vesting period Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. Share-based Compensation Arrangement by Share-based Payment Award, Award Extension to Vesting Period Extension to vesting period Commitment made to pay severance payments expressed as a term of individual's then base salary. Deferred Compensation Arrangement with Individual, Severance Payments Term Severance payments term of base salary Commitment made to pay bonus expressed as a percentage of the individual's base salary. Deferred Compensation Arrangement with Individual, Target Bonus Percentage Target bonus percentage for 2020 Person with designation of president and chief operating officer. President and Chief Operating Officer [Member] President and Chief Operating Officer [Member] Alleged claimed battery defects for an electronic cigarette device. Alleged Claimed Battery Defects For Electronic Cigarette Device [Member] Alleged Claimed Battery Defects For Electronic Cigarette Device Member [Member] Medical costs claimed by Plaintiffs. Medical Costs [Member] The amount of investment under litigation. Loss Contingencies, Investment Amount Invested amount Fontem License Agreement [Member] Represents the name of an agreement. Exclusive Distribution Agreement [Member] Represents the name of an entity. MJ Holdings, Inc. [Member] Represents the name of an entity. Philip Morris [Member] Represents the name of an entity. Fontem Ventures B.V. [Member] Represents the percentage of revenues derived from the sale of qualifying products as defined in the license agreement. Royalty Rate Percentage Percentage of royalty rate The number of users approached by the entity. Number of Users Approached Number of users approached Exclusive Distribution and Fontem License Agreement [Abstract] Exclusive Distribution and Fontem License Agreement [Abstract] Refers to food service and restaurants stores that sell vapor products. Food Service and Restaurant [Member] Food Service/Restaurant [Member] A person that is a dealer primarily engaged in the full-line wholesale distribution and resale of grocery and related nonfood items. Wholesale Grocery [Member] Wholesale Grocery [Member] Refers to the online stores and other e-commerce platforms that sell vape products. Online and E-commerce [Member] Online/eCommerce [Member] A retail vapor outlet specializing in the selling of electronic cigarette products. Retail Vapor [Member] A person that is a dealer primarily engaged in the full-line wholesale distribution of vape products. Wholesale Vapor [Member] A grocery retailer primarily sells food. Grocery stores also offer non-perishable foods that are packaged in bottles, boxes, and cans; some also have bakeries, butchers, delis, and fresh produce. Retail Grocery [Member] Retail Grocery [Member] Disclosure of accounting policy for sourcing and vendors. Sourcing and Vendors [Policy Text Block] Sourcing and Vendors The entire disclosure of liquidity. Liquidity [Text Block] LIQUIDITY LIQUIDITY [Abstract] Issuance of common stock in connection with cashless exercise of Series A warrants. Issuance Of Common Stock In Connection With Cashless Exercise Of Series A Warrants Issuance of common stock Amount of increase (decrease) in prepaid expenses, and vendor deposits. Increase (Decrease) in Prepaid Expense and Vendor Deposits Prepaid expenses and vendor deposits The increase (decrease) during the period lease liability. Increase Decrease In Lease Liabilities Lease liability Proceeds from paycheck protection program loan. Proceeds From Paycheck Protection Program Loan Proceeds from paycheck protection program Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Series D Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Equity impact of the value of new stock issued during the period in connection with Rights Offering. Stock Issued During Period, Value, New Issues, Rights Offering Issuance of common stock in connection with the Rights Offering, net of offering expenses Number of new stock issued in connection with Rights Offering during the period. Stock Issued During Period, Shares, New Issues, Rights Offering Issuance of common stock in connection with the Rights Offering, net of offering expenses (in shares) Number of stock cancelled sued during the period. Stock Cancelled During Period, Shares, New Issues Cancellation of Convertible Preferred Stock (in shares) Equity impact of the value of stock cancelled during the period. Stock Cancelled During Period, Value, New Issues Cancellation of Convertible Preferred Stock Number of shares of convertible preferred stock that were converted to other securities. Convertible Preferred Stock Converted to Other Securities, Shares Preferred stock exercised (in shares) Number of new stock issued during the period. Convertible Preferred Stock Issued During Period, Shares, New Issues Issuance of Convertible Preferred Stock (in shares) Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Convertible Preferred Stock Issued During Period, Value, New Issues Issuance of Convertible Preferred Stock Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Series C Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Tabular disclosure of notes receivable. Schedule Of Accounts Notes Receivable [Text Block] Summary of Notes The extension term of notes receivable in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Notes Receivable, Extension Term Extension term Promissory notes a signed document containing a written promise to pay a stated sum to a specified person or the bearer at a specified date or on demand. Promissory Notes [Member] Promissory Note [Member] A type of loan that is backed by the borrower's assets. If a borrower defaults on a secured note, the assets pledged as collateral can be sold to repay the note. Secured Notes [Member] The cash inflow associated with the balloon payments. Proceeds from Balloon Payments Balloon payments The payment term of notes receivable in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Notes Receivable Payment Term Payment term Represents EIR Hydration, an IV therapy center located in Roslyn Heights, NY. EIR Hydration [Member] EIR Hydration [Member] A grocer is a bulk seller of food and products. Grocery [Member] Grocery Sales, Net [Member] Grocery Business [Member] Refers to a substance diffused or suspended in the air, especially one normally liquid or solid. Vapor [Member] Vapor Sales, Net [Member] Vapor Business [Member] Displays [Member] Displays [Member] The entire disclosure of contract balances and changes in contract balances. Contract with Customer, Asset and Liability [Text Block] CONTRACT LIABILITIES EX-101.PRE 19 hcmc-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 20 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Mar. 18, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Period End Date Dec. 31, 2021    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Document Transition Report false    
Entity Registrant Name HEALTHIER CHOICES MANAGEMENT CORP.    
Entity Central Index Key 0000844856    
Entity Incorporation, State or Country Code DE    
Entity File Number 001-36469    
Entity Tax Identification Number 84-1070932    
Entity Address, Address Line One 3800 North 28th Way    
Entity Address, City or Town Hollywood    
Entity Address, State or Province FL    
Entity Address, Postal Zip Code 33020    
City Area Code 305    
Local Phone Number 600-5004    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Trading Symbol HCMC    
Security Exchange Name NONE    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 366.5
Entity Common Stock, Shares Outstanding   339,741,632,384  
Auditor Firm ID 688    
Auditor Name Marcum LLP    
Auditor Location New York, NY    
XML 21 R2.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2021
Dec. 31, 2020
CURRENT ASSETS    
Cash and cash equivalents $ 26,496,404 $ 925,475
Accounts receivable 28,481 23,675
Notes Receivable 247,915 0
Inventories 1,521,199 1,749,246
Prepaid expenses and vendor deposits 456,397 286,065
Investment 23,143 22,731
TOTAL CURRENT ASSETS 28,773,539 3,007,192
Restricted Cash 0 2,000,000
Property and equipment, net of accumulated depreciation 176,988 230,719
Intangible assets, net of accumulated amortization 947,593 1,248,352
Goodwill 916,000 916,000
Note receivable 0 304,511
Right of use asset - operating lease, net 3,543,930 4,078,621
Other assets 85,437 89,598
TOTAL ASSETS 34,443,487 11,874,993
CURRENT LIABILITIES    
Accounts payable and accrued expenses 1,642,848 1,085,663
Contract liabilities 23,178 21,262
Operating lease liability, current 437,328 474,686
Current portion of line of credit 418,036 2,000,000
Current portion of loan payment 2,604 2,072,484
TOTAL CURRENT LIABILITIES 2,523,994 5,654,095
Loan payable, net of current portion 815 849,009
Operating lease liability, net of current 2,685,021 3,114,521
TOTAL LIABILITIES 5,209,830 9,617,625
COMMITMENTS AND CONTINGENCIES (SEE NOTE 12)
STOCKHOLDERS' EQUITY    
Common Stock, $0.0001 par value per share, 750,000,000,000 shares authorized; 339,741,632,384 and 143,840,848,017 shares issued and outstanding as of December 31, 2021 and 2020, respectively 33,974,163 14,384,084
Additional paid-in capital 30,855,824 3,955,039
Accumulated deficit (36,396,330) (32,358,871)
TOTAL STOCKHOLDERS' EQUITY 29,233,657 2,257,368
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 34,443,487 11,874,993
Series C Convertible Preferred Stock [Member]    
STOCKHOLDERS' EQUITY    
Convertible preferred stock 0 16,277,116
Series D Convertible Preferred Stock [Member]    
STOCKHOLDERS' EQUITY    
Convertible preferred stock $ 800,000 $ 0
XML 22 R3.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
STOCKHOLDERS' EQUITY    
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 750,000,000,000 750,000,000,000
Common stock, shares issued (in shares) 339,741,632,384 143,840,848,017
Common stock, shares outstanding (in shares) 339,741,632,384 143,840,848,017
Series C Convertible Preferred Stock [Member]    
STOCKHOLDERS' EQUITY    
Preferred stock, par value (in dollars per share) $ 1,000 $ 1,000
Preferred stock, shares authorized (in shares) 30,000 30,000
Preferred stock, shares issued (in shares) 0 16,277
Preferred stock, shares outstanding (in shares) 0 16,277
Preferred stock, aggregate liquidation preference   $ 16.3
Series D Convertible Preferred Stock [Member]    
STOCKHOLDERS' EQUITY    
Preferred stock, par value (in dollars per share) $ 1,000  
Preferred stock, shares authorized (in shares) 5,000  
Preferred stock, shares issued (in shares) 800 0
Preferred stock, shares outstanding (in shares) 800 0
Preferred stock, aggregate liquidation preference $ 0.8  
XML 23 R4.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
SALES:    
SALES, NET $ 13,319,854 $ 13,920,745
GROSS PROFIT 5,292,554 5,777,221
OPERATING EXPENSES:    
Impairment of goodwill and intangible assets 0 380,646
Selling, general and administrative 10,033,048 8,844,947
Total operating expenses 10,033,048 9,225,593
LOSS FROM OPERATIONS (4,740,494) (3,448,372)
OTHER INCOME (EXPENSE):    
Gain on Debt Settlements 767,930 0
Other expense, net (26) (100)
Interest expense, net (65,281) (272,651)
Gain (loss) on investment 412 (1,269)
Total other income (expense), net 703,035 (274,020)
NET LOSS $ (4,037,459) $ (3,722,392)
NET LOSS PER SHARE, BASIC (in dollars per share) $ 0.00 $ 0.00
NET LOSS PER SHARE, DILUTED (in dollars per share) $ 0.00 $ 0.00
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC (in shares) 307,912,959,368 90,351,540,618
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, DILUTED (in shares) 307,912,959,368 90,351,540,618
Vapor [Member]    
SALES:    
SALES, NET $ 2,084,813 $ 2,458,945
Cost of sales 839,599 1,033,805
Grocery [Member]    
SALES:    
SALES, NET 11,235,041 11,461,800
Cost of sales $ 7,187,701 $ 7,109,719
XML 24 R5.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
Preferred Stock [Member]
Preferred Stock [Member]
Officer [Member]
Preferred Stock [Member]
Board [Member]
Preferred Stock [Member]
Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Officer [Member]
Common Stock [Member]
Board [Member]
Common Stock [Member]
Series B Convertible Preferred Stock [Member]
Common Stock [Member]
Series C Convertible Preferred Stock [Member]
Common Stock [Member]
Series D Convertible Preferred Stock [Member]
Additional Paid-In Capital [Member]
Additional Paid-In Capital [Member]
Officer [Member]
Additional Paid-In Capital [Member]
Board [Member]
Additional Paid-In Capital [Member]
Series B Convertible Preferred Stock [Member]
Additional Paid-In Capital [Member]
Series C Convertible Preferred Stock [Member]
Additional Paid-In Capital [Member]
Series D Convertible Preferred Stock [Member]
Accumulated Deficit [Member]
Accumulated Deficit [Member]
Officer [Member]
Accumulated Deficit [Member]
Board [Member]
Accumulated Deficit [Member]
Series B Convertible Preferred Stock [Member]
Accumulated Deficit [Member]
Series C Convertible Preferred Stock [Member]
Accumulated Deficit [Member]
Series D Convertible Preferred Stock [Member]
Total
Officer [Member]
Board [Member]
Series B Convertible Preferred Stock [Member]
Series C Convertible Preferred Stock [Member]
Series D Convertible Preferred Stock [Member]
Balance at Dec. 31, 2019       $ 20,150,116       $ 6,769,849           $ 7,618,245           $ (28,636,479)           $ 5,901,731          
Balance (in shares) at Dec. 31, 2019       20,150       67,698,494,244                                              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                              
Issuance of common stock $ 0             $ 3,741,235           (3,741,235)           0           0          
Issuance of common stock (in shares) 0             37,412,353,772                                              
Cancellation of Convertible Preferred Stock         $ (20,150,116)           $ 0           $ 0           $ 0           $ (20,150,116)    
Cancellation of Convertible Preferred Stock (in shares)         (20,150)           0                                        
Issuance of Convertible Preferred Stock           $ 20,150,116           $ 0           $ 0           $ 0           $ 20,150,116  
Issuance of Convertible Preferred Stock (in shares)           20,150           0                                      
Series C Preferred stock exercised $ (3,873,000)             $ 3,873,000           0           0           0          
Preferred stock exercised (in shares) (3,873)             38,730,000,001                                              
Issuance of Convertible Preferred stock in connection with the Securities Purchase Agreement (in shares)               38,700,000,000                                              
Stock-based compensation expense $ 0             $ 0           78,029           0           78,029          
Net loss 0             0           0           (3,722,392)           (3,722,392)          
Balance at Dec. 31, 2020       $ 16,277,116       $ 14,384,084           3,955,039           (32,358,871)           2,257,368          
Balance (in shares) at Dec. 31, 2020       16,277       143,840,848,017                                              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                              
Issuance of common stock $ 0             $ 118,283           1,289,273           0           1,407,556          
Issuance of common stock (in shares) 0             1,182,831,056                                              
Series C Preferred stock exercised           $ (16,277,116) $ (4,200,000)         $ 16,277,116 $ 656,250         $ 0 $ 3,543,750         $ 0 $ 0         $ 0 $ 0
Preferred stock exercised (in shares)           (16,277) (4,200)         162,771,153,001 6,562,500,000                                    
Stock options exercised $ 0             $ 227,500           0           0           227,500          
Stock options exercised (in shares) 0             2,275,000,000                                              
Issuance of Convertible Preferred stock in connection with the Securities Purchase Agreement             $ 5,000,000           $ 0           $ 0           $ 0           $ 5,000,000
Issuance of Convertible Preferred stock in connection with the Securities Purchase Agreement (in shares)             5,000 162,800,000,000         0                                    
Issuance of common stock in connection with the Rights Offering, net of offering expenses $ 0             $ 2,704,680           21,639,637           0           24,344,317          
Issuance of common stock in connection with the Rights Offering, net of offering expenses (in shares) 0             27,046,800,310                                              
Issuance of awarded stock   $ 0 $ 0           $ 220,000 $ 5,000         $ (220,000) $ (5,000)         $ 0 $ 0         $ 0 $ 0      
Issuance of awarded stock (in shares)   0 0           2,200,000,000 50,000,000                                          
Cancellation of awarded stock   $ 0 $ 0           $ (605,000) $ (13,750)         $ 605,000 $ 13,750         $ 0 $ 0         $ 0 $ 0      
Cancellation of awarded stock (in shares)   0 0           (6,050,000,000) (137,500,000)                                          
Stock-based compensation expense $ 0             $ 0           34,375           0           34,375          
Net loss $ 0             0           0           (4,037,459)           (4,037,459)          
Balance at Dec. 31, 2021       $ 800,000       $ 33,974,163           $ 30,855,824           $ (36,396,330)           $ 29,233,657          
Balance (in shares) at Dec. 31, 2021       800       339,741,632,384                                              
XML 25 R6.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
OPERATING ACTIVITIES:    
Net loss $ (4,037,459) $ (3,722,392)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 497,408 550,098
Net gain on debt settlements (767,930) 0
Amortization of right-of-use asset 534,691 584,398
Gain (loss) on investment (412) 1,269
Write-down of obsolete and slow-moving inventory 707,710 340,905
Stock-based compensation expense 34,375 78,029
Impairment of goodwill and intangible assets 0 380,646
Accrued interest on loan payable 60,809 7,117
Changes in operating assets and liabilities:    
Accounts receivable (4,806) 41,726
Inventories (478,663) (333,139)
Prepaid expenses and vendor deposits (170,332) (16,233)
Contract assets 0 0
Other assets 4,161 57,269
Accounts payable and accrued liabilities 557,185 265,552
Contract liabilities 1,916 (5,561)
Lease liability (466,858) (511,481)
NET CASH USED IN OPERATING ACTIVITIES (3,528,205) (2,281,797)
INVESTING ACTIVITIES:    
Payment for acquisition (75,000) 0
Collection of note receivable 56,596 38,876
Purchases of patent (12,500) (89,415)
Purchases of property and equipment (56,418) (24,663)
NET CASH USED IN INVESTING ACTIVITIES (87,322) (75,202)
FINANCING ACTIVITIES:    
Proceeds from line of credit 418,036 0
Principal payment on the line of credit (2,000,000) 0
Principal payments on loan payable (803,397) (1,659,456)
Proceeds from paycheck protection program 0 876,515
Proceeds from loan and security agreement 0 2,540,000
Proceeds from preferred stock 5,000,000 0
Proceeds from rights offering, net of offering costs 24,344,317 0
Proceeds from exercise of stock options 227,500 0
NET CASH USED IN FINANCING ACTIVITIES 27,186,456 1,757,059
DECREASE IN CASH 23,570,929 (599,940)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - BEGINNING OF YEAR 2,925,475 3,525,415
CASH, CASH EQUIVALENTS AND RESTRICTED CASH - END OF YEAR 26,496,404 2,925,475
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Cash paid for interest 115,584 314,925
NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Issuance of common stock $ 1,407,556 $ 0
XML 26 R7.htm IDEA: XBRL DOCUMENT v3.22.1
ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS
12 Months Ended
Dec. 31, 2021
ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS [Abstract]  
ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS
Note 1. ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS

Organization

Healthier Choices Management Corp. (the “Company”) is a holding company focused on providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives. The Company currently operates six retail vape stores in the Southeast region of the United States, through which it offers e-liquids, vaporizers and related products. The Company also operates Ada’s Natural Market, a natural and organic grocery store, through its wholly owned subsidiary Healthy Choice Markets, Inc. Ada’s Natural Market and Paradise Health and Nutrition offers fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health & beauty products and natural household items. The Company also sells vitamins and supplements on the Amazon.com marketplace through its wholly owned subsidiary Healthy U Wholesale, Inc. The Company also operates HCMC Intellectual Property Holdings, LLC, a wholly owned subsidiary formed to hold, market and expand on its current intellectual property assets. The Company markets the Q-Cup™ technology under the vape segment; this patented technology is based on a small, quartz cup called the Q-Cup™, which a customer partially fills with either cannabis or CBD concentrate (approximately 50mg) purchased from a third party. The Q-Cup™ is then inserted into the Q-Cup™ Tank or Globe, that heats the cup from the outside without coming in direct contact with the solid concentrate. This Q-Cup™ technology provides significantly more efficiency and an “on the go” solution for consumers who prefer to vape concentrates either medicinally or recreationally. The Company acquired Mother Earth’s Storehouse on February 2022, which operates a two store organic and health food and vitamin chain in New York’s Hudson Valley, a business that has been operating for over 40 years.

COVID-19 Management Update

The global outbreak of COVID-19 was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020 and has negatively impacted the U.S. and global economies, disrupted global supply chains and, mandated closures and stay-at-home orders and created significant disruptions of the global financial markets. The Company adjusted certain aspects of the operations to protect their employees and customers while still meeting customers’ needs. While to date the Company has not been required to close any of its stores, the Company is currently operating under regular hours and we are expecting COVID-19 to have a long-term beneficial impact to the future financial results of the grocery segment. The Company continues to monitor the impact of the COVID-19 outbreak closely.  The extent to which the COVID-19 outbreak will impact our operations is manageable, and there is no imminent risk on business continuity and future operations.

Sourcing and Vendors

We source from multiple suppliers. These suppliers range from small independent businesses to multinational conglomerates. For the fiscal years ended December 31, 2021 and 2020, approximately 25% and 27% of our total purchases were from one vendor.

Basis of Presentation and Principles of Consolidation

The Company’s consolidated financial statements are prepared in accordance with GAAP. The consolidated financial statements include the accounts of all subsidiaries in which the Company holds a controlling financial interest as of the financial statement date.

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Healthy Choice Markets, Inc., Healthy Choice Markets 2, LLC (“Paradise Health and Nutrition”), Healthy Choice Markets 3, LLC (“Mother Earth’s Storehouse”), Healthy Choices Markets 3 Real Estate LLC, HCMC Intellectual Property Holdings, LLC, Healthy Choice Wellness, LLC, The Vitamin Store, LLC, Healthy U Wholesale, Inc., The Vape Store, Inc. (“Vape Store”), Vaporin, Inc. (“Vaporin”), Smoke Anywhere U.S.A., Inc. (“Smoke”), Emagine the Vape Store, LLC (“Emagine”), IVGI Acquisition, Inc., Vapormax Franchising LLC, Vaporin LLC, and Vaporin Florida, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
XML 27 R8.htm IDEA: XBRL DOCUMENT v3.22.1
LIQUIDITY
12 Months Ended
Dec. 31, 2021
LIQUIDITY [Abstract]  
LIQUIDITY
Note 2. LIQUIDITY

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of any uncertainties related to our going concern assessment. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values.

The Company incurred a loss from operations of approximately $4.7 million for the year ended December 31, 2021. As of December 31, 2021, cash and cash equivalents totaled approximately $26.5 million. Management anticipates that its current cash, cash equivalent and cash generated from operations will be sufficient to meet the projected operating expenses for the foreseeable future through at least the next twelve months from the issuance of these consolidated financial statements.
XML 28 R9.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the operating decision makers, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company’s decision-making group are the senior executive management team. The Company and the decision-making group view the Company’s operations and manage its business as two operating segments. All long-lived assets of the Company reside in the U.S.

Use of Estimates in the Preparation of the Financial Statements

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting periods. Actual results could differ from those estimates. These estimates and assumptions include allowances, reserves and write-downs of inventory, valuing equity securities and hybrid instruments, share-based payment arrangements, deferred taxes and related valuation allowances, and the valuation of the assets and liabilities acquired in business combinations. Certain of management’s estimates could be affected by external conditions, including those unique to our industry, and general economic conditions. It is possible that these external factors could have an effect on our estimates that could cause actual results to differ from our estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary.

Revenue Recognition

Revenues from product sales and services rendered, net of promotional discounts, manufacturer coupons and rebates, return allowances, and sales and consumption taxes, are recorded when products are delivered, title passes to customers and collection is likely to occur. Title passes to customers at the point of sale for retail and upon delivery of products for wholesale. Return allowances, which reduce revenue, are estimated using historical experience.

The Company recognizes revenue in accordance with the following five-step model:

identify arrangements with customers;

identify performance obligations;

determine transaction price;

allocate transaction price to the separate performance obligations in the arrangement, if more than one exists; and

recognize revenue as performance obligations are satisfied.

Shipping and Handling

Shipping charges billed to customers are included in net sales and the related shipping and handling costs are included in cost of sales. For the years ended December 31, 2021 and 2020, shipping and handling costs of approximately $68,000 and $48,000, were included in cost of sales, respectively.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with an original maturity of three months or less, when purchased, to be cash and cash equivalents. The majority of the Company’s cash and cash equivalents are concentrated in one large financial institution, which is in excess of Federal Deposit Insurance Corporation (FDIC) coverage. At December 31, 2021, cash in excess of FDIC limits of $250,000 per financial institution were approximately $26.0 million. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests, as deposits are held in excess of federally insured limits. The Company’s cash equivalent at December 31, 2021 was a money market account. The Company has not experienced any losses in such accounts.

Accounts Receivable, Contract Assets and Contract Liabilities

Accounts receivables are claims to consideration which are unconditional; meaning no performance obligations remain for the Company and only the passage of time is necessary before collection. Contract assets are distinguished from accounts receivable as performance obligations remain before claims to consideration become unconditional. By nature of the Company’s operations, contract assets are typically not recognized. Contract liabilities are recorded when customers transfer consideration in advance of delivery of products or services, which the Company records for gift cards and loyalty reward programs. When one party to an arrangement performs before the other(s), the Company records an account receivable, contract asset or contract liability.

The majority of arrangements with customers contain one performance obligation: to provide a distinct set of products or services. Most performance obligations are satisfied simultaneously as the Company exchanges products or services for customer payment. Exceptions include gift cards and loyalty rewards, for which the Company has a performance obligation to deliver products or services at a future date. As gift cards are purchased and loyalty points earned, contract liabilities are recorded until the performance obligations are satisfied through delivery of products or services or breakage based on gift card and loyalty reward program term limits.

The Company’s breakage policy is twenty-four months for gift cards, twelve months for Grocery loyalty rewards, and six months for Vapor loyalty rewards. Loyalty rewards are earned at five percent on qualifying purchases and the reward functions as an allocation of transaction price from the period earned by the customer to the period the performance obligation is satisfied by the Company. As such, all contract liabilities are expected to be recognized within a twenty-four month period.

Concentration of accounts receivable consist of the following:

 
December 31, 2021
   
December 31, 2020
 
             
Customer A
   
30
%
   
0
%
Customer B
   
12
%
   
0
%
Customer C
   
0
%
   
34
%

Due from Merchant Credit Card Processor

Due from merchant credit card processor represents monies held by the Company’s credit card processors. The funds are being held by the merchant credit card processors pending satisfaction of their hold requirements and expiration of charge backs/refunds from customers.

Inventories

Inventories are stated at average cost. If the cost of the inventories exceeds their net realizable value, adjustments are recorded to write down excess inventory to their net realizable value. The Company’s inventories consist primarily of merchandise available for resale, such as vaporizers, electronic cigarettes, e-liquids, fresh produce, perishable grocery items and non-perishable consumable goods.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the expected useful life of the respective asset, after the asset is placed in service. Revenue earning property and equipment includes signage, furniture and fixtures, computer hardware, appliance, cooler, displays with useful lives range from two to seven years. Leasehold improvements are amortized over life of lease.

Identifiable Intangible Assets and Goodwill

Identifiable intangible assets are recorded at cost, or when acquired as part of a business acquisition, at estimated fair value. Certain identifiable intangible assets are amortized over 4 and 10 years. Similar to tangible personal property and equipment, the Company periodically evaluates identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Indefinite-lived intangible assets, such as goodwill are not amortized.

Impairment of Long-Lived Assets

The Company reviews all long-lived assets such as property and equipment and amortized intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future cash flows expected to be generated by the asset or asset group. Impairment is measured by the amount by which the carrying value of the asset(s) exceeds their fair value. There were no triggering events that would indicate impairment of long-lived assets at December 31, 2021. For the year ended December 31, 2020, the Company determined the estimated undiscounted cash flows related to the sales of the VitaminStore.com were less than the carrying value of the intangible assets and recorded an impairment charge of $0.3 million.

Goodwill

The Company assesses the carrying amounts of goodwill for recoverability on at least an annual basis or when events or changes in circumstances indicate evidence of potential impairment exists, using a fair value based test. Application of the goodwill impairment test requires significant judgments including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the businesses, and the useful life over which cash flows will occur. Changes in these estimates and assumptions could materially affect the determination of fair value and/or conclusions on goodwill impairment for the Company. Our annual impairment test is conducted on September 30 of each year or more often if deemed necessary. As part of management's qualitative analysis at December 31, 2021 management determines whether any triggering events have occurred since the annual test date of September 30, 2021, which would indicate an impairment. Management determined no triggering events had occurred through December 31, 2021. The Company recorded an impairment charge of $40,000 for the year ended December 31, 2020.

Advertising

The Company expenses advertising costs as incurred. For the years ended December 31, 2021 and 2020, the company incurred advertising expenses of $43,000 and $92,000, respectively.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021 or December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

Stock-Based Compensation

The Company accounts for stock-based compensation for employees and directors under ASC Topic No. 718, “Compensation-Stock Compensation” (“ASC 718”). These standards define a fair value based method of accounting for stock-based compensation. In accordance with ASC 718, the cost of stock-based compensation is measured at the grant date based on the value of the award and is recognized over the vesting period. The value of the stock-based award is determined using an appropriate valuation model, whereby compensation cost is the fair value of the award as determined by the valuation model at the grant date. The resulting amount is charged to expense on the straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period. The Company recognize forfeitures as they are incur. Stock-based compensation for non-employees is measured at the grant date, is re-measured at subsequent vesting dates and reporting dates, and is amortized over the service period.

Fair Value Measurements

The fair value framework under FASB’s guidance requires the categorization of assets and liabilities into three levels based upon the assumptions used to measure the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3, if applicable, would generally require significant management judgment. The three levels for categorizing assets and liabilities under the fair value measurement requirements are as follows:

Level 1: Fair value measurement of the asset or liability using observable inputs such as quoted prices in active markets for identical assets or liabilities;

Level 2: Fair value measurement of the asset or liability using inputs other than quoted prices that are observable for the applicable asset or liability, either directly or indirectly, such as quoted prices for similar (as opposed to identical) assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and

Level 3: Fair value measurement of the asset or liability using unobservable inputs that reflect the Company’s own assumptions regarding the applicable asset or liability.

Nonfinancial assets such as goodwill, other intangible assets, and long-lived assets held and used are measured at fair value when there is an indicator of impairment and recorded at fair value when impairment is recognized or for a business combination.

Sequencing Policy

Under ASC 815-40-35, the Company has adopted a sequencing policy, whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares.
XML 29 R10.htm IDEA: XBRL DOCUMENT v3.22.1
DISAGGREGATION OF REVENUES
12 Months Ended
Dec. 31, 2021
DISAGGREGATION OF REVENUES [Abstract]  
DISAGGREGATION OF REVENUES
Note 4. DISAGGREGATION OF REVENUES

The Company reports the following segments in accordance with management guidance: Vapor and Grocery. When the Company prepares its internal management reporting to evaluate business performance, we disaggregate revenue into the following categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 
December 31, 2021
   
December 31, 2020
 
             
Vapor sales, net
 
$
2,084,813
   
$
2,458,945
 
Grocery sales, net
   
11,235,041
     
11,461,800
 
Total revenue
 
$
13,319,854
   
$
13,920,745
 
                 
Retail Vapor
 
$
2,084,744
   
$
2,458,945
 
Retail Grocery
   
9,923,137
     
10,047,437
 
Food service/restaurant
   
1,202,122
     
1,088,162
 
Online/e-Commerce
   
93,600
     
307,487
 
Wholesale Grocery
   
16,182
     
18,714
 
Wholesale Vapor
   
69
     
-
 
Total revenue
 
$
13,319,854
   
$
13,920,745
 
XML 30 R11.htm IDEA: XBRL DOCUMENT v3.22.1
INVESTMENT
12 Months Ended
Dec. 31, 2021
INVESTMENT [Abstract]  
INVESTMENT
Note 5. INVESTMENT

In 2018, the Company invested $150,000 in 85,714 common stock shares at MJ Holdings, Inc. (“MJNE”), a publicly traded company. The investment was made based on the assumption of an increase in MJNE stock due to the sales agreement with the Company. The Company recorded the investment in MJNE at fair value with changes in the fair value reported through the income statement as the stock is traded on the OTC market. Investment is classed with Level 1 of the valuation hierarchy. Fair value for the investment is based on quoted prices in active markets.

The following table summarizes the investment measured at fair value on a recurring basis as of December 31, 2021:

Description
Fair Value Measurements Using Quoted Prices in Active Market (Level 1)
 
Mark to Market
 
December 31, 2021
 
Investment
 
$
22,731
   
$
412
   
$
23,143
 

The following table summarizes the investment measured at fair value on a recurring basis as of December 31, 2020:

Description
Fair Value Measurements Using Quoted Prices in Active Market (Level 1)
 
Mark to Market
 
December 31, 2021
 
Investment
 
$
24,000
   
$
(1,269
)
 
$
22,731
 
XML 31 R12.htm IDEA: XBRL DOCUMENT v3.22.1
INVENTORIES
12 Months Ended
Dec. 31, 2021
INVENTORIES [Abstract]  
INVENTORIES
Note 6. INVENTORIES

Inventories are stated at average cost. If the cost of the inventories exceeds their market value, adjustments are recorded to write down excess inventory to its net realizable value. Throughout the year, the Company did not have independent third party counts of its inventory due to the Coronavirus (COVID-19) pandemic and recorded the write down of inventories amounting to $0.7 million and $0.3 million, approximately, in 2021 and 2020, respectively. The Company’s inventories consist primarily of merchandise available for resale.

 
December 31, 2021
   
December 31, 2020
 
             
Vapor Business
 
$
188,793
   
$
304,614
 
Grocery Business
   
1,332,406
     
1,444,632
 
Total
 
$
1,521,199
   
$
1,749,246
 
XML 32 R13.htm IDEA: XBRL DOCUMENT v3.22.1
NOTES RECEIVABLE AND OTHER INCOME
12 Months Ended
Dec. 31, 2021
NOTES RECEIVABLE AND OTHER INCOME [Abstract]  
NOTES RECEIVABLE AND OTHER INCOME
Note 7. NOTES RECEIVABLE AND OTHER INCOME

On September 6, 2018, the Company entered into a secured, 36-month promissory note with VPR Brands L.P. for $582,260. The Note bears an interest rate of 7%, which payments thereunder are $4,141 weekly. The Company records all proceeds related to the interest of the Note as interest income as proceeds are received.

On August 31, 2021, the Company amended and restated the Secured Promissory Note (the "Note") with VPRB Brands L.P. for the outstanding balance in the note of $268,126. The Note bears an interest rate of 7%, which payments thereunder are $1,500 weekly, with such payments commencing as of September 03, 2021. The Note has a balloon payment of $213,028 for all remaining accrued interest and principal balance due in the final week of the 1-year extension of the Note.

A summary of the Note as of December 31, 2021 and 2020 is presented below:

 
December 31,
 
Description
2021
 
2020
 
Promissory Note
 
$
247,915
   
$
304,511
 

For the years ended December 31, 2021 and 2020, the Company had notes receivable collections of approximately $57,000 and $39,000, respectively. These collections are recorded to other income in the Consolidated Statement of Operations.
XML 33 R14.htm IDEA: XBRL DOCUMENT v3.22.1
PROPERTY & EQUIPMENT
12 Months Ended
Dec. 31, 2021
PROPERTY & EQUIPMENT [Abstract]  
PROPERTY & EQUIPMENT
Note 8. PROPERTY & EQUIPMENT

Property and equipment consists of the following

 
Year Ended December 31,
 
   
2021
   
2020
 
             
Displays
 
$
305,558
   
$
305,558
 
Furniture and fixtures
   
246,496
     
246,496
 
Leasehold improvements
   
136,504
     
128,004
 
Computer hardware & equipment
   
151,924
     
143,082
 
Other
   
315,788
     
276,711
 
     
1,156,270
     
1,099,851
 
Less: accumulated depreciation and amortization
   
(979,282
)
   
(869,132
)
Total property and equipment
 
$
176,988
   
$
230,719
 

The Company incurred approximately $0.1 million and $0.1 million of depreciation expense for the years ended December 31, 2021 and 2020, respectively.
XML 34 R15.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS
12 Months Ended
Dec. 31, 2021
GOODWILL AND INTANGIBLE ASSETS [Abstract]  
GOODWILL AND INTANGIBLE ASSETS
Note 9. GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows:

 
December 31, 2021
   
December 31, 2020
 
             
Beginning balance
 
$
916,000
   
$
956,000
 
Impairment of goodwill-retail business
   
-
     
(40,000
)
Ending balance
 
$
916,000
   
$
916,000
 

Intangible assets, net are as follows:

December 31, 2021
Useful Lives (Years)
 
Gross Carrying Amount
   
Accumulated Amortization
   
Net Carrying Amount
 
Customer relationships
4-5 years
 
$
883,000
   
$
(685,823
)
 
$
197,177
 
Trade names
8-10 years
   
923,000
     
(536,661
)
   
386,339
 
Patents
10 years
   
372,165
     
(122,233
)
   
249,932
 
Non-compete
4 years
   
238,000
     
(133,646
)
   
104,354
 
Website
4 years
   
10,000
     
(209
)
   
9,791
 
Intangible assets, net
   
$
2,426,165
   
$
(1,478,572
)
 
$
947,593
 

December 31, 2020
Useful Lives (Years)
 
Gross Carrying Amount
   
Accumulated Amortization
   
Net Carrying Amount
 
Customer relationships
4-10 years
 
$
883,000
   
$
(475,073
)
 
$
407,927
 
Trade names
8-10 years
   
923,000
     
(441,786
)
   
481,214
 
Patents
10 years
   
359,665
     
(85,641
)
   
274,024
 
Non-compete
4 years
   
174,000
     
(88,813
)
   
85,187
 
Intangible assets, net
   
$
2,339,665
   
$
(1,091,313
)
 
$
1,248,352
 

Amortization expense was approximately $0.4 million for the years ended December 31, 2021 and 2020.

Acquisition of EIR Hydration

On November 30, 2021, the Company, through its wholly owned subsidiary, Healthy Choice Wellness Center, LLP, acquired EIR Hydration, an IV therapy center located in Roslyn Heights, NY. The cost of the transaction was $75,000 and it was treated as an asset purchase.
The weighted-average remaining amortization period of the Company’s amortizable intangible assets is approximately 6 years as of December 31, 2021. The estimated future amortization of the intangible assets is as follows:

For the years ending December 31,
     
2022
 
$
389,456
 
2023
   
150,591
 
2024
   
150,591
 
2025
   
143,549
 
2026
   
48,655
 
Thereafter
   
64,751
 
Total
 
$
947,593
 
XML 35 R16.htm IDEA: XBRL DOCUMENT v3.22.1
CONTRACT LIABILITIES
12 Months Ended
Dec. 31, 2021
CONTRACT LIABILITIES [Abstract]  
CONTRACT LIABILITIES
Note 10. CONTRACT LIABILITIES

The Company’s contract liabilities consist of customer deposits, gift cards and loyalty rewards, for which the Company has a performance obligation to deliver products when customers redeem balances or terms expire through breakage. The Company’s breakage policy is twenty-four months for gift cards, twelve months for Grocery loyalty rewards, and six months for Vapor loyalty rewards. As such, all contract liabilities are expected to be recognized within a twenty-four month period.

A summary of the contract liabilities activity for the years ended December 31, 2021 and 2020 is presented below:

 
Year ended December 31,
 
   
2021
   
2020
 
Beginning balance as of January1,
 
$
21,262
   
$
26,823
 
Issued
   
39,469
     
53,929
 
Redeemed
   
(37,463
)
   
(58,263
)
Breakage recognized
   
(90
)
   
(1,227
)
Ending balance as of December 31,
 
$
23,178
   
$
21,262
 
XML 36 R17.htm IDEA: XBRL DOCUMENT v3.22.1
LINE OF CREDIT AND DEBT
12 Months Ended
Dec. 31, 2021
LINE OF CREDIT AND DEBT [Abstract]  
LINE OF CREDIT AND DEBT
Note 11. LINE OF CREDIT AND DEBT

The following table provides a breakdown of the Company's debt as of December 31, 2021 and 2020 is presented below:

 
December 31,
 
2021
 
2020
Line of Credit
$
418,036
 
$
2,000,000
Term Loan Credit Agreement
 
-
   
800,924
Paycheck Protection Program
 
-
   
882,264
Loan and Security Agreement ("PPE Loan")
 
-
   
1,232,414
Other debt
 
3,419
   
5,891
Total Line of Credit and Debt
$
421,455
 
$
4,921,493

Revolving Line of Credit

On November 3, 2021, the Company entered into an agreement for a new revolving line of credit of $2.0 million and a blocked/restricted deposit account (“blocked account”) with Professional Bank in Coral Gables, Florida. The agreement included a variable interest rate that it is based on a rate of 1.0% over what is earned on the collateral account. Based on the agreement with the bank, each draw request from the credit line will be 100% cash secured with moneys held from the blocked account.

Term Loan Credit Agreement

On December 31, 2018, the Company entered into a Term Loan Credit Agreement (the “Credit Agreement”) with Professional Bank, a Florida banking corporation (the “Bank”), pursuant to which the Company issued a Term Note (the “Term Note”) in the principal amount of $1,400,000 in favor of the Bank. The Term Note bears interest at a rate equal to 1.5 percentage points in excess of that rate shown in the Wall Street Journal as the prime rate, adjusted annually (which was 5.50% as of December 31, 2020 and 2021). The proceeds of the Term Note were used for acquisitions and for general working capital requirements.

On December 21, 2021, the Company paid in full the outstanding balance of $410,000 from the Term Loan.

Paycheck Protection Program

On May 15, 2020, the Company was granted a loan (the “Loan”) from Customers Bank, in the aggregate amount of $876,515, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020.

The Loan, which was in the form of a Note dated May 6, 2020 issued by the Company, matures on May 6, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 6, 2020. Note may be prepaid by the Borrower at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, costs used to continue group health care benefits, mortgage payments, rent, utilities, and interest on other debt obligations incurred after May 6, 2020. The Company intends to use the entire Loan amount for these qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. On December 9, 2020, the Company submitted the forgiveness application for the PPP Loan to the Small Business Bureau.

On May 3, 2021, the Company received a letter from Customers Bank to inform the Company that the PPP Loan was paid and fully forgiven by the Small Business Administration (SBA). The forgiveness of $885,227 was reported in gain on debt settlements on the consolidated statements of operations.
XML 37 R18.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2021
COMMITMENTS AND CONTINGENCIES [Abstract]  
COMMITMENTS AND CONTINGENCIES
Note 12. COMMITMENTS AND CONTINGENCIES

Employment Agreements 
 
On August 13, 2018, the Company amended and restated its existing employment agreement with Jeffrey Holman, the Company’s Chief Executive Officer (the “Holman Employment Agreement”). The Holman Employment Agreement is for an additional three year term and provides for an annual base salary of $450 and a target bonus for 2020 only in an amount ranging from 20% to 200% of his base salaries subject to the Company meeting certain earnings before interest, taxes depreciation and amortization performance milestones. Mr. Holman is entitled to receive severance payments, including two years of his then base salary and other benefits in the event of a change of control, termination by the Company without cause, termination for good reason by the executive or non-renewal by the Company. Mr. Holman was also granted 11 billion shares of restricted common stock pursuant to the Holman Employment Agreement Amendment on the condition that 11 billion of his options to purchase Company common stock are forfeited. This restricted stock will vest one year following the date of issuance provided that the grantee remains an employee of the Company through each applicable vesting date. On August 12, 2019, the Company agreed to extend the expiration date of the vesting period for the restricted stock by six months to February 13, 2020. On August 12, 2020, the Company agreed to extend for a second time the expiration date of the vesting period for the restricted stock by six months to February 13, 2021. The Term shall be automatically renewed for successive one-year terms unless notice of non-renewal is given by either party at least 30 days before the end of the Term. The above description of the terms of the Holman Employment Agreement is not complete and is qualified by reference to the complete document.

On February 26, 2021, the Company entered into an amended and restated employment agreement (the “Employment Agreement Amendment”) with the Company’s President and Chief Operating Officer, Christopher Santi. Pursuant to the Employment Agreement Amendment, Mr. Santi will continue to be employed as the Company’s President and Chief Operating Officer through January 30, 2024.  Mr. Santi will receive a base salary of $0.4 million for 2021 and his salary will increase 10% in each subsequent year. The Term shall be automatically renewed for successive one-year terms unless notice of non-renewal is given by either party at least 30 days before the end of the Term. The above description of the terms of the Santi Employment Agreement is not complete and is qualified by reference to the complete document.

Legal Proceedings

Two lawsuits were filed against the Company and its subsidiaries in connection with alleged claimed battery defects for an electronic cigarette device. Plaintiffs claim these batteries were sold by a store of the Company’s subsidiary and have sued for an undetermined amount of damages (other than a total of $0.4 million of medical costs). The initial complaints were filed between January 2019 and April 2019. We responded to the complaints on April 2019 and May 2019, respectively. Given the lack of information presented by the plaintiffs to date, the Company is unable to predict the outcome of these matters and, at this time, cannot reasonably estimate the possible loss or range of loss with respect to these legal proceedings.

On November 30, 2020, the Company filed a patent infringement lawsuit against Philip Morris USA, Inc. and Philip Morris Products S.A. in the U.S. District Court for the Northern District of Georgia.  The lawsuit alleges infringement on HCMC-owned patent(s) by the Philip Morris product known and marketed as “IQOS®”.  Philip Morris claims that it is currently approaching 14 million users of its IQOS® product and has reportedly invested over $3 billion in their smokeless tobacco products. On December 3, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A.  On December 14, 2021, the Company filed an appeal of the District Court for the Northern District of Georgia’s dismissal of the Company’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. HCMC believes the Georgia Court committed legal error by dismissing its complaint for patent infringement and also by denying the Company’s motion to amend its pleading.

From time to time the Company is involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations December 31, 2021. With respect to legal costs, we record such costs as incurred.

Fontem License Agreement

The Company has a non-exclusive license to certain products with Fontem Ventures B.V. (“Fontem”). The Company will make quarterly license and royalty payments in perpetuity to Fontem, based on the sale of qualifying products as defined in the license agreement at a royalty rate of 5.25%. For the years ended December 31, 2021 and 2020, the Company recorded expenses of $12,000 and $15,000 as part of its cost of goods.
XML 38 R19.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY
12 Months Ended
Dec. 31, 2021
STOCKHOLDERS' EQUITY [Abstract]  
STOCKHOLDERS' EQUITY
Note 13. STOCKHOLDERS’ EQUITY

Equity Compensation Plans

The Company’s 2015 Equity Incentive Plan, as amended (the “2015 Plan”), awards grants to employees. The plan can award up to 100 billion shares of common stock and currently 10.3 billion shares are available for grant as of December 31, 2021.

The Company’s 2009 Equity Incentive Plan (the “2009 Plan”) awards grants to employees, non-employee directors and consultants in connection with their retention and/or continued employment by the Company. The 2009 Plan had no shares of common stock available for grant as of December 31, 2021.

Rights Offering

On June 18, 2021, the Company issued 27,046,800,310 shares of common stock in connection with the Rights Offering at a subscription price of $0.0010 per share, generating gross proceeds of $27.0 million. The Company incurred direct financing costs of $2.7 million in connection with the offering resulting in net proceeds to the Company of $24.3 million.

Exchange Agreement

On March 29, 2021, the Company entered into exchange agreements with the holders of the $2.7 million Loan and Security Agreement (the "Credit Agreement"). The agreement with the holders of the Company’s indebtedness (the “Notes”) in an aggregate amount of $1.3 million to exchange the Notes for 1,172,964,218 shares at a conversion price of $0.0011. The Notes were issued pursuant to the Credit Agreement dated as of August 18, 2020, among The Vape Store, Inc., the Company, Healthy Choice Markets, Inc., Sabby Healthcare Master Fund, Ltd., and Sabby Volatility Warrant Master Fund, Ltd.  In connection with the Exchange, the Credit Agreement and all related loan documents was terminated and the Holder’s on the assets of the Company and its subsidiaries was cancelled.  The Company recognized a loss on debt extinguishment of $0.1 million for the year ended December 31, 2021.

Preferred Stock

The Company’s amended and restated articles of incorporation authorizes the Company’s Board of Directors to issue up to 1,000,000 shares of “blank check” preferred stock, having a $0.001 par value, in one or more series without stockholder approval. Each such series of preferred stock may have such number of shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges as determined by the Company’s Board of Directors. See below for details associated with the designation of the 1,000,000 shares of the Series A preferred stock.

Series C Convertible Preferred Stock

On November 17, 2020, the Company finalized the closing of the stock exchange with certain holders of its Series B Stock to exchange all the Series B Stock for 20,150 shares of Series C Convertible Preferred Stock (the “Series C Stock”). Each share of Series C Stock has a stated value equal to $1,000 and is convertible into Common Stock on a fixed basis at a conversion price of $0.0001 per share.

During the years ended December 31, 2021 and 2020, the Company issued 162.8 billion shares and 38.7 billion shares of Company common stock in connection with the exercise of Series C stock.


Series D Convertible Preferred Stock

On February 7, 2021, the Company entered into a Securities Purchase Agreement, pursuant to which the Company sold and issued 5,000 shares of its Series D Convertible Preferred Stock (the “Preferred Stock”) to accredited investors for $1,000 per share or an aggregate subscription of $5.0 million. As of December 31, 2021, the Company has issued 6.6 billion shares of Company common stock in connection with the exercise of 4,200 shares of the Series D Convertible Preferred Stock at a conversion price of $0.00064 per share. The conversion price for the exercise of the preferred stock was reset to the 80% of the lowest daily volume-weighted average price ("VWAP") during the 5 Trading Days immediately preceding the effective date of August 11, 2021.

Warrants

October 5, 2016, the Company’s amended and restated its Series A Warrant Standstill Agreements (the "Amended Standstill Agreements") to permit each holder (each, a "Holder") to effect a "cashless" exercise of the Series A Warrants only on dates when the closing bid price used to determine the "net number" of shares to be issued upon exercise is at or above $0.00. The shares issuable upon the exercise of the Series A Warrants are calculated (1) using a Black Scholes Value of 1,517,936 per share and a closing stock bid price at or above 0.00 and (2) the Company will deliver only common stock upon exercise of the Series A Warrants.

On July 27, 2020, the Company's Series A Warrants expired and the balance of outstanding warrants not exercised was 355,661 warrants.

During the year ended December 31, 2020, the Company issued 3,466,153 shares of the Company Common Stock in connection with the exercise of the Series A Warrant.

Modification of share-based payment awards to officers

On August 13, 2018, the Compensation Committee of the Company approved a modification of share-based payment awards to the Chief Executive Officer and Chief Operating Officer of the Company. As part of the share modification, the Chief Executive Officer and Chief Operating Officer were granted 11 billion and 8 billion shares of restricted common stock on the condition that the same number of shares from their options to purchase the Company’s common stock are forfeited. However, the shares were issued to the officers and have been reflected in the statement of stockholders’ equity. Initially, this restricted stock was schedule to vest one year following the date of issuance provided that the grantee remains an employee of the Company through the vesting date.

On August 12, 2019, the Company agreed to extend the expiration date of the vesting period for the restricted stock by six months to February 13, 2020.

On August 12, 2020, the Company agreed to extend for a second time the expiration date of the vesting period for the restricted stock by six months to February 13, 2021.

On January 14, 2021, the Compensation Committee of the Company approved an issuance of restricted stock to the Officers and a Director of the Company, in consideration for agreeing to a new vesting schedule for the existing awarded restricted stock. Each individual was granted a 10% increase from the original award agreement for a total of 2.3 billion shares of restricted common stock, which will vest quarterly in equal amounts until December 31, 2022, provided that the grantee remains an employee of the Company through the vesting date.

Restricted Stock

On August 13, 2018, the Compensation Committee of the Company approved an issuance of restricted stock to the Chief Financial Officer (the "Officer") of the Company. The Officer was granted 3 billion shares of restricted common stock, which will vest one year following the date of issuance, provided that the grantee remains an employee of the Company through the vesting date.

On August 12, 2019, the Company agreed to extend the expiration date of the vesting period for the restricted stock by six months to February 13, 2020.

On August 12, 2020, the Company agreed to extend for a second time the expiration date of the vesting period for the restricted stock by six months to February 13, 2021.

On January 14, 2021, the Compensation Committee of the Company approved an issuance of restricted stock to the Officers and a Director of the Company, in consideration for agreeing to a new vesting schedule for the existing awarded restricted stock. Each individual was granted a 10% increase from the original award agreement for a total of 2.3 billion shares of restricted common stock, which will vest quarterly in equal amounts until December 31, 2022, provided that the grantee remains an employee of the Company through the vesting date.

On March 30, 2021, the Company and the Officers and a Director of the Company agreed to forfeit a total of 3.09 billion of restricted shares of common stock that were due to vest on March 31, 2021.

On June 29, 2021, the Company and the Officers and a Director of the Company agreed to forfeit a total of 3.09 billion of restricted shares of common stock that were due to vest on June 30, 2021.

Stock Options

During the years ended December 31, 2021 and 2020, the Company did not grant any options for the purchase of shares of its common stocks.

A summary of option activity during the years ended December 31, 2021 and 2020 is as follows:

 
Number of Options
   
Weighted Average
Exercise
Price
   
Weighted Average Remaining Term (Yrs.)
   
Aggregate Intrinsic Value
 
                         
Outstanding, January 1, 2020
   
69,862,230,680
   
$
0.00
     
7
   
$
-
 
Options granted
   
-
     
0.00
             
-
 
Options forfeited or expired
   
-
     
0.00
             
-
 
Outstanding, December 31, 2020
   
69,862,230,680
   
$
0.00
     
6
   
$
-
 
Options granted
   
-
     
0.00
             
-
 
Options exercised
   
(2,275,000,000
)
   
0.00
             
-
 
Options forfeited or expired
   
-
     
0.00
             
-
 
Outstanding, December 31, 2021
   
67,587,230,680
   
$
0.00
     
5
     
-
 
Exercisable at December 31, 2021
   
67,587,230,680
   
$
0.00
     
5
   
$
-
 

During the years ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense of approximately $34,375 and $78,029, respectively, in connection with the amortization of stock options, net of recovery of stock-based charges for forfeited stock options. Stock-based compensation expense is included as part of selling, general and administrative expense in the accompanying consolidated statements of operations.

Income (Loss) per Share

Basic income (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon (a) the exercise of stock options (using the treasury stock method); (b) the conversion of Series A convertible preferred stock; (c) the exercise of warrants (using the if-converted method); (d) the vesting of restricted stock units; and (e) the conversion of convertible notes payable. Diluted income (loss) per share excludes the potential common shares, as their effect is antidilutive. The following table summarizes the Company’s securities that have been excluded from the calculation of basic and dilutive income (loss) per share as their effect would be anti-dilutive:

 
December 31,
 
   
2021
   
2020
 
             
Preferred stock
   
1,250,000,000
     
162,771,153,000
 
Stock options
   
67,587,230,680
     
69,862,230,680
 
Total
   
68,837,230,680
     
232,633,383,680
 
XML 39 R20.htm IDEA: XBRL DOCUMENT v3.22.1
LEASE
12 Months Ended
Dec. 31, 2021
LEASE [Abstract]  
LEASE
Note 14. LEASE

The Company has various lease agreements with terms up to 20 years, including leases of retail stores, headquarter and equipment. All the leases are classified as operating leases.

The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of December 31, 2021.

Maturity of Lease Liabilities by Fiscal Year
     
2022
 
$
572,335
 
2023
   
450,877
 
2024
   
342,005
 
2025
   
337,685
 
2026
   
267,759
 
Thereafter
   
1,941,250
 
Total undiscounted operating lease payments
 
$
3,911,911
 
Less: Imputed interest
   
(789,562
)
Present value of operating lease liabilities
 
$
3,122,349
 

The following summarizes the Company's operating leases:

Balance Sheet Classification
 
December 31, 2021
   
December 31, 2020
 
Right of use asset
 
$
3,543,930
   
$
4,078,621
 
                 
Operating lease liability, current
 
$
437,328
   
$
474,686
 
Operating lease liability, net of current
   
2,685,021
     
3,114,521
 
Total operating lease liabilities
 
$
3,122,349
   
$
3,589,207
 

The amortization of the right-of-use asset of $534,691 was included in operating cash flows.

Other Information
     
Weighted-average remaining lease term for operating leases
 
10 years
 
Weighted-average discount rate for operating leases
   
4.74
%

Rent expense for the years ended December 31, 2021 and 2020 was approximately $0.9 million and $1.0 million, respectively, is included in selling, general and administrative expenses in the accompanying consolidated statement of operations.

The following table represents the components of lease cost are as follows for twelve months ended December 31, 2021:

 
December 31, 2021
 
Operating lease cost
 
$
389,538
 
Variable lease cost
   
372,608
 
Short-term lease cost
   
139,291
 
Total rent expense
 
$
901,437
 

The aggregate cash payments under the leasing arrangement was approximately $467,000 for the year ended December 31, 2021 and was included in operating cash flows.
XML 40 R21.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES
12 Months Ended
Dec. 31, 2021
INCOME TAXES [Abstract]  
INCOME TAXES
Note 15. INCOME TAXES

The Company did not have a provision for income taxes (current or deferred tax expense) for tax years ended December 31, 2021 and 2020. The following is a reconciliation of the expected tax expense (benefit) at the U.S. statutory rate to the actual tax expense (benefit) reflected in the accompanying statement of operations:

 
Year Ended December 31,
 
   
2021
   
2020
 
             
U.S. federal statutory rate
 
$
(847,867
)
 
$
(781,704
)
State and local taxes, net of federal benefit
   
(111,900
)
   
(132,291
)
Change in valuation allowance
   
734,615
     
1,201,450
 
True-up & deferred adjustment
   
11,441
     
23,614
 
Stock based compensation
   
8,171
     
19,159
 
Forgiveness of PPP loan
   
(210,432
)
   
-
 
Other permanent items
   
-
     
935
 
Change in tax rate
   
89,360
     
2,429
 
Expired warrants
   
-
     
(422,655
)
Other
   
326,612
     
89,063
 
   
$
-
   
$
-
 

As of December 31, 2021 and 2020, the Company’s deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following:

 
Year Ended December 31,
 
   
2021
   
2020
 
Deferred tax assets:
           
Net operating losses
 
$
14,136,491
   
$
13,366,483
 
Inventory reserves and allowances
   
30,156
     
31,249
 
Accrued Expenses and Deferred Income
   
136,686
     
45,358
 
Charitable contribution
   
5,134
     
5,303
 
Stock based compensation
   
1,903,413
     
1,966,058
 
Net book value of fixed assets
   
1,961
     
6,574
 
Net book value of intangible assets
   
671,954
     
731,365
 
ASC 842 - Lease Accounting
   
33,891
     
32,681
 
Total deferred tax assets
   
16,919,686
     
16,185,071
 
                 
Net deferred tax assets
   
16,919,686
     
16,185,071
 
Valuation allowance
   
(16,919,686
)
   
(16,185,071
)
Net deferred tax assets
 
$
-
   
$
-
 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the positive and negative evidence available, management has determined that a valuation allowance is required at December 31, 2021 and 2020 to reduce the deferred tax assets to amounts that are more likely than not to be realized. The Company’s valuation increased by $734,615 and $1,201,450 for the tax years ended 2021 and 2020, respectively. Should the factors underlying management’s analysis change, future valuation adjustments to the Company’s net deferred tax assets may be necessary.

At December 31, 2021 the Company had U.S. federal and state net operating loss carryforwards (“NOLS”) of 61.0 million and 46.6 million, respectively. Federal NOLs of $46.3 million expire beginning in 2032 through 2037 and $14.7 million do not expire and are subject to 80% of taxable income under Internal Revenue Code Section 172. State NOLs of $35.4 million expire beginning in 2032 through 2037 and $11.2 million do not expire and maybe subject to income limitations under each State statute. Utilization of our NOLS may be subject to an annual limitation under section 382 and similar state provisions of the Internal Revenue Code due to changes of ownership that may have occurred or that could occur in the future, as defined under the regulations.

On March 27, 2020, the CARES Act was enacted in response to COVID-19 pandemic, which, among other things, outlines the provisions of the Paycheck Protection Program (the “PPP”). The Company determined that it met the criteria to be eligible to obtain a loan under the PPP because, among other reasons, in light of the COVID-19 outbreak and the uncertainty of economic conditions related thereto, the loan was considered necessary to support the Company’s ongoing operations and retain all its employees. Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of loan granted under the program. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The Company submitted its application for 100% loan forgiveness and in May 2021 the loan was 100% forgiven by the SBA. As a result, the Company recorded a gain on the forgiveness of the loan in the amount of $885,226.

The Company files a federal income tax return and income tax returns in various state tax jurisdictions and the Company is generally no longer subject examinations by federal and state tax authorities for years before 2018.
XML 41 R22.htm IDEA: XBRL DOCUMENT v3.22.1
SEGMENT INFORMATION
12 Months Ended
Dec. 31, 2021
SEGMENT INFORMATION [Abstract]  
SEGMENT INFORMATION
Note 16. SEGMENT INFORMATION

Management determines the reportable segments based on the internal reporting used by our executives to evaluate performance and to assess where to allocate resources. The Company evaluates segment performance based on the segment gross profit before corporate expenses.

Summarized below are the total net sales and segment operating profit for each reporting segment:

 
Year Ended
 
   
Net Sales
   
Segment Gross Profit
 
   
December 31, 2021
   
December 31, 2020
   
December 31, 2021
   
December 31, 2020
 
Vapor
 
$
2,084,813
   
$
2,458,945
   
$
1,245,214
   
$
1,425,140
 
Grocery
   
11,235,041
     
11,461,800
     
4,047,340
     
4,352,081
 
Total
 
$
13,319,854
   
$
13,920,745
     
5,292,554
     
5,777,221
 
Corporate expenses
                   
10,033,048
     
9,225,593
 
Operating loss
                   
(4,740,494
)
   
(3,448,372
)
Corporate other income (expense), net
                   
703,035
     
(274,020
)
Net loss
                   
(4,037,459
)
   
(3,722,392
)

For the year ended December 31, 2021 depreciation and amortization was approximately $1,000 and $0.5 million for Vapor and Grocery, respectively.

For the year ended December 31, 2020 depreciation and amortization was approximately $10,000 and $0.5 million for Vapor and Grocery, respectively.
XML 42 R23.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2021
SUBSEQUENT EVENTS [Abstract]  
SUBSEQUENT EVENTS
Note 17. SUBSEQUENT EVENTS

Acquisition of Mother Earth's Storehouse

On February 8, 2022, the Company through its wholly owned subsidiary, Healthy Choice Markets 3, LLC, entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Mother Earth’s Storehouse Inc. (“HCM3”) and its shareholders.  Pursuant to the Purchase Agreement, HCM3 acquired certain assets and assume certain liabilities related to Mother Earth’s grocery stores in Kingston and Saugerties, New York.  The Company intends to continue to operate the grocery stores under their existing name.  The cash purchase price under the Purchase Agreement is approximately $3.9 million, with an additional $677,500 paid for inventory at closing.  In addition, the Company assumed a lease obligation for the Kingston, NY store and entered into an employment agreement with the store manager.

In connection with the HCM3 acquisition of the assets of Mother Earth's, a wholly owned subsidiary of HCMC acquired for approximately $575,000 the historic building that houses the Saugerties, NY store.

John Ollet Employment Agreement

On February 02, 2022, the Company entered into a Second Amended and Restated Employment Agreement (the “Employment Agreement Amendment”) with the Company’s Chief Financial Officer, John Ollet.  Pursuant to the Employment Agreement Amendment, Mr. Ollet will continue to be employed as the Company’s Chief Financial Officer through February 14, 2025.  Mr. Ollet will receive a base salary of $300,000 for 2022 and his salary will increase 10% in each subsequent calendar year.

Patent infringement litigation

On December 31, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. In connection with such dismissal, the defendants sought to recover attorney’s fees from the Plaintiff. On February 22, 2022, the District Court for the Northern District of Georgia granted the defendant’s an award of approximately $575,000 in attorneys’ fees to be paid by the Company. The Company has fully provisioned this amount as of December 31, 2021.
XML 43 R24.htm IDEA: XBRL DOCUMENT v3.22.1
ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS (Policies)
12 Months Ended
Dec. 31, 2021
ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS [Abstract]  
Sourcing and Vendors
Sourcing and Vendors

We source from multiple suppliers. These suppliers range from small independent businesses to multinational conglomerates. For the fiscal years ended December 31, 2021 and 2020, approximately 25% and 27% of our total purchases were from one vendor.
Basis of Presentation
The Company’s consolidated financial statements are prepared in accordance with GAAP. The consolidated financial statements include the accounts of all subsidiaries in which the Company holds a controlling financial interest as of the financial statement date.
Principles of Consolidation
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Healthy Choice Markets, Inc., Healthy Choice Markets 2, LLC (“Paradise Health and Nutrition”), Healthy Choice Markets 3, LLC (“Mother Earth’s Storehouse”), Healthy Choices Markets 3 Real Estate LLC, HCMC Intellectual Property Holdings, LLC, Healthy Choice Wellness, LLC, The Vitamin Store, LLC, Healthy U Wholesale, Inc., The Vape Store, Inc. (“Vape Store”), Vaporin, Inc. (“Vaporin”), Smoke Anywhere U.S.A., Inc. (“Smoke”), Emagine the Vape Store, LLC (“Emagine”), IVGI Acquisition, Inc., Vapormax Franchising LLC, Vaporin LLC, and Vaporin Florida, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
XML 44 R25.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Segment Reporting
Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the operating decision makers, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company’s decision-making group are the senior executive management team. The Company and the decision-making group view the Company’s operations and manage its business as two operating segments. All long-lived assets of the Company reside in the U.S.
Use of Estimates in the Preparation of the Financial Statements
Use of Estimates in the Preparation of the Financial Statements

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting periods. Actual results could differ from those estimates. These estimates and assumptions include allowances, reserves and write-downs of inventory, valuing equity securities and hybrid instruments, share-based payment arrangements, deferred taxes and related valuation allowances, and the valuation of the assets and liabilities acquired in business combinations. Certain of management’s estimates could be affected by external conditions, including those unique to our industry, and general economic conditions. It is possible that these external factors could have an effect on our estimates that could cause actual results to differ from our estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary.
Revenue Recognition
Revenue Recognition

Revenues from product sales and services rendered, net of promotional discounts, manufacturer coupons and rebates, return allowances, and sales and consumption taxes, are recorded when products are delivered, title passes to customers and collection is likely to occur. Title passes to customers at the point of sale for retail and upon delivery of products for wholesale. Return allowances, which reduce revenue, are estimated using historical experience.

The Company recognizes revenue in accordance with the following five-step model:

identify arrangements with customers;

identify performance obligations;

determine transaction price;

allocate transaction price to the separate performance obligations in the arrangement, if more than one exists; and

recognize revenue as performance obligations are satisfied.
Shipping and Handling
Shipping and Handling

Shipping charges billed to customers are included in net sales and the related shipping and handling costs are included in cost of sales. For the years ended December 31, 2021 and 2020, shipping and handling costs of approximately $68,000 and $48,000, were included in cost of sales, respectively.
Cash and Cash Equivalents
Cash and Cash Equivalents

The Company considers all highly liquid instruments with an original maturity of three months or less, when purchased, to be cash and cash equivalents. The majority of the Company’s cash and cash equivalents are concentrated in one large financial institution, which is in excess of Federal Deposit Insurance Corporation (FDIC) coverage. At December 31, 2021, cash in excess of FDIC limits of $250,000 per financial institution were approximately $26.0 million. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests, as deposits are held in excess of federally insured limits. The Company’s cash equivalent at December 31, 2021 was a money market account. The Company has not experienced any losses in such accounts.
Accounts Receivable, Contract Assets and Contract Liabilities
Accounts Receivable, Contract Assets and Contract Liabilities

Accounts receivables are claims to consideration which are unconditional; meaning no performance obligations remain for the Company and only the passage of time is necessary before collection. Contract assets are distinguished from accounts receivable as performance obligations remain before claims to consideration become unconditional. By nature of the Company’s operations, contract assets are typically not recognized. Contract liabilities are recorded when customers transfer consideration in advance of delivery of products or services, which the Company records for gift cards and loyalty reward programs. When one party to an arrangement performs before the other(s), the Company records an account receivable, contract asset or contract liability.

The majority of arrangements with customers contain one performance obligation: to provide a distinct set of products or services. Most performance obligations are satisfied simultaneously as the Company exchanges products or services for customer payment. Exceptions include gift cards and loyalty rewards, for which the Company has a performance obligation to deliver products or services at a future date. As gift cards are purchased and loyalty points earned, contract liabilities are recorded until the performance obligations are satisfied through delivery of products or services or breakage based on gift card and loyalty reward program term limits.

The Company’s breakage policy is twenty-four months for gift cards, twelve months for Grocery loyalty rewards, and six months for Vapor loyalty rewards. Loyalty rewards are earned at five percent on qualifying purchases and the reward functions as an allocation of transaction price from the period earned by the customer to the period the performance obligation is satisfied by the Company. As such, all contract liabilities are expected to be recognized within a twenty-four month period.

Concentration of accounts receivable consist of the following:

 
December 31, 2021
   
December 31, 2020
 
             
Customer A
   
30
%
   
0
%
Customer B
   
12
%
   
0
%
Customer C
   
0
%
   
34
%
Due from Merchant Credit Card Processor
Due from Merchant Credit Card Processor

Due from merchant credit card processor represents monies held by the Company’s credit card processors. The funds are being held by the merchant credit card processors pending satisfaction of their hold requirements and expiration of charge backs/refunds from customers.
Inventories
Inventories

Inventories are stated at average cost. If the cost of the inventories exceeds their net realizable value, adjustments are recorded to write down excess inventory to their net realizable value. The Company’s inventories consist primarily of merchandise available for resale, such as vaporizers, electronic cigarettes, e-liquids, fresh produce, perishable grocery items and non-perishable consumable goods.
Property and Equipment
Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the expected useful life of the respective asset, after the asset is placed in service. Revenue earning property and equipment includes signage, furniture and fixtures, computer hardware, appliance, cooler, displays with useful lives range from two to seven years. Leasehold improvements are amortized over life of lease.
Identifiable Intangible Assets and Goodwill
Identifiable Intangible Assets and Goodwill

Identifiable intangible assets are recorded at cost, or when acquired as part of a business acquisition, at estimated fair value. Certain identifiable intangible assets are amortized over 4 and 10 years. Similar to tangible personal property and equipment, the Company periodically evaluates identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Indefinite-lived intangible assets, such as goodwill are not amortized.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets

The Company reviews all long-lived assets such as property and equipment and amortized intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future cash flows expected to be generated by the asset or asset group. Impairment is measured by the amount by which the carrying value of the asset(s) exceeds their fair value. There were no triggering events that would indicate impairment of long-lived assets at December 31, 2021. For the year ended December 31, 2020, the Company determined the estimated undiscounted cash flows related to the sales of the VitaminStore.com were less than the carrying value of the intangible assets and recorded an impairment charge of $0.3 million.
Goodwill
Goodwill

The Company assesses the carrying amounts of goodwill for recoverability on at least an annual basis or when events or changes in circumstances indicate evidence of potential impairment exists, using a fair value based test. Application of the goodwill impairment test requires significant judgments including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the businesses, and the useful life over which cash flows will occur. Changes in these estimates and assumptions could materially affect the determination of fair value and/or conclusions on goodwill impairment for the Company. Our annual impairment test is conducted on September 30 of each year or more often if deemed necessary. As part of management's qualitative analysis at December 31, 2021 management determines whether any triggering events have occurred since the annual test date of September 30, 2021, which would indicate an impairment. Management determined no triggering events had occurred through December 31, 2021. The Company recorded an impairment charge of $40,000 for the year ended December 31, 2020.
Advertising
Advertising

The Company expenses advertising costs as incurred. For the years ended December 31, 2021 and 2020, the company incurred advertising expenses of $43,000 and $92,000, respectively.
Income Taxes
Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021 or December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
Stock-Based Compensation
Stock-Based Compensation

The Company accounts for stock-based compensation for employees and directors under ASC Topic No. 718, “Compensation-Stock Compensation” (“ASC 718”). These standards define a fair value based method of accounting for stock-based compensation. In accordance with ASC 718, the cost of stock-based compensation is measured at the grant date based on the value of the award and is recognized over the vesting period. The value of the stock-based award is determined using an appropriate valuation model, whereby compensation cost is the fair value of the award as determined by the valuation model at the grant date. The resulting amount is charged to expense on the straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period. The Company recognize forfeitures as they are incur. Stock-based compensation for non-employees is measured at the grant date, is re-measured at subsequent vesting dates and reporting dates, and is amortized over the service period.
Sequencing Policy
Sequencing Policy

Under ASC 815-40-35, the Company has adopted a sequencing policy, whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares.
XML 45 R26.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Concentration of Accounts Receivable
Concentration of accounts receivable consist of the following:

 
December 31, 2021
   
December 31, 2020
 
             
Customer A
   
30
%
   
0
%
Customer B
   
12
%
   
0
%
Customer C
   
0
%
   
34
%
XML 46 R27.htm IDEA: XBRL DOCUMENT v3.22.1
DISAGGREGATION OF REVENUES (Tables)
12 Months Ended
Dec. 31, 2021
DISAGGREGATION OF REVENUES [Abstract]  
Disaggregate Revenue
The Company reports the following segments in accordance with management guidance: Vapor and Grocery. When the Company prepares its internal management reporting to evaluate business performance, we disaggregate revenue into the following categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 
December 31, 2021
   
December 31, 2020
 
             
Vapor sales, net
 
$
2,084,813
   
$
2,458,945
 
Grocery sales, net
   
11,235,041
     
11,461,800
 
Total revenue
 
$
13,319,854
   
$
13,920,745
 
                 
Retail Vapor
 
$
2,084,744
   
$
2,458,945
 
Retail Grocery
   
9,923,137
     
10,047,437
 
Food service/restaurant
   
1,202,122
     
1,088,162
 
Online/e-Commerce
   
93,600
     
307,487
 
Wholesale Grocery
   
16,182
     
18,714
 
Wholesale Vapor
   
69
     
-
 
Total revenue
 
$
13,319,854
   
$
13,920,745
 
XML 47 R28.htm IDEA: XBRL DOCUMENT v3.22.1
INVESTMENT (Tables)
12 Months Ended
Dec. 31, 2021
INVESTMENT [Abstract]  
Fair Value of Investment
The following table summarizes the investment measured at fair value on a recurring basis as of December 31, 2021:

Description
Fair Value Measurements Using Quoted Prices in Active Market (Level 1)
 
Mark to Market
 
December 31, 2021
 
Investment
 
$
22,731
   
$
412
   
$
23,143
 

The following table summarizes the investment measured at fair value on a recurring basis as of December 31, 2020:

Description
Fair Value Measurements Using Quoted Prices in Active Market (Level 1)
 
Mark to Market
 
December 31, 2021
 
Investment
 
$
24,000
   
$
(1,269
)
 
$
22,731
 
XML 48 R29.htm IDEA: XBRL DOCUMENT v3.22.1
INVENTORIES (Tables)
12 Months Ended
Dec. 31, 2021
INVENTORIES [Abstract]  
Inventories
Inventories are stated at average cost. If the cost of the inventories exceeds their market value, adjustments are recorded to write down excess inventory to its net realizable value. Throughout the year, the Company did not have independent third party counts of its inventory due to the Coronavirus (COVID-19) pandemic and recorded the write down of inventories amounting to $0.7 million and $0.3 million, approximately, in 2021 and 2020, respectively. The Company’s inventories consist primarily of merchandise available for resale.

 
December 31, 2021
   
December 31, 2020
 
             
Vapor Business
 
$
188,793
   
$
304,614
 
Grocery Business
   
1,332,406
     
1,444,632
 
Total
 
$
1,521,199
   
$
1,749,246
 
XML 49 R30.htm IDEA: XBRL DOCUMENT v3.22.1
NOTES RECEIVABLE AND OTHER INCOME (Tables)
12 Months Ended
Dec. 31, 2021
NOTES RECEIVABLE AND OTHER INCOME [Abstract]  
Summary of Notes
A summary of the Note as of December 31, 2021 and 2020 is presented below:

 
December 31,
 
Description
2021
 
2020
 
Promissory Note
 
$
247,915
   
$
304,511
 
XML 50 R31.htm IDEA: XBRL DOCUMENT v3.22.1
PROPERTY & EQUIPMENT (Tables)
12 Months Ended
Dec. 31, 2021
PROPERTY & EQUIPMENT [Abstract]  
Property and Equipment
Property and equipment consists of the following

 
Year Ended December 31,
 
   
2021
   
2020
 
             
Displays
 
$
305,558
   
$
305,558
 
Furniture and fixtures
   
246,496
     
246,496
 
Leasehold improvements
   
136,504
     
128,004
 
Computer hardware & equipment
   
151,924
     
143,082
 
Other
   
315,788
     
276,711
 
     
1,156,270
     
1,099,851
 
Less: accumulated depreciation and amortization
   
(979,282
)
   
(869,132
)
Total property and equipment
 
$
176,988
   
$
230,719
 
XML 51 R32.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS (Tables)
12 Months Ended
Dec. 31, 2021
GOODWILL AND INTANGIBLE ASSETS [Abstract]  
Changes in Carrying Amount of Goodwill
The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows:

 
December 31, 2021
   
December 31, 2020
 
             
Beginning balance
 
$
916,000
   
$
956,000
 
Impairment of goodwill-retail business
   
-
     
(40,000
)
Ending balance
 
$
916,000
   
$
916,000
 
Intangible Assets, Net
Intangible assets, net are as follows:

December 31, 2021
Useful Lives (Years)
 
Gross Carrying Amount
   
Accumulated Amortization
   
Net Carrying Amount
 
Customer relationships
4-5 years
 
$
883,000
   
$
(685,823
)
 
$
197,177
 
Trade names
8-10 years
   
923,000
     
(536,661
)
   
386,339
 
Patents
10 years
   
372,165
     
(122,233
)
   
249,932
 
Non-compete
4 years
   
238,000
     
(133,646
)
   
104,354
 
Website
4 years
   
10,000
     
(209
)
   
9,791
 
Intangible assets, net
   
$
2,426,165
   
$
(1,478,572
)
 
$
947,593
 

December 31, 2020
Useful Lives (Years)
 
Gross Carrying Amount
   
Accumulated Amortization
   
Net Carrying Amount
 
Customer relationships
4-10 years
 
$
883,000
   
$
(475,073
)
 
$
407,927
 
Trade names
8-10 years
   
923,000
     
(441,786
)
   
481,214
 
Patents
10 years
   
359,665
     
(85,641
)
   
274,024
 
Non-compete
4 years
   
174,000
     
(88,813
)
   
85,187
 
Intangible assets, net
   
$
2,339,665
   
$
(1,091,313
)
 
$
1,248,352
 
Future Annual Estimated Amortization Expense
The weighted-average remaining amortization period of the Company’s amortizable intangible assets is approximately 6 years as of December 31, 2021. The estimated future amortization of the intangible assets is as follows:

For the years ending December 31,
     
2022
 
$
389,456
 
2023
   
150,591
 
2024
   
150,591
 
2025
   
143,549
 
2026
   
48,655
 
Thereafter
   
64,751
 
Total
 
$
947,593
 
XML 52 R33.htm IDEA: XBRL DOCUMENT v3.22.1
CONTRACT LIABILITIES (Tables)
12 Months Ended
Dec. 31, 2021
CONTRACT LIABILITIES [Abstract]  
Contract Liabilities Activity
A summary of the contract liabilities activity for the years ended December 31, 2021 and 2020 is presented below:

 
Year ended December 31,
 
   
2021
   
2020
 
Beginning balance as of January1,
 
$
21,262
   
$
26,823
 
Issued
   
39,469
     
53,929
 
Redeemed
   
(37,463
)
   
(58,263
)
Breakage recognized
   
(90
)
   
(1,227
)
Ending balance as of December 31,
 
$
23,178
   
$
21,262
 
XML 53 R34.htm IDEA: XBRL DOCUMENT v3.22.1
LINE OF CREDIT AND DEBT (Tables)
12 Months Ended
Dec. 31, 2021
LINE OF CREDIT AND DEBT [Abstract]  
Breakdown of Debt
The following table provides a breakdown of the Company's debt as of December 31, 2021 and 2020 is presented below:

 
December 31,
 
2021
 
2020
Line of Credit
$
418,036
 
$
2,000,000
Term Loan Credit Agreement
 
-
   
800,924
Paycheck Protection Program
 
-
   
882,264
Loan and Security Agreement ("PPE Loan")
 
-
   
1,232,414
Other debt
 
3,419
   
5,891
Total Line of Credit and Debt
$
421,455
 
$
4,921,493
XML 54 R35.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2021
STOCKHOLDERS' EQUITY [Abstract]  
Summary of Option Activity
A summary of option activity during the years ended December 31, 2021 and 2020 is as follows:

 
Number of Options
   
Weighted Average
Exercise
Price
   
Weighted Average Remaining Term (Yrs.)
   
Aggregate Intrinsic Value
 
                         
Outstanding, January 1, 2020
   
69,862,230,680
   
$
0.00
     
7
   
$
-
 
Options granted
   
-
     
0.00
             
-
 
Options forfeited or expired
   
-
     
0.00
             
-
 
Outstanding, December 31, 2020
   
69,862,230,680
   
$
0.00
     
6
   
$
-
 
Options granted
   
-
     
0.00
             
-
 
Options exercised
   
(2,275,000,000
)
   
0.00
             
-
 
Options forfeited or expired
   
-
     
0.00
             
-
 
Outstanding, December 31, 2021
   
67,587,230,680
   
$
0.00
     
5
     
-
 
Exercisable at December 31, 2021
   
67,587,230,680
   
$
0.00
     
5
   
$
-
 
Securities Excluded from Calculation of Basic and Dilutive Income (loss) per Share
Basic income (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon (a) the exercise of stock options (using the treasury stock method); (b) the conversion of Series A convertible preferred stock; (c) the exercise of warrants (using the if-converted method); (d) the vesting of restricted stock units; and (e) the conversion of convertible notes payable. Diluted income (loss) per share excludes the potential common shares, as their effect is antidilutive. The following table summarizes the Company’s securities that have been excluded from the calculation of basic and dilutive income (loss) per share as their effect would be anti-dilutive:

 
December 31,
 
   
2021
   
2020
 
             
Preferred stock
   
1,250,000,000
     
162,771,153,000
 
Stock options
   
67,587,230,680
     
69,862,230,680
 
Total
   
68,837,230,680
     
232,633,383,680
 
XML 55 R36.htm IDEA: XBRL DOCUMENT v3.22.1
LEASE (Tables)
12 Months Ended
Dec. 31, 2021
LEASE [Abstract]  
Maturity of Lease Liabilities
The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of December 31, 2021.

Maturity of Lease Liabilities by Fiscal Year
     
2022
 
$
572,335
 
2023
   
450,877
 
2024
   
342,005
 
2025
   
337,685
 
2026
   
267,759
 
Thereafter
   
1,941,250
 
Total undiscounted operating lease payments
 
$
3,911,911
 
Less: Imputed interest
   
(789,562
)
Present value of operating lease liabilities
 
$
3,122,349
 
Balance Sheet Classification and Other Information
The following summarizes the Company's operating leases:

Balance Sheet Classification
 
December 31, 2021
   
December 31, 2020
 
Right of use asset
 
$
3,543,930
   
$
4,078,621
 
                 
Operating lease liability, current
 
$
437,328
   
$
474,686
 
Operating lease liability, net of current
   
2,685,021
     
3,114,521
 
Total operating lease liabilities
 
$
3,122,349
   
$
3,589,207
 

Other Information
     
Weighted-average remaining lease term for operating leases
 
10 years
 
Weighted-average discount rate for operating leases
   
4.74
%
Components of Lease Cost
The following table represents the components of lease cost are as follows for twelve months ended December 31, 2021:

 
December 31, 2021
 
Operating lease cost
 
$
389,538
 
Variable lease cost
   
372,608
 
Short-term lease cost
   
139,291
 
Total rent expense
 
$
901,437
 
XML 56 R37.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2021
INCOME TAXES [Abstract]  
Reconciliation of Expected Tax Expense (Benefit)
The Company did not have a provision for income taxes (current or deferred tax expense) for tax years ended December 31, 2021 and 2020. The following is a reconciliation of the expected tax expense (benefit) at the U.S. statutory rate to the actual tax expense (benefit) reflected in the accompanying statement of operations:

 
Year Ended December 31,
 
   
2021
   
2020
 
             
U.S. federal statutory rate
 
$
(847,867
)
 
$
(781,704
)
State and local taxes, net of federal benefit
   
(111,900
)
   
(132,291
)
Change in valuation allowance
   
734,615
     
1,201,450
 
True-up & deferred adjustment
   
11,441
     
23,614
 
Stock based compensation
   
8,171
     
19,159
 
Forgiveness of PPP loan
   
(210,432
)
   
-
 
Other permanent items
   
-
     
935
 
Change in tax rate
   
89,360
     
2,429
 
Expired warrants
   
-
     
(422,655
)
Other
   
326,612
     
89,063
 
   
$
-
   
$
-
 
Deferred Tax Assets and Liabilities
As of December 31, 2021 and 2020, the Company’s deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following:

 
Year Ended December 31,
 
   
2021
   
2020
 
Deferred tax assets:
           
Net operating losses
 
$
14,136,491
   
$
13,366,483
 
Inventory reserves and allowances
   
30,156
     
31,249
 
Accrued Expenses and Deferred Income
   
136,686
     
45,358
 
Charitable contribution
   
5,134
     
5,303
 
Stock based compensation
   
1,903,413
     
1,966,058
 
Net book value of fixed assets
   
1,961
     
6,574
 
Net book value of intangible assets
   
671,954
     
731,365
 
ASC 842 - Lease Accounting
   
33,891
     
32,681
 
Total deferred tax assets
   
16,919,686
     
16,185,071
 
                 
Net deferred tax assets
   
16,919,686
     
16,185,071
 
Valuation allowance
   
(16,919,686
)
   
(16,185,071
)
Net deferred tax assets
 
$
-
   
$
-
 
XML 57 R38.htm IDEA: XBRL DOCUMENT v3.22.1
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2021
SEGMENT INFORMATION [Abstract]  
Summary of Reporting Segment
Summarized below are the total net sales and segment operating profit for each reporting segment:

 
Year Ended
 
   
Net Sales
   
Segment Gross Profit
 
   
December 31, 2021
   
December 31, 2020
   
December 31, 2021
   
December 31, 2020
 
Vapor
 
$
2,084,813
   
$
2,458,945
   
$
1,245,214
   
$
1,425,140
 
Grocery
   
11,235,041
     
11,461,800
     
4,047,340
     
4,352,081
 
Total
 
$
13,319,854
   
$
13,920,745
     
5,292,554
     
5,777,221
 
Corporate expenses
                   
10,033,048
     
9,225,593
 
Operating loss
                   
(4,740,494
)
   
(3,448,372
)
Corporate other income (expense), net
                   
703,035
     
(274,020
)
Net loss
                   
(4,037,459
)
   
(3,722,392
)
XML 58 R39.htm IDEA: XBRL DOCUMENT v3.22.1
ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS (Details)
12 Months Ended
Dec. 31, 2021
Vendor
Store
Dec. 31, 2020
Feb. 28, 2022
Store
Organization [Abstract]      
Number of stores 6    
Sources and Vendors [Abstract]      
Number of vendor | Vendor 1    
Total Purchases [Member] | Supplier Concentration Risk [Member] | Vendor [Member]      
Sources and Vendors [Abstract]      
Concentration risk percentage 25.00% 27.00%  
Mother Earth's Storehouse [Member]      
Organization [Abstract]      
Duration of company existence in market 40 years    
Mother Earth's Storehouse [Member] | Subsequent Event [Member]      
Organization [Abstract]      
Number of stores     2
XML 59 R40.htm IDEA: XBRL DOCUMENT v3.22.1
LIQUIDITY (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
LIQUIDITY [Abstract]    
Loss from operations $ (4,740,494) $ (3,448,372)
Cash and cash equivalents $ 26,496,404 $ 925,475
XML 60 R41.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Segment Reporting (Details)
12 Months Ended
Dec. 31, 2021
Segment
Segment Reporting [Abstract]  
Number of operating segments 2
XML 61 R42.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Shipping and Handling (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Shipping and Handling Costs [Abstract]    
Shipping and handling costs $ 68,000 $ 48,000
XML 62 R43.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Cash and Cash Equivalents (Details)
Dec. 31, 2021
USD ($)
Cash and Cash Equivalents [Abstract]  
FDIC insured amount $ 250,000
Total Cash in excess of FDIC limits of $250,000 $ 26,000,000.0
XML 63 R44.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable, Contract Assets and Contract Liabilities (Details)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Accounts Receivable, Contract Assets and Contract Liabilities [Abstract]    
Loyalty rewards earned percentage 5.00%  
Contract liabilities expected recognition period 24 months  
Customer A [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
Customers Balances in Excess of 10% of Total Accounts Receivable [Abstract]    
Concentration risk percentage 30.00% 0.00%
Customer B [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
Customers Balances in Excess of 10% of Total Accounts Receivable [Abstract]    
Concentration risk percentage 12.00% 0.00%
Customer C [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]    
Customers Balances in Excess of 10% of Total Accounts Receivable [Abstract]    
Concentration risk percentage 0.00% 34.00%
Gift Cards [Member]    
Accounts Receivable, Contract Assets and Contract Liabilities [Abstract]    
Breakage policy period 24 months  
Grocery Loyalty Rewards [Member]    
Accounts Receivable, Contract Assets and Contract Liabilities [Abstract]    
Breakage policy period 12 months  
Vapor Loyalty Rewards [Member]    
Accounts Receivable, Contract Assets and Contract Liabilities [Abstract]    
Breakage policy period 6 months  
XML 64 R45.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment (Details)
12 Months Ended
Dec. 31, 2021
Minimum [Member]  
Property, Plant and Equipment [Abstract]  
Expected useful life 2 years
Maximum [Member]  
Property, Plant and Equipment [Abstract]  
Expected useful life 7 years
XML 65 R46.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Identifiable Intangible Assets and Goodwill (Details)
12 Months Ended
Dec. 31, 2021
Minimum [Member]  
Identifiable Intangible Assets and Goodwill [Abstract]  
Amortization period 4 years
Maximum [Member]  
Identifiable Intangible Assets and Goodwill [Abstract]  
Amortization period 10 years
XML 66 R47.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-Lived Assets (Details)
$ in Millions
12 Months Ended
Dec. 31, 2020
USD ($)
Impairment of Long-Lived Assets [Abstract]  
Impairment charge of intangible assets $ 0.3
XML 67 R48.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Goodwill [Abstract]    
Impairment charge of goodwill $ 0 $ 40,000
XML 68 R49.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Advertising (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Advertising [Abstract]    
Advertising expenses $ 43,000 $ 92,000
XML 69 R50.htm IDEA: XBRL DOCUMENT v3.22.1
DISAGGREGATION OF REVENUES (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Abstract]    
Revenue $ 13,319,854 $ 13,920,745
Retail Vapor [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 2,084,744 2,458,945
Retail Grocery [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 9,923,137 10,047,437
Food Service/Restaurant [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 1,202,122 1,088,162
Online/eCommerce [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 93,600 307,487
Wholesale Grocery [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 16,182 18,714
Wholesale Vapor [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 69 0
Vapor Sales, Net [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 2,084,813 2,458,945
Grocery Sales, Net [Member]    
Disaggregation of Revenue [Abstract]    
Revenue $ 11,235,041 $ 11,461,800
XML 70 R51.htm IDEA: XBRL DOCUMENT v3.22.1
INVESTMENT (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2021
Dec. 31, 2020
Investment at Fair Value [Abstract]      
Investment cost $ 150,000    
Investment of common stock at MJ Holdings, Inc. (in shares) 85,714    
Investment   $ 23,143 $ 22,731
Mark to Market [Member]      
Investment at Fair Value [Abstract]      
Investment   412 (1,269)
Fair Value Measurements Using Quoted Prices in Active Market (Level 1) [Member]      
Investment at Fair Value [Abstract]      
Investment   $ 22,731 $ 24,000
XML 71 R52.htm IDEA: XBRL DOCUMENT v3.22.1
INVENTORIES (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Inventories [Abstract]    
Inventory write down $ 707,710 $ 340,905
Inventories 1,521,199 1,749,246
Third Party [Member]    
Inventories [Abstract]    
Inventory write down 700,000 300,000
Vapor Business [Member]    
Inventories [Abstract]    
Inventories 188,793 304,614
Grocery Business [Member]    
Inventories [Abstract]    
Inventories $ 1,332,406 $ 1,444,632
XML 72 R53.htm IDEA: XBRL DOCUMENT v3.22.1
NOTES RECEIVABLE AND OTHER INCOME (Details) - USD ($)
12 Months Ended
Aug. 31, 2021
Sep. 06, 2018
Dec. 31, 2021
Dec. 31, 2020
Receivables with Imputed Interest [Abstract]        
Proceeds     $ 56,596 $ 38,876
Interest income     $ 57,000 39,000
Promissory Note [Member]        
Receivables with Imputed Interest [Abstract]        
Payment term     36 months  
Interest rate 7.00% 7.00%    
Loan amount $ 268,126 $ 582,260    
Proceeds 1,500 $ 4,141    
Balloon payments $ 213,028      
Extension term     1 year  
Remaining balance     $ 247,915 $ 304,511
XML 73 R54.htm IDEA: XBRL DOCUMENT v3.22.1
PROPERTY & EQUIPMENT (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property and equipment [Abstract]    
Property plant and equipment, gross $ 1,156,270 $ 1,099,851
Less: accumulated depreciation and amortization (979,282) (869,132)
Total property and equipment 176,988 230,719
Depreciation expense 100,000 100,000
Displays [Member]    
Property and equipment [Abstract]    
Property plant and equipment, gross 305,558 305,558
Furniture and Fixtures [Member]    
Property and equipment [Abstract]    
Property plant and equipment, gross 246,496 246,496
Leasehold Improvements [Member]    
Property and equipment [Abstract]    
Property plant and equipment, gross 136,504 128,004
Computer Hardware & Equipment [Member]    
Property and equipment [Abstract]    
Property plant and equipment, gross 151,924 143,082
Other [Member]    
Property and equipment [Abstract]    
Property plant and equipment, gross $ 315,788 $ 276,711
XML 74 R55.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS, Changes in Carrying Amount (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
GOODWILL AND INTANGIBLE ASSETS [Abstract]    
Beginning balance $ 916,000 $ 956,000
Impairment of goodwill-retail business 0 (40,000)
Ending balance $ 916,000 $ 916,000
XML 75 R56.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS, Intangible Assets, Net (Details) - USD ($)
12 Months Ended
Nov. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]      
Impairment of intangible assets     $ 300,000
Intangible Assets, Net [Abstract]      
Gross carrying amount   $ 2,426,165 2,339,665
Accumulated amortization   (1,478,572) (1,091,313)
Net carrying amount   947,593 1,248,352
Amortization expense   $ 400,000 400,000
Weighted-average remaining amortization period   6 years  
EIR Hydration [Member]      
Intangible Assets, Net [Abstract]      
Asset purchase transaction cost $ 75,000    
Minimum [Member]      
Intangible Assets, Net [Abstract]      
Useful lives   4 years  
Maximum [Member]      
Intangible Assets, Net [Abstract]      
Useful lives   10 years  
Customer Relationships [Member]      
Intangible Assets, Net [Abstract]      
Gross carrying amount   $ 883,000 883,000
Accumulated amortization   (685,823) (475,073)
Net carrying amount   $ 197,177 $ 407,927
Customer Relationships [Member] | Minimum [Member]      
Intangible Assets, Net [Abstract]      
Useful lives   4 years 4 years
Customer Relationships [Member] | Maximum [Member]      
Intangible Assets, Net [Abstract]      
Useful lives   5 years 10 years
Trade Names [Member]      
Intangible Assets, Net [Abstract]      
Gross carrying amount   $ 923,000 $ 923,000
Accumulated amortization   (536,661) (441,786)
Net carrying amount   $ 386,339 $ 481,214
Trade Names [Member] | Minimum [Member]      
Intangible Assets, Net [Abstract]      
Useful lives   8 years 8 years
Trade Names [Member] | Maximum [Member]      
Intangible Assets, Net [Abstract]      
Useful lives   10 years 10 years
Patents [Member]      
Intangible Assets, Net [Abstract]      
Useful lives   10 years 10 years
Gross carrying amount   $ 372,165 $ 359,665
Accumulated amortization   (122,233) (85,641)
Net carrying amount   $ 249,932 $ 274,024
Non-compete [Member]      
Intangible Assets, Net [Abstract]      
Useful lives   4 years 4 years
Gross carrying amount   $ 238,000 $ 174,000
Accumulated amortization   (133,646) (88,813)
Net carrying amount   $ 104,354 $ 85,187
Website [Member]      
Intangible Assets, Net [Abstract]      
Useful lives   4 years  
Gross carrying amount   $ 10,000  
Accumulated amortization   (209)  
Net carrying amount   $ 9,791  
XML 76 R57.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS, Future Annual Estimated Amortization Expense (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Future Annual Estimated Amortization Expense [Abstract]    
2022 $ 389,456  
2023 150,591  
2024 150,591  
2025 143,549  
2026 48,655  
Thereafter 64,751  
Net carrying amount $ 947,593 $ 1,248,352
XML 77 R58.htm IDEA: XBRL DOCUMENT v3.22.1
CONTRACT LIABILITIES (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Deferred Revenue [Abstract]    
Contract liabilities expected recognition period 24 months  
Changes in Contract Liabilities Activity [Roll Forward]    
Beginning balance $ 21,262 $ 26,823
Issued 39,469 53,929
Redeemed (37,463) (58,263)
Breakage recognized (90) (1,227)
Ending balance $ 23,178 $ 21,262
Gift Cards [Member]    
Deferred Revenue [Abstract]    
Breakage policy period 24 months  
Grocery Loyalty Rewards [Member]    
Deferred Revenue [Abstract]    
Breakage policy period 12 months  
Vapor Loyalty Rewards [Member]    
Deferred Revenue [Abstract]    
Breakage policy period 6 months  
XML 78 R59.htm IDEA: XBRL DOCUMENT v3.22.1
LINE OF CREDIT AND DEBT (Details) - USD ($)
12 Months Ended
Dec. 21, 2021
Nov. 03, 2021
Mar. 05, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2018
Mar. 29, 2021
May 15, 2020
Debt [Abstract]                
Total Line of Credit and Debt       $ 421,455 $ 4,921,493      
Debt Instruments [Abstract]                
Revolving credit line       2,000,000 0      
Restricted Cash       0 2,000,000      
Gain on debt settlements       767,930 0      
Principal Repayments of Long-Term Debt [Abstract]                
Expected payments for the upcoming years       421,455 4,921,493      
Term Loan Credit Agreement [Member]                
Debt [Abstract]                
Total Line of Credit and Debt       $ 0 800,924      
Debt Instruments [Abstract]                
Face amount           $ 1,400,000    
Debt instrument interest rate       5.50%        
Repayment of debt $ 410,000              
Principal Repayments of Long-Term Debt [Abstract]                
Expected payments for the upcoming years       $ 0 800,924      
Total Payments           $ 1,400,000    
Term Loan Credit Agreement [Member] | Prime Rate [Member]                
Debt Instruments [Abstract]                
Basis adjustment to variable rate           1.50%    
Paycheck Protection Program [Member]                
Debt [Abstract]                
Total Line of Credit and Debt       $ 0 882,264      
Debt Instruments [Abstract]                
Face amount               $ 876,515
Maturity date       May 06, 2022        
Interest rate               1.00%
Frequency of payment       monthly        
Gain on debt settlements     $ 885,227          
Principal Repayments of Long-Term Debt [Abstract]                
Expected payments for the upcoming years       $ 0 882,264      
Total Payments               $ 876,515
Loan and Security Agreement [Member]                
Debt [Abstract]                
Total Line of Credit and Debt       0 1,232,414      
Debt Instruments [Abstract]                
Face amount             $ 2,700,000  
Gain on debt settlements       (100,000)        
Principal Repayments of Long-Term Debt [Abstract]                
Expected payments for the upcoming years       0 1,232,414      
Total Payments             $ 2,700,000  
Other Debt [Member]                
Debt [Abstract]                
Total Line of Credit and Debt       3,419 5,891      
Principal Repayments of Long-Term Debt [Abstract]                
Expected payments for the upcoming years       3,419 5,891      
Line of Credit [Member]                
Debt [Abstract]                
Total Line of Credit and Debt       418,036 2,000,000      
Debt Instruments [Abstract]                
Maximum borrowing capacity   $ 2,000,000.0            
Basis adjustment to variable rate   1.00%            
Percentage of cash secured with funds held from blocked account   100.00%            
Principal Repayments of Long-Term Debt [Abstract]                
Expected payments for the upcoming years       $ 418,036 $ 2,000,000      
XML 79 R60.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES (Details)
User in Millions
12 Months Ended
Feb. 26, 2021
USD ($)
Aug. 12, 2020
Aug. 12, 2019
Aug. 13, 2018
USD ($)
shares
Dec. 31, 2021
USD ($)
Lawsuit
Dec. 31, 2020
USD ($)
Nov. 30, 2020
USD ($)
User
Alleged Claimed Battery Defects For Electronic Cigarette Device Member [Member]              
Legal Proceedings [Abstract]              
Number of lawsuits | Lawsuit         2    
Alleged Claimed Battery Defects For Electronic Cigarette Device Member [Member] | Medical Costs [Member]              
Legal Proceedings [Abstract]              
Damages sought         $ 400,000    
Philip Morris [Member]              
Commitments [Abstract]              
Number of users approached | User             14
Invested amount             $ 3,000,000,000
Chief Executive Officer [Member]              
Legal Proceedings [Abstract]              
Additional employment agreement term       3 years      
Annual base salary       $ 450,000      
Severance payments term of base salary       2 years      
Options forfeited (in shares) | shares       11      
Extension to vesting period     6 months        
Second extension to vesting period   6 months          
Automatic renewal of agreement term       1 year      
Notice period for non-renewal of agreement term       30 days      
Chief Executive Officer [Member] | Restricted Stock [Member]              
Legal Proceedings [Abstract]              
Restricted common stock grants (in shares) | shares       11      
Vesting period       1 year      
Chief Executive Officer [Member] | Minimum [Member]              
Legal Proceedings [Abstract]              
Target bonus percentage for 2020       20.00%      
Chief Executive Officer [Member] | Maximum [Member]              
Legal Proceedings [Abstract]              
Target bonus percentage for 2020       200.00%      
President and Chief Operating Officer [Member]              
Legal Proceedings [Abstract]              
Annual base salary $ 400,000            
Automatic renewal of agreement term 1 year            
Notice period for non-renewal of agreement term 30 days            
Increment percentage on salary each subsequent year 10.00%            
Fontem License Agreement [Member] | Fontem Ventures B.V. [Member]              
Commitments [Abstract]              
Percentage of royalty rate         5.25%    
Royalty expense         $ 12,000 $ 15,000  
XML 80 R61.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY, Equity Compensation Plans (Details) - shares
Dec. 31, 2021
Jul. 07, 2015
2015 Equity Incentive Plan [Member]    
Equity Compensation Plans [Abstract]    
Common stock available for grant (in shares) 10,300,000,000  
2015 Equity Incentive Plan [Member] | Maximum [Member]    
Equity Compensation Plans [Abstract]    
Common stock available for grant (in shares)   100,000,000,000
2009 Equity Incentive Plan [Member]    
Equity Compensation Plans [Abstract]    
Common stock available for grant (in shares) 0  
XML 81 R62.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY, Rights Offering (Details) - USD ($)
12 Months Ended
Jun. 18, 2021
Mar. 29, 2021
Dec. 31, 2021
Dec. 31, 2020
Rights Offering [Abstract]        
Common stock shares issued from offering (in shares) 27,046,800,310 1,172,964,218    
Subscription price (in dollars per share) $ 0.0010 $ 0.0011    
Gross proceeds $ 27,000,000.0      
Direct financing costs 2,700,000      
Net proceeds $ 24,300,000   $ 24,344,317 $ 0
XML 82 R63.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY, Exchange Agreement (Details) - USD ($)
12 Months Ended
Jun. 18, 2021
Mar. 29, 2021
Dec. 31, 2021
Dec. 31, 2020
Exchange Agreement [Abstract]        
Issuance of common stock pursuant to exchange agreement   $ 1,300,000 $ 1,407,556 $ 0
Exchange of notes for shares of common stock (in shares) 27,046,800,310 1,172,964,218    
Common stock at a price per share (in dollars per share) $ 0.0010 $ 0.0011    
Loss on extinguishment of debt     767,930 $ 0
Loan and Security Agreement [Member]        
Exchange Agreement [Abstract]        
Face amount   $ 2,700,000    
Loss on extinguishment of debt     $ (100,000)  
XML 83 R64.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY, Preferred Stock and Convertible Preferred Stock (Details) - USD ($)
$ / shares in Units, $ in Millions
9 Months Ended 12 Months Ended
Nov. 17, 2020
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Feb. 07, 2021
Board of Directors [Member]          
Preferred Stock [Abstract]          
Preferred shares, par value (in dollars per share)     $ 0.001    
Board of Directors [Member] | Maximum [Member]          
Preferred Stock [Abstract]          
Preferred stock, shares authorized ( (in shares)     1,000,000    
Series C Convertible Preferred Stock [Member]          
Preferred Stock [Abstract]          
Preferred stock, shares authorized ( (in shares)     30,000 30,000  
Preferred shares, par value (in dollars per share) $ 1,000   $ 1,000 $ 1,000  
Convertible Preferred Stock [Abstract]          
Number of warrants exchanged for preferred stock (in shares) 20,150        
Conversion price (in dollars per share) $ 0.0001        
Number of preferred stock, shares sold and issued (in shares)     0 16,277  
Series D Convertible Preferred Stock [Member]          
Preferred Stock [Abstract]          
Preferred stock, shares authorized ( (in shares)     5,000    
Preferred shares, par value (in dollars per share)     $ 1,000    
Convertible Preferred Stock [Abstract]          
Conversion price (in dollars per share)   $ 0.00064      
Shares conversion percentage   80.00%      
Number of preferred stock, shares sold and issued (in shares)     800 0  
Preferred stock exercised (in shares)   4,200      
Number of trading days for conversion of shares   5 days      
Series D Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member]          
Preferred Stock [Abstract]          
Preferred shares, par value (in dollars per share)         $ 1,000
Convertible Preferred Stock [Abstract]          
Number of preferred stock, shares sold and issued (in shares)         5,000
Aggregate subscription price         $ 5.0
Common Stock [Member]          
Convertible Preferred Stock [Abstract]          
Number of common stock shares issued upon conversion preferred stock (in shares)   6,600,000,000 162,800,000,000 38,700,000,000  
Preferred stock exercised (in shares)       38,730,000,001  
Common Stock [Member] | Series C Convertible Preferred Stock [Member]          
Convertible Preferred Stock [Abstract]          
Preferred stock exercised (in shares)     162,771,153,001    
Common Stock [Member] | Series D Convertible Preferred Stock [Member]          
Convertible Preferred Stock [Abstract]          
Number of common stock shares issued upon conversion preferred stock (in shares)     0    
Preferred stock exercised (in shares)     6,562,500,000    
XML 84 R65.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY, Summary of Warrant Activity (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Jul. 27, 2020
Oct. 05, 2016
Warrant [Member]          
Warrants [Abstract]          
Closing bid stock price (in dollars per share)         $ 0.00
Black Scholes value         $ 1,517,936
Warrants expired (in shares)       (355,661)  
Common Stock [Member]          
Warrants [Abstract]          
Number of common stock shares issued upon conversion preferred stock (in shares) 6,600,000,000 162,800,000,000 38,700,000,000    
Common Stock [Member] | Warrant [Member]          
Warrants [Abstract]          
Number of common stock shares issued upon conversion preferred stock (in shares)     3,466,153    
XML 85 R66.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY, Share-based Awards to Officers and Restricted Stock (Details) - USD ($)
shares in Millions
12 Months Ended
Jun. 29, 2021
Mar. 30, 2021
Jan. 14, 2021
Aug. 13, 2018
Dec. 31, 2021
Dec. 31, 2020
Equity Securities, Restricted [Abstract]            
Stock-based compensation expense         $ 34,375 $ 78,029
Restricted Stock [Member] | Chief Executive Officer [Member]            
Equity Securities, Restricted [Abstract]            
Granted (in shares)       11,000    
Vesting period         1 year  
Extension to vesting period         6 months  
Restricted Stock [Member] | Chief Operating Officer [Member]            
Equity Securities, Restricted [Abstract]            
Granted (in shares)       8,000    
Vesting period         1 year  
Extension to vesting period         6 months  
Restricted Stock [Member] | Chief Financial Officer [Member]            
Equity Securities, Restricted [Abstract]            
Granted (in shares)       3,000    
Vesting period         1 year  
Extension to vesting period         6 months  
Restricted Stock [Member] | Officers and a Director [Member]            
Equity Securities, Restricted [Abstract]            
Granted (in shares)     2,300      
Percentage of increase in restricted stock grants from its original award agreement to officers     10.00%      
Forfeited (in shares) (3,090) (3,090)        
XML 86 R67.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY, Stock Options Activity (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Stock Options [Abstract]      
Options aggregate grant date value $ 0 $ 0  
Weighted Average Remaining Term and Aggregate Intrinsic Value [Abstract]      
Stock-based compensation expense $ 34,375 $ 78,029  
Stock Options [Member]      
Summary of Options Activity [Abstract]      
Outstanding, Beginning (in shares) 69,862,230,680 69,862,230,680  
Options granted (in shares) 0 0  
Options exercised (in shares) (2,275,000,000)    
Options forfeited or expired (in shares) 0 0  
Outstanding, Ending (in shares) 67,587,230,680 69,862,230,680 69,862,230,680
Exercisable (in shares) 67,587,230,680    
Weighted Average Exercise Price [Abstract]      
Outstanding, Beginning (in dollars per share) $ 0.00 $ 0.00  
Options granted (in dollars per share) 0.00 0.00  
Options exercised (in dollars per share) 0.00    
Options forfeited or expired (in dollars per share) 0.00 0.00  
Outstanding, Ending (in dollars per share) 0.00 $ 0.00 $ 0.00
Exercisable (in dollars per share) $ 0.00    
Weighted Average Remaining Term and Aggregate Intrinsic Value [Abstract]      
Weighted average remaining term, outstanding 5 years 6 years 7 years
Weighted average remaining term, exercisable 5 years    
Aggregate intrinsic value, outstanding $ 0 $ 0 $ 0
Aggregate intrinsic value, exercisable $ 0    
XML 87 R68.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY, Income (Loss) Per Share (Details) - shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Common Share Equivalents Excluded from Calculation of Basic and Dilutive Income (Loss) Per Share [Abstract]    
Antidilutive securities excluded from computation of basic and dilutive income (loss) per share (in shares) 68,837,230,680 232,633,383,680
Basic and Diluted Net Income (Loss) Per Share [Abstract]    
Basic (in shares) 307,912,959,368 90,351,540,618
Diluted (in shares) 307,912,959,368 90,351,540,618
Preferred Stock [Member]    
Common Share Equivalents Excluded from Calculation of Basic and Dilutive Income (Loss) Per Share [Abstract]    
Antidilutive securities excluded from computation of basic and dilutive income (loss) per share (in shares) 1,250,000,000 162,771,153,000
Stock Options [Member]    
Common Share Equivalents Excluded from Calculation of Basic and Dilutive Income (Loss) Per Share [Abstract]    
Antidilutive securities excluded from computation of basic and dilutive income (loss) per share (in shares) 67,587,230,680 69,862,230,680
XML 88 R69.htm IDEA: XBRL DOCUMENT v3.22.1
LEASE, Summary (Details)
Dec. 31, 2021
Maximum [Member]  
Operating Leases [Abstract]  
Lease agreements term 20 years
XML 89 R70.htm IDEA: XBRL DOCUMENT v3.22.1
LEASE, Maturity of Lease Liabilities (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Maturity of Lease Liabilities by Fiscal Year [Abstract]    
2022 $ 572,335  
2023 450,877  
2024 342,005  
2025 337,685  
2026 267,759  
Thereafter 1,941,250  
Total undiscounted operating lease payments 3,911,911  
Less: Imputed interest (789,562)  
Present value of operating lease liabilities $ 3,122,349 $ 3,589,207
XML 90 R71.htm IDEA: XBRL DOCUMENT v3.22.1
LEASE, Balance Sheet Classification and Other Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Balance Sheet Classification [Abstract]    
Right of use asset $ 3,543,930 $ 4,078,621
Operating lease liability, current 437,328 474,686
Operating lease liability, net of current 2,685,021 3,114,521
Total operating lease liabilities 3,122,349 3,589,207
Amortization of right-of-use asset $ 534,691 $ 584,398
Other Information [Abstract]    
Weighted-average remaining lease term for operating leases 10 years  
Weighted-average discount rate for operating leases 4.74%  
XML 91 R72.htm IDEA: XBRL DOCUMENT v3.22.1
LEASE, Components of Lease Cost (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Components of Lease Cost [Abstract]    
Operating lease cost $ 389,538  
Variable lease cost 372,608  
Short-term lease cost 139,291  
Total Rent Expense 901,437 $ 1,000,000.0
Cash paid for leasing arrangement $ 467,000  
XML 92 R73.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES, Reconciliation of Tax Expense (Benefit) (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
INCOME TAXES [Abstract]    
U.S. federal statutory rate $ (847,867) $ (781,704)
State and local taxes, net of federal benefit (111,900) (132,291)
Change in valuation allowance 734,615 1,201,450
True-up & deferred adjustment 11,441 23,614
Stock based compensation 8,171 19,159
Forgiveness of PPP loan (210,432) 0
Other permanent items 0 935
Change in tax rate 89,360 2,429
Expired warrants 0 (422,655)
Other 326,612 89,063
Income tax provision (benefit) $ 0 $ 0
XML 93 R74.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES, Deferred Tax Assets and Liabilities (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets [Abstract]    
Net operating losses $ 14,136,491 $ 13,366,483
Inventory reserves and allowances 30,156 31,249
Accrued Expenses and Deferred Income 136,686 45,358
Charitable contribution 5,134 5,303
Stock based compensation 1,903,413 1,966,058
Net book value of fixed assets 1,961 6,574
Net book value of intangible assets 671,954 731,365
ASC 842 - Lease Accounting 33,891 32,681
Total deferred tax assets 16,919,686 16,185,071
Deferred tax liabilities [Abstract]    
Net deferred tax assets 16,919,686 16,185,071
Valuation allowance (16,919,686) (16,185,071)
Net deferred tax assets $ 0 $ 0
XML 94 R75.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES, Other Information (Details) - USD ($)
1 Months Ended 12 Months Ended
May 31, 2021
Dec. 31, 2021
Dec. 31, 2020
INCOME TAXES [Abstract]      
Change in valuation allowance   $ 16,919,686 $ 16,185,071
Increase in valuation allowance   734,615 $ 1,201,450
Operating Loss Carryforwards [Abstract]      
Gain on loan forgiveness $ 885,226    
U.S. Federal [Member]      
Operating Loss Carryforwards [Abstract]      
Operating Loss Carryforwards   61,000,000.0  
U.S. Federal [Member] | 2032 through 2037 [Member]      
Operating Loss Carryforwards [Abstract]      
Operating Loss Carryforwards   46,300,000  
U.S. Federal [Member] | No Expiration Date [Member]      
Operating Loss Carryforwards [Abstract]      
Operating Loss Carryforwards   14,700,000  
State [Member]      
Operating Loss Carryforwards [Abstract]      
Operating Loss Carryforwards   46,600,000  
State [Member] | 2032 through 2037 [Member]      
Operating Loss Carryforwards [Abstract]      
Operating Loss Carryforwards   35,400,000  
State [Member] | No Expiration Date [Member]      
Operating Loss Carryforwards [Abstract]      
Operating Loss Carryforwards   $ 11,200,000  
XML 95 R76.htm IDEA: XBRL DOCUMENT v3.22.1
SEGMENT INFORMATION (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Segment Reporting Information, Profit (Loss) [Abstract]    
Net sales $ 13,319,854 $ 13,920,745
Segment gross profit 5,292,554 5,777,221
Corporate expenses 10,033,048 9,225,593
LOSS FROM OPERATIONS (4,740,494) (3,448,372)
Corporate other income (expense), net 703,035 (274,020)
NET LOSS (4,037,459) (3,722,392)
Depreciation and amortization 497,408 550,098
Vapor [Member]    
Segment Reporting Information, Profit (Loss) [Abstract]    
Net sales 2,084,813 2,458,945
Grocery [Member]    
Segment Reporting Information, Profit (Loss) [Abstract]    
Net sales 11,235,041 11,461,800
Operating Segments [Member] | Vapor [Member]    
Segment Reporting Information, Profit (Loss) [Abstract]    
Net sales 2,084,813 2,458,945
Segment gross profit 1,245,214 1,425,140
Depreciation and amortization 1,000 10,000
Operating Segments [Member] | Grocery [Member]    
Segment Reporting Information, Profit (Loss) [Abstract]    
Net sales 11,235,041 11,461,800
Segment gross profit 4,047,340 4,352,081
Depreciation and amortization $ 500,000 $ 500,000
XML 96 R77.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS (Details) - USD ($)
9 Months Ended 12 Months Ended
Feb. 22, 2022
Feb. 08, 2022
Feb. 02, 2022
Feb. 26, 2021
Aug. 13, 2018
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Common Stock [Member]                
Series D Preferred Stock [Abstract]                
Preferred Stock exercised (in shares)           6,600,000,000 162,800,000,000 38,700,000,000
Stock options exercised (in shares)             2,275,000,000  
Chief Executive Officer [Member]                
Subsequent Event [Abstract]                
Base salary         $ 450,000      
Chief Executive Officer [Member] | Restricted Stock [Member]                
Equity Securities, Restricted [Abstract]                
Granted (in shares)         11      
President and Chief Operating Officer [Member]                
Subsequent Event [Abstract]                
Base salary       $ 400,000        
Increment percentage on salary each subsequent year       10.00%        
Mother Earth's Storehouse [Member] | Asset Purchase Agreement [Member]                
Subsequent Event [Abstract]                
Consideration paid for acquisition   $ 575,000            
Subsequent Event [Member] | Philip Morris [Member] | Patent Infringement Litigation [Member]                
Subsequent Event [Abstract]                
Attorney fees paid $ 575,000              
Subsequent Event [Member] | Chief Financial Officer [Member]                
Subsequent Event [Abstract]                
Base salary     $ 300,000          
Increment percentage on salary each subsequent year     10.00%          
Subsequent Event [Member] | Mother Earth's Storehouse [Member] | Asset Purchase Agreement [Member]                
Subsequent Event [Abstract]                
Cash purchase price   3,900,000            
Cash paid for inventory   $ 677,500            
XML 97 form10k_htm.xml IDEA: XBRL DOCUMENT 0000844856 2021-01-01 2021-12-31 0000844856 2021-06-30 0000844856 2022-03-18 0000844856 2021-12-31 0000844856 2020-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember 2021-12-31 0000844856 hcmc:SeriesDConvertiblePreferredStockMember 2020-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember 2020-12-31 0000844856 hcmc:SeriesDConvertiblePreferredStockMember 2021-12-31 0000844856 hcmc:VaporMember 2020-01-01 2020-12-31 0000844856 hcmc:GroceryMember 2020-01-01 2020-12-31 0000844856 hcmc:VaporMember 2021-01-01 2021-12-31 0000844856 hcmc:GroceryMember 2021-01-01 2021-12-31 0000844856 2020-01-01 2020-12-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000844856 2019-12-31 0000844856 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0000844856 us-gaap:CommonStockMember 2019-12-31 0000844856 us-gaap:RetainedEarningsMember 2019-12-31 0000844856 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000844856 us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000844856 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000844856 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000844856 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000844856 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000844856 hcmc:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000844856 hcmc:SeriesBConvertiblePreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000844856 hcmc:SeriesBConvertiblePreferredStockMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000844856 hcmc:SeriesBConvertiblePreferredStockMember 2020-01-01 2020-12-31 0000844856 hcmc:SeriesBConvertiblePreferredStockMember us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember 2020-01-01 2020-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000844856 hcmc:SeriesDConvertiblePreferredStockMember 2021-01-01 2021-12-31 0000844856 hcmc:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000844856 hcmc:SeriesDConvertiblePreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000844856 hcmc:SeriesDConvertiblePreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000844856 hcmc:SeriesDConvertiblePreferredStockMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember 2021-01-01 2021-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000844856 srt:BoardOfDirectorsChairmanMember 2021-01-01 2021-12-31 0000844856 srt:BoardOfDirectorsChairmanMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000844856 srt:BoardOfDirectorsChairmanMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000844856 srt:BoardOfDirectorsChairmanMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000844856 srt:OfficerMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000844856 srt:BoardOfDirectorsChairmanMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000844856 srt:OfficerMember 2021-01-01 2021-12-31 0000844856 srt:OfficerMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000844856 srt:OfficerMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000844856 srt:OfficerMember us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000844856 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000844856 us-gaap:CommonStockMember 2021-12-31 0000844856 us-gaap:RetainedEarningsMember 2020-12-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000844856 us-gaap:CommonStockMember 2020-12-31 0000844856 us-gaap:RetainedEarningsMember 2021-12-31 0000844856 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000844856 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000844856 hcmc:MotherEarthSStorehouseMember us-gaap:SubsequentEventMember 2022-02-28 0000844856 hcmc:MotherEarthSStorehouseMember 2021-01-01 2021-12-31 0000844856 hcmc:VendorMember us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-12-31 0000844856 hcmc:VendorMember us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember 2020-01-01 2020-12-31 0000844856 hcmc:VaporLoyaltyRewardsMember 2021-01-01 2021-12-31 0000844856 hcmc:GiftCardsMember 2021-01-01 2021-12-31 0000844856 hcmc:GroceryLoyaltyRewardsMember 2021-01-01 2021-12-31 0000844856 hcmc:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000844856 hcmc:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000844856 hcmc:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000844856 hcmc:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000844856 hcmc:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000844856 hcmc:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000844856 srt:MaximumMember 2021-01-01 2021-12-31 0000844856 srt:MinimumMember 2021-01-01 2021-12-31 0000844856 hcmc:RetailVaporMember 2021-01-01 2021-12-31 0000844856 hcmc:RetailGroceryMember 2020-01-01 2020-12-31 0000844856 hcmc:OnlineAndECommerceMember 2020-01-01 2020-12-31 0000844856 hcmc:RetailGroceryMember 2021-01-01 2021-12-31 0000844856 hcmc:WholesaleVaporMember 2021-01-01 2021-12-31 0000844856 hcmc:FoodServiceAndRestaurantMember 2021-01-01 2021-12-31 0000844856 hcmc:WholesaleGroceryMember 2021-01-01 2021-12-31 0000844856 hcmc:RetailVaporMember 2020-01-01 2020-12-31 0000844856 hcmc:OnlineAndECommerceMember 2021-01-01 2021-12-31 0000844856 hcmc:WholesaleGroceryMember 2020-01-01 2020-12-31 0000844856 hcmc:FoodServiceAndRestaurantMember 2020-01-01 2020-12-31 0000844856 hcmc:WholesaleVaporMember 2020-01-01 2020-12-31 0000844856 2018-12-31 0000844856 2018-01-01 2018-12-31 0000844856 us-gaap:MeasurementInputQuotedPriceMember 2021-12-31 0000844856 us-gaap:FairValueInputsLevel1Member 2021-12-31 0000844856 us-gaap:FairValueInputsLevel1Member 2020-12-31 0000844856 us-gaap:MeasurementInputQuotedPriceMember 2020-12-31 0000844856 hcmc:ThirdPartyMember 2020-01-01 2020-12-31 0000844856 hcmc:ThirdPartyMember 2021-01-01 2021-12-31 0000844856 hcmc:GroceryMember 2020-12-31 0000844856 hcmc:VaporMember 2020-12-31 0000844856 hcmc:GroceryMember 2021-12-31 0000844856 hcmc:VaporMember 2021-12-31 0000844856 hcmc:PromissoryNotesMember 2021-01-01 2021-12-31 0000844856 hcmc:PromissoryNotesMember 2018-09-06 2018-09-06 0000844856 hcmc:PromissoryNotesMember 2021-08-31 2021-08-31 0000844856 hcmc:PromissoryNotesMember 2021-08-31 0000844856 hcmc:PromissoryNotesMember 2018-09-06 0000844856 hcmc:PromissoryNotesMember 2020-12-31 0000844856 hcmc:PromissoryNotesMember 2021-12-31 0000844856 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000844856 us-gaap:OtherMachineryAndEquipmentMember 2020-12-31 0000844856 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000844856 hcmc:DisplaysMember 2020-12-31 0000844856 us-gaap:OtherMachineryAndEquipmentMember 2021-12-31 0000844856 hcmc:DisplaysMember 2021-12-31 0000844856 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000844856 us-gaap:ComputerEquipmentMember 2021-12-31 0000844856 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000844856 us-gaap:ComputerEquipmentMember 2020-12-31 0000844856 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-12-31 0000844856 us-gaap:NoncompeteAgreementsMember 2020-01-01 2020-12-31 0000844856 us-gaap:PatentsMember 2021-01-01 2021-12-31 0000844856 srt:MaximumMember us-gaap:TradeNamesMember 2020-01-01 2020-12-31 0000844856 srt:MinimumMember us-gaap:TradeNamesMember 2021-01-01 2021-12-31 0000844856 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0000844856 us-gaap:NoncompeteAgreementsMember 2021-01-01 2021-12-31 0000844856 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0000844856 us-gaap:PatentsMember 2020-01-01 2020-12-31 0000844856 srt:MinimumMember us-gaap:TradeNamesMember 2020-01-01 2020-12-31 0000844856 us-gaap:InternetDomainNamesMember 2021-01-01 2021-12-31 0000844856 srt:MaximumMember us-gaap:TradeNamesMember 2021-01-01 2021-12-31 0000844856 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-12-31 0000844856 us-gaap:TradeNamesMember 2021-12-31 0000844856 us-gaap:TradeNamesMember 2020-12-31 0000844856 us-gaap:InternetDomainNamesMember 2021-12-31 0000844856 us-gaap:CustomerRelationshipsMember 2020-12-31 0000844856 us-gaap:PatentsMember 2020-12-31 0000844856 us-gaap:NoncompeteAgreementsMember 2021-12-31 0000844856 us-gaap:CustomerRelationshipsMember 2021-12-31 0000844856 us-gaap:PatentsMember 2021-12-31 0000844856 us-gaap:NoncompeteAgreementsMember 2020-12-31 0000844856 hcmc:EIRHydrationMember 2021-11-30 2021-11-30 0000844856 hcmc:TermLoanCreditAgreementMember 2021-12-31 0000844856 hcmc:TermLoanCreditAgreementMember 2020-12-31 0000844856 us-gaap:LineOfCreditMember 2020-12-31 0000844856 hcmc:OtherDebtMember 2020-12-31 0000844856 hcmc:PaycheckProtectionProgramMember 2020-12-31 0000844856 hcmc:TermLoanAndSecurityAgreementMember 2021-12-31 0000844856 hcmc:OtherDebtMember 2021-12-31 0000844856 us-gaap:LineOfCreditMember 2021-12-31 0000844856 hcmc:TermLoanAndSecurityAgreementMember 2020-12-31 0000844856 hcmc:PaycheckProtectionProgramMember 2021-12-31 0000844856 us-gaap:LineOfCreditMember 2021-11-03 0000844856 us-gaap:LineOfCreditMember 2021-11-03 2021-11-03 0000844856 hcmc:TermLoanCreditAgreementMember us-gaap:PrimeRateMember 2018-01-01 2018-12-31 0000844856 hcmc:TermLoanCreditAgreementMember 2018-12-31 0000844856 hcmc:PaycheckProtectionProgramMember 2020-05-15 0000844856 hcmc:TermLoanCreditAgreementMember 2021-12-21 2021-12-21 0000844856 hcmc:PaycheckProtectionProgramMember 2021-01-01 2021-12-31 0000844856 hcmc:PaycheckProtectionProgramMember 2021-03-05 2021-03-05 0000844856 hcmc:FontemVenturesBVMember hcmc:FontemLicenseAgreementMember 2021-01-01 2021-12-31 0000844856 hcmc:FontemVenturesBVMember hcmc:FontemLicenseAgreementMember 2020-01-01 2020-12-31 0000844856 hcmc:PhilipMorrisMember 2020-11-30 0000844856 srt:ChiefExecutiveOfficerMember 2018-08-13 2018-08-13 0000844856 hcmc:PresidentAndChiefOperatingOfficerMember 2021-02-26 2021-02-26 0000844856 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2018-08-13 2018-08-13 0000844856 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2018-08-13 2018-08-13 0000844856 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2018-08-13 2018-08-13 0000844856 srt:ChiefExecutiveOfficerMember 2019-08-12 2019-08-12 0000844856 srt:ChiefExecutiveOfficerMember 2020-08-12 2020-08-12 0000844856 hcmc:AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember 2021-01-01 2021-12-31 0000844856 hcmc:AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember hcmc:MedicalCostsMember 2021-01-01 2021-12-31 0000844856 hcmc:TwoThousandAndNineEquityIncentivePlanMember 2021-12-31 0000844856 srt:MaximumMember hcmc:TwoThousandAndFifteenEquityIncentivePlanMember 2015-07-07 0000844856 hcmc:TwoThousandAndFifteenEquityIncentivePlanMember 2021-12-31 0000844856 2021-06-18 2021-06-18 0000844856 2021-06-18 0000844856 hcmc:TermLoanAndSecurityAgreementMember 2021-03-29 0000844856 2021-03-29 2021-03-29 0000844856 2021-03-29 0000844856 hcmc:TermLoanAndSecurityAgreementMember 2021-01-01 2021-12-31 0000844856 srt:MaximumMember srt:BoardOfDirectorsChairmanMember 2021-12-31 0000844856 hcmc:SeriesCConvertiblePreferredStockMember 2020-11-17 0000844856 srt:BoardOfDirectorsChairmanMember 2021-12-31 0000844856 hcmc:SeriesDConvertiblePreferredStockMember hcmc:SecuritiesPurchaseAgreementMember 2021-02-07 0000844856 hcmc:SeriesCConvertiblePreferredStockMember 2020-11-17 2020-11-17 0000844856 hcmc:SeriesDConvertiblePreferredStockMember 2021-09-30 0000844856 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000844856 hcmc:SeriesDConvertiblePreferredStockMember 2021-01-01 2021-09-30 0000844856 us-gaap:WarrantMember 2016-10-05 0000844856 us-gaap:WarrantMember 2020-07-27 0000844856 us-gaap:WarrantMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000844856 us-gaap:RestrictedStockMember srt:ChiefFinancialOfficerMember 2018-08-13 2018-08-13 0000844856 us-gaap:RestrictedStockMember srt:ChiefExecutiveOfficerMember 2018-08-13 2018-08-13 0000844856 us-gaap:RestrictedStockMember hcmc:OfficersAndADirectorMember 2021-01-14 2021-01-14 0000844856 us-gaap:RestrictedStockMember srt:ChiefOperatingOfficerMember 2018-08-13 2018-08-13 0000844856 us-gaap:RestrictedStockMember srt:ChiefExecutiveOfficerMember 2021-01-01 2021-12-31 0000844856 us-gaap:RestrictedStockMember srt:ChiefOperatingOfficerMember 2021-01-01 2021-12-31 0000844856 us-gaap:RestrictedStockMember srt:ChiefFinancialOfficerMember 2021-01-01 2021-12-31 0000844856 us-gaap:RestrictedStockMember hcmc:OfficersAndADirectorMember 2021-03-30 2021-03-30 0000844856 us-gaap:RestrictedStockMember hcmc:OfficersAndADirectorMember 2021-06-29 2021-06-29 0000844856 us-gaap:StockOptionMember 2019-12-31 0000844856 us-gaap:StockOptionMember 2020-01-01 2020-12-31 0000844856 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0000844856 us-gaap:StockOptionMember 2021-12-31 0000844856 us-gaap:StockOptionMember 2020-12-31 0000844856 us-gaap:StockOptionMember 2019-01-01 2019-12-31 0000844856 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000844856 us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000844856 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000844856 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0000844856 srt:MaximumMember 2021-12-31 0000844856 us-gaap:DomesticCountryMember 2021-12-31 0000844856 us-gaap:StateAndLocalJurisdictionMember hcmc:TaxYearNoExpirationDateMember 2021-12-31 0000844856 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000844856 us-gaap:DomesticCountryMember hcmc:TaxYearNoExpirationDateMember 2021-12-31 0000844856 us-gaap:StateAndLocalJurisdictionMember hcmc:TaxYear2032Through2037Member 2021-12-31 0000844856 us-gaap:DomesticCountryMember hcmc:TaxYear2032Through2037Member 2021-12-31 0000844856 2021-05-01 2021-05-31 0000844856 us-gaap:OperatingSegmentsMember hcmc:GroceryMember 2020-01-01 2020-12-31 0000844856 us-gaap:OperatingSegmentsMember hcmc:VaporMember 2021-01-01 2021-12-31 0000844856 us-gaap:OperatingSegmentsMember hcmc:VaporMember 2020-01-01 2020-12-31 0000844856 us-gaap:OperatingSegmentsMember hcmc:GroceryMember 2021-01-01 2021-12-31 0000844856 hcmc:MotherEarthSStorehouseMember us-gaap:SubsequentEventMember hcmc:AssetPurchaseAgreementMember 2022-02-08 2022-02-08 0000844856 hcmc:MotherEarthSStorehouseMember hcmc:AssetPurchaseAgreementMember 2022-02-08 2022-02-08 0000844856 srt:ChiefFinancialOfficerMember us-gaap:SubsequentEventMember 2022-02-02 2022-02-02 0000844856 hcmc:PhilipMorrisMember hcmc:PatentInfringementLitigationMember us-gaap:SubsequentEventMember 2022-02-22 2022-02-22 iso4217:USD shares iso4217:USD shares hcmc:Store pure hcmc:Vendor hcmc:Segment hcmc:User hcmc:Lawsuit false --12-31 2021 FY 0000844856 NONE P24M P24M 0.05 P24M P24M P2Y 688 10-K true 2021-12-31 false HEALTHIER CHOICES MANAGEMENT CORP. DE 001-36469 84-1070932 3800 North 28th Way Hollywood FL 33020 305 600-5004 Common Stock, par value $0.0001 per share HCMC No No Yes Yes Non-accelerated Filer true false false true false 366500000 339741632384 -300000 Marcum LLP Marcum LLP New York, NY 26496404 925475 28481 23675 247915 0 1521199 1749246 456397 286065 23143 22731 28773539 3007192 0 2000000 176988 230719 947593 1248352 916000 916000 0 304511 3543930 4078621 85437 89598 34443487 11874993 1642848 1085663 23178 21262 437328 474686 418036 2000000 2604 2072484 2523994 5654095 815 849009 2685021 3114521 5209830 9617625 1000 1000 30000 30000 0 0 16277 16277 16300000 0 16277116 1000 1000 5000 800 800 0 0 800000 800000 0 0.0001 0.0001 750000000000 750000000000 339741632384 339741632384 143840848017 143840848017 33974163 14384084 30855824 3955039 -36396330 -32358871 29233657 2257368 34443487 11874993 2084813 2458945 11235041 11461800 13319854 13920745 839599 1033805 7187701 7109719 5292554 5777221 0 380646 10033048 8844947 10033048 9225593 -4740494 -3448372 767930 0 -26 -100 65281 272651 412 -1269 703035 -274020 -4037459 -3722392 0.00 0.00 0.00 0.00 307912959368 307912959368 90351540618 90351540618 20150 20150116 67698494244 6769849 7618245 -28636479 5901731 0 0 37412353772 3741235 -3741235 0 0 -20150 -20150116 0 0 0 0 -20150116 20150 20150116 0 0 0 0 20150116 -3873 3873000 38730000001 -3873000 0 0 0 0 0 78029 0 78029 0 0 0 -3722392 -3722392 16277 16277116 143840848017 14384084 3955039 -32358871 2257368 -16277 16277116 162771153001 -16277116 0 0 0 0 0 2275000000 227500 0 0 227500 5000 5000000 0 0 0 0 5000000 -4200 4200000 6562500000 -656250 -3543750 0 0 0 0 1182831056 118283 1289273 0 1407556 0 0 27046800310 2704680 21639637 0 24344317 0 0 2200000000 220000 -220000 0 0 0 0 50000000 5000 -5000 0 0 0 0 6050000000 -605000 605000 0 0 0 0 137500000 -13750 13750 0 0 0 0 34375 0 34375 0 0 0 -4037459 -4037459 800 800000 339741632384 33974163 30855824 -36396330 29233657 -4037459 -3722392 497408 550098 767930 0 534691 584398 412 -1269 707710 340905 34375 78029 0 380646 60809 7117 4806 -41726 478663 333139 170332 16233 0 0 -4161 -57269 557185 265552 1916 -5561 466858 511481 -3528205 -2281797 75000 0 56596 38876 12500 89415 56418 24663 -87322 -75202 418036 0 2000000 0 -803397 -1659456 0 876515 0 2540000 5000000 0 24344317 0 227500 0 27186456 1757059 23570929 -599940 2925475 3525415 26496404 2925475 115584 314925 1407556 0 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 1. ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Organization</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Healthier Choices Management Corp. (the “Company”) is a holding company focused on providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives. The Company currently operates six retail vape stores in the Southeast region of the United States, through which it offers e-liquids, vaporizers and related products. The Company also operates Ada’s Natural Market, a natural and organic grocery store, through its wholly owned subsidiary Healthy Choice Markets, Inc. Ada’s Natural Market and Paradise Health and Nutrition offers fresh produce, bulk foods, vitamins and supplements, packaged groceries, meat and seafood, deli, baked goods, dairy products, frozen foods, health &amp; beauty products and natural household items. The Company also sells vitamins and supplements on the Amazon.com marketplace through its wholly owned subsidiary Healthy U Wholesale, Inc. The Company also operates HCMC Intellectual Property Holdings, LLC, a wholly owned subsidiary formed to hold, market and expand on its current intellectual property assets. The Company markets the Q-Cup™ technology under the vape segment; this patented technology is based on a small, quartz cup called the Q-Cup™, which a customer partially fills with either cannabis or CBD concentrate (approximately 50mg) purchased from a third party. The Q-Cup™ is then inserted into the Q-Cup™ Tank or Globe, that heats the cup from the outside without coming in direct contact with the solid concentrate. This Q-Cup™ technology provides significantly more efficiency and an “on the go” solution for consumers who prefer to vape concentrates either medicinally or recreationally. The Company acquired Mother Earth’s Storehouse on February 2022, which operates a two store organic and health food and vitamin chain in New York’s Hudson Valley, a business that has been operating for over 40 years.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">COVID-19 Management Update</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The global outbreak of COVID-19 was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020 and has negatively impacted the U.S. and global economies, disrupted global supply chains and, mandated closures and stay-at-home orders and created significant disruptions of the global financial markets. The Company adjusted certain aspects of the operations to protect their employees and customers while still meeting customers’ needs. While to date the Company has not been required to close any of its stores, the Company is currently operating under regular hours and we are expecting COVID-19 to have a long-term beneficial impact to the future financial results of the grocery segment. The Company continues to monitor the impact of the COVID-19 outbreak closely.  The extent to which the COVID-19 outbreak will impact our operations is manageable, and there is no imminent risk on business continuity and future operations.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Sourcing and Vendors</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We source from multiple suppliers. These suppliers range from small independent businesses to multinational conglomerates. For the fiscal years ended December 31, 2021 and 2020, approximately 25% and 27% of our total purchases were from one vendor.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Basis of Presentation and Principles of Consolidation</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company’s consolidated financial statements are prepared in accordance with GAAP. The consolidated financial statements include the accounts of all subsidiaries in which the Company holds a controlling financial interest as of the financial statement date.</div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Healthy Choice Markets, Inc., Healthy Choice Markets 2, LLC (“Paradise Health and Nutrition”), Healthy Choice Markets 3, LLC (“Mother Earth’s Storehouse”), Healthy Choices Markets 3 Real Estate LLC, HCMC Intellectual Property Holdings, LLC, Healthy Choice Wellness, LLC, The Vitamin Store, LLC, Healthy U Wholesale, Inc., The Vape Store, Inc. (“Vape Store”), Vaporin, Inc. (“Vaporin”), Smoke Anywhere U.S.A., Inc. (“Smoke”), Emagine the Vape Store, LLC (“Emagine”), IVGI Acquisition, Inc., Vapormax Franchising LLC, Vaporin LLC, and Vaporin Florida, Inc. All intercompany accounts and transactions have been eliminated in consolidation.</div> 6 2 P40Y <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Sourcing and Vendors</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We source from multiple suppliers. These suppliers range from small independent businesses to multinational conglomerates. For the fiscal years ended December 31, 2021 and 2020, approximately 25% and 27% of our total purchases were from one vendor.</div> 0.25 0.27 1 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company’s consolidated financial statements are prepared in accordance with GAAP. The consolidated financial statements include the accounts of all subsidiaries in which the Company holds a controlling financial interest as of the financial statement date.</div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Healthy Choice Markets, Inc., Healthy Choice Markets 2, LLC (“Paradise Health and Nutrition”), Healthy Choice Markets 3, LLC (“Mother Earth’s Storehouse”), Healthy Choices Markets 3 Real Estate LLC, HCMC Intellectual Property Holdings, LLC, Healthy Choice Wellness, LLC, The Vitamin Store, LLC, Healthy U Wholesale, Inc., The Vape Store, Inc. (“Vape Store”), Vaporin, Inc. (“Vaporin”), Smoke Anywhere U.S.A., Inc. (“Smoke”), Emagine the Vape Store, LLC (“Emagine”), IVGI Acquisition, Inc., Vapormax Franchising LLC, Vaporin LLC, and Vaporin Florida, Inc. All intercompany accounts and transactions have been eliminated in consolidation.</div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 2. LIQUIDITY</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of any uncertainties related to our going concern assessment. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company incurred a loss from operations of approximately $4.7 million for the year ended December 31, 2021. As of December 31, 2021, cash and cash equivalents totaled approximately $26.5 million. Management anticipates that its current cash, cash equivalent and cash generated from operations will be sufficient to meet the projected operating expenses for the foreseeable future through at least the next twelve months from the issuance of these consolidated financial statements.</div> -4700000 26500000 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Segment Reporting</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the operating decision makers, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company’s decision-making group are the senior executive management team. The Company and the decision-making group view the Company’s operations and manage its business as two operating segments. All long-lived assets of the Company reside in the U.S.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Use of Estimates in the Preparation of the Financial Statements</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting periods. Actual results could differ from those estimates. These estimates and assumptions include allowances, reserves and write-downs of inventory, valuing equity securities and hybrid instruments, share-based payment arrangements, deferred taxes and related valuation allowances, and the valuation of the assets and liabilities acquired in business combinations. Certain of management’s estimates could be affected by external conditions, including those unique to our industry, and general economic conditions. It is possible that these external factors could have an effect on our estimates that could cause actual results to differ from our estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Revenue Recognition</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenues from product sales and services rendered, net of promotional discounts, manufacturer coupons and rebates, return allowances, and sales and consumption taxes, are recorded when products are delivered, title passes to customers and collection is likely to occur. Title passes to customers at the point of sale for retail and upon delivery of products for wholesale. Return allowances, which reduce revenue, are estimated using historical experience.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company recognizes revenue in accordance with the following five-step model:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">identify arrangements with customers;</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">identify performance obligations;</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">determine transaction price;</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">allocate transaction price to the separate performance obligations in the arrangement, if more than one exists; and</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">recognize revenue as performance obligations are satisfied.</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Shipping and Handling</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shipping charges billed to customers are included in net sales and the related shipping and handling costs are included in cost of sales. For the years ended December 31, 2021 and 2020, shipping and handling costs of approximately $68,000 and $48,000, were included in cost of sales, respectively.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Cash and Cash Equivalents</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company considers all highly liquid instruments with an original maturity of three months or less, when purchased, to be cash and cash equivalents. The majority of the Company’s cash and cash equivalents are concentrated in one large financial institution, which is in excess of Federal Deposit Insurance Corporation (FDIC) coverage. At December 31, 2021, cash in excess of FDIC limits of $250,000 per financial institution were approximately $26.0 million. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests, as deposits are held in excess of federally insured limits. The Company’s cash equivalent at December 31, 2021 was a money market account. The Company has not experienced any losses in such accounts.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Accounts Receivable, Contract Assets and Contract Liabilities</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accounts receivables are claims to consideration which are unconditional; meaning no performance obligations remain for the Company and only the passage of time is necessary before collection. Contract assets are distinguished from accounts receivable as performance obligations remain before claims to consideration become unconditional. By nature of the Company’s operations, contract assets are typically not recognized. Contract liabilities are recorded when customers transfer consideration in advance of delivery of products or services, which the Company records for gift cards and loyalty reward programs. When one party to an arrangement performs before the other(s), the Company records an account receivable, contract asset or contract liability.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The majority of arrangements with customers contain one performance obligation: to provide a distinct set of products or services. Most performance obligations are satisfied simultaneously as the Company exchanges products or services for customer payment. Exceptions include gift cards and loyalty rewards, for which the Company has a performance obligation to deliver products or services at a future date. As gift cards are purchased and loyalty points earned, contract liabilities are recorded until the performance obligations are satisfied through delivery of products or services or breakage based on gift card and loyalty reward program term limits.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company’s breakage policy is <span style="-sec-ix-hidden:Fact_933125b2510b403f82c05451eb3a958a">twenty-four months</span> for gift cards, twelve months for Grocery loyalty rewards, and six months for Vapor loyalty rewards. Loyalty rewards are earned at <span style="-sec-ix-hidden:Fact_5155a523a1564e3b8c1b078237239d21">five</span> percent on qualifying purchases and the reward functions as an allocation of transaction price from the period earned by the customer to the period the performance obligation is satisfied by the Company. As such, all contract liabilities are expected to be recognized within a <span style="-sec-ix-hidden:Fact_3dbb5df438c74c68b3b6e1b7a851a2d5">twenty-four month</span> period.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Concentration of accounts receivable consist of the following:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer A</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">30</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer B</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">12</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer C</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">34</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div> </td> </tr> </table> <div style="text-align: left;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Due from Merchant Credit Card Processor</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Due from merchant credit card processor represents monies held by the Company’s credit card processors. The funds are being held by the merchant credit card processors pending satisfaction of their hold requirements and expiration of charge backs/refunds from customers.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Inventories</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inventories are stated at average cost. If the cost of the inventories exceeds their net realizable value, adjustments are recorded to write down excess inventory to their net realizable value. The Company’s inventories consist primarily of merchandise available for resale, such as vaporizers, electronic cigarettes, e-liquids, fresh produce, perishable grocery items and non-perishable consumable goods.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Property and Equipment</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the expected useful life of the respective asset, after the asset is placed in service. Revenue earning property and equipment includes signage, furniture and fixtures, computer hardware, appliance, cooler, displays with useful lives range from <span style="-sec-ix-hidden:Fact_f6aa6d74d45a410cb0c12bfec8ba8551">two</span> to seven years. Leasehold improvements are amortized over life of lease.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Identifiable Intangible Assets and Goodwill</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Identifiable intangible assets are recorded at cost, or when acquired as part of a business acquisition, at estimated fair value. Certain identifiable intangible assets are amortized over 4 and 10 years. Similar to tangible personal property and equipment, the Company periodically evaluates identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Indefinite-lived intangible assets, such as goodwill are not amortized.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Impairment of Long-Lived Assets</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company reviews all long-lived assets such as property and equipment and amortized intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future cash flows expected to be generated by the asset or asset group. Impairment is measured by the amount by which the carrying value of the asset(s) exceeds their fair value. There were no triggering events that would indicate impairment of long-lived assets at December 31, 2021. For the year ended December 31, 2020, the Company determined the estimated undiscounted cash flows related to the sales of the VitaminStore.com were less than the carrying value of the intangible assets and recorded an impairment charge of $0.3 million.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Goodwill</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company assesses the carrying amounts of goodwill for recoverability on at least an annual basis or when events or changes in circumstances indicate evidence of potential impairment exists, using a fair value based test. Application of the goodwill impairment test requires significant judgments including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the businesses, and the useful life over which cash flows will occur. Changes in these estimates and assumptions could materially affect the determination of fair value and/or conclusions on goodwill impairment for the Company. Our annual impairment test is conducted on September 30 of each year or more often if deemed necessary. As part of management's qualitative analysis at December 31, 2021 management determines whether any triggering events have occurred since the annual test date of September 30, 2021, which would indicate an impairment. Management determined no triggering events had occurred through December 31, 2021. The Company recorded an impairment charge of $40,000 for the year ended December 31, 2020.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Advertising</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company expenses advertising costs as incurred. For the years ended December 31, 2021 and 2020, the company incurred advertising expenses of $43,000 and $92,000, respectively.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Income Taxes</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021 or December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.</span></div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Stock-Based Compensation</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company accounts for stock-based compensation for employees and directors under ASC Topic No. 718, “Compensation-Stock Compensation” (“ASC 718”). These standards define a fair value based method of accounting for stock-based compensation. In accordance with ASC 718, the cost of stock-based compensation is measured at the grant date based on the value of the award and is recognized over the vesting period. The value of the stock-based award is determined using an appropriate valuation model, whereby compensation cost is the fair value of the award as determined by the valuation model at the grant date. The resulting amount is charged to expense on the straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period. The Company recognize forfeitures as they are incur. Stock-based compensation for non-employees is measured at the grant date, is re-measured at subsequent vesting dates and reporting dates, and is amortized over the service period.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Fair Value Measurements</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The fair value framework under FASB’s guidance requires the categorization of assets and liabilities into three levels based upon the assumptions used to measure the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3, if applicable, would generally require significant management judgment. The three levels for categorizing assets and liabilities under the fair value measurement requirements are as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Level 1: Fair value measurement of the asset or liability using observable inputs such as quoted prices in active markets for identical assets or liabilities;</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Level 2: Fair value measurement of the asset or liability using inputs other than quoted prices that are observable for the applicable asset or liability, either directly or indirectly, such as quoted prices for similar (as opposed to identical) assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Level 3: Fair value measurement of the asset or liability using unobservable inputs that reflect the Company’s own assumptions regarding the applicable asset or liability.</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nonfinancial assets such as goodwill, other intangible assets, and long-lived assets held and used are measured at fair value when there is an indicator of impairment and recorded at fair value when impairment is recognized or for a business combination.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Sequencing Policy</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under ASC 815-40-35, the Company has adopted a sequencing policy, whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares.</div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Segment Reporting</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the operating decision makers, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company’s decision-making group are the senior executive management team. The Company and the decision-making group view the Company’s operations and manage its business as two operating segments. All long-lived assets of the Company reside in the U.S.</div> 2 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Use of Estimates in the Preparation of the Financial Statements</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of net revenue and expenses during the reporting periods. Actual results could differ from those estimates. These estimates and assumptions include allowances, reserves and write-downs of inventory, valuing equity securities and hybrid instruments, share-based payment arrangements, deferred taxes and related valuation allowances, and the valuation of the assets and liabilities acquired in business combinations. Certain of management’s estimates could be affected by external conditions, including those unique to our industry, and general economic conditions. It is possible that these external factors could have an effect on our estimates that could cause actual results to differ from our estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary.</div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Revenue Recognition</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenues from product sales and services rendered, net of promotional discounts, manufacturer coupons and rebates, return allowances, and sales and consumption taxes, are recorded when products are delivered, title passes to customers and collection is likely to occur. Title passes to customers at the point of sale for retail and upon delivery of products for wholesale. Return allowances, which reduce revenue, are estimated using historical experience.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company recognizes revenue in accordance with the following five-step model:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">identify arrangements with customers;</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">identify performance obligations;</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">determine transaction price;</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">allocate transaction price to the separate performance obligations in the arrangement, if more than one exists; and</div> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt;"/> <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">●</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">recognize revenue as performance obligations are satisfied.</div> </td> </tr> </table> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Shipping and Handling</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shipping charges billed to customers are included in net sales and the related shipping and handling costs are included in cost of sales. For the years ended December 31, 2021 and 2020, shipping and handling costs of approximately $68,000 and $48,000, were included in cost of sales, respectively.</div> 68000 48000 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Cash and Cash Equivalents</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company considers all highly liquid instruments with an original maturity of three months or less, when purchased, to be cash and cash equivalents. The majority of the Company’s cash and cash equivalents are concentrated in one large financial institution, which is in excess of Federal Deposit Insurance Corporation (FDIC) coverage. At December 31, 2021, cash in excess of FDIC limits of $250,000 per financial institution were approximately $26.0 million. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests, as deposits are held in excess of federally insured limits. The Company’s cash equivalent at December 31, 2021 was a money market account. The Company has not experienced any losses in such accounts.</div> 250000 26000000.0 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Accounts Receivable, Contract Assets and Contract Liabilities</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accounts receivables are claims to consideration which are unconditional; meaning no performance obligations remain for the Company and only the passage of time is necessary before collection. Contract assets are distinguished from accounts receivable as performance obligations remain before claims to consideration become unconditional. By nature of the Company’s operations, contract assets are typically not recognized. Contract liabilities are recorded when customers transfer consideration in advance of delivery of products or services, which the Company records for gift cards and loyalty reward programs. When one party to an arrangement performs before the other(s), the Company records an account receivable, contract asset or contract liability.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The majority of arrangements with customers contain one performance obligation: to provide a distinct set of products or services. Most performance obligations are satisfied simultaneously as the Company exchanges products or services for customer payment. Exceptions include gift cards and loyalty rewards, for which the Company has a performance obligation to deliver products or services at a future date. As gift cards are purchased and loyalty points earned, contract liabilities are recorded until the performance obligations are satisfied through delivery of products or services or breakage based on gift card and loyalty reward program term limits.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company’s breakage policy is <span style="-sec-ix-hidden:Fact_933125b2510b403f82c05451eb3a958a">twenty-four months</span> for gift cards, twelve months for Grocery loyalty rewards, and six months for Vapor loyalty rewards. Loyalty rewards are earned at <span style="-sec-ix-hidden:Fact_5155a523a1564e3b8c1b078237239d21">five</span> percent on qualifying purchases and the reward functions as an allocation of transaction price from the period earned by the customer to the period the performance obligation is satisfied by the Company. As such, all contract liabilities are expected to be recognized within a <span style="-sec-ix-hidden:Fact_3dbb5df438c74c68b3b6e1b7a851a2d5">twenty-four month</span> period.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Concentration of accounts receivable consist of the following:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer A</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">30</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer B</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">12</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer C</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">34</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div> </td> </tr> </table> P12M P6M <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Concentration of accounts receivable consist of the following:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer A</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">30</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer B</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">12</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer C</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">34</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div> </td> </tr> </table> 0.30 0 0.12 0 0 0.34 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Due from Merchant Credit Card Processor</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Due from merchant credit card processor represents monies held by the Company’s credit card processors. The funds are being held by the merchant credit card processors pending satisfaction of their hold requirements and expiration of charge backs/refunds from customers.</div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Inventories</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inventories are stated at average cost. If the cost of the inventories exceeds their net realizable value, adjustments are recorded to write down excess inventory to their net realizable value. The Company’s inventories consist primarily of merchandise available for resale, such as vaporizers, electronic cigarettes, e-liquids, fresh produce, perishable grocery items and non-perishable consumable goods.</div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Property and Equipment</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the expected useful life of the respective asset, after the asset is placed in service. Revenue earning property and equipment includes signage, furniture and fixtures, computer hardware, appliance, cooler, displays with useful lives range from <span style="-sec-ix-hidden:Fact_f6aa6d74d45a410cb0c12bfec8ba8551">two</span> to seven years. Leasehold improvements are amortized over life of lease.</div> P7Y <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Identifiable Intangible Assets and Goodwill</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Identifiable intangible assets are recorded at cost, or when acquired as part of a business acquisition, at estimated fair value. Certain identifiable intangible assets are amortized over 4 and 10 years. Similar to tangible personal property and equipment, the Company periodically evaluates identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Indefinite-lived intangible assets, such as goodwill are not amortized.</div> P4Y P10Y <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Impairment of Long-Lived Assets</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company reviews all long-lived assets such as property and equipment and amortized intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future cash flows expected to be generated by the asset or asset group. Impairment is measured by the amount by which the carrying value of the asset(s) exceeds their fair value. There were no triggering events that would indicate impairment of long-lived assets at December 31, 2021. For the year ended December 31, 2020, the Company determined the estimated undiscounted cash flows related to the sales of the VitaminStore.com were less than the carrying value of the intangible assets and recorded an impairment charge of $0.3 million.</div> 300000 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Goodwill</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company assesses the carrying amounts of goodwill for recoverability on at least an annual basis or when events or changes in circumstances indicate evidence of potential impairment exists, using a fair value based test. Application of the goodwill impairment test requires significant judgments including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the businesses, and the useful life over which cash flows will occur. Changes in these estimates and assumptions could materially affect the determination of fair value and/or conclusions on goodwill impairment for the Company. Our annual impairment test is conducted on September 30 of each year or more often if deemed necessary. As part of management's qualitative analysis at December 31, 2021 management determines whether any triggering events have occurred since the annual test date of September 30, 2021, which would indicate an impairment. Management determined no triggering events had occurred through December 31, 2021. The Company recorded an impairment charge of $40,000 for the year ended December 31, 2020.</div> 40000 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Advertising</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company expenses advertising costs as incurred. For the years ended December 31, 2021 and 2020, the company incurred advertising expenses of $43,000 and $92,000, respectively.</div> 43000 92000 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Income Taxes</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021 or December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.</span></div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Stock-Based Compensation</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company accounts for stock-based compensation for employees and directors under ASC Topic No. 718, “Compensation-Stock Compensation” (“ASC 718”). These standards define a fair value based method of accounting for stock-based compensation. In accordance with ASC 718, the cost of stock-based compensation is measured at the grant date based on the value of the award and is recognized over the vesting period. The value of the stock-based award is determined using an appropriate valuation model, whereby compensation cost is the fair value of the award as determined by the valuation model at the grant date. The resulting amount is charged to expense on the straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period. The Company recognize forfeitures as they are incur. Stock-based compensation for non-employees is measured at the grant date, is re-measured at subsequent vesting dates and reporting dates, and is amortized over the service period.</div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Sequencing Policy</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under ASC 815-40-35, the Company has adopted a sequencing policy, whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares.</div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 4. DISAGGREGATION OF REVENUES</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company reports the following segments in accordance with management guidance: Vapor and Grocery. When the Company prepares its internal management reporting to evaluate business performance, we disaggregate revenue into the following categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vapor sales, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,084,813</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,458,945</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Grocery sales, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">11,235,041</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,461,800</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13,319,854</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,920,745</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Retail Vapor</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,084,744</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,458,945</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Retail Grocery</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">9,923,137</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,047,437</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Food service/restaurant</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,202,122</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,088,162</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Online/e-Commerce</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">93,600</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">307,487</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Wholesale Grocery</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">16,182</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,714</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Wholesale Vapor</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">69</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13,319,854</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,920,745</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company reports the following segments in accordance with management guidance: Vapor and Grocery. When the Company prepares its internal management reporting to evaluate business performance, we disaggregate revenue into the following categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vapor sales, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,084,813</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,458,945</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Grocery sales, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">11,235,041</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,461,800</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13,319,854</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,920,745</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Retail Vapor</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,084,744</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,458,945</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Retail Grocery</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">9,923,137</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,047,437</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Food service/restaurant</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,202,122</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,088,162</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Online/e-Commerce</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">93,600</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">307,487</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Wholesale Grocery</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">16,182</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,714</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Wholesale Vapor</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">69</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13,319,854</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,920,745</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 2084813 2458945 11235041 11461800 13319854 13920745 2084744 2458945 9923137 10047437 1202122 1088162 93600 307487 16182 18714 69 0 13319854 13920745 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 5. INVESTMENT</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In 2018, the Company invested $150,000 in 85,714 common stock shares at MJ Holdings, Inc. (“MJNE”), a publicly traded company. The investment was made based on the assumption of an increase in MJNE stock due to the sales agreement with the Company. The Company recorded the investment in MJNE at fair value with changes in the fair value reported through the income statement as the stock is traded on the OTC market. Investment is classed with Level 1 of the valuation hierarchy. Fair value for the investment is based on quoted prices in active markets.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the investment measured at fair value on a recurring basis as of December 31, 2021:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value Measurements Using Quoted Prices in Active Market (Level 1)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Mark to Market</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22,731</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">412</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,143</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the investment measured at fair value on a recurring basis as of December 31, 2020:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value Measurements Using Quoted Prices in Active Market (Level 1)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Mark to Market</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">24,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,269</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22,731</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 150000 85714 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the investment measured at fair value on a recurring basis as of December 31, 2021:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value Measurements Using Quoted Prices in Active Market (Level 1)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Mark to Market</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22,731</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">412</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,143</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the investment measured at fair value on a recurring basis as of December 31, 2020:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value Measurements Using Quoted Prices in Active Market (Level 1)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Mark to Market</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">24,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,269</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22,731</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 22731 412 23143 24000 -1269 22731 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 6. INVENTORIES</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inventories are stated at average cost. If the cost of the inventories exceeds their market value, adjustments are recorded to write down excess inventory to its net realizable value. Throughout the year, the Company did not have independent third party counts of its inventory due to the Coronavirus (COVID-19) pandemic and recorded the write down of inventories amounting to $0.7 million and $0.3 million, approximately, in 2021 and 2020, respectively. The Company’s inventories consist primarily of merchandise available for resale.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vapor Business</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">188,793</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">304,614</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Grocery Business</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,332,406</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,444,632</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,521,199</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,749,246</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inventories are stated at average cost. If the cost of the inventories exceeds their market value, adjustments are recorded to write down excess inventory to its net realizable value. Throughout the year, the Company did not have independent third party counts of its inventory due to the Coronavirus (COVID-19) pandemic and recorded the write down of inventories amounting to $0.7 million and $0.3 million, approximately, in 2021 and 2020, respectively. The Company’s inventories consist primarily of merchandise available for resale.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vapor Business</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">188,793</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">304,614</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Grocery Business</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,332,406</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,444,632</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,521,199</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,749,246</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 700000 300000 188793 304614 1332406 1444632 1521199 1749246 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 7. NOTES RECEIVABLE AND OTHER INCOME</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On September 6, 2018, the Company entered into a secured, 36-month promissory note with VPR Brands L.P. for $582,260. The Note bears an interest rate of 7%, which payments thereunder are $4,141 weekly. The Company records all proceeds related to the interest of the Note as interest income as proceeds are received.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On August 31, 2021, the Company amended and restated the Secured Promissory Note (the "Note") with VPRB Brands L.P. for the outstanding balance in the note of $268,126. The Note bears an interest rate of 7%, which payments thereunder are $1,500 weekly, with such payments commencing as of September 03, 2021. The Note has a balloon payment of $213,028 for all remaining accrued interest and principal balance due in the final week of the 1-year extension of the Note.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A summary of the Note as of December 31, 2021 and 2020 is presented below:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="7" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Promissory Note</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">247,915</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">304,511</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the years ended December 31, 2021 and 2020, the Company had notes receivable collections of approximately $57,000 and $39,000, respectively. These collections are recorded to other income in the Consolidated Statement of Operations.</div> P36M 582260 0.07 4141 268126 0.07 1500 213028 P1Y <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A summary of the Note as of December 31, 2021 and 2020 is presented below:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="7" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Promissory Note</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">247,915</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">304,511</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 247915 304511 57000 39000 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 8. PROPERTY &amp; EQUIPMENT</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Property and equipment consists of the following</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Displays</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">305,558</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">305,558</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Furniture and fixtures</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">246,496</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">246,496</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leasehold improvements</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">136,504</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">128,004</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Computer hardware &amp; equipment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">151,924</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">143,082</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">315,788</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,711</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,156,270</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,099,851</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: accumulated depreciation and amortization</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(979,282</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(869,132</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total property and equipment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">176,988</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">230,719</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company incurred approximately $0.1 million and $0.1 million of depreciation expense for the years ended December 31, 2021 and 2020, respectively.</div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Property and equipment consists of the following</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Displays</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">305,558</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">305,558</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Furniture and fixtures</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">246,496</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">246,496</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leasehold improvements</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">136,504</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">128,004</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Computer hardware &amp; equipment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">151,924</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">143,082</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">315,788</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,711</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,156,270</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,099,851</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: accumulated depreciation and amortization</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(979,282</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(869,132</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total property and equipment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">176,988</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">230,719</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 305558 305558 246496 246496 136504 128004 151924 143082 315788 276711 1156270 1099851 979282 869132 176988 230719 100000 100000 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 9. GOODWILL AND INTANGIBLE ASSETS</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">916,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">956,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Impairment of goodwill-retail business</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(40,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">916,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">916,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible assets, net are as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Useful Lives (Years)</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross Carrying Amount</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated Amortization</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Carrying Amount</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer relationships</div> </td> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4-5 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">883,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(685,823</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">197,177</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trade names</div> </td> <td style="vertical-align: bottom; width: 32%;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8-10 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">923,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(536,661</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">386,339</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patents</div> </td> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">372,165</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(122,233</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">249,932</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-compete</div> </td> <td style="vertical-align: bottom; width: 32%;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">238,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(133,646</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">104,354</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Website</div> </td> <td style="vertical-align: bottom; width: 32%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">10,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(209</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">9,791</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intangible assets, net</div> </td> <td style="vertical-align: bottom; width: 32%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,426,165</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(1,478,572</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">947,593</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, <span style="text-indent: 0pt;">2020</span></div> </td> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Useful Lives (Years)</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross Carrying Amount</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated Amortization</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Carrying Amount</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer relationships</div> </td> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4-10 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">883,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(475,073</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">407,927</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trade names</div> </td> <td style="vertical-align: bottom; width: 32%;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8-10 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">923,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(441,786</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">481,214</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patents</div> </td> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">359,665</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(85,641</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">274,024</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-compete</div> </td> <td style="vertical-align: bottom; width: 32%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">174,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(88,813</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">85,187</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intangible assets, net</div> </td> <td style="vertical-align: bottom; width: 32%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,339,665</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,091,313</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,248,352</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amortization expense was approximately $0.4 million for the years ended December 31, 2021 and 2020.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Acquisition of EIR Hydration</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On </span>November 30, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the Company, through its wholly owned subsidiary, Healthy Choice Wellness Center, LLP, acquired EIR Hydration, an IV therapy center located in Roslyn Heights, NY. The cost of the transaction was $</span>75,000<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and it was treated as an asset purchase</span>.</div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The weighted-average remaining amortization period of the Company’s amortizable intangible assets is approximately 6 years as of December 31, 2021. The estimated future amortization of the intangible assets is as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">For the years ending December 31,</div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">2022</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">389,456</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">2023</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">150,591</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">2024</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">150,591</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">2025</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">143,549</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">2026</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">48,655</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Thereafter</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">64,751</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">947,593</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The changes in the carrying amount of goodwill for the years ended December 31, 2021 and 2020 are as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">916,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">956,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Impairment of goodwill-retail business</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(40,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">916,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">916,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 916000 956000 0 40000 916000 916000 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible assets, net are as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Useful Lives (Years)</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross Carrying Amount</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated Amortization</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Carrying Amount</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer relationships</div> </td> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4-5 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">883,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(685,823</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">197,177</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trade names</div> </td> <td style="vertical-align: bottom; width: 32%;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8-10 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">923,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(536,661</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">386,339</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patents</div> </td> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">372,165</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(122,233</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">249,932</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-compete</div> </td> <td style="vertical-align: bottom; width: 32%;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">238,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(133,646</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">104,354</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Website</div> </td> <td style="vertical-align: bottom; width: 32%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">10,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(209</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">9,791</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intangible assets, net</div> </td> <td style="vertical-align: bottom; width: 32%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,426,165</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(1,478,572</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">947,593</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, <span style="text-indent: 0pt;">2020</span></div> </td> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Useful Lives (Years)</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross Carrying Amount</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated Amortization</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Carrying Amount</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Customer relationships</div> </td> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4-10 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">883,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(475,073</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">407,927</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trade names</div> </td> <td style="vertical-align: bottom; width: 32%;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8-10 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">923,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(441,786</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">481,214</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patents</div> </td> <td style="vertical-align: bottom; width: 32%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">359,665</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(85,641</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">274,024</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-compete</div> </td> <td style="vertical-align: bottom; width: 32%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4 years</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">174,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(88,813</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">85,187</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 32%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intangible assets, net</div> </td> <td style="vertical-align: bottom; width: 32%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,339,665</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,091,313</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,248,352</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> P4Y P5Y 883000 685823 197177 P8Y P10Y 923000 536661 386339 P10Y 372165 122233 249932 P4Y 238000 133646 104354 P4Y 10000 209 9791 2426165 1478572 947593 P4Y P10Y 883000 475073 407927 P8Y P10Y 923000 441786 481214 P10Y 359665 85641 274024 P4Y 174000 88813 85187 2339665 1091313 1248352 400000 400000 75000 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The weighted-average remaining amortization period of the Company’s amortizable intangible assets is approximately 6 years as of December 31, 2021. The estimated future amortization of the intangible assets is as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">For the years ending December 31,</div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">2022</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">389,456</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">2023</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">150,591</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">2024</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">150,591</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">2025</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">143,549</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">2026</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">48,655</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Thereafter</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">64,751</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">947,593</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> P6Y 389456 150591 150591 143549 48655 64751 947593 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 10. CONTRACT LIABILITIES</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company’s contract liabilities consist of customer deposits, gift cards and loyalty rewards, for which the Company has a performance obligation to deliver products when customers redeem balances or terms expire through breakage. The Company’s breakage policy is <span style="-sec-ix-hidden:Fact_f17d55ecaf2a4c1cbd18b949c7e556e8">twenty-four months</span> for gift cards, twelve months for Grocery loyalty rewards, and six months for Vapor loyalty rewards. As such, all contract liabilities are expected to be recognized within a <span style="-sec-ix-hidden:Fact_4a56c55934af4b728ca3a86ba05e1681">twenty-four month</span> period.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A summary of the contract liabilities activity for the years ended December 31, 2021 and 2020 is presented below:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year ended December 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance as of January1,</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">21,262</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26,823</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Issued</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">39,469</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">53,929</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Redeemed</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(37,463</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(58,263</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Breakage recognized</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(90</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,227</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance as of December 31,</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">23,178</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21,262</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> P12M P6M <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A summary of the contract liabilities activity for the years ended December 31, 2021 and 2020 is presented below:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year ended December 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance as of January1,</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">21,262</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26,823</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Issued</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">39,469</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">53,929</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Redeemed</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(37,463</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(58,263</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Breakage recognized</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(90</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,227</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance as of December 31,</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">23,178</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21,262</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 21262 26823 39469 53929 37463 58263 -90 -1227 23178 21262 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 11. LINE OF CREDIT AND DEBT</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table provides a breakdown of the Company's debt as of December 31, 2021 and 2020 is presented below:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 69.87%; vertical-align: top; background-color: #CCEEFF;"> </td> <td colspan="5" style="width: 30.13%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31,</div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 14.58%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td style="width: 2.4%; vertical-align: top; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 13.14%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2020</span></div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Line of Credit</div> </td> <td style="width: 3.37%; vertical-align: bottom;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 11.22%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">418,036</div> </td> <td style="width: 2.4%; vertical-align: bottom;"> </td> <td style="width: 2.4%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 10.74%; vertical-align: bottom;"> <div style="text-align: right; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2,000,000</span></div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Term Loan Credit Agreement</div> </td> <td style="width: 3.37%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 11.22%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.74%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">800,924</span></div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Paycheck Protection Program</div> </td> <td style="width: 3.37%; vertical-align: bottom;"> </td> <td style="width: 11.22%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td style="width: 2.4%; vertical-align: bottom;"> </td> <td style="width: 2.4%; vertical-align: bottom;"> </td> <td style="width: 10.74%; vertical-align: bottom;"> <div style="text-align: right; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">882,264</span></div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loan and Security Agreement ("PPE Loan")</div> </td> <td style="width: 3.37%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 11.22%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.74%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">1,232,414</span></div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other debt</div> </td> <td style="width: 3.37%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td> <td style="width: 11.22%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3,419</div> </td> <td style="width: 2.4%; vertical-align: bottom;"> </td> <td style="width: 2.4%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td> <td style="width: 10.74%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: right; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">5,891</span></div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total Line of Credit and Debt</div> </td> <td style="width: 3.37%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 11.22%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">421,455</div> </td> <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 10.74%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,921,493</div> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Revolving Line of Credit</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On </span>November 3, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the Company entered into an agreement for a new revolving line of credit of $</span>2.0<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and a blocked/restricted deposit account (“blocked account”) with Professional Bank in Coral Gables, Florida. The agreement included a variable interest rate that it is based on a rate of </span>1.0%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> over what is earned on the collateral account. Based on the agreement with the bank, each draw request from the credit line will be </span>100%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> cash secured with moneys held from the blocked account.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Term Loan Credit Agreement</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On December 31, 2018, the Company entered into a Term Loan Credit Agreement (the “Credit Agreement”) with Professional Bank, a Florida banking corporation (the “Bank”), pursuant to which the Company issued a Term Note (the “Term Note”) in the principal amount of $1,400,000 in favor of the Bank. The Term Note bears interest at a rate equal to 1.5 percentage points in excess of that rate shown in the Wall Street Journal as the prime rate, adjusted annually (which was 5.50% as of December 31, 2020 and 2021). The proceeds of the Term Note were used for acquisitions and for general working capital requirements.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On December 21, 2021, the Company paid in full the outstanding balance of $410,000 from the Term Loan.</div> <div style="text-align: left;"><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Paycheck Protection Program</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On May 15, 2020, the Company was granted a loan (the “Loan”) from Customers Bank, in the aggregate amount of $876,515, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Loan, which was in the form of a Note dated May 6, 2020 issued by the Company, matures on May 6, 2022 and bears interest at a rate of 1% per annum, payable monthly commencing on November 6, 2020. Note may be prepaid by the Borrower at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, costs used to continue group health care benefits, mortgage payments, rent, utilities, and interest on other debt obligations incurred after May 6, 2020. The Company intends to use the entire Loan amount for these qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. On December 9, 2020, the Company submitted the forgiveness application for the PPP Loan to the Small Business Bureau.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On May 3, 2021, the Company received a letter from Customers Bank to inform the Company that the PPP Loan was paid and fully forgiven by the Small Business Administration (SBA). The forgiveness of $885,227 was reported in gain on debt settlements on the consolidated statements of operations.</div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table provides a breakdown of the Company's debt as of December 31, 2021 and 2020 is presented below:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 69.87%; vertical-align: top; background-color: #CCEEFF;"> </td> <td colspan="5" style="width: 30.13%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31,</div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 14.58%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td style="width: 2.4%; vertical-align: top; background-color: #CCEEFF;"> </td> <td colspan="2" style="width: 13.14%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2020</span></div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Line of Credit</div> </td> <td style="width: 3.37%; vertical-align: bottom;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 11.22%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">418,036</div> </td> <td style="width: 2.4%; vertical-align: bottom;"> </td> <td style="width: 2.4%; vertical-align: bottom;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 10.74%; vertical-align: bottom;"> <div style="text-align: right; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2,000,000</span></div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Term Loan Credit Agreement</div> </td> <td style="width: 3.37%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 11.22%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.74%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">800,924</span></div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Paycheck Protection Program</div> </td> <td style="width: 3.37%; vertical-align: bottom;"> </td> <td style="width: 11.22%; vertical-align: bottom;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td style="width: 2.4%; vertical-align: bottom;"> </td> <td style="width: 2.4%; vertical-align: bottom;"> </td> <td style="width: 10.74%; vertical-align: bottom;"> <div style="text-align: right; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">882,264</span></div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loan and Security Agreement ("PPE Loan")</div> </td> <td style="width: 3.37%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 11.22%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.74%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">1,232,414</span></div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other debt</div> </td> <td style="width: 3.37%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td> <td style="width: 11.22%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3,419</div> </td> <td style="width: 2.4%; vertical-align: bottom;"> </td> <td style="width: 2.4%; vertical-align: bottom; border-bottom: #000000 2px solid;"> </td> <td style="width: 10.74%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: right; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">5,891</span></div> </td> </tr> <tr> <td style="width: 69.87%; vertical-align: top; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total Line of Credit and Debt</div> </td> <td style="width: 3.37%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 11.22%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">421,455</div> </td> <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 2.4%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td style="width: 10.74%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 4px double;"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,921,493</div> </td> </tr> </table> 418036 2000000 0 800924 0 882264 0 1232414 3419 5891 421455 4921493 2000000.0 0.010 1 1400000 0.015 0.0550 410000 876515 2022-05-06 0.01 monthly 885227 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 12. COMMITMENTS AND CONTINGENCIES</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Employment Agreements </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On August 13, 2018, the Company amended and restated its existing employment agreement with Jeffrey Holman, the Company’s Chief Executive Officer (the “</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Holman Employment Agreement</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">”). The Holman Employment Agreement is for an additional </span>three year<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> term and provides for an annual base salary of $</span>450<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and a target bonus for 2020 only in an amount ranging from </span>20%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to </span>200%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> of his base salaries subject to the Company meeting certain earnings before interest, taxes depreciation and amortization performance milestones. Mr. Holman is entitled to receive severance payments, including </span>two years<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> of his then base salary and other benefits in the event of a change of control, termination by the Company without cause, termination for good reason by the executive or non-renewal by the Company. Mr. Holman was also granted </span>11<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion shares of restricted common stock pursuant to the Holman Employment Agreement Amendment on the condition that </span>11<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion of his options to purchase Company common stock are forfeited. This restricted stock will vest </span>one year<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> following the date of issuance provided that the grantee remains an employee of the Company through each applicable vesting date. On August 12, 2019, the Company agreed to extend the expiration date of the vesting period for the restricted stock by </span>six months<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to February 13, 2020. On August 12, 2020, the Company agreed to extend for a second time the expiration date of the vesting period for the restricted stock by </span>six months<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to February 13, 2021. </span>The Term shall be automatically renewed for successive one-year terms unless notice of non-renewal is given by either party at least 30 days before the end of the Term. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The above description of the terms of the Holman Employment Agreement is not complete and is qualified by reference to the complete document.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On February 26, 2021, the Company entered into an amended and restated employment agreement (the “</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Employment Agreement Amendment</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">”) with the Company’s President and Chief Operating Officer, Christopher Santi. Pursuant to the Employment Agreement Amendment, Mr. Santi will continue to be employed as the Company’s President and Chief Operating Officer through January 30, 2024.  Mr. Santi will receive a base salary of $</span>0.4<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for 2021 and his salary will increase </span>10%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in each subsequent year. </span>The Term shall be automatically renewed for successive one-year terms unless notice of non-renewal is given by either party at least 30 days before the end of the Term. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The above description of the terms of the Santi Employment Agreement is not complete and is qualified by reference to the complete document.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Legal Proceedings</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Two lawsuits were filed against the Company and its subsidiaries in connection with alleged claimed battery defects for an electronic cigarette device. Plaintiffs claim these batteries were sold by a store of the Company’s subsidiary and have sued for an undetermined amount of damages (other than a total of $0.4 million of medical costs). The initial complaints were filed between January 2019 and April 2019. We responded to the complaints on April 2019 and May 2019, respectively. Given the lack of information presented by the plaintiffs to date, the Company is unable to predict the outcome of these matters and, at this time, cannot reasonably estimate the possible loss or range of loss with respect to these legal proceedings.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On November 30, 2020, the Company filed a patent infringement lawsuit against Philip Morris USA, Inc. and Philip Morris Products S.A. in the U.S. District Court for the Northern District of Georgia.  The lawsuit alleges infringement on HCMC-owned patent(s) by the Philip Morris product known and marketed as “IQOS®”.  Philip Morris claims that it is currently approaching </span>14<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million users of its IQOS® product and has reportedly invested over $</span>3<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion in their smokeless tobacco products. </span>On December 3, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A.  On December 14, 2021, the Company filed an appeal of the District Court for the Northern District of Georgia’s dismissal of the Company’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. HCMC believes the Georgia Court committed legal error by dismissing its complaint for patent infringement and also by denying the Company’s motion to amend its pleading.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">From time to time the Company is involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations December 31, 2021. With respect to legal costs, we record such costs as incurred.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Fontem License Agreement</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company has a non-exclusive license to certain products with Fontem Ventures B.V. (“Fontem”). The Company will make quarterly license and royalty payments in perpetuity to Fontem, based on the sale of qualifying products as defined in the license agreement at a royalty rate of 5.25%. For the years ended December 31, 2021 and 2020, the Company recorded expenses of $12,000 and $15,000 as part of its cost of goods.</div> P3Y 450000 0.20 2 P2Y 11 11 P1Y P6M P6M P1Y P30D 400000 0.10 P1Y P30D 2 400000 14000000 3000000000 0.0525 12000 15000 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 13. STOCKHOLDERS’ EQUITY</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Equity Compensation Plans</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company’s 2015 Equity Incentive Plan, as amended (the “2015 Plan”), awards grants to employees. The plan can award up to 100 billion shares of common stock and currently 10.3 billion shares are available for grant as of December 31, 2021.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company’s 2009 Equity Incentive Plan (the “2009 Plan”) awards grants to employees, non-employee directors and consultants in connection with their retention and/or continued employment by the Company. The 2009 Plan had no shares of common stock available for grant as of December 31, 2021.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Rights Offering</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On </span>June 18, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the Company issued </span>27,046,800,310<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> shares of common stock in connection with the Rights Offering at a subscription price of $</span>0.0010<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> per share, generating gross proceeds of $</span>27.0<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million. The Company incurred direct financing costs of $</span>2.7<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in connection with the offering resulting in net proceeds to the Company of $</span>24.3<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Exchange Agreement</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On </span>March 29, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the Company entered into exchange agreements with the holders of the $</span>2.7<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million Loan and Security Agreement (the "Credit Agreement"). The agreement with the holders of the Company’s indebtedness (the “Notes”) in an aggregate amount of $</span>1.3<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million to exchange the Notes for </span>1,172,964,218<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> shares at a conversion price of $</span>0.0011<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The Notes were issued pursuant to the Credit Agreement dated as of </span>August 18, 2020<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, among The Vape Store, Inc., the Company, Healthy Choice Markets, Inc., Sabby Healthcare Master Fund, Ltd., and Sabby Volatility Warrant Master Fund, Ltd.  In connection with the Exchange, the Credit Agreement and all related loan documents was terminated and the Holder’s on the assets of the Company and its subsidiaries was cancelled.  The Company recognized a loss on debt extinguishment of $</span>0.1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the year ended </span>December 31, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Preferred Stock</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company’s amended and restated articles of incorporation authorizes the Company’s Board of Directors to issue up to 1,000,000 shares of “blank check” preferred stock, having a $0.001 par value, in one or more series without stockholder approval. Each such series of preferred stock may have such number of shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges as determined by the Company’s Board of Directors. See below for details associated with the designation of the 1,000,000 shares of the Series A preferred stock.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Series C Convertible Preferred Stock</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On November 17, 2020, the Company finalized the closing of the stock exchange with certain holders of its Series B Stock to exchange all the Series B Stock for 20,150 shares of Series C Convertible Preferred Stock (the “Series C Stock”). Each share of Series C Stock has a stated value equal to $1,000 and is convertible into Common Stock on a fixed basis at a conversion price of $0.0001 per share.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2021 and 2020, the Company issued 162.8 billion shares and 38.7 billion shares of Company common stock in connection with the exercise of Series C stock.</div> <div><br/> </div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Series D Convertible Preferred Stock</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On </span>February 7, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the Company entered into a Securities Purchase Agreement, pursuant to which the Company sold and issued </span>5,000<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> shares of its Series D Convertible Preferred Stock (the “Preferred Stock”) to accredited investors for $</span>1,000<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> per share or an aggregate subscription of $</span>5.0<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million. As of Dec</span>ember 31, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the Company has issued </span>6.6<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion shares of Company common stock in connection with the exercise of </span>4,200<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> shares of the Series D Convertible Preferred Stock at a conversion price of $</span>0.00064<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> per share. The conversion price for the exercise of the preferred stock was reset to the </span>80%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> of the lowest daily volume-weighted average price ("VWAP") during the </span>5<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Trading Days immediately preceding the effective date of </span>August 11, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Warrants</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">October 5, 2016, the Company’s amended and restated its Series A Warrant Standstill Agreements (the "Amended Standstill Agreements") to permit each holder (each, a "Holder") to effect a "cashless" exercise of the Series A Warrants only on dates when the closing bid price used to determine the "net number" of shares to be issued upon exercise is at or above $0.00. The shares issuable upon the exercise of the Series A Warrants are calculated (1) using a Black Scholes Value of 1,517,936 per share and a closing stock bid price at or above 0.00 and (2) the Company will deliver only common stock upon exercise of the Series A Warrants.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On July 27, 2020, the Company's Series A Warrants expired and the balance of outstanding warrants not exercised was 355,661 warrants.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the year ended December 31, 2020, the Company issued 3,466,153 shares of the Company Common Stock in connection with the exercise of the Series A Warrant.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Modification of share-based payment awards to officers</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On August 13, 2018, the Compensation Committee of the Company approved a modification of share-based payment awards to the Chief Executive Officer and Chief Operating Officer of the Company. As part of the share modification, the Chief Executive Officer and Chief Operating Officer were granted 11 billion and 8 billion shares of restricted common stock on the condition that the same number of shares from their options to purchase the Company’s common stock are forfeited. However, the shares were issued to the officers and have been reflected in the statement of stockholders’ equity. Initially, this restricted stock was schedule to vest one year following the date of issuance provided that the grantee remains an employee of the Company through the vesting date.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On August 12, 2019, the Company agreed to extend the expiration date of the vesting period for the restricted stock by six months to February 13, 2020.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On August 12, 2020, the Company agreed to extend for a second time the expiration date of the vesting period for the restricted stock by six months to February 13, 2021.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On </span>January 14, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the Compensation Committee of the Company approved an issuance of restricted stock to the Officers and a Director of the Company, in consideration for agreeing to a new vesting schedule for the existing awarded restricted stock. Each individual was granted a </span>10%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> increase from the original award agreement for a total of </span>2.3<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion shares of restricted common stock, which will vest quarterly in equal amounts until </span>December 31, 2022<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, provided that the grantee remains an employee of the Company through the vesting date.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Restricted Stock</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On August 13, 2018, the Compensation Committee of the Company approved an issuance of restricted stock to the Chief Financial Officer (the "Officer") of the Company. The Officer was granted 3 billion shares of restricted common stock, which will vest one year following the date of issuance, provided that the grantee remains an employee of the Company through the vesting date.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On August 12, 2019, the Company agreed to extend the expiration date of the vesting period for the restricted stock by six months to February 13, 2020.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On August 12, 2020, the Company agreed to extend for a second time the expiration date of the vesting period for the restricted stock by six months to February 13, 2021.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On </span>January 14, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the Compensation Committee of the Company approved an issuance of restricted stock to the Officers and a Director of the Company, in consideration for agreeing to a new vesting schedule for the existing awarded restricted stock. Each individual was granted a </span>10%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> increase from the original award agreement for a total of </span>2.3<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion shares of restricted common stock, which will vest quarterly in equal amounts until </span>December 31, 2022<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, provided that the grantee remains an employee of the Company through the vesting date.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On </span>March 30, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the Company and the Officers and a Director of the Company agreed to forfeit a total of </span>3.09<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion of restricted shares of common stock that were due to vest on </span>March 31, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On </span>June 29, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, the Company and the Officers and a Director of the Company agreed to forfeit a total of </span>3.09<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion of restricted shares of common stock that were due to vest on </span>June 30, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Stock Options</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2021 and 2020, the Company did not grant any options for the purchase of shares of its common stocks.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A summary of option activity during the years ended December 31, 2021 and 2020 is as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number of Options</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Remaining Term (Yrs.)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Aggregate Intrinsic Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding, January 1, <span style="text-indent: 0pt;">2020</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">69,862,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Options granted</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Options forfeited or expired</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding, December 31, <span style="text-indent: 0pt;">2020</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">69,862,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">6</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Options granted</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Options exercised</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(2,275,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Options forfeited or expired</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding, December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">67,587,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exercisable at December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">67,587,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense of approximately $34,375 and $78,029, respectively, in connection with the amortization of stock options, net of recovery of stock-based charges for forfeited stock options. Stock-based compensation expense is included as part of selling, general and administrative expense in the accompanying consolidated statements of operations.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Income (Loss) per Share</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic income (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon (a) the exercise of stock options (using the treasury stock method); (b) the conversion of Series A convertible preferred stock; (c) the exercise of warrants (using the if-converted method); (d) the vesting of restricted stock units; and (e) the conversion of convertible notes payable. Diluted income (loss) per share excludes the potential common shares, as their effect is antidilutive. The following table summarizes the Company’s securities that have been excluded from the calculation of basic and dilutive income (loss) per share as their effect would be anti-dilutive:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preferred stock</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,250,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">162,771,153,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock options</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">67,587,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">69,862,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">68,837,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">232,633,383,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 100000000000 10300000000 0 27046800310 0.0010 27000000.0 2700000 24300000 2700000 1300000 1172964218 0.0011 -100000 1000000 0.001 1000000 20150 1000 0.0001 162800000000 38700000000 5000 1000 5000000.0 6600000000 4200 0.00064 0.80 P5D 0.00 1517936 0.00 355661 3466153 11000000000 8000000000 P1Y P1Y P6M P6M P6M P6M 0.10 2300000000 3000000000 P1Y P6M P6M 0.10 2300000000 3090000000.00 3090000000.00 0 0 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A summary of option activity during the years ended December 31, 2021 and 2020 is as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number of Options</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average Remaining Term (Yrs.)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Aggregate Intrinsic Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding, January 1, <span style="text-indent: 0pt;">2020</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">69,862,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Options granted</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Options forfeited or expired</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding, December 31, <span style="text-indent: 0pt;">2020</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">69,862,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">6</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Options granted</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Options exercised</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(2,275,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Options forfeited or expired</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding, December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">67,587,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exercisable at December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">67,587,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.00</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 69862230680 0.00 P7Y 0 0 0.00 0 0.00 0 69862230680 0.00 P6Y 0 0.00 2275000000 0.00 0 0.00 67587230680 0.00 P5Y 0 67587230680 0.00 P5Y 0 34375 78029 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic income (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon (a) the exercise of stock options (using the treasury stock method); (b) the conversion of Series A convertible preferred stock; (c) the exercise of warrants (using the if-converted method); (d) the vesting of restricted stock units; and (e) the conversion of convertible notes payable. Diluted income (loss) per share excludes the potential common shares, as their effect is antidilutive. The following table summarizes the Company’s securities that have been excluded from the calculation of basic and dilutive income (loss) per share as their effect would be anti-dilutive:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preferred stock</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,250,000,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">162,771,153,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock options</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">67,587,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">69,862,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">68,837,230,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">232,633,383,680</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 1250000000 162771153000 67587230680 69862230680 68837230680 232633383680 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 14. LEASE</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company has various lease agreements with terms up to 20 years, including leases of retail stores, headquarter and equipment. All the leases are classified as operating leases.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of December 31, 2021.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Maturity of Lease Liabilities by Fiscal Year</span></div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2022</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">572,335</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2023</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">450,877</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2024</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">342,005</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2025</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">337,685</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2026</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">267,759</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thereafter</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,941,250</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total undiscounted operating lease payments</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,911,911</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: Imputed interest</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(789,562</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Present value of operating lease liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3,122,349</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following summarizes the Company's operating leases:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Balance Sheet Classification</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-indent: -7pt;"><span style="text-indent: 0pt;">December 31, 2020</span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Right of use asset</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3,543,930</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,078,621</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating lease liability, current</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">437,328</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">474,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating lease liability, net of current</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,685,021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,114,521</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total operating lease liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3,122,349</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,589,207</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The amortization of the right-of-use asset of $534,691 was included in operating cash flows.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic;">Other Information</span></div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted-average remaining lease term for operating leases</div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10 years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted-average discount rate for operating leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.74</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Rent expense for the years ended December 31, 2021 and 2020 was approximately $0.9 million and $1.0 million, respectively, is included in selling, general and administrative expenses in the accompanying consolidated statement of operations.</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table represents the components of lease cost are as follows for twelve months ended December 31, 2021:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating lease cost</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">389,538</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Variable lease cost</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">372,608</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Short-term lease cost</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">139,291</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total rent expense</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">901,437</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The aggregate cash payments under the leasing arrangement was approximately $467,000 for the year ended December 31, 2021 and was included in operating cash flows.</div> P20Y <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of December 31, 2021.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Maturity of Lease Liabilities by Fiscal Year</span></div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2022</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">572,335</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2023</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">450,877</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2024</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">342,005</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2025</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">337,685</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-indent: 0pt;">2026</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">267,759</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thereafter</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,941,250</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total undiscounted operating lease payments</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,911,911</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: Imputed interest</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(789,562</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Present value of operating lease liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3,122,349</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 572335 450877 342005 337685 267759 1941250 3911911 789562 3122349 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following summarizes the Company's operating leases:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Balance Sheet Classification</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-indent: -7pt;"><span style="text-indent: 0pt;">December 31, 2020</span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Right of use asset</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3,543,930</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,078,621</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating lease liability, current</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">437,328</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">474,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating lease liability, net of current</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,685,021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,114,521</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total operating lease liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3,122,349</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,589,207</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic;">Other Information</span></div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted-average remaining lease term for operating leases</div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10 years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted-average discount rate for operating leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.74</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div> </td> </tr> </table> 3543930 4078621 437328 474686 2685021 3114521 3122349 3589207 534691 P10Y 0.0474 900000 1000000.0 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table represents the components of lease cost are as follows for twelve months ended December 31, 2021:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating lease cost</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">389,538</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Variable lease cost</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">372,608</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Short-term lease cost</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">139,291</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total rent expense</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">901,437</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 389538 372608 139291 901437 467000 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 15. INCOME TAXES</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company did not have a provision for income taxes (current or deferred tax expense) for tax years ended December 31, 2021 and 2020. The following is a reconciliation of the expected tax expense (benefit) at the U.S. statutory rate to the actual tax expense (benefit) reflected in the accompanying statement of operations:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">U.S. federal statutory rate</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(847,867</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(781,704</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">State and local taxes, net of federal benefit</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(111,900</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(132,291</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Change in valuation allowance</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">734,615</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,201,450</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">True-up &amp; deferred adjustment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">11,441</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,614</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock based compensation</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">8,171</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19,159</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Forgiveness of PPP loan</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(210,432</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other permanent items</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">935</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Change in tax rate</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">89,360</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,429</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expired warrants</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(422,655</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">326,612</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">89,063</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of December 31, 2021 and 2020, the Company’s deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred tax assets:</div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net operating losses</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">14,136,491</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,366,483</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inventory reserves and allowances</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">30,156</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">31,249</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accrued Expenses and Deferred Income</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">136,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">45,358</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Charitable contribution</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5,134</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,303</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock based compensation</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,903,413</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,966,058</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net book value of fixed assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,961</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,574</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net book value of intangible assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">671,954</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">731,365</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ASC 842 - Lease Accounting</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">33,891</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">32,681</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total deferred tax assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">16,919,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16,185,071</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net deferred tax assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">16,919,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16,185,071</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Valuation allowance</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(16,919,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(16,185,071</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net deferred tax assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the positive and negative evidence available, management has determined that a valuation allowance is required at </span>December 31, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and 2020 to reduce the deferred tax assets to amounts that are more likely than not to be realized. The Company’s valuation increased by $</span>734,615<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and $</span>1,201,450<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the tax years ended 2021 and 2020, respectively. Should the factors underlying management’s analysis change, future valuation adjustments to the Company’s net deferred tax assets may be necessary.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">At </span>December 31, 2021<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> the Company had U.S. federal and state net operating loss carryforwards (“NOLS”) of </span>61.0<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and </span>46.6<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, respectively. Federal NOLs of $</span>46.3<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million expire beginning in 2032 through 2037 and $</span>14.7<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million do not expire and are subject to 80% of taxable income under Internal Revenue Code Section 172. State NOLs of </span>$35.4<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million expire beginning in 2032 through 2037 and $</span>11.2<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million do not expire and maybe subject to income limitations under each State statute. Utilization of our NOLS may be subject to an annual limitation under section 382 and similar state provisions of the Internal Revenue Code due to changes of ownership that may have occurred or that could occur in the future, as defined under the regulations.</span></div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On March 27, 2020, the CARES Act was enacted in response to COVID-19 pandemic, which, among other things, outlines the provisions of the Paycheck Protection Program (the “PPP”). The Company determined that it met the criteria to be eligible to obtain a loan under the PPP because, among other reasons, in light of the COVID-19 outbreak and the uncertainty of economic conditions related thereto, the loan was considered necessary to support the Company’s ongoing operations and retain all its employees. Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of loan granted under the program. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The Company submitted its application for 100% loan forgiveness and in May 2021 the loan was 100% forgiven by the SBA. As a result, the Company recorded a gain on the forgiveness of the loan in the amount of $885,226.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company files a federal income tax return and income tax returns in various state tax jurisdictions and the Company is generally no longer subject examinations by federal and state tax authorities for years before 2018.</span></div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company did not have a provision for income taxes (current or deferred tax expense) for tax years ended December 31, 2021 and 2020. The following is a reconciliation of the expected tax expense (benefit) at the U.S. statutory rate to the actual tax expense (benefit) reflected in the accompanying statement of operations:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">U.S. federal statutory rate</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(847,867</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(781,704</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">State and local taxes, net of federal benefit</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(111,900</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(132,291</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Change in valuation allowance</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">734,615</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,201,450</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">True-up &amp; deferred adjustment</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">11,441</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,614</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock based compensation</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">8,171</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19,159</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Forgiveness of PPP loan</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(210,432</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other permanent items</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">935</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Change in tax rate</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">89,360</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,429</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expired warrants</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(422,655</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">326,612</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">89,063</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> -847867 -781704 -111900 -132291 734615 1201450 11441 23614 8171 19159 -210432 0 0 935 89360 2429 0 -422655 326612 89063 0 0 <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of December 31, 2021 and 2020, the Company’s deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred tax assets:</div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net operating losses</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">14,136,491</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,366,483</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inventory reserves and allowances</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">30,156</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">31,249</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accrued Expenses and Deferred Income</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">136,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">45,358</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Charitable contribution</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5,134</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,303</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock based compensation</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,903,413</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,966,058</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net book value of fixed assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,961</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,574</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net book value of intangible assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">671,954</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">731,365</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ASC 842 - Lease Accounting</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">33,891</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">32,681</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total deferred tax assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">16,919,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16,185,071</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net deferred tax assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">16,919,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16,185,071</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Valuation allowance</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(16,919,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(16,185,071</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net deferred tax assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 14136491 13366483 30156 31249 136686 45358 5134 5303 1903413 1966058 1961 6574 671954 731365 33891 32681 16919686 16185071 16919686 16185071 16919686 16185071 0 0 734615 1201450 61000000.0 46600000 46300000 14700000 35400000 11200000 885226 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 16. SEGMENT INFORMATION</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Management determines the reportable segments based on the internal reporting used by our executives to evaluate performance and to assess where to allocate resources. The Company evaluates segment performance based on the segment gross profit before corporate expenses.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Summarized below are the total net sales and segment operating profit for each reporting segment:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Sales</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Segment Gross Profit</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vapor</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,084,813</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,458,945</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,245,214</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,425,140</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Grocery</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">11,235,041</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,461,800</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4,047,340</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,352,081</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13,319,854</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,920,745</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5,292,554</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,777,221</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate expenses</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">10,033,048</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,225,593</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating loss</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(4,740,494</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3,448,372</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate other income (expense), net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">703,035</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(274,020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(4,037,459</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3,722,392</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the year ended December 31, 2021 depreciation and amortization was approximately $1,000 and $0.5 million for Vapor and Grocery, respectively.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the year ended December 31, 2020 depreciation and amortization was approximately $10,000 and $0.5 million for Vapor and Grocery, respectively.</div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Summarized below are the total net sales and segment operating profit for each reporting segment:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Sales</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Segment Gross Profit</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vapor</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2,084,813</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,458,945</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1,245,214</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,425,140</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Grocery</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">11,235,041</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,461,800</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4,047,340</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,352,081</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13,319,854</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,920,745</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5,292,554</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,777,221</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate expenses</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">10,033,048</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,225,593</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating loss</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(4,740,494</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3,448,372</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate other income (expense), net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">703,035</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(274,020</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(4,037,459</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3,722,392</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div> </td> </tr> </table> 2084813 2458945 1245214 1425140 11235041 11461800 4047340 4352081 13319854 13920745 5292554 5777221 10033048 9225593 -4740494 -3448372 703035 -274020 -4037459 -3722392 1000 500000 10000 500000 <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Note 17. SUBSEQUENT EVENTS</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Acquisition of Mother Earth's Storehouse</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On February 8, 2022, the Company through its wholly owned subsidiary, Healthy Choice Markets 3, LLC, entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Mother Earth’s Storehouse Inc. (“HCM3”) and its shareholders.  Pursuant to the Purchase Agreement, HCM3 acquired certain assets and assume certain liabilities related to Mother Earth’s grocery stores in Kingston and Saugerties, New York.  The Company intends to continue to operate the grocery stores under their existing name.  The cash purchase price under the Purchase Agreement is approximately $3.9 million, with an additional $677,500 paid for inventory at closing.  In addition, the Company assumed a lease obligation for the Kingston, NY store and entered into an employment agreement with the store manager.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In connection with the HCM3 acquisition of the assets of Mother Earth's, a wholly owned subsidiary of HCMC acquired for approximately $575,000 the historic building that houses the Saugerties, NY store.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">John Ollet Employment Agreement</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On February 02, 2022, the Company entered into a Second Amended and Restated Employment Agreement (the “<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Employment Agreement Amendment</span>”) with the Company’s Chief Financial Officer, John Ollet.  Pursuant to the Employment Agreement Amendment, Mr. Ollet will continue to be employed as the Company’s Chief Financial Officer through February 14, 2025.  Mr. Ollet will receive a base salary of $300,000 for 2022 and his salary will increase 10% in each subsequent calendar year.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Patent infringement litigation</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On December 31, 2021, the District Court for the Northern District of Georgia effectively dismissed HCMC’s patent infringement action against Philip Morris USA, Inc. and Philip Morris Products S.A. In connection with such dismissal, the defendants sought to recover attorney’s fees from the Plaintiff. On February 22, 2022, the District Court for the Northern District of Georgia granted the defendant’s an award of approximately $575,000 in attorneys’ fees to be paid by the Company. The Company has fully provisioned this amount as of December 31, 2021.</div> 3900000 677500 575000 300000 0.10 575000 EXCEL 98 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 99 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 100 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 101 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 229 347 1 false 83 0 false 9 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://healthiercmc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://healthiercmc.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://healthiercmc.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 030000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 060100 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS Sheet http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopments ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS Notes 7 false false R8.htm 060200 - Disclosure - LIQUIDITY Sheet http://healthiercmc.com/role/Liquidity LIQUIDITY Notes 8 false false R9.htm 060300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://healthiercmc.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 060400 - Disclosure - DISAGGREGATION OF REVENUES Sheet http://healthiercmc.com/role/DisaggregationOfRevenues DISAGGREGATION OF REVENUES Notes 10 false false R11.htm 060500 - Disclosure - INVESTMENT Sheet http://healthiercmc.com/role/Investment INVESTMENT Notes 11 false false R12.htm 060600 - Disclosure - INVENTORIES Sheet http://healthiercmc.com/role/Inventories INVENTORIES Notes 12 false false R13.htm 060700 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME Notes http://healthiercmc.com/role/NotesReceivableAndOtherIncome NOTES RECEIVABLE AND OTHER INCOME Notes 13 false false R14.htm 060800 - Disclosure - PROPERTY & EQUIPMENT Sheet http://healthiercmc.com/role/PropertyEquipment PROPERTY & EQUIPMENT Notes 14 false false R15.htm 060900 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://healthiercmc.com/role/GoodwillAndIntangibleAssets GOODWILL AND INTANGIBLE ASSETS Notes 15 false false R16.htm 061000 - Disclosure - CONTRACT LIABILITIES Sheet http://healthiercmc.com/role/ContractLiabilities CONTRACT LIABILITIES Notes 16 false false R17.htm 061100 - Disclosure - LINE OF CREDIT AND DEBT Sheet http://healthiercmc.com/role/LineOfCreditAndDebt LINE OF CREDIT AND DEBT Notes 17 false false R18.htm 061200 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://healthiercmc.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 18 false false R19.htm 061300 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://healthiercmc.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 19 false false R20.htm 061400 - Disclosure - LEASE Sheet http://healthiercmc.com/role/Lease LEASE Notes 20 false false R21.htm 061500 - Disclosure - INCOME TAXES Sheet http://healthiercmc.com/role/IncomeTaxes INCOME TAXES Notes 21 false false R22.htm 061600 - Disclosure - SEGMENT INFORMATION Sheet http://healthiercmc.com/role/SegmentInformation SEGMENT INFORMATION Notes 22 false false R23.htm 061700 - Disclosure - SUBSEQUENT EVENTS Sheet http://healthiercmc.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 23 false false R24.htm 070100 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS (Policies) Sheet http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsPolicies ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS (Policies) Policies 24 false false R25.htm 070300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 25 false false R26.htm 080300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://healthiercmc.com/role/SummaryOfSignificantAccountingPolicies 26 false false R27.htm 080400 - Disclosure - DISAGGREGATION OF REVENUES (Tables) Sheet http://healthiercmc.com/role/DisaggregationOfRevenuesTables DISAGGREGATION OF REVENUES (Tables) Tables http://healthiercmc.com/role/DisaggregationOfRevenues 27 false false R28.htm 080500 - Disclosure - INVESTMENT (Tables) Sheet http://healthiercmc.com/role/InvestmentTables INVESTMENT (Tables) Tables http://healthiercmc.com/role/Investment 28 false false R29.htm 080600 - Disclosure - INVENTORIES (Tables) Sheet http://healthiercmc.com/role/InventoriesTables INVENTORIES (Tables) Tables http://healthiercmc.com/role/Inventories 29 false false R30.htm 080700 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME (Tables) Notes http://healthiercmc.com/role/NotesReceivableAndOtherIncomeTables NOTES RECEIVABLE AND OTHER INCOME (Tables) Tables http://healthiercmc.com/role/NotesReceivableAndOtherIncome 30 false false R31.htm 080800 - Disclosure - PROPERTY & EQUIPMENT (Tables) Sheet http://healthiercmc.com/role/PropertyEquipmentTables PROPERTY & EQUIPMENT (Tables) Tables http://healthiercmc.com/role/PropertyEquipment 31 false false R32.htm 080900 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://healthiercmc.com/role/GoodwillAndIntangibleAssetsTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://healthiercmc.com/role/GoodwillAndIntangibleAssets 32 false false R33.htm 081000 - Disclosure - CONTRACT LIABILITIES (Tables) Sheet http://healthiercmc.com/role/ContractLiabilitiesTables CONTRACT LIABILITIES (Tables) Tables http://healthiercmc.com/role/ContractLiabilities 33 false false R34.htm 081100 - Disclosure - LINE OF CREDIT AND DEBT (Tables) Sheet http://healthiercmc.com/role/LineOfCreditAndDebtTables LINE OF CREDIT AND DEBT (Tables) Tables http://healthiercmc.com/role/LineOfCreditAndDebt 34 false false R35.htm 081300 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://healthiercmc.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://healthiercmc.com/role/StockholdersEquity 35 false false R36.htm 081400 - Disclosure - LEASE (Tables) Sheet http://healthiercmc.com/role/LeaseTables LEASE (Tables) Tables http://healthiercmc.com/role/Lease 36 false false R37.htm 081500 - Disclosure - INCOME TAXES (Tables) Sheet http://healthiercmc.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://healthiercmc.com/role/IncomeTaxes 37 false false R38.htm 081600 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://healthiercmc.com/role/SegmentInformationTables SEGMENT INFORMATION (Tables) Tables http://healthiercmc.com/role/SegmentInformation 38 false false R39.htm 090100 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS (Details) Sheet http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS (Details) Details http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsPolicies 39 false false R40.htm 090200 - Disclosure - LIQUIDITY (Details) Sheet http://healthiercmc.com/role/LiquidityDetails LIQUIDITY (Details) Details http://healthiercmc.com/role/Liquidity 40 false false R41.htm 090300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Segment Reporting (Details) Sheet http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Segment Reporting (Details) Details 41 false false R42.htm 090302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Shipping and Handling (Details) Sheet http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesShippingAndHandlingDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Shipping and Handling (Details) Details 42 false false R43.htm 090304 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Cash and Cash Equivalents (Details) Sheet http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Cash and Cash Equivalents (Details) Details 43 false false R44.htm 090306 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable, Contract Assets and Contract Liabilities (Details) Sheet http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable, Contract Assets and Contract Liabilities (Details) Details 44 false false R45.htm 090308 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment (Details) Sheet http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment (Details) Details 45 false false R46.htm 090310 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Identifiable Intangible Assets and Goodwill (Details) Sheet http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesIdentifiableIntangibleAssetsAndGoodwillDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Identifiable Intangible Assets and Goodwill (Details) Details 46 false false R47.htm 090312 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-Lived Assets (Details) Sheet http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-Lived Assets (Details) Details 47 false false R48.htm 090314 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details) Sheet http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details) Details http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesTables 48 false false R49.htm 090316 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Advertising (Details) Sheet http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Advertising (Details) Details 49 false false R50.htm 090400 - Disclosure - DISAGGREGATION OF REVENUES (Details) Sheet http://healthiercmc.com/role/DisaggregationOfRevenuesDetails DISAGGREGATION OF REVENUES (Details) Details http://healthiercmc.com/role/DisaggregationOfRevenuesTables 50 false false R51.htm 090500 - Disclosure - INVESTMENT (Details) Sheet http://healthiercmc.com/role/InvestmentDetails INVESTMENT (Details) Details http://healthiercmc.com/role/InvestmentTables 51 false false R52.htm 090600 - Disclosure - INVENTORIES (Details) Sheet http://healthiercmc.com/role/InventoriesDetails INVENTORIES (Details) Details http://healthiercmc.com/role/InventoriesTables 52 false false R53.htm 090700 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME (Details) Notes http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails NOTES RECEIVABLE AND OTHER INCOME (Details) Details http://healthiercmc.com/role/NotesReceivableAndOtherIncomeTables 53 false false R54.htm 090800 - Disclosure - PROPERTY & EQUIPMENT (Details) Sheet http://healthiercmc.com/role/PropertyEquipmentDetails PROPERTY & EQUIPMENT (Details) Details http://healthiercmc.com/role/PropertyEquipmentTables 54 false false R55.htm 090900 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, Changes in Carrying Amount (Details) Sheet http://healthiercmc.com/role/GoodwillAndIntangibleAssetsChangesInCarryingAmountDetails GOODWILL AND INTANGIBLE ASSETS, Changes in Carrying Amount (Details) Details 55 false false R56.htm 090902 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, Intangible Assets, Net (Details) Sheet http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails GOODWILL AND INTANGIBLE ASSETS, Intangible Assets, Net (Details) Details 56 false false R57.htm 090904 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, Future Annual Estimated Amortization Expense (Details) Sheet http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails GOODWILL AND INTANGIBLE ASSETS, Future Annual Estimated Amortization Expense (Details) Details 57 false false R58.htm 091000 - Disclosure - CONTRACT LIABILITIES (Details) Sheet http://healthiercmc.com/role/ContractLiabilitiesDetails CONTRACT LIABILITIES (Details) Details http://healthiercmc.com/role/ContractLiabilitiesTables 58 false false R59.htm 091100 - Disclosure - LINE OF CREDIT AND DEBT (Details) Sheet http://healthiercmc.com/role/LineOfCreditAndDebtDetails LINE OF CREDIT AND DEBT (Details) Details http://healthiercmc.com/role/LineOfCreditAndDebtTables 59 false false R60.htm 091200 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://healthiercmc.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://healthiercmc.com/role/CommitmentsAndContingencies 60 false false R61.htm 091300 - Disclosure - STOCKHOLDERS' EQUITY, Equity Compensation Plans (Details) Sheet http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails STOCKHOLDERS' EQUITY, Equity Compensation Plans (Details) Details 61 false false R62.htm 091302 - Disclosure - STOCKHOLDERS' EQUITY, Rights Offering (Details) Sheet http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails STOCKHOLDERS' EQUITY, Rights Offering (Details) Details 62 false false R63.htm 091304 - Disclosure - STOCKHOLDERS' EQUITY, Exchange Agreement (Details) Sheet http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails STOCKHOLDERS' EQUITY, Exchange Agreement (Details) Details 63 false false R64.htm 091306 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock and Convertible Preferred Stock (Details) Sheet http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails STOCKHOLDERS' EQUITY, Preferred Stock and Convertible Preferred Stock (Details) Details 64 false false R65.htm 091308 - Disclosure - STOCKHOLDERS' EQUITY, Summary of Warrant Activity (Details) Sheet http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails STOCKHOLDERS' EQUITY, Summary of Warrant Activity (Details) Details 65 false false R66.htm 091310 - Disclosure - STOCKHOLDERS' EQUITY, Share-based Awards to Officers and Restricted Stock (Details) Sheet http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails STOCKHOLDERS' EQUITY, Share-based Awards to Officers and Restricted Stock (Details) Details 66 false false R67.htm 091312 - Disclosure - STOCKHOLDERS' EQUITY, Stock Options Activity (Details) Sheet http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails STOCKHOLDERS' EQUITY, Stock Options Activity (Details) Details 67 false false R68.htm 091314 - Disclosure - STOCKHOLDERS' EQUITY, Income (Loss) Per Share (Details) Sheet http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails STOCKHOLDERS' EQUITY, Income (Loss) Per Share (Details) Details 68 false false R69.htm 091400 - Disclosure - LEASE, Summary (Details) Sheet http://healthiercmc.com/role/LeaseSummaryDetails LEASE, Summary (Details) Details 69 false false R70.htm 091402 - Disclosure - LEASE, Maturity of Lease Liabilities (Details) Sheet http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails LEASE, Maturity of Lease Liabilities (Details) Details 70 false false R71.htm 091404 - Disclosure - LEASE, Balance Sheet Classification and Other Information (Details) Sheet http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails LEASE, Balance Sheet Classification and Other Information (Details) Details 71 false false R72.htm 091406 - Disclosure - LEASE, Components of Lease Cost (Details) Sheet http://healthiercmc.com/role/LeaseComponentsOfLeaseCostDetails LEASE, Components of Lease Cost (Details) Details 72 false false R73.htm 091500 - Disclosure - INCOME TAXES, Reconciliation of Tax Expense (Benefit) (Details) Sheet http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails INCOME TAXES, Reconciliation of Tax Expense (Benefit) (Details) Details 73 false false R74.htm 091502 - Disclosure - INCOME TAXES, Deferred Tax Assets and Liabilities (Details) Sheet http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails INCOME TAXES, Deferred Tax Assets and Liabilities (Details) Details 74 false false R75.htm 091504 - Disclosure - INCOME TAXES, Other Information (Details) Sheet http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails INCOME TAXES, Other Information (Details) Details 75 false false R76.htm 091600 - Disclosure - SEGMENT INFORMATION (Details) Sheet http://healthiercmc.com/role/SegmentInformationDetails SEGMENT INFORMATION (Details) Details http://healthiercmc.com/role/SegmentInformationTables 76 false false R77.htm 091700 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://healthiercmc.com/role/SubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://healthiercmc.com/role/SubsequentEvents 77 false false All Reports Book All Reports form10k.htm ex10_10.htm ex10_9.htm ex21_1.htm ex23_1.htm ex2_1-f.htm ex_3-1i.htm exhibit31_1.htm exhibit31_2.htm exhibit32_1.htm hcmc-20211231.xsd hcmc-20211231_cal.xml hcmc-20211231_def.xml hcmc-20211231_lab.xml hcmc-20211231_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 104 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10k.htm": { "axisCustom": 0, "axisStandard": 32, "contextCount": 229, "dts": { "calculationLink": { "local": [ "hcmc-20211231_cal.xml" ] }, "definitionLink": { "local": [ "hcmc-20211231_def.xml" ] }, "inline": { "local": [ "form10k.htm" ] }, "labelLink": { "local": [ "hcmc-20211231_lab.xml" ] }, "presentationLink": { "local": [ "hcmc-20211231_pre.xml" ] }, "schema": { "local": [ "hcmc-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 682, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 1, "http://healthiercmc.com/20211231": 5, "http://xbrl.sec.gov/dei/2021q4": 7, "total": 13 }, "keyCustom": 58, "keyStandard": 289, "memberCustom": 41, "memberStandard": 37, "nsprefix": "hcmc", "nsuri": "http://healthiercmc.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://healthiercmc.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060400 - Disclosure - DISAGGREGATION OF REVENUES", "role": "http://healthiercmc.com/role/DisaggregationOfRevenues", "shortName": "DISAGGREGATION OF REVENUES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060500 - Disclosure - INVESTMENT", "role": "http://healthiercmc.com/role/Investment", "shortName": "INVESTMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060600 - Disclosure - INVENTORIES", "role": "http://healthiercmc.com/role/Inventories", "shortName": "INVENTORIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060700 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME", "role": "http://healthiercmc.com/role/NotesReceivableAndOtherIncome", "shortName": "NOTES RECEIVABLE AND OTHER INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060800 - Disclosure - PROPERTY & EQUIPMENT", "role": "http://healthiercmc.com/role/PropertyEquipment", "shortName": "PROPERTY & EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060900 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "role": "http://healthiercmc.com/role/GoodwillAndIntangibleAssets", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:ContractWithCustomerAssetAndLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061000 - Disclosure - CONTRACT LIABILITIES", "role": "http://healthiercmc.com/role/ContractLiabilities", "shortName": "CONTRACT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:ContractWithCustomerAssetAndLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061100 - Disclosure - LINE OF CREDIT AND DEBT", "role": "http://healthiercmc.com/role/LineOfCreditAndDebt", "shortName": "LINE OF CREDIT AND DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061200 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://healthiercmc.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061300 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://healthiercmc.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "010000 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061400 - Disclosure - LEASE", "role": "http://healthiercmc.com/role/Lease", "shortName": "LEASE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061500 - Disclosure - INCOME TAXES", "role": "http://healthiercmc.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061600 - Disclosure - SEGMENT INFORMATION", "role": "http://healthiercmc.com/role/SegmentInformation", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061700 - Disclosure - SUBSEQUENT EVENTS", "role": "http://healthiercmc.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:SourcingAndVendorsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070100 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS (Policies)", "role": "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsPolicies", "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:SourcingAndVendorsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080400 - Disclosure - DISAGGREGATION OF REVENUES (Tables)", "role": "http://healthiercmc.com/role/DisaggregationOfRevenuesTables", "shortName": "DISAGGREGATION OF REVENUES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080500 - Disclosure - INVESTMENT (Tables)", "role": "http://healthiercmc.com/role/InvestmentTables", "shortName": "INVESTMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080600 - Disclosure - INVENTORIES (Tables)", "role": "http://healthiercmc.com/role/InventoriesTables", "shortName": "INVENTORIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:ScheduleOfAccountsNotesReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080700 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME (Tables)", "role": "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeTables", "shortName": "NOTES RECEIVABLE AND OTHER INCOME (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:ScheduleOfAccountsNotesReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080800 - Disclosure - PROPERTY & EQUIPMENT (Tables)", "role": "http://healthiercmc.com/role/PropertyEquipmentTables", "shortName": "PROPERTY & EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080900 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "role": "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081000 - Disclosure - CONTRACT LIABILITIES (Tables)", "role": "http://healthiercmc.com/role/ContractLiabilitiesTables", "shortName": "CONTRACT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081100 - Disclosure - LINE OF CREDIT AND DEBT (Tables)", "role": "http://healthiercmc.com/role/LineOfCreditAndDebtTables", "shortName": "LINE OF CREDIT AND DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081300 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://healthiercmc.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081400 - Disclosure - LEASE (Tables)", "role": "http://healthiercmc.com/role/LeaseTables", "shortName": "LEASE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081500 - Disclosure - INCOME TAXES (Tables)", "role": "http://healthiercmc.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081600 - Disclosure - SEGMENT INFORMATION (Tables)", "role": "http://healthiercmc.com/role/SegmentInformationTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfStores", "reportCount": 1, "unique": true, "unitRef": "U004", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090100 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS (Details)", "role": "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails", "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfStores", "reportCount": 1, "unique": true, "unitRef": "U004", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090200 - Disclosure - LIQUIDITY (Details)", "role": "http://healthiercmc.com/role/LiquidityDetails", "shortName": "LIQUIDITY (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U007", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Segment Reporting (Details)", "role": "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U007", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "hcmc:ShippingHandlingAndTransportationsCost", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Shipping and Handling (Details)", "role": "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesShippingAndHandlingDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Shipping and Handling (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "hcmc:ShippingHandlingAndTransportationsCost", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090304 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Cash and Cash Equivalents (Details)", "role": "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_CustomerOneMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U005", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090306 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable, Contract Assets and Contract Liabilities (Details)", "role": "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable, Contract Assets and Contract Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_CustomerOneMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U005", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231_RangeAxis_MaximumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090308 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment (Details)", "role": "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231_RangeAxis_MaximumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231_RangeAxis_MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090310 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Identifiable Intangible Assets and Goodwill (Details)", "role": "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesIdentifiableIntangibleAssetsAndGoodwillDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Identifiable Intangible Assets and Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20200101to20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090312 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-Lived Assets (Details)", "role": "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-Lived Assets (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090314 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)", "role": "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090316 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Advertising (Details)", "role": "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Advertising (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20191231_StatementClassOfStockAxis_ConvertiblePreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "030000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "role": "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20191231_StatementClassOfStockAxis_ConvertiblePreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090400 - Disclosure - DISAGGREGATION OF REVENUES (Details)", "role": "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails", "shortName": "DISAGGREGATION OF REVENUES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231_ContractWithCustomerSalesChannelAxis_RetailVaporMember", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20181231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090500 - Disclosure - INVESTMENT (Details)", "role": "http://healthiercmc.com/role/InvestmentDetails", "shortName": "INVESTMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20181231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryWriteDown", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090600 - Disclosure - INVENTORIES (Details)", "role": "http://healthiercmc.com/role/InventoriesDetails", "shortName": "INVENTORIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231_CounterpartyNameAxis_ThirdPartyMember", "decimals": "-5", "lang": null, "name": "us-gaap:InventoryWriteDown", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromSaleOfNotesReceivable", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090700 - Disclosure - NOTES RECEIVABLE AND OTHER INCOME (Details)", "role": "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails", "shortName": "NOTES RECEIVABLE AND OTHER INCOME (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "lang": null, "name": "us-gaap:InvestmentIncomeInterest", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090800 - Disclosure - PROPERTY & EQUIPMENT (Details)", "role": "http://healthiercmc.com/role/PropertyEquipmentDetails", "shortName": "PROPERTY & EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20201231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090900 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, Changes in Carrying Amount (Details)", "role": "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsChangesInCarryingAmountDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS, Changes in Carrying Amount (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20191231", "decimals": "0", "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20200101to20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090902 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, Intangible Assets, Net (Details)", "role": "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS, Intangible Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090904 - Disclosure - GOODWILL AND INTANGIBLE ASSETS, Future Annual Estimated Amortization Expense (Details)", "role": "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS, Future Annual Estimated Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20201231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091000 - Disclosure - CONTRACT LIABILITIES (Details)", "role": "http://healthiercmc.com/role/ContractLiabilitiesDetails", "shortName": "CONTRACT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20191231", "decimals": "0", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091100 - Disclosure - LINE OF CREDIT AND DEBT (Details)", "role": "http://healthiercmc.com/role/LineOfCreditAndDebtDetails", "shortName": "LINE OF CREDIT AND DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231_DebtInstrumentAxis_TermLoanCreditAgreementMember", "decimals": "4", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "reportCount": 1, "unique": true, "unitRef": "U005", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231_LitigationCaseAxis_AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "reportCount": 1, "unique": true, "unitRef": "U009", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091200 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231_LitigationCaseAxis_AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "reportCount": 1, "unique": true, "unitRef": "U009", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231_PlanNameAxis_TwoThousandAndFifteenEquityIncentivePlanMember", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091300 - Disclosure - STOCKHOLDERS' EQUITY, Equity Compensation Plans (Details)", "role": "http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails", "shortName": "STOCKHOLDERS' EQUITY, Equity Compensation Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231_PlanNameAxis_TwoThousandAndFifteenEquityIncentivePlanMember", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210618to20210618", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091302 - Disclosure - STOCKHOLDERS' EQUITY, Rights Offering (Details)", "role": "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails", "shortName": "STOCKHOLDERS' EQUITY, Rights Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210618to20210618", "decimals": "-5", "lang": null, "name": "hcmc:GrossProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210329to20210329", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091304 - Disclosure - STOCKHOLDERS' EQUITY, Exchange Agreement (Details)", "role": "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails", "shortName": "STOCKHOLDERS' EQUITY, Exchange Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210329to20210329", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231_GranteeStatusAxis_BoardOfDirectorsChairmanMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091306 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock and Convertible Preferred Stock (Details)", "role": "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "shortName": "STOCKHOLDERS' EQUITY, Preferred Stock and Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231_GranteeStatusAxis_BoardOfDirectorsChairmanMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20161005_ClassOfWarrantOrRightAxis_WarrantMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091308 - Disclosure - STOCKHOLDERS' EQUITY, Summary of Warrant Activity (Details)", "role": "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails", "shortName": "STOCKHOLDERS' EQUITY, Summary of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20161005_ClassOfWarrantOrRightAxis_WarrantMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "U003", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091310 - Disclosure - STOCKHOLDERS' EQUITY, Share-based Awards to Officers and Restricted Stock (Details)", "role": "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "shortName": "STOCKHOLDERS' EQUITY, Share-based Awards to Officers and Restricted Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20180813to20180813_AwardTypeAxis_RestrictedStockMember_GranteeStatusAxis_ChiefExecutiveOfficerMember", "decimals": "-9", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091312 - Disclosure - STOCKHOLDERS' EQUITY, Stock Options Activity (Details)", "role": "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails", "shortName": "STOCKHOLDERS' EQUITY, Stock Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091314 - Disclosure - STOCKHOLDERS' EQUITY, Income (Loss) Per Share (Details)", "role": "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails", "shortName": "STOCKHOLDERS' EQUITY, Income (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231_RangeAxis_MaximumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091400 - Disclosure - LEASE, Summary (Details)", "role": "http://healthiercmc.com/role/LeaseSummaryDetails", "shortName": "LEASE, Summary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231_RangeAxis_MaximumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060100 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS", "role": "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopments", "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091402 - Disclosure - LEASE, Maturity of Lease Liabilities (Details)", "role": "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails", "shortName": "LEASE, Maturity of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091404 - Disclosure - LEASE, Balance Sheet Classification and Other Information (Details)", "role": "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails", "shortName": "LEASE, Balance Sheet Classification and Other Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091406 - Disclosure - LEASE, Components of Lease Cost (Details)", "role": "http://healthiercmc.com/role/LeaseComponentsOfLeaseCostDetails", "shortName": "LEASE, Components of Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091500 - Disclosure - INCOME TAXES, Reconciliation of Tax Expense (Benefit) (Details)", "role": "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails", "shortName": "INCOME TAXES, Reconciliation of Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091502 - Disclosure - INCOME TAXES, Deferred Tax Assets and Liabilities (Details)", "role": "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "INCOME TAXES, Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091504 - Disclosure - INCOME TAXES, Other Information (Details)", "role": "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails", "shortName": "INCOME TAXES, Other Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091600 - Disclosure - SEGMENT INFORMATION (Details)", "role": "http://healthiercmc.com/role/SegmentInformationDetails", "shortName": "SEGMENT INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_VaporMember", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20210930_StatementEquityComponentsAxis_CommonStockMember", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091700 - Disclosure - SUBSEQUENT EVENTS (Details)", "role": "http://healthiercmc.com/role/SubsequentEventsDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20220208to20220208_AssetAcquisitionAxis_MotherEarthSStorehouseMember_TypeOfArrangementAxis_AssetPurchaseAgreementMember", "decimals": "0", "lang": null, "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:LiquidityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060200 - Disclosure - LIQUIDITY", "role": "http://healthiercmc.com/role/Liquidity", "shortName": "LIQUIDITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "hcmc:LiquidityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060300 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://healthiercmc.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form10k.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 83, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://healthiercmc.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "hcmc_AccountsReceivableContractAssetsAndContractLiabilitiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable related to contract assets and contract liabilities.", "label": "Accounts Receivable Contract Assets And Contract Liabilities [Policy Text Block]", "terseLabel": "Accounts Receivable, Contract Assets and Contract Liabilities" } } }, "localname": "AccountsReceivableContractAssetsAndContractLiabilitiesPolicyTextBlock", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hcmc_AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alleged claimed battery defects for an electronic cigarette device.", "label": "Alleged Claimed Battery Defects For Electronic Cigarette Device [Member]", "verboseLabel": "Alleged Claimed Battery Defects For Electronic Cigarette Device Member [Member]" } } }, "localname": "AllegedClaimedBatteryDefectsForElectronicCigaretteDeviceMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "hcmc_AssetPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of purchase agreement.", "label": "Asset Purchase Agreement [Member]", "terseLabel": "Asset Purchase Agreement [Member]" } } }, "localname": "AssetPurchaseAgreementMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hcmc_AutomaticRenewalOfAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Successive automatically renewal of agreement term unless notice of non-renewal is given.", "label": "Automatic Renewal of Agreement Term", "terseLabel": "Automatic renewal of agreement term" } } }, "localname": "AutomaticRenewalOfAgreementTerm", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "durationItemType" }, "hcmc_BalanceSheetClassificationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Classification", "terseLabel": "Balance Sheet Classification [Abstract]" } } }, "localname": "BalanceSheetClassificationAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails" ], "xbrltype": "stringItemType" }, "hcmc_BalanceSheetClassificationAndOtherInformationRelatedToOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of balance sheet information and other information related to operating leases.", "label": "Balance Sheet Classification and Other Information Related to Operating Leases [Table Text Block]", "terseLabel": "Balance Sheet Classification and Other Information" } } }, "localname": "BalanceSheetClassificationAndOtherInformationRelatedToOperatingLeasesTableTextBlock", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LeaseTables" ], "xbrltype": "textBlockItemType" }, "hcmc_BreakagePolicyPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and redemption of gift cards, rewards and points, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Breakage Policy Period", "terseLabel": "Breakage policy period" } } }, "localname": "BreakagePolicyPeriod", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "hcmc_ClassOfWarrantOrRightExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights expired.", "label": "Class of Warrant or Right, Expired", "negatedLabel": "Warrants expired (in shares)" } } }, "localname": "ClassOfWarrantOrRightExpired", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "hcmc_ClassOfWarrantOrRightRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants remaining contractual term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class of Warrant or Right, Remaining Contractual Term", "terseLabel": "Weighted average remaining term outstanding" } } }, "localname": "ClassOfWarrantOrRightRemainingContractualTerm", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "hcmc_CommonShareEquivalentsExcludedFromCalculationOfBasicAndDilutiveIncomeLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Share Equivalents Excluded from Calculation of Basic and Dilutive Income (Loss) Per Share [Abstract]", "terseLabel": "Common Share Equivalents Excluded from Calculation of Basic and Dilutive Income (Loss) Per Share [Abstract]" } } }, "localname": "CommonShareEquivalentsExcludedFromCalculationOfBasicAndDilutiveIncomeLossPerShareAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "hcmc_ContractLiabilitiesExpectedRecognitionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period in which contract liabilities is expected to be recognized, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Contract Liabilities Expected Recognition Period", "terseLabel": "Contract liabilities expected recognition period" } } }, "localname": "ContractLiabilitiesExpectedRecognitionPeriod", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "hcmc_ContractWithCustomerAssetAndLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Text Block]", "terseLabel": "CONTRACT LIABILITIES" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTextBlock", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ContractLiabilities" ], "xbrltype": "textBlockItemType" }, "hcmc_ContractWithCustomerLiabilityBreakageRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Breakage Recognized", "terseLabel": "Breakage recognized" } } }, "localname": "ContractWithCustomerLiabilityBreakageRecognized", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_ContractWithCustomerLiabilityCustomerDeposits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of customer deposits in contract with customer.", "label": "Contract with Customer, Liability, Customer Deposits", "terseLabel": "Fulfillment of Obligations" } } }, "localname": "ContractWithCustomerLiabilityCustomerDeposits", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_ContractWithCustomerLiabilityIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gift cards and loyalty rewards issued as obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability, Issued", "terseLabel": "Issued" } } }, "localname": "ContractWithCustomerLiabilityIssued", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_ContractWithCustomerLiabilityRedeemed": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense from redemption of gift cards and loyalty rewards in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Liability, Redeemed", "negatedLabel": "Redeemed" } } }, "localname": "ContractWithCustomerLiabilityRedeemed", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_ConversionOfStockPercentageSharesConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of stock associated with the financial instrument issued in exchange for the original being converted in a noncash or part noncash transaction.", "label": "Conversion of Stock Percentage Shares Converted", "terseLabel": "Shares conversion percentage" } } }, "localname": "ConversionOfStockPercentageSharesConverted", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "hcmc_ConvertiblePreferredStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Abstract]", "terseLabel": "Convertible Preferred Stock [Abstract]" } } }, "localname": "ConvertiblePreferredStockAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "hcmc_ConvertiblePreferredStockConvertedToOtherSecuritiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of convertible preferred stock that were converted to other securities.", "label": "Convertible Preferred Stock Converted to Other Securities, Shares", "terseLabel": "Preferred stock exercised (in shares)" } } }, "localname": "ConvertiblePreferredStockConvertedToOtherSecuritiesShares", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "hcmc_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Convertible Preferred Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of Convertible Preferred Stock (in shares)" } } }, "localname": "ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "hcmc_ConvertiblePreferredStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Convertible Preferred Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "hcmc_CustomerFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Four [Member]", "verboseLabel": "Customer D [Member]" } } }, "localname": "CustomerFourMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "hcmc_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer One [Member]", "verboseLabel": "Customer A [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "hcmc_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Three [Member]", "verboseLabel": "Customer C [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "hcmc_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "verboseLabel": "Customer B [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "hcmc_CustomersBalancesInExcessOf10OfTotalAccountsReceivableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customers Balances in Excess of 10% of Total Accounts Receivable [Abstract]", "terseLabel": "Customers Balances in Excess of 10% of Total Accounts Receivable [Abstract]" } } }, "localname": "CustomersBalancesInExcessOf10OfTotalAccountsReceivableAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "hcmc_DebtInstrumentCovenantMinimumDebtServiceCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The customary financial covenant for a minimum debt service coverage ratio.", "label": "Debt Instrument Covenant Minimum Debt Service Coverage Ratio", "terseLabel": "Debt service coverage ratio" } } }, "localname": "DebtInstrumentCovenantMinimumDebtServiceCoverageRatio", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "pureItemType" }, "hcmc_DebtInstrumentDiscountPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-refundable discount to the face amount of the loan under the debt agreement.", "label": "Debt Instrument, Discount Percentage", "terseLabel": "Non-refundable discount percentage" } } }, "localname": "DebtInstrumentDiscountPercentage", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "percentItemType" }, "hcmc_DebtInstrumentExtendedMaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument, Extended Maturity Date", "terseLabel": "Extended maturity date" } } }, "localname": "DebtInstrumentExtendedMaturityDate", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "dateItemType" }, "hcmc_DebtInstrumentRemainingBalanceAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of loan amount used for operational purposes.", "label": "Debt Instrument, Remaining Balance Amount", "terseLabel": "Loan amount used for operational purposes" } } }, "localname": "DebtInstrumentRemainingBalanceAmount", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_DeferredCompensationArrangementWithIndividualSeverancePaymentsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment made to pay severance payments expressed as a term of individual's then base salary.", "label": "Deferred Compensation Arrangement with Individual, Severance Payments Term", "terseLabel": "Severance payments term of base salary" } } }, "localname": "DeferredCompensationArrangementWithIndividualSeverancePaymentsTerm", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "durationItemType" }, "hcmc_DeferredCompensationArrangementWithIndividualTargetBonusPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment made to pay bonus expressed as a percentage of the individual's base salary.", "label": "Deferred Compensation Arrangement with Individual, Target Bonus Percentage", "terseLabel": "Target bonus percentage for 2020" } } }, "localname": "DeferredCompensationArrangementWithIndividualTargetBonusPercentage", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "hcmc_DeferredIncomeTaxLiability": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "hcmc_DeferredTaxAssetsGrossNetOfDeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Income Tax Liability", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiability", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_DeferredTaxAssetsGrossNetOfDeferredTaxLiabilities": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax asset before allocation of valuation allowances attributable to deductible differences and carryforwards, without jurisdictional netting, net of deferred tax liability.", "label": "Deferred Tax Assets, Gross, Net of Deferred Tax Liabilities", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsGrossNetOfDeferredTaxLiabilities", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_DeferredTaxAssetsLeasingArrangements": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from leasing arrangements.", "label": "Deferred Tax Assets, Leasing Arrangements", "terseLabel": "ASC 842 - Lease Accounting" } } }, "localname": "DeferredTaxAssetsLeasingArrangements", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_DeferredTaxLiabilitiesExtinguishmentOfWarrants": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "hcmc_DeferredIncomeTaxLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from extinguishment of warrants.", "label": "Deferred Tax Liabilities, Extinguishment of Warrants", "negatedLabel": "Extinguishment of Warrants" } } }, "localname": "DeferredTaxLiabilitiesExtinguishmentOfWarrants", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_DetailOfSegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Detail of Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "DetailOfSegmentReportingAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails" ], "xbrltype": "stringItemType" }, "hcmc_DisplaysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Displays [Member]", "terseLabel": "Displays [Member]" } } }, "localname": "DisplaysMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails" ], "xbrltype": "domainItemType" }, "hcmc_DueFromMerchantCreditCardProcessorTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for due from merchant credit card processor.", "label": "Due from Merchant Credit Card Processor [Text Block]", "terseLabel": "Due from Merchant Credit Card Processor" } } }, "localname": "DueFromMerchantCreditCardProcessorTextBlock", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hcmc_DurationOfCompanyExistenceInMarket": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The duration of company existence in market, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Duration of Company Existence in Market", "terseLabel": "Duration of company existence in market" } } }, "localname": "DurationOfCompanyExistenceInMarket", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "durationItemType" }, "hcmc_EIRHydrationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents EIR Hydration, an IV therapy center located in Roslyn Heights, NY.", "label": "EIR Hydration [Member]", "terseLabel": "EIR Hydration [Member]" } } }, "localname": "EIRHydrationMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "hcmc_EffectiveIncomeTaxRateReconciliationExpiredWarrantsAmount": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expired warrants.", "label": "Effective Income Tax Rate Reconciliation Expired Warrants Amount", "terseLabel": "Expired warrants" } } }, "localname": "EffectiveIncomeTaxRateReconciliationExpiredWarrantsAmount", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_EffectiveIncomeTaxRateReconciliationForgivenessOfPaycheckProtectionProgramLoan": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to forgiveness of paycheck protection program loan.", "label": "Effective Income Tax Rate Reconciliation Forgiveness of Paycheck Protection Program Loan", "terseLabel": "Forgiveness of PPP loan" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForgivenessOfPaycheckProtectionProgramLoan", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_EffectiveIncomeTaxRateReconciliationTrueUpAndDeferredAdjustmentAmount": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to true-up &amp; deferred adjustment.", "label": "True-up & deferred adjustment", "terseLabel": "True-up & deferred adjustment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTrueUpAndDeferredAdjustmentAmount", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_ExchangeAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exchange Agreement [Abstract]", "terseLabel": "Exchange Agreement [Abstract]" } } }, "localname": "ExchangeAgreementAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails" ], "xbrltype": "stringItemType" }, "hcmc_ExclusiveDistributionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the name of an agreement.", "label": "Exclusive Distribution Agreement [Member]" } } }, "localname": "ExclusiveDistributionAgreementMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "hcmc_ExclusiveDistributionAndFontemLicenseAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exclusive Distribution and Fontem License Agreement [Abstract]", "terseLabel": "Exclusive Distribution and Fontem License Agreement [Abstract]" } } }, "localname": "ExclusiveDistributionAndFontemLicenseAgreementAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "hcmc_FontemLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fontem License Agreement [Member]" } } }, "localname": "FontemLicenseAgreementMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "hcmc_FontemVenturesBVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the name of an entity.", "label": "Fontem Ventures B.V. [Member]" } } }, "localname": "FontemVenturesBVMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "hcmc_FoodServiceAndRestaurantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to food service and restaurants stores that sell vapor products.", "label": "Food Service and Restaurant [Member]", "verboseLabel": "Food Service/Restaurant [Member]" } } }, "localname": "FoodServiceAndRestaurantMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_GainOnLoanForgiveness": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of gain recorded on forgiveness of loan.", "label": "Gain on Loan Forgiveness", "terseLabel": "Gain on loan forgiveness" } } }, "localname": "GainOnLoanForgiveness", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_GiftCardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to product of gift cards.", "label": "Gift Cards [Member]", "terseLabel": "Gift Cards [Member]" } } }, "localname": "GiftCardsMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "hcmc_GoingConcernAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Abstract]" } } }, "localname": "GoingConcernAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LiquidityDetails" ], "xbrltype": "stringItemType" }, "hcmc_GoingConcernAndLiquidityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern And Liquidity [Line Items]" } } }, "localname": "GoingConcernAndLiquidityLineItems", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LiquidityDetails" ], "xbrltype": "stringItemType" }, "hcmc_GoingConcernAndLiquidityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule that describes going concern and liquidity.", "label": "Going Concern And Liquidity [Table]" } } }, "localname": "GoingConcernAndLiquidityTable", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LiquidityDetails" ], "xbrltype": "stringItemType" }, "hcmc_GroceryLoyaltyRewardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to product of the grocery loyalty rewards.", "label": "Grocery Loyalty Rewards [Member]", "terseLabel": "Grocery Loyalty Rewards [Member]" } } }, "localname": "GroceryLoyaltyRewardsMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "hcmc_GroceryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A grocer is a bulk seller of food and products.", "label": "Grocery [Member]", "terseLabel": "Grocery Business [Member]", "verboseLabel": "Grocery Sales, Net [Member]" } } }, "localname": "GroceryMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails", "http://healthiercmc.com/role/InventoriesDetails", "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "hcmc_GrossProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The gross proceeds from the additional capital contribution to the entity.", "label": "Gross Proceeds from Issuance of Common Stock", "terseLabel": "Gross proceeds" } } }, "localname": "GrossProceedsFromIssuanceOfCommonStock", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_IdentifiableIntangibleAssetsAndGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Identifiable Intangible Assets and Goodwill [Abstract]", "terseLabel": "Identifiable Intangible Assets and Goodwill [Abstract]" } } }, "localname": "IdentifiableIntangibleAssetsAndGoodwillAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesIdentifiableIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "hcmc_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period lease liability.", "label": "Increase Decrease In Lease Liabilities", "negatedLabel": "Lease liability" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hcmc_IncreaseDecreaseInPrepaidExpenseAndVendorDeposits": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and vendor deposits.", "label": "Increase (Decrease) in Prepaid Expense and Vendor Deposits", "negatedLabel": "Prepaid expenses and vendor deposits" } } }, "localname": "IncreaseDecreaseInPrepaidExpenseAndVendorDeposits", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hcmc_InvestmentInCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of common stock shares for investment.", "label": "Investment in Common Stock Shares", "terseLabel": "Investment of common stock at MJ Holdings, Inc. (in shares)" } } }, "localname": "InvestmentInCommonStockShares", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/InvestmentDetails" ], "xbrltype": "sharesItemType" }, "hcmc_IssuanceOfCommonStockInConnectionWithCashlessExerciseOfSeriesWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in connection with cashless exercise of Series A warrants.", "label": "Issuance Of Common Stock In Connection With Cashless Exercise Of Series A Warrants", "verboseLabel": "Issuance of common stock" } } }, "localname": "IssuanceOfCommonStockInConnectionWithCashlessExerciseOfSeriesWarrants", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hcmc_LiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIQUIDITY [Abstract]" } } }, "localname": "LiquidityAbstract", "nsuri": "http://healthiercmc.com/20211231", "xbrltype": "stringItemType" }, "hcmc_LiquidityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of liquidity.", "label": "Liquidity [Text Block]", "terseLabel": "LIQUIDITY" } } }, "localname": "LiquidityTextBlock", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/Liquidity" ], "xbrltype": "textBlockItemType" }, "hcmc_LossContingenciesInvestmentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of investment under litigation.", "label": "Loss Contingencies, Investment Amount", "terseLabel": "Invested amount" } } }, "localname": "LossContingenciesInvestmentAmount", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_MJHoldingsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the name of an entity.", "label": "MJ Holdings, Inc. [Member]" } } }, "localname": "MJHoldingsIncMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "hcmc_MedicalCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical costs claimed by Plaintiffs.", "label": "Medical Costs [Member]" } } }, "localname": "MedicalCostsMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "hcmc_MotherEarthSStorehouseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the acquiree.", "label": "Mother Earth's Storehouse [Member]", "terseLabel": "Mother Earth's Storehouse [Member]" } } }, "localname": "MotherEarthSStorehouseMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hcmc_NotesReceivableExtensionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The extension term of notes receivable in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Notes Receivable, Extension Term", "terseLabel": "Extension term" } } }, "localname": "NotesReceivableExtensionTerm", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "durationItemType" }, "hcmc_NotesReceivablePaymentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The payment term of notes receivable in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Notes Receivable Payment Term", "terseLabel": "Payment term" } } }, "localname": "NotesReceivablePaymentTerm", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "durationItemType" }, "hcmc_NoticePeriodForNonRenewalOfAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notice Period need to be given by either party for non-renewal of agreement term.", "label": "Notice Period for Non-Renewal of Agreement Term", "terseLabel": "Notice period for non-renewal of agreement term" } } }, "localname": "NoticePeriodForNonRenewalOfAgreementTerm", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "durationItemType" }, "hcmc_NumberOfTradingDaysForConversionOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of trading days for the exercise of the convertible preferred stock as the conversion price for the shares was reset to the lowest daily volume-weighted average price (\"VWAP\"), in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Number of Trading Days for Conversion of Shares", "terseLabel": "Number of trading days for conversion of shares" } } }, "localname": "NumberOfTradingDaysForConversionOfShares", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "durationItemType" }, "hcmc_NumberOfUsersApproached": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of users approached by the entity.", "label": "Number of Users Approached", "terseLabel": "Number of users approached" } } }, "localname": "NumberOfUsersApproached", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "hcmc_NumberOfVendors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of vendors considered a major supplier.", "label": "Number of vendors", "terseLabel": "Number of vendor" } } }, "localname": "NumberOfVendors", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "integerItemType" }, "hcmc_OfficersAndADirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Persons with designation of chief executive officer, chief operating officer and chief financial officer.", "label": "Officers and a Director [Member]", "terseLabel": "Officers and a Director [Member]" } } }, "localname": "OfficersAndADirectorMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "hcmc_OnlineAndECommerceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to the online stores and other e-commerce platforms that sell vape products.", "label": "Online and E-commerce [Member]", "verboseLabel": "Online/eCommerce [Member]" } } }, "localname": "OnlineAndECommerceMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_OperatingLossCarryforwardsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Abstract]" } } }, "localname": "OperatingLossCarryforwardsAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "stringItemType" }, "hcmc_OrganizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization [Abstract]" } } }, "localname": "OrganizationAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "stringItemType" }, "hcmc_OtherDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to other debt.", "label": "Other Debt [Member]", "terseLabel": "Other Debt [Member]" } } }, "localname": "OtherDebtMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "domainItemType" }, "hcmc_OtherInformationRelatedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Information", "terseLabel": "Other Information [Abstract]" } } }, "localname": "OtherInformationRelatedAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails" ], "xbrltype": "stringItemType" }, "hcmc_PatentInfringementLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The patent infringement litigation.", "label": "Patent Infringement Litigation [Member]", "terseLabel": "Patent Infringement Litigation [Member]" } } }, "localname": "PatentInfringementLitigationMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hcmc_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Paycheck Protection Program (the \"PPP\") under Division A, Title I of the CARES Act, which was enacted March 27, 2020.", "label": "Paycheck Protection Program [Member]", "terseLabel": "Paycheck Protection Program [Member]" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "domainItemType" }, "hcmc_PaymentsToAcquireAssetsGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of assets during the period. The cash portion only of the asset acquisition price.", "label": "Payments to Acquire Assets Gross", "terseLabel": "Cash purchase price" } } }, "localname": "PaymentsToAcquireAssetsGross", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_PaymentsToAcquireInventory": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of inventory.", "label": "Payments to Acquire Inventory", "terseLabel": "Cash paid for inventory" } } }, "localname": "PaymentsToAcquireInventory", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_PercentageLoyaltyRewardsEarned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of loyalty reward earnings on purchases.", "label": "Percentage, Loyalty Rewards Earned", "verboseLabel": "Loyalty rewards earned percentage" } } }, "localname": "PercentageLoyaltyRewardsEarned", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "hcmc_PercentageOfCashSecuredWithFundsHeldFromBlockedAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of cash secured with moneys held from the blocked account under the revolving line of credit.", "label": "Percentage of Cash Secured with Funds Held from Blocked Account", "terseLabel": "Percentage of cash secured with funds held from blocked account" } } }, "localname": "PercentageOfCashSecuredWithFundsHeldFromBlockedAccount", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "percentItemType" }, "hcmc_PercentageOfNetProfitsReceivedFromSalesOfPersonalProtectiveEquipment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of net profits received from the sales of personal protective equipment (\"PPE\").", "label": "Percentage of net profits received from sales of personal protective equipment", "terseLabel": "Percentage of net profits received from sales of PPE" } } }, "localname": "PercentageOfNetProfitsReceivedFromSalesOfPersonalProtectiveEquipment", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "percentItemType" }, "hcmc_PhilipMorrisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the name of an entity.", "label": "Philip Morris [Member]" } } }, "localname": "PhilipMorrisMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hcmc_PrepaidExpenseAndVendorDepositsCurrent": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of vendor deposits that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Vendor Deposits, Current", "terseLabel": "Prepaid expenses and vendor deposits" } } }, "localname": "PrepaidExpenseAndVendorDepositsCurrent", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "hcmc_PresidentAndChiefOperatingOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Person with designation of president and chief operating officer.", "label": "President and Chief Operating Officer [Member]", "terseLabel": "President and Chief Operating Officer [Member]" } } }, "localname": "PresidentAndChiefOperatingOfficerMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hcmc_ProceedsFromBalloonPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the balloon payments.", "label": "Proceeds from Balloon Payments", "terseLabel": "Balloon payments" } } }, "localname": "ProceedsFromBalloonPayments", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_ProceedsFromPaycheckProtectionProgramLoan": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from paycheck protection program loan.", "label": "Proceeds From Paycheck Protection Program Loan", "terseLabel": "Proceeds from paycheck protection program" } } }, "localname": "ProceedsFromPaycheckProtectionProgramLoan", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hcmc_ProfessionalBankCoralGablesFloridaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Professional Bank Coral Gables Florida [Member]", "terseLabel": "Professional Bank Coral Gables, Florida [Member]" } } }, "localname": "ProfessionalBankCoralGablesFloridaMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hcmc_PromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory notes a signed document containing a written promise to pay a stated sum to a specified person or the bearer at a specified date or on demand.", "label": "Promissory Notes [Member]", "terseLabel": "Promissory Note [Member]" } } }, "localname": "PromissoryNotesMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "hcmc_PropertyPlantAndEquipmentUsefulLifeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentUsefulLifeAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "hcmc_RepaymentsOfMoneyMarket": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represent money market amount.", "label": "Repayments Of Money Market", "terseLabel": "Money market amount" } } }, "localname": "RepaymentsOfMoneyMarket", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_RetailGroceryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A grocery retailer primarily sells food. Grocery stores also offer non-perishable foods that are packaged in bottles, boxes, and cans; some also have bakeries, butchers, delis, and fresh produce.", "label": "Retail Grocery [Member]", "terseLabel": "Retail Grocery [Member]" } } }, "localname": "RetailGroceryMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_RetailVaporMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A retail vapor outlet specializing in the selling of electronic cigarette products.", "label": "Retail Vapor [Member]" } } }, "localname": "RetailVaporMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_RevolvingCreditLineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A revolving credit line (together with a money market account) with Professional Bank in Coral Gables, Florida agreed to on April 13, 2018.", "label": "Revolving Credit Line [Member]", "terseLabel": "Revolving Credit Line [Member]" } } }, "localname": "RevolvingCreditLineMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "domainItemType" }, "hcmc_RightsOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights Offering [Abstract]", "terseLabel": "Rights Offering [Abstract]" } } }, "localname": "RightsOfferingAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "stringItemType" }, "hcmc_RoyaltyRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of revenues derived from the sale of qualifying products as defined in the license agreement.", "label": "Royalty Rate Percentage", "terseLabel": "Percentage of royalty rate" } } }, "localname": "RoyaltyRatePercentage", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "hcmc_ScheduleOfAccountsNotesReceivableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of notes receivable.", "label": "Schedule Of Accounts Notes Receivable [Text Block]", "terseLabel": "Summary of Notes" } } }, "localname": "ScheduleOfAccountsNotesReceivableTextBlock", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeTables" ], "xbrltype": "textBlockItemType" }, "hcmc_SecuredNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A type of loan that is backed by the borrower's assets. If a borrower defaults on a secured note, the assets pledged as collateral can be sold to repay the note.", "label": "Secured Notes [Member]" } } }, "localname": "SecuredNotesMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "hcmc_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of purchase agreement.", "label": "Securities Purchase Agreement [Member]", "terseLabel": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LiquidityDetails", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hcmc_SequencingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for sequencing policies.", "label": "Sequencing [Policy Text Block]", "terseLabel": "Sequencing Policy" } } }, "localname": "SequencingPolicyTextBlock", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hcmc_SeriesAWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Warrants [Member]", "terseLabel": "Series A Warrants [Member]" } } }, "localname": "SeriesAWarrantsMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "hcmc_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Series B Convertible Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "hcmc_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Series C Convertible Preferred Stock [Member]", "terseLabel": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "hcmc_SeriesDConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Series D Convertible Preferred Stock [Member]", "terseLabel": "Series D Convertible Preferred Stock [Member]" } } }, "localname": "SeriesDConvertiblePreferredStockMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "hcmc_SeriesDPreferredStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series D Preferred Stock [Abstract]" } } }, "localname": "SeriesDPreferredStockAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "hcmc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExtensionToVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Extension to Vesting Period", "terseLabel": "Extension to vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExtensionToVestingPeriod", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "hcmc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsIncreaseInVestingPercentageFromItsOriginalAwardsInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of increase in grants from its original award agreement, made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Grants, Increase in Vesting Percentage from its Original Awards In Period", "terseLabel": "Percentage of increase in restricted stock grants from its original award agreement to officers", "verboseLabel": "Percentage of increase in restricted stock grants from its original award agreement to officers" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsIncreaseInVestingPercentageFromItsOriginalAwardsInPeriod", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "hcmc_ShareBasedCompensationArrangementByShareBasedPaymentAwardSecondExtensionAwardVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second extension period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Second Extension Award Vesting Period", "terseLabel": "Second extension to vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSecondExtensionAwardVestingPeriod", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "durationItemType" }, "hcmc_ShippingAndHandlingCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shipping and Handling Costs [Abstract]", "terseLabel": "Shipping and Handling Costs [Abstract]" } } }, "localname": "ShippingAndHandlingCostsAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesShippingAndHandlingDetails" ], "xbrltype": "stringItemType" }, "hcmc_ShippingAndHandlingCostsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.", "label": "Shipping And Handling Costs [Text Block]", "terseLabel": "Shipping and Handling" } } }, "localname": "ShippingAndHandlingCostsTextBlock", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hcmc_ShippingHandlingAndTransportationsCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Shipping and handling costs", "terseLabel": "Shipping and handling costs" } } }, "localname": "ShippingHandlingAndTransportationsCost", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesShippingAndHandlingDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_SourcesAndVendorsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sources and Vendors [Abstract]" } } }, "localname": "SourcesAndVendorsAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "stringItemType" }, "hcmc_SourcingAndVendorsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for sourcing and vendors.", "label": "Sourcing and Vendors [Policy Text Block]", "terseLabel": "Sourcing and Vendors" } } }, "localname": "SourcingAndVendorsPolicyTextBlock", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsPolicies" ], "xbrltype": "textBlockItemType" }, "hcmc_StockCancelledDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock cancelled sued during the period.", "label": "Stock Cancelled During Period, Shares, New Issues", "terseLabel": "Cancellation of Convertible Preferred Stock (in shares)" } } }, "localname": "StockCancelledDuringPeriodSharesNewIssues", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "hcmc_StockCancelledDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock cancelled during the period.", "label": "Stock Cancelled During Period, Value, New Issues", "terseLabel": "Cancellation of Convertible Preferred Stock" } } }, "localname": "StockCancelledDuringPeriodValueNewIssues", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "hcmc_StockIssuedDuringPeriodSharesNewIssuesRightsOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued in connection with Rights Offering during the period.", "label": "Stock Issued During Period, Shares, New Issues, Rights Offering", "terseLabel": "Issuance of common stock in connection with the Rights Offering, net of offering expenses (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssuesRightsOffering", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "hcmc_StockIssuedDuringPeriodValueNewIssuesRightsOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period in connection with Rights Offering.", "label": "Stock Issued During Period, Value, New Issues, Rights Offering", "terseLabel": "Issuance of common stock in connection with the Rights Offering, net of offering expenses" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesRightsOffering", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "hcmc_SubsequentEventAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Event [Abstract]", "terseLabel": "Subsequent Event [Abstract]" } } }, "localname": "SubsequentEventAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "hcmc_TaxYear2030Through2037Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2030 through 2037.", "label": "Tax Year 2030 through 2037 [Member]", "terseLabel": "2030 through 2037 [Member]" } } }, "localname": "TaxYear2030Through2037Member", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "domainItemType" }, "hcmc_TaxYear2032Through2037Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified as tax year 2032 through 2037.", "label": "Tax Year 2032 through 2037 [Member]", "terseLabel": "2032 through 2037 [Member]" } } }, "localname": "TaxYear2032Through2037Member", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "domainItemType" }, "hcmc_TaxYearNoExpirationDateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified with no expiration date.", "label": "Tax Year No Expiration Date [Member]", "terseLabel": "No Expiration Date [Member]" } } }, "localname": "TaxYearNoExpirationDateMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "domainItemType" }, "hcmc_TermLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "On August 18, 2020, the Company agreed to a term loan and security agreement (the \"Loan\") with Sabby Healthcare Master Fund, LTD and Sabby Volatility Warrant Master Fund, LTD (\"collectively, the Lender\").", "label": "Term Loan and Security Agreement [Member]", "terseLabel": "Loan and Security Agreement [Member]", "verboseLabel": "Term Loan and Security Agreement [Member]" } } }, "localname": "TermLoanAndSecurityAgreementMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hcmc_TermLoanCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term loan credit agreement with Professional Bank.", "label": "Term Loan Credit Agreement [Member]", "terseLabel": "Term Loan Credit Agreement [Member]" } } }, "localname": "TermLoanCreditAgreementMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "domainItemType" }, "hcmc_ThirdPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Independent Third Party [Member]", "terseLabel": "Third Party [Member]" } } }, "localname": "ThirdPartyMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/InventoriesDetails" ], "xbrltype": "domainItemType" }, "hcmc_TwoThousandAndFifteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand fifteen equity incentive plan is an arrangement where employees own a percentage of their company's shares so that they make money when the company makes a profit.", "label": "Two Thousand and Fifteen Equity Incentive Plan [Member]", "terseLabel": "2015 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandAndFifteenEquityIncentivePlanMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "hcmc_TwoThousandAndNineEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nine equity incentive plan is an arrangement where employees own a percentage of their company's shares so that they make money when the company makes a profit.", "label": "Two Thousand and Nine Equity Incentive Plan [Member]", "terseLabel": "2009 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandAndNineEquityIncentivePlanMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "hcmc_VaporLoyaltyRewardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to product of the vapor loyalty rewards.", "label": "Vapor Loyalty Rewards [Member]", "terseLabel": "Vapor Loyalty Rewards [Member]" } } }, "localname": "VaporLoyaltyRewardsMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "hcmc_VaporMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to a substance diffused or suspended in the air, especially one normally liquid or solid.", "label": "Vapor [Member]", "terseLabel": "Vapor Business [Member]", "verboseLabel": "Vapor Sales, Net [Member]" } } }, "localname": "VaporMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails", "http://healthiercmc.com/role/InventoriesDetails", "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "hcmc_VendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A party from whom the goods or services were or are to be received.", "label": "Vendor [Member]" } } }, "localname": "VendorMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "domainItemType" }, "hcmc_WarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Abstract]", "terseLabel": "Warrants [Abstract]" } } }, "localname": "WarrantsAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "hcmc_WarrantsActivityOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Warrants Activity, Outstanding [Roll Forward]", "terseLabel": "Number of Warrants [Abstract]" } } }, "localname": "WarrantsActivityOutstandingRollForward", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "hcmc_WarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised during the period.", "label": "Warrants, Exercised", "negatedLabel": "Warrants exercised (in shares)" } } }, "localname": "WarrantsExercised", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "hcmc_WarrantsOutstandingBlackScholesValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of warrants outstanding determined using the black-Scholes model.", "label": "Warrants Outstanding, Black Scholes Value", "terseLabel": "Black Scholes value" } } }, "localname": "WarrantsOutstandingBlackScholesValue", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_WarrantsWeightedAverageExercisePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of warrants as of the balance sheet date.", "label": "Warrants, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at ending of period", "periodStartLabel": "Outstanding at beginning of period" } } }, "localname": "WarrantsWeightedAverageExercisePrice", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_WarrantsWeightedAverageExercisePriceExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of warrants exercised during the period.", "label": "Warrants, Weighted Average Exercise Price exercised", "terseLabel": "Warrants exercised" } } }, "localname": "WarrantsWeightedAverageExercisePriceExercised", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_WarrantsWeightedAverageExercisePriceExpired": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of warrants expired during the period.", "label": "Warrants, Weighted Average Exercise Price, Expired", "terseLabel": "Warrants expired" } } }, "localname": "WarrantsWeightedAverageExercisePriceExpired", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "monetaryItemType" }, "hcmc_WeightedAverageExercisePriceWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Warrants [Abstract]", "terseLabel": "Weighted Average Exercise Price [Abstract]" } } }, "localname": "WeightedAverageExercisePriceWarrantsAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "hcmc_WeightedAverageRemainingTermWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Term, Warrants [Abstract]", "terseLabel": "Weighted Average Remaining Term [Abstract]" } } }, "localname": "WeightedAverageRemainingTermWarrantsAbstract", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "hcmc_WholesaleGroceryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A person that is a dealer primarily engaged in the full-line wholesale distribution and resale of grocery and related nonfood items.", "label": "Wholesale Grocery [Member]", "terseLabel": "Wholesale Grocery [Member]" } } }, "localname": "WholesaleGroceryMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "hcmc_WholesaleVaporMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A person that is a dealer primarily engaged in the full-line wholesale distribution of vape products.", "label": "Wholesale Vapor [Member]" } } }, "localname": "WholesaleVaporMember", "nsuri": "http://healthiercmc.com/20211231", "presentation": [ "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]", "terseLabel": "Board of Directors [Member]", "verboseLabel": "Board [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefOperatingOfficerMember": { "auth_ref": [ "r203", "r523" ], "lang": { "en-us": { "role": { "label": "Chief Operating Officer [Member]" } } }, "localname": "ChiefOperatingOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r115", "r172", "r185", "r186", "r187", "r188", "r190", "r192", "r196", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r277", "r279", "r281", "r282" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r115", "r172", "r185", "r186", "r187", "r188", "r190", "r192", "r196", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r277", "r279", "r281", "r282" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r59", "r61", "r113", "r114", "r288", "r319" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/InventoriesDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r120", "r127", "r133", "r219", "r407", "r408", "r409", "r434", "r435", "r466", "r469", "r471", "r472", "r616" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r120", "r127", "r133", "r219", "r407", "r408", "r409", "r434", "r435", "r466", "r469", "r471", "r472", "r616" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r120", "r127", "r133", "r219", "r407", "r408", "r409", "r434", "r435", "r466", "r469", "r471", "r472", "r616" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r201", "r356", "r361", "r578" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r287", "r318", "r378", "r380", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r576", "r579", "r602", "r603" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/LeaseSummaryDetails", "http://healthiercmc.com/role/LineOfCreditAndDebtDetails", "http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesIdentifiableIntangibleAssetsAndGoodwillDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r287", "r318", "r378", "r380", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r576", "r579", "r602", "r603" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/LineOfCreditAndDebtDetails", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesIdentifiableIntangibleAssetsAndGoodwillDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r201", "r356", "r361", "r578" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "label": "Officer [Member]" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r198", "r356", "r359", "r542", "r575", "r577" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/ContractLiabilitiesDetails", "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails", "http://healthiercmc.com/role/InventoriesDetails", "http://healthiercmc.com/role/SegmentInformationDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r198", "r356", "r359", "r542", "r575", "r577" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/ContractLiabilitiesDetails", "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails", "http://healthiercmc.com/role/InventoriesDetails", "http://healthiercmc.com/role/SegmentInformationDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r287", "r318", "r368", "r378", "r380", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r576", "r579", "r602", "r603" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/LeaseSummaryDetails", "http://healthiercmc.com/role/LineOfCreditAndDebtDetails", "http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesIdentifiableIntangibleAssetsAndGoodwillDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r287", "r318", "r368", "r378", "r380", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r576", "r579", "r602", "r603" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/LeaseSummaryDetails", "http://healthiercmc.com/role/LineOfCreditAndDebtDetails", "http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesIdentifiableIntangibleAssetsAndGoodwillDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r60", "r61", "r113", "r114", "r288", "r319" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/InventoriesDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r203", "r523" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASU 2016-02 [Member]", "verboseLabel": "ASC842 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/LeaseSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r597" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "verboseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r9", "r27", "r204", "r205" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r39", "r248" ], "calculation": { "http://healthiercmc.com/role/PropertyEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalFairValueElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment at Fair Value [Abstract]" } } }, "localname": "AdditionalFairValueElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28", "r410", "r526" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r117", "r118", "r119", "r407", "r408", "r409", "r471" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "verboseLabel": "Additional Paid-In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r121", "r122", "r123", "r124", "r133", "r208", "r209", "r216", "r217", "r218", "r219", "r220", "r221", "r268", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r432", "r433", "r434", "r435", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r522", "r544", "r545", "r546", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r614", "r615", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/LeaseSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r412" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expenses" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r93", "r234", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of basic and dilutive income (loss) per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/LiquidityDetails", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r452", "r453", "r454", "r455" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Consideration paid for acquisition" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "auth_ref": [ "r452", "r453", "r454", "r455" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Asset purchase transaction cost" } } }, "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r110", "r176", "r187", "r194", "r213", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r278", "r280", "r282", "r283", "r457", "r460", "r483", "r524", "r526", "r549", "r566" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r11", "r12", "r57", "r110", "r213", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r278", "r280", "r282", "r283", "r457", "r460", "r483", "r524", "r526" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r384", "r401" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r377", "r379" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r377", "r379", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r36", "r95" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/LiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r15", "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r89", "r95", "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH - END OF YEAR", "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH - BEGINNING OF YEAR" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r89", "r492" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "DECREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "FDIC insured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in Contract Liabilities Activity [Roll Forward]" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r107", "r110", "r136", "r141", "r142", "r144", "r146", "r152", "r153", "r154", "r213", "r269", "r274", "r275", "r276", "r282", "r283", "r315", "r316", "r321", "r325", "r483", "r611" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r342", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r50", "r255", "r556", "r571" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "verboseLabel": "COMMITMENTS AND CONTINGENCIES (SEE NOTE 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r252", "r253", "r254", "r264", "r598" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation.", "label": "Common Class C [Member]", "terseLabel": "Series C Stock [Member]" } } }, "localname": "CommonClassCMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r117", "r118", "r471" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r25", "r333" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r25", "r526" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, $0.0001 par value per share, 750,000,000,000 shares authorized; 339,741,632,384 and 143,840,848,017 shares issued and outstanding as of December 31, 2021 and 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Hardware & Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r161", "r162", "r201", "r480", "r481", "r597" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r161", "r162", "r201", "r480", "r481", "r592", "r597" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r161", "r162", "r201", "r480", "r481", "r592", "r597" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r161", "r162", "r201", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r159", "r161", "r162", "r163", "r480", "r482", "r597" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r161", "r162", "r201", "r480", "r481", "r597" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r103", "r459" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONTRACT LIABILITIES [Abstract]" } } }, "localname": "ContractWithCustomerAssetAndLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Contract Liabilities Activity" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r344", "r346", "r357" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r344", "r345", "r357" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Revenue [Abstract]", "terseLabel": "Accounts Receivable, Contract Assets and Contract Liabilities [Abstract]" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r344", "r345", "r357" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r356", "r365" ], "lang": { "en-us": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [ "r356", "r365" ], "lang": { "en-us": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r98", "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Converted and cancelled of shares (in shares)", "verboseLabel": "Number of warrants exchanged for preferred stock (in shares)" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities": { "auth_ref": [ "r334" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of convertible preferred stock that was converted to other securities.", "label": "Convertible Preferred Stock Converted to Other Securities", "negatedLabel": "Series C Preferred stock exercised" } } }, "localname": "ConvertiblePreferredStockConvertedToOtherSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r315", "r316", "r321" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r23", "r24", "r328", "r334", "r337" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Number of convertible preferred stock issued on conversion of warrants (in shares)" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r73", "r542" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r160", "r201" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableContractAssetsAndContractLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LINE OF CREDIT AND DEBT [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "auth_ref": [ "r22" ], "calculation": { "http://healthiercmc.com/role/TermLoanCreditAgreementDetailsCalc2": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the total principal payments made during the annual reporting period.", "label": "Plus: Payments made during 2020" } } }, "localname": "DebtInstrumentAnnualPrincipalPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r19", "r21", "r22", "r109", "r115", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r305", "r306", "r307", "r308", "r504", "r550", "r551", "r564" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Basis adjustment to variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r284", "r305", "r306", "r502", "r504", "r505" ], "calculation": { "http://healthiercmc.com/role/TermLoanCreditAgreementDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Face amount", "verboseLabel": "Total Payments" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "auth_ref": [ "r49", "r562" ], "lang": { "en-us": { "role": { "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).", "label": "Frequency of payment" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r47", "r297", "r502" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r47", "r303", "r502", "r504" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt instrument interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r47", "r285" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r48", "r287", "r478" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r49", "r109", "r115", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r305", "r306", "r307", "r308", "r504" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Monthly principle payments" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r49", "r109", "r115", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r305", "r306", "r307", "r308", "r334", "r338", "r339", "r340", "r501", "r502", "r504", "r505", "r563" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Instruments [Abstract]" } } }, "localname": "DebtInstrumentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.", "label": "Increment percentage on salary each subsequent year" } } }, "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1": { "auth_ref": [ "r367", "r386" ], "lang": { "en-us": { "role": { "documentation": "Maximum term of the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Additional employment agreement term" } } }, "localname": "DeferredCompensationArrangementWithIndividualMaximumContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.", "label": "Charitable contribution" } } }, "localname": "DeferredTaxAssetsCharitableContributionCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Net book value of intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r422" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 0.0, "parentTag": "hcmc_DeferredTaxAssetsGrossNetOfDeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets [Abstract]" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Inventory reserves and allowances" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r424" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets, Property, Plant and Equipment", "terseLabel": "Net book value of fixed assets" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "verboseLabel": "Stock based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Accrued Expenses and Deferred Income" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r423" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "verboseLabel": "Change in valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails", "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities [Abstract]" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r93", "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r93", "r246" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Derivative liabilities - warrants" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]", "terseLabel": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails", "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r356", "r359", "r360", "r361", "r362", "r363", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ContractLiabilitiesDetails", "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregate Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/DisaggregationOfRevenuesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "U.S. Federal [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted Net Income (Loss) Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r70", "r125", "r126", "r127", "r128", "r129", "r134", "r136", "r144", "r145", "r146", "r148", "r149", "r472", "r473", "r558", "r573" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "NET LOSS PER SHARE, BASIC (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r70", "r125", "r126", "r127", "r128", "r129", "r136", "r144", "r145", "r146", "r148", "r149", "r472", "r473", "r558", "r573" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "NET LOSS PER SHARE, DILUTED (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options [Abstract]" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average amortization period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Unamortized stock based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "verboseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r65", "r66", "r67", "r117", "r118", "r119", "r122", "r130", "r132", "r151", "r219", "r333", "r341", "r407", "r408", "r409", "r434", "r435", "r471", "r493", "r494", "r495", "r496", "r497", "r498", "r582", "r583", "r584", "r618" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesRestrictedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securities, Restricted [Abstract]" } } }, "localname": "EquitySecuritiesRestrictedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r474", "r475", "r476", "r479" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r293", "r305", "r306", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r475", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r293", "r369", "r370", "r375", "r376", "r475", "r530" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "verboseLabel": "Fair Value Measurements Using Quoted Prices in Active Market (Level 1) [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InvestmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r293", "r305", "r306", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r530", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InvestmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Useful lives", "terseLabel": "Amortization period" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesIdentifiableIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r239" ], "calculation": { "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r241" ], "calculation": { "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r241" ], "calculation": { "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r241" ], "calculation": { "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r241" ], "calculation": { "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r241" ], "calculation": { "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r235", "r236", "r239", "r242", "r543", "r547" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Future Annual Estimated Amortization Expense [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r239", "r547" ], "calculation": { "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Gross carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesIdentifiableIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r235", "r238" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r239", "r543" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, net of accumulated amortization", "totalLabel": "Net carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsFutureAnnualEstimatedAmortizationExpenseDetails", "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining amortization period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r77", "r93", "r210" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "negatedLabel": "Gain (loss) on investment", "terseLabel": "Gain (loss) on investment" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r93", "r309", "r310" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Loss on extinguishment of debt", "negatedLabel": "Net gain on debt settlements", "terseLabel": "Gain on Debt Settlements", "verboseLabel": "Gain on debt settlements" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/LineOfCreditAndDebtDetails", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r227", "r229", "r526", "r548" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsChangesInCarryingAmountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Impairment of goodwill and intangible assets", "terseLabel": "Impairment of goodwill and intangible assets" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GOODWILL AND INTANGIBLE ASSETS [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "GOODWILL AND INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r231", "r237" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Identifiable Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill [Abstract]" } } }, "localname": "GoodwillImpairedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r93", "r228", "r230", "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Impairment charge of goodwill", "negatedLabel": "Impairment of goodwill-retail business" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsChangesInCarryingAmountDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r381", "r382", "r399" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r72", "r110", "r176", "r186", "r190", "r193", "r196", "r213", "r269", "r270", "r271", "r274", "r275", "r276", "r278", "r280", "r282", "r283", "r483" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Segment gross profit", "totalLabel": "GROSS PROFIT" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets [Abstract]" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r93", "r243" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment charge of intangible assets", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r245", "r250" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r111", "r418", "r420", "r426", "r436", "r438", "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r112", "r131", "r132", "r175", "r416", "r437", "r439", "r574" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "totalLabel": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r64", "r414", "r415", "r420", "r421", "r425", "r431" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r417" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r413", "r417" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Change in tax rate" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r417" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "U.S. federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r417" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Other permanent items" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r417" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Stock based compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r417" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails": { "order": 11.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r417" ], "calculation": { "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State and local taxes, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesReconciliationOfTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r92" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "auth_ref": [ "r92" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Increase (Decrease) in Contract with Customer, Asset", "negatedLabel": "Contract assets" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r92", "r540" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Contract liabilities" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "auth_ref": [ "r92" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).", "label": "Increase (Decrease) in Derivative Liabilities", "terseLabel": "Change in fair value of derivative liabilities" } } }, "localname": "IncreaseDecreaseInDerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r92" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r92" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r92" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r137", "r138", "r139", "r146" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Effect of exercise warrants (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r137", "r138", "r140", "r146" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Effect of exercise stock options (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r68", "r174", "r500", "r503", "r559" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r79", "r298", "r304", "r307", "r308" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Accrued interest on loan payable" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r88", "r90", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternetDomainNamesMember": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "String of typographic characters used to describe the location of a specific individual, business, computer, or piece of information online. Formally known as the Uniform Resource Locator or URL, it is often considered to be the address of a certain World Wide Web site.", "label": "Website [Member]" } } }, "localname": "InternetDomainNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVENTORIES [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r8", "r55", "r526" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories [Abstract]" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r14", "r56", "r104", "r150", "r223", "r225", "r226", "r541" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r224" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Write-down of obsolete and slow-moving inventory", "verboseLabel": "Inventory write down" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTMENT [Abstract]" } } }, "localname": "InvestmentCompanyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r76", "r173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtCost": { "auth_ref": [ "r593" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of the investment.", "label": "Investment cost" } } }, "localname": "InvestmentOwnedAtCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r593", "r594", "r595" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.", "label": "Investment Owned, at Fair Value", "terseLabel": "Investment" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTableTextBlock": { "auth_ref": [ "r211", "r212", "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment.", "label": "Fair Value of Investment" } } }, "localname": "InvestmentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InvestmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r211", "r212", "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "INVESTMENT" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/Investment" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r518", "r520" ], "calculation": { "http://healthiercmc.com/role/LeaseComponentsOfLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total Rent Expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Lease Cost [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseComponentsOfLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Components of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LEASE [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases [Abstract]" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Maturity of Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r519" ], "calculation": { "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetailsCalc01": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r519" ], "calculation": { "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r519" ], "calculation": { "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r519" ], "calculation": { "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "verboseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r519" ], "calculation": { "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r519" ], "calculation": { "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r519" ], "calculation": { "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r519" ], "calculation": { "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetailsCalc01": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lease agreements term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseSummaryDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASE" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/Lease" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r44", "r110", "r188", "r213", "r269", "r270", "r271", "r274", "r275", "r276", "r278", "r280", "r282", "r283", "r458", "r460", "r461", "r483", "r524", "r525" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r32", "r110", "r213", "r483", "r526", "r552", "r569" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r46", "r110", "r213", "r269", "r270", "r271", "r274", "r275", "r276", "r278", "r280", "r282", "r283", "r458", "r460", "r461", "r483", "r524", "r525", "r526" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCollateralFeesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fees associated with providing collateral for the credit facility.", "label": "Collateral arrangement amount" } } }, "localname": "LineOfCreditFacilityCollateralFeesAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Line of Credit Facility, Expiration Period", "terseLabel": "Renewal period" } } }, "localname": "LineOfCreditFacilityExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r19", "r550" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Current portion of line of credit" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Attorney fees paid" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.", "label": "NOTES RECEIVABLE AND OTHER INCOME" } } }, "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Current portion of loan payment" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r22", "r292", "r302", "r305", "r306", "r551", "r567" ], "calculation": { "http://healthiercmc.com/role/LineOfCreditAndDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthiercmc.com/role/TermLoanCreditAgreementDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Expected payments for the upcoming years", "verboseLabel": "Total Line of Credit and Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, by Current and Noncurrent [Abstract]", "terseLabel": "Debt [Abstract]" } } }, "localname": "LongTermDebtByCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Principal Repayments of Long-Term Debt [Abstract]" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r115", "r267", "r296" ], "calculation": { "http://healthiercmc.com/role/LineOfCreditAndDebtDetails": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "verboseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r115", "r267", "r296" ], "calculation": { "http://healthiercmc.com/role/LineOfCreditAndDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "verboseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r115", "r267", "r296" ], "calculation": { "http://healthiercmc.com/role/LineOfCreditAndDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "verboseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "LINE OF CREDIT AND DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r49" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loan payable, net of current portion" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r255", "r256", "r257", "r259", "r260", "r261", "r263", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r255", "r256", "r257", "r259", "r260", "r261", "r263", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r255", "r258", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Damages sought" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss Contingency, Information about Litigation Matters [Abstract]", "terseLabel": "Legal Proceedings [Abstract]" } } }, "localname": "LossContingencyInformationAboutLitigationMattersAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r255", "r256", "r257", "r259", "r260", "r261", "r263", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Number of lawsuits" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketingAndAdvertisingExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Advertising [Abstract]" } } }, "localname": "MarketingAndAdvertisingExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesAdvertisingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputQuotedPriceMember": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using quoted price.", "label": "Mark to Market [Member]" } } }, "localname": "MeasurementInputQuotedPriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InvestmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InvestmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH USED IN FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r89", "r91", "r94" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r62", "r63", "r67", "r69", "r94", "r110", "r121", "r125", "r126", "r127", "r128", "r131", "r132", "r143", "r176", "r186", "r190", "r193", "r196", "r213", "r269", "r270", "r271", "r274", "r275", "r276", "r278", "r280", "r282", "r283", "r473", "r483", "r557", "r572" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "NET LOSS" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Non-compete [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r78" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Corporate other income (expense), net", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME (EXPENSE):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r9", "r10", "r26", "r204", "r205", "r555" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Notes Receivable" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "auth_ref": [ "r27" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.", "label": "Note receivable" } } }, "localname": "NotesAndLoansReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesSegmentReportingDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStores": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of stores.", "label": "Number of Stores", "terseLabel": "Number of stores" } } }, "localname": "NumberOfStores", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OffMarketFavorableLeaseMember": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Identifiable intangible asset established upon acquisition based on a favorable difference between the terms of an acquired lease and the current market terms for that lease.", "label": "Favorable Lease [Member]" } } }, "localname": "OffMarketFavorableLeaseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Corporate expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r176", "r186", "r190", "r193", "r196" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Loss from operations", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/LiquidityDetails", "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r512", "r520" ], "calculation": { "http://healthiercmc.com/role/LeaseComponentsOfLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maturity of Lease Liabilities by Fiscal Year [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r508" ], "calculation": { "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetailsCalc01": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of operating lease liabilities", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails", "http://healthiercmc.com/role/LeaseMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r508" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r508" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, net of current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r509", "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for leasing arrangement" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r507" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of use asset - operating lease, net", "terseLabel": "Right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r93" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of right-of-use asset", "terseLabel": "Amortization of right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r517", "r520" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate for operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r516", "r520" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term for operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseBalanceSheetClassificationAndOtherInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r185", "r186", "r187", "r188", "r190", "r196" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r6", "r462" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION, BASIS OF PRESENTATION, AND RECENT DEVELOPMENTS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopments" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Commitments [Abstract]", "verboseLabel": "Commitments [Abstract]" } } }, "localname": "OtherCommitmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherMachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.", "label": "Other Machinery and Equipment [Member]", "verboseLabel": "Other [Member]" } } }, "localname": "OtherMachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Direct financing costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r82", "r450" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "negatedLabel": "Payment for acquisition" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r83" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Purchases of patent" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r83" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r384", "r401" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred Stock, Convertible, Conversion Price", "terseLabel": "Conversion price (in dollars per share)", "verboseLabel": "Preferred stock conversion price (in dollars per share)" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r107", "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred stock, aggregate liquidation preference" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock [Abstract]" } } }, "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r24", "r315" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)", "terseLabel": "Preferred stock stated value (in dollars per share)", "verboseLabel": "Preferred shares, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)", "terseLabel": "Preferred stock, shares authorized ( (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r24", "r315" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)", "terseLabel": "Number of preferred stock, shares sold and issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesSubscribedButUnissuedValue": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of subscription received from investors who have been allocated nonredeemable preferred stock or preferred stock redeemable solely at the option of the issuer.", "label": "Aggregate subscription price" } } }, "localname": "PreferredStockSharesSubscribedButUnissuedValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r24", "r526" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Convertible preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r84" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from rights offering, net of offering costs", "verboseLabel": "Net proceeds" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r84" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r85", "r109" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from line of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r85" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from loan and security agreement" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities": { "auth_ref": [], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt, including capital lease obligations and mandatory redeemable capital securities.", "label": "Principal payments on loan payable" } } }, "localname": "ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfNotesReceivable": { "auth_ref": [ "r81" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale of a borrowing supported by a written promise to pay an obligation.", "label": "Collection of note receivable", "terseLabel": "Proceeds" } } }, "localname": "ProceedsFromSaleOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r84", "r402" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PROPERTY & EQUIPMENT [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r39", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r251", "r599", "r600", "r601" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY & EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r38", "r247" ], "calculation": { "http://healthiercmc.com/role/PropertyEquipmentDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r16", "r17", "r249", "r526", "r560", "r570" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthiercmc.com/role/PropertyEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net of accumulated depreciation", "totalLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/PropertyEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentNetByTypeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r37", "r249", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r16", "r249" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r16", "r247" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "verboseLabel": "Expected useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r71", "r222" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Change in provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivableWithImputedInterestDueDates": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Date the receivable or note with imputed interest is due, in YYYY-MM-DD format.", "label": "Due date" } } }, "localname": "ReceivableWithImputedInterestDueDates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": { "auth_ref": [ "r502", "r504" ], "lang": { "en-us": { "role": { "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.", "label": "Receivable with Imputed Interest, Effective Yield (Interest Rate)", "terseLabel": "Interest rate" } } }, "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ReceivableWithImputedInterestFaceAmount": { "auth_ref": [ "r502", "r504" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The principal amount of the receivable or note before consideration of the discount or premium.", "label": "Receivable with Imputed Interest, Face Amount", "terseLabel": "Loan amount" } } }, "localname": "ReceivableWithImputedInterestFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableWithImputedInterestNetAmount": { "auth_ref": [ "r501" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The receivable or note face amount less the unamortized discount or premium.", "label": "Remaining balance" } } }, "localname": "ReceivableWithImputedInterestNetAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTES RECEIVABLE AND OTHER INCOME [Abstract]" } } }, "localname": "ReceivablesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ReceivablesWithImputedInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables with Imputed Interest [Abstract]" } } }, "localname": "ReceivablesWithImputedInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayment of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r86", "r109" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Revolving credit line", "negatedLabel": "Principal payment on the line of credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r13", "r18", "r101", "r596" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r341", "r410", "r526", "r568", "r586", "r591" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r117", "r118", "r119", "r122", "r130", "r132", "r219", "r407", "r408", "r409", "r434", "r435", "r471", "r582", "r584" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DISAGGREGATION OF REVENUES [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r171", "r172", "r185", "r191", "r192", "r198", "r199", "r201", "r355", "r356", "r542" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "SALES, NET", "terseLabel": "Revenue", "verboseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/DisaggregationOfRevenuesDetails", "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r358", "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "DISAGGREGATION OF REVENUES" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/DisaggregationOfRevenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SALES:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesWagesAndOfficersCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Base salary", "terseLabel": "Annual base salary" } } }, "localname": "SalariesWagesAndOfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Closing bid stock price (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r161", "r201" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Total Purchases [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/NotesReceivableAndOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Concentration of Accounts Receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Securities Excluded from Calculation of Basic and Dilutive Income (loss) per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Breakdown of Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Reconciliation of Expected Tax Expense (Benefit)" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r235", "r238", "r543" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesIdentifiableIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r235", "r238" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Intangible Assets, Net" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r231", "r233" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Changes in Carrying Amount of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r14", "r33", "r34", "r35" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r39", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/PropertyEquipmentDetails", "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r176", "r177", "r189", "r231" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r176", "r177", "r189", "r231" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Summary of Reporting Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r394", "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Summary of Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r384", "r401" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r51", "r107", "r152", "r153", "r312", "r313", "r314", "r315", "r316", "r318", "r319", "r321", "r325", "r331", "r334", "r335", "r336", "r338", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Future Annual Estimated Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEGMENT INFORMATION [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r167", "r169", "r170", "r176", "r178", "r190", "r194", "r195", "r196", "r197", "r198", "r200", "r201", "r202" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Profit (Loss) [Abstract]" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r179", "r180", "r181", "r182", "r183", "r184", "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Compensation Plans [Abstract]" } } }, "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r92" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows", "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)", "verboseLabel": "Restricted common stock grants (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Equity instruments exercised (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Common stock available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityEquityCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Term and Aggregate Intrinsic Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options forfeited or expired (in shares)", "terseLabel": "Options forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "negatedLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Aggregate intrinsic value, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r390", "r401" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, Ending (in shares)", "periodStartLabel": "Outstanding, Beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Summary of Options Activity [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, Ending (in dollars per share)", "periodStartLabel": "Outstanding, Beginning (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "verboseLabel": "Weighted Average Exercise Price [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r383", "r387" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/StockholdersEquitySharebasedAwardsToOfficersAndRestrictedStockDetails", "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Options forfeited or expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r384", "r388" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Aggregate intrinsic value, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining term, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining term, outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Common stock at a price per share (in dollars per share)", "terseLabel": "Subscription price (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails", "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r20", "r553", "r554", "r565" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Investment" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r513", "r520" ], "calculation": { "http://healthiercmc.com/role/LeaseComponentsOfLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r102", "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r23", "r24", "r25", "r107", "r110", "r136", "r141", "r142", "r144", "r146", "r152", "r153", "r154", "r213", "r269", "r274", "r275", "r276", "r282", "r283", "r315", "r316", "r321", "r325", "r333", "r483", "r611" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r53", "r65", "r66", "r67", "r117", "r118", "r119", "r122", "r130", "r132", "r151", "r219", "r333", "r341", "r407", "r408", "r409", "r434", "r435", "r471", "r493", "r494", "r495", "r496", "r497", "r498", "r582", "r583", "r584", "r618" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r117", "r118", "r119", "r151", "r542" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical", "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture", "terseLabel": "Options aggregate grant date value" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r52", "r295", "r333", "r334", "r341" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Number of common stock shares issued upon conversion preferred stock (in shares)", "terseLabel": "Issuance of Convertible Preferred stock in connection with the Securities Purchase Agreement (in shares)", "verboseLabel": "Preferred Stock exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Issuance of awarded common stock for professional services (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r24", "r25", "r333", "r341" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock shares issued from offering (in shares)", "terseLabel": "Issuance of common stock (in shares)", "verboseLabel": "Exchange of notes for shares of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails", "http://healthiercmc.com/role/StockholdersEquityRightsOfferingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r24", "r25", "r333", "r341" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedLabel": "Cancellation of awarded stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r333", "r341" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Issuance of awarded stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r24", "r25", "r333", "r341", "r392" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock options exercised (in shares)", "negatedLabel": "Options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r53", "r333", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of Convertible Preferred stock in connection with the Securities Purchase Agreement" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of awarded common stock for professional services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r24", "r25", "r333", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock", "verboseLabel": "Issuance of common stock pursuant to exchange agreement" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/StockholdersEquityExchangeAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "auth_ref": [ "r24", "r25", "r333", "r341" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.", "label": "Cancellation of awarded stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r24", "r25", "r333", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Issuance of awarded stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r53", "r333", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Stock Options [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityStockOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r25", "r30", "r31", "r110", "r206", "r213", "r483", "r526" ], "calculation": { "http://healthiercmc.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedBalanceSheets", "http://healthiercmc.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r108", "r316", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r329", "r330", "r332", "r341", "r343" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r499", "r528" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LiquidityDetails", "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r499", "r528" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r499", "r528" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LiquidityDetails", "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r499", "r528" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LiquidityDetails", "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r527", "r529" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/OrganizationBasisOfPresentationAndRecentDevelopmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit": { "auth_ref": [ "r561" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit.", "label": "Time Deposits, at or Above FDIC Insurance Limit", "terseLabel": "Total Cash in excess of FDIC limits of $250,000" } } }, "localname": "TimeDepositsAtOrAboveFDICInsuranceLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/GoodwillAndIntangibleAssetsIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r121", "r122", "r123", "r124", "r133", "r208", "r209", "r216", "r217", "r218", "r219", "r220", "r221", "r268", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r432", "r433", "r434", "r435", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r522", "r544", "r545", "r546", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r614", "r615", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://healthiercmc.com/role/LeaseSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/CommitmentsAndContingenciesDetails", "http://healthiercmc.com/role/LiquidityDetails", "http://healthiercmc.com/role/StockholdersEquityPreferredStockAndConvertiblePreferredStockDetails", "http://healthiercmc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r155", "r156", "r157", "r158", "r164", "r165", "r166" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates in the Preparation of the Financial Statements" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r424" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/IncomeTaxesOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r514", "r520" ], "calculation": { "http://healthiercmc.com/role/LeaseComponentsOfLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LeaseComponentsOfLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/LineOfCreditAndDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "verboseLabel": "Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails", "http://healthiercmc.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r135", "r146" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)", "terseLabel": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, DILUTED (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r134", "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)", "terseLabel": "WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthiercmc.com/role/ConsolidatedStatementsOfOperations", "http://healthiercmc.com/role/StockholdersEquityIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1828-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r207": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "http://asc.fasb.org/topic&trid=75115024" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "http://asc.fasb.org/topic&trid=2197064" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r343": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r442": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r462": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r521": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r529": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r604": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r605": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r606": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r607": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r608": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r609": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r610": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r611": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r612": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r613": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" } }, "version": "2.1" } ZIP 105 0000844856-22-000019-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000844856-22-000019-xbrl.zip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end

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